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ABSTRACT
Alzheimer’s disease (AD) is increasing in prevalence due to increasing lifespan and
altered lifestyle. It is the fourth major cause of death in Western countries, resulting in
significant economic and social impact (Von Strauss, et al., 1999; Goate, 1997). There
are no blood biomarkers currently accepted for the diagnosis of AD, and the
identification of suitable biomarkers would eventually reduce the necessity for
invasive, expensive and slow diagnostic procedures, as well as facilitate prognostic
studies. An AD blood test would decrease the need for delaying diagnosis due to
ambivalent presentation, and allow therapeutic intervention to commence at an
earlier and more functional stage for the sufferer, thereby maximising the benefits of
treatment.

It is also feasible that a blood biomarker would be of use in the

development of therapeutic treatments, which are currently inadequate.
Numerous studies have suggested that hyperinsulinemia and type II diabetes (DM2)
significantly increase the risk of developing Alzheimer’s disease (AD). Therefore, much
research interest has been aimed recently toward determining the putative common
mechanisms of these conditions. One enzyme which has been implicated in both AD
and DM2 is insulin degrading enzyme (IDE). This project focuses largely on the
characterisation of plasma IDE expression and catalytic activity, to help determine
potential role/s of IDE in the development of AD, and the suitability of IDE as an AD
biomarker. Evidence is also provided to support the concept that IDE impairments
may be the common factor that links AD, hyperinsulinemia and DM2.
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CHAPTER 1 - Literature review/introduction.
AD Introduction
Alzheimer’s disease (AD) is a progressive, neurodegenerative disorder, and is the most
common form of dementia, accounting for between 50% and 80% of all dementia
cases (Alzheimer’s disease facts and figures (2012)).

Clinical symptoms include

increasing memory loss and cognitive functioning, ultimately leading to severe
disability and death. The prevalence of AD is rising globally, and the prevalence and
incidence increases with age (Von Strauss, et al., 1999; Gascόn-Bayarri et al., 2007). In
Australia, the number of individuals with dementia is currently around 266,000, and is
expected to exceed 940,000 by 2050 (Deloitte Access Economics, 2011). In the United
States of America (USA), AD has been found to be the sixth highest cause of death
(Alzheimer’s disease facts and figures (2012)) and results in significant economic and
social impact, yet research funding to date has been grossly inadequate.
One of the key hallmarks of AD pathology is the development of senile plaques in
various regions of the brain, of which the core component is a 4kDa peptide termed
beta-amyloid or A-beta (Aβ). It is widely believed that the initiation of AD pathology is
triggered by abnormal increases in the steady-state levels of Aβ in the brain, as
described by the “amyloid cascade hypothesis” (Hardy & Higgins, 1992).
AD can be classified according to the age of onset, with the majority of cases occurring
after the age of 65 years (around 95%). This type of AD is termed “late-onset AD”
(LOAD), whereas AD with an onset occurring prior to 65 years of age is termed “earlyonset AD” (EOAD). While most EOAD cases are known to be caused by mutations in
one of three genes, the aetiology of LOAD is less clear. The accumulation of Aβ in
EOAD appears to be due primarily to increased production of Aβ peptides, or a
proportionate increase in the production of the longer, more amyloidogenic Aβ1-42
peptide (Hardy, 1997), however evidence suggests that faulty Aβ clearance
mechanisms may also be implicated in the development of LOAD (Selkoe, 2001). At
present, the most significant known genetic risk factor for LOAD is possession of the
Apolipoprotein E epsilon 4 allele (APOE ε4).
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Numerous studies have found an association between Type 2 diabetes (DM2) and AD;
however the mechanisms that are common to these two diseases, and mechanisms of
DM2 that cause an increased risk of AD are not well understood. One enzyme which is
believed to have a role in both diseases is insulin-degrading enzyme (IDE): this enzyme
can degrade Aβ therefore it is believed to play a major part in the clearance of Aβ. This
chapter will explain the processes and key features of AD pathology, specifically
focusing on recent literature and encompassing IDE-related Aβ clearance mechanisms
as well as factors that link type-2 diabetes and LOAD.

1.1 AD symptoms and characteristics
1.1.1 Clinical Characteristics of AD
Clinically, individuals with AD present with amnestic memory deficits and usually one
or more other symptoms such as aphasia (language impairment), agnosia (impaired
ability to recognise objects, people, sounds, shapes or smells) or impairment of
executive functioning (Cummings & Cole, 2002).

These symptoms progressively

worsen, leading to functional and behavioural difficulties in daily life activities and
eventually severe disability and death. There are also a number of neuropsychiatric
symptoms that are regularly seen in AD such as depression, anxiety, psychosis and
hallucinations, among others (Cummings, 2001). In advanced AD, apraxia (inability to
perform voluntary movements) also becomes apparent and the patient can be prone
to secondary infection, which is the usual cause of death (McKhann, et al., 1984). On
average, the life expectancy after diagnosis of AD is approximately 3-10 years (Zanetti,
et al., 2009), and this is highly influenced by the age at which a person is diagnosed –
for example, newly diagnosed patients in their 60s or 70s will live an average of 7-10
years, whereas a person diagnosed in their 90s is expected to have a life expectancy of
around 3 years.
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1.1.2 Macroscopic Characteristics
At a macroscopic level, severe atrophy occurs in the amygdala, the entorhinal cortex
(EC) and the hippocampus, with the latter being one of the earliest affected brain
regions (Duyckaerts, et al., 2009; Scahill, et al., 2002). These areas have essential roles
in memory formation, spatial awareness, and emotional reaction, which are functions
that are affected in the early AD stages. This atrophy appears to result from the
degeneration of neurons and other cells, leading to loss of volume in the inferior
temporal and superior and middle frontal gyri (Duyckaerts, et al., 2009). The rate of
the atrophy also appears to be accelerated in individuals with one or more APOE ε4
alleles, in a dose-dependent manner (Chen et al., 2007, Agnosta, et al., 2009).

1.1.3 Pathological Characteristics
At a microscopic level, the primary pathological features of AD include extracellular
deposits of amyloid called senile plaques (SP) and intracellular neurofibrillary tangles
(NFT) that appear in cortical and limbic areas of the brain, and the number and
distribution of these lesions increase as the disease progresses. As mentioned earlier,
the main components of amyloid are aggregates of Aβ peptides. Another pathological
feature frequently found in AD is cerebral amyloid angiopathy (CAA), sometimes called
congophilic angiopathy (Glenner & Wong, 1984).

This is characterised by the

deposition of Aβ aggregates in the cerebrovascular walls in a regional pattern which is
similar to the deposition of SP, leading to vascular damage (Thal et al., 2008). Aβ
deposition in the vasculature indicates peripherally circulating Aβ may influence AD
pathogenesis.
There are other pathological features commonly seen in AD, including granulovacuolar
degeneration (GVD) which involves intraneuronal double-membraned bodies that
appear to be related to autophagic mechanisms (Funk, et al., 2011). GVD is not only
found in AD, but in other neurodegenerative disorders as well. Another feature, hirano
bodies (HB) - actin-related aggregates - are also found in neurons in AD, however are
also considered to be common in normal ageing as well (Gibson & Tomlinson, 1977).
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These disturbances cause neuronal dysfunction and synaptic loss, leading to brain
atrophy and cognitive impairment.

1.1.3.1 Neurofibrillary Tangles (NFT)
Like HB, NFT are not just found in AD, but can be found in some specific regions of the
brain in healthy ageing. NFT are also found in some other brain degenerative
conditions (Nelson, et al., 2012; Bouras, et al., 1994). It has been shown that the
number of NFT correlates with the level of cognitive impairment in AD (McKee et al.,
1991). It is widely believed that the processes leading to SP deposition may cause the
subsequent formation of NFT which leads to neuronal death (Hardy & Allsop, 1991;
Yamaguchi, et al., 2001). NFT are insoluble aggregates that build up following the
hyperphosphorylation of tau protein. Tau is normally associated with microtubule
stability related to cytoskeletal structure, as well as the formation of axons and
dendrites.

1.1.3.2 Senile Plaques (SP)
First recognised over 100 years ago by Alois Alzheimer (Stelzmann, et al., 1995), the
main component of SP is insoluble, fibrillar beta-amyloid (Aβ) which forms its core
(Glenner & Wong, 1984), and plaques are often bordered by activated microglia and
abnormal neurites (Zubenko, 2007). Plaques do contain other components, including
ApoE (Barger, et al. 2008; Sheng, et al., 1996), IDE (Bernstein, et al., 1999) alpha1
antichymotrypsin, alpha2 macroglobulin, interleukin 6, complement proteins C1Q, C3,
and C4, amongst others (Liao, et al., 2004). SP form extracellularly and are often found
in close proximity to neurons containing NFT (Masters, et al., 1985).
The deposition of Aβ fibrils and SP in specific regions of the brain appears to precede
the onset of neuronal loss and synaptic dysfunction (Glenner & Wong, 1984; Masters,
et al., 1985). As Aβ is the major component of SP, and abnormal accumulation of this
peptide is thought to initiate the pathogenic cascade of processes seen in AD (Hardy &
Selkoe, 2002), the regulation of Aβ concentration and factors that may accelerate its
aggregation are believed to be of vital importance.
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1.2 Beta Amyloid (Aβ) - A Key Molecule
The Aβ molecule is a 39-43 amino acid 4kDa peptide, which is synthesised and
detectable throughout the body under normal physiological circumstances, however
its role is unclear (Masters et al., 1985; Haass et al., 1992; Seubert et al., 1992). It is a
breakdown product of a larger protein (see below), and is normally cleared quickly,
however during pathological processes such as AD, there appears to be an imbalance
between its production, and its degradation and/or clearance (Savage, et al., 1998;
Selkoe, 2001). This leads to the accumulation of Aβ, and as it is highly fibrillogenic,
aggregation and deposition of amyloid fibrils occur in the brain in the form of SP as
well as diffuse aggregates (Hardy & Selkoe, 2002; Suzuki et al., 1994).

1.2.1 Early onset and Late onset AD
AD is broadly divided into two main subtypes, referred to as early-onset AD (EOAD)
and late-onset AD (LOAD). EOAD, in which the onset of symptoms occurs before the
age of 65 years, is caused by autosomal dominant mutations in either the presenilin 1
(PS1), presenilin 2 (PS2) or the amyloid precursor protein (APP) genes, and is often also
termed early-onset familial AD (EOFAD) (Goate, et al., 1991; Sherrington, et al., 1995;
Levy-Lahad, et al., 1995). There is also a very small subgroup of sporadic EOAD. EOAD,
however, only accounts for around 5% of AD cases, with LOAD accounting for the
majority of cases (Cummings & Cole, 2002). However, some AD cases exhibit
Mendelian inheritance in which no mutations in any of the recognised genes exist,
indicating the involvement of genes which are yet to be identified (Goate, 1997).
A greater understanding of AD has come from studies of EOAD. The discoveries of the
many APP, PS1 and PS2 genetic mutations that lead to AD highlight the central role of
Aβ in AD, as Aβ peptide is a proteolytic product of APP, and the presenilins are
proteins involved in the last proteolytic process that cleaves Aβ from the parent
molecule. In EOAD, genetic mutations in PS1, PS2 and APP have been demonstrated to
cause the disease mostly via increased production of Aβ (Selkoe, 2001; Verdile, et al.,
2004; Hardy, 1997), and depending on the site of the APP mutation, can also alter Aβ’s
affinity for fibrillogenesis (Walsh & Selkoe, 2007). The increased understanding of Aβ
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properties associated with identifying these mutations initiated one of the most widely
accepted hypotheses amongst AD researchers, “the amyloid cascade hypothesis”
(Hardy & Allsop, 1991). The hypothesis contends that AD pathology is initiated by
increased levels of Aβ, which leads to Aβ accumulation and aggregation, as well as a
cascade of other events including NFT formation, oxidative stress, mitochondrial
dysfunction (reviewed in Lin & Beal, 2006), inflammatory responses and vascular
damage, culminating in neuronal loss (Hardy & Higgins, 1992). There is substantial and
growing evidence which supports this hypothesis, however it remains controversial
due to a number of discrepancies (Hardy & Selkoe, 2002; Selkoe, 2011; Karran, et al.,
2011). As yet, it has not been either proved or disproved, but regardless, Aβ is widely
believed to be central in the pathogenesis of AD. In the case of LOAD, which comprises
approximately 95% of AD cases, it appears that the accumulation of Aβ may be largely
due

to

defective

clearance

and/or

degradation

mechanisms

rather

than

overproduction (Selkoe, 2001). As such, proteins which are directly involved in Aβ
degradation and clearance mechanisms are being studied to characterise AD
neuropathology better, as well as to identify potential AD biomarkers.

1.2.2 Amyloid Precursor Protein (APP)
Through multi-step proteolytic processing, Aβ is generated from its parent molecule,
the amyloid precursor protein (APP). Aβ is synthesised via sequential cleavage of APP
(see Figure 1), a transmembrane protein which is ubiquitously expressed (Kinoshita et
al., 2003; Haass et al., 1992). This process involves two enzymatic proteases, βsecretase (also referred to as “BACE”) and γ-secretase. APP is initially cleaved by BACE
extracellularly, and the remaining membrane bound portion (termed “C99”) is then
cleaved within the membrane by γ-secretase to liberate Aβ (LaFerla et al., 2007).
Because γ-secretase does not have sequence specificity, the intra-membrane cleavage
site at the C-terminus can vary, producing Aβ peptides that range from 38-43 residues
long (Wolfe et al., 1999). The two main Aβ peptides in the human brain are 40 and 42
amino acids long, of which Aβ1-40 (Aβ40) is the principal species in normal physiology
(Seubert, et al., 1992; Haass, et al., 1992). Aβ42 appears to be the most conducive to
self-association and fibrillogenesis (Jarrett, et al., 1993; Burdick, et al., 1992; Snyder, et
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al., 1994), and has also been found to be more neurotoxic than the shorter species
(Davis & Van Nostrand, 1996). APP can also be cleaved by α-secretase which cleaves
within the Aβ sequence,at position 16, thus precluding the formation of the full length
Aβ peptide.

Figure 1.1 Representation of the generation of Aβ.
1. Cleavage of membrane-bound APP extracellularly by β-secretase (BACE).
2. Cleavage of remaining C99 portion of APP within the plasma membrane by γsecretase.
3. Liberation of Aβ into the extracellular milieu. The remaining portion of APP (AICD)
is released into the cytosol (intracellular space).

It should be noted that while Aβ is shown in Figure 1 to be released extracellularly, and
this was originally the accepted location for its generation, further studies have shown
that it can also be produced intracellularly (Wertkin, et al., 1993; reviewed in La Ferla,
et al., 2007).

There is also now considerable evidence that Aβ can accumulate

intracellularly as well as extracellularly in the human brain (Gouras, et al., 2000;
Martin, et al., 1995; Cabrejo, et al., 2006) and that this precedes plaque formation
(Gyure, et al., 2001; Knobloch, et al., 2007).

This indicates that intracellular
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accumulation of Aβ is an early event in AD pathogenesis and may be an upstream
event to extracellular accumulation.
As well as intracellular accumulation, recent evidence suggests that Aβ accumulates
within the mitochondria early in AD, and this appears to be due to its importation into
the mitochondria from the cytosol (Manczak, et al., 2006; Reddy, et al., 2008; reviewed
in Chen & Yan, 2010; Leal, et al., 2013). Increased mitochondrial Aβ (mitAβ) has
recently been associated with the severity of both mitochondrial dysfunction and
cognitive function in transgenic mouse models of AD (Dragicevic, et al., 2010;
Caspersen, et al., 2005). Furthermore, the distribution of mitAβ in AD brains is similar
to the distribution of AD pathology. Therefore the regulation of mitAβ as well as
intracellular Aβ is crucial in preserving normal mitochondrial function and disruption of
mitochondrial function may be an initiating factor in the development of AD.

1.2.3 Aβ Toxicity in AD
Monomers of Aβ self-associate to form oligomers, and subsequently fibrils, that
appear to be associated with the level of toxicity and degree of neurodegeneration
(Roher, et al., 1996; Pike, et al., 1991). These Aβ fibrils then aggregate into SP.
Originally, it was thought that the neurotoxicity of Aβ could be primarily attributed to
the insoluble amyloid fibrils present in SP, however further research has suggested
that plaques are relatively inert, and it is more likely to be soluble, pre-fibrillar small Aβ
oligomers which cause neuronal injury (Stine, et al., 2003; Walsh & Selkoe, 2007; Pike,
et al., 1993; McLean, et al., 1999; Lue, et al., 1999). Aβ has been demonstrated to
have neurotrophic properties in vitro, which are dependent on low peptide
concentration, and reduced length of exposure time (Pike, et al., 1991; Yankner, et al.,
1990; Pike, et al., 1993). Similarly, oligomer and fibril formation, and the respective
neurotoxicity of these aggregates, have been shown to be isoform-dependent,
concentration-dependent and time-dependent, as well as dependent on certain metal
ions such as Zn2+ or Cu2+ (Stine, et al., 2003; Hartley, et al., 1999). In addition, studies
have uncovered an apparent intermediate between oligomers and mature fibrils,
termed “protofibrils” which appear to be similar to oligomers regarding formation and
neurotoxicity (Dahlgren, et al., 2002; Hartley, et al., 1999; Walsh, et al., 1997; Stine, et
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al., 2003). Oligomers of Aβ have also been found to inhibit long-term potentiation
(LTP), which is associated with memory formation (Walsh, et al., 2005; Wang, et al.,
2002). Therefore, the accumulation of Aβ, and in particular the Aβ42 isoform, may
instigate the self-association of this peptide into soluble, pre-fibrillar forms, initiating
the neurotoxicity that precedes plaque formation.
One mechanism which is believed to be partly responsible for the accumulation and
aggregation of cerebral Aβ is the impairment of its degradation or clearance from the
CNS.

1.3 Aetiology of LOAD
The aetiology of LOAD is complex and not completely understood. The major risk
factor for AD is age. There have been a number of other risk factors reported, such as a
family history of AD, which have also been shown to be significant (van Duijn, et al.,
1994; Lindsay, et al., 2002). Other risk factors include female gender, low education
level, head trauma, late maternal age and depression, among others, however the
results of some studies have been conflicting (Launer, et al., 1999; Lindsay, et al., 2002;
van Duijn, et al., 1994; van Duijn, 1996).
The major genetic risk factor to date appears to be possession of one or more ε4 allele
of the APOE gene, as mentioned previously (Goate, 1997; Corder, et al., 1993;
Strittmatter, et al.,1993(a); Rebeck, et al., 1993). However, around 50% of LOAD cases
do not carry the APOEε4 genotype and this indicates that other factors are involved in
the aetiology of LOAD (Corder, et al., 1993). Genetic studies have uncovered several
other genes which appear to have some influence on the risk of LOAD, although not as
great an influence as the APOE gene. It is highly probable that environmental and
lifestyle factors also influence the risk of sporadic AD, and probably interact with
relevant genetic factors (Roher, et al., 2009).
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1.4 Diagnostic Techniques
There are currently two diagnostic standards used for AD, the National Institute of
Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease
and Related Disorders Association (NINCDS-ADRDA) Alzheimer’s criteria, and criteria
outlined by the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text
Revision (DSM-IV-TR®) (American Psychiatric Association, 2000). These two standards
are similar in nature. There are also several imaging techniques in use, which can
complement these diagnostic standards.
NINCDS-ADRDA criteria categorises patients into one of four categories; “definite”,
“probable”, “possible” or “unlikely” Alzheimer’s disease. A diagnosis of “definite” AD
requires histopathologic confirmation, via an autopsy or brain biopsy. For a diagnosis
of “probable” AD, there must be impairment in at least two of the eight cognitive
domains: “memory, language, perceptual skills, attention, constructive abilities,
orientation, problem solving and functional abilities” (McKhann, et al., 1984). A
diagnosis of “possible” or “unlikely” AD indicates that there is dementia present with
features that are atypical of AD, yet which cannot be explained by any other diseases
that may cause dementia.
Similarly, the current DSM-IV-TR® diagnostic procedure involves initially ascertaining
the presence of dementia, by the confirmation of memory impairment, accompanied
by at least one other symptom such as aphasia, apraxia, agnosia and/or impairment of
executive functioning. The severity of these deficits must be sufficient to impair
functionality of daily living (DSM-IV-TR®, American Psychiatric Association, 2000), and
are evaluated using assessment tools such as the Mini-Mental State Exam (MMSE).
The DSM-IV-TR® states that onset of the disease should be gradual, and that the
decline in impairment must be progressive and distinguishable from the decline that
occurs in the normal ageing process. Essentially, the diagnosis of Alzheimer’s disease
can only be made once all other causes of dementia and disorders with similar
symptoms have been excluded, and consideration must be given to potentially
confounding factors such as ethnicity, culture and educational history, all of which may
have an effect on the outcome of the evaluation.
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1.4.1 Imaging Techniques and Biopsy
Cerebral computerised tomography (CT) and/or magnetic resonance imaging (MRI) can
also be used to confirm specific macroscopic changes that are characteristic of AD such
as atrophy, particularly of the hippocampus, and to eliminate any other pathological
cause of dementia which is not of the Alzheimer type. Less commonly, functional
imaging techniques such as MRI, positron-emission tomography (PET) or single photon
emission computed tomography (SPECT) have been used to assist in differential
diagnosis. Although not part of the standard diagnostic screening, these imaging
techniques have been shown to be very useful for differentiation of AD, and
suggestions have been made for revision of the NINCDS-ADRDA to include them in the
criteria, along with CSF biomarkers such as Aβ and tau which have also shown promise
(Dubois et al., 2007; Visser, et al., 2009). In the last ten years advances have been
made with the discovery of amyloid-imaging agents such as “Pittsburgh Compound-B”
(PiB) which are used in conjunction with PET imaging (Klunk, et al., 2004). PiB-PET
allows quantification of amyloid deposition in the brains of living individuals. The
deposition of Aβ amyloid (as well as synaptic loss and neuronal death) occurs for many
years before symptoms manifest, therefore the PiB-PET imaging technique can also
identify patients with no symptoms, yet who are likely to develop AD - people at a preclinical stage (Okello, et al., 2009; Pike, et al., 2007). Microscopic analysis from a
biopsy may also reveal pathological hallmarks of AD such as SP and NFT, and similarly
can help exclude or confirm a diagnosis of AD (DSM-IV-TR®, 2000). However these
techniques are costly and invasive, require an expert clinician or surgeon, and in the
case of biopsy, there are considerable risks. Due to these factors, their usefulness in a
clinical setting is limited.
As mentioned above, by the time AD symptoms appear, considerable synaptic and
neuronal loss has occurred. For the foreseeable future, potential treatments are at
best likely to stop or slow the pathogenesis of the disease, not reverse it. To maximise
the effect of potential future treatments, early pre-clinical diagnosis is necessary. Thus
it is clear that current standard diagnostic techniques for AD are insufficient, as they do
not identify the disease at an early stage, and are definitive only after autopsy
examination.

Therefore, the identification of AD pre-clinical biomarkers would

improve diagnostic efficacy.
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While Aβ would seem to be an obvious candidate as a biomarker for AD, research
findings have been inconclusive concerning its validity, and it is probable that a
combination of biomarkers may be necessary for accurate diagnostics.

While the

mutations responsible for EOAD appear to alter Aβ concentration via increased
production, particularly of the Aβ42 peptide (Hardy, 1997), increasing evidence
suggests that impaired clearance of this peptide may be responsible for the majority of
sporadic AD cases (Selkoe, 2001). As such, proteins or other biological substances that
directly affect the regulation of Aβ levels via clearance mechanisms may have value as
possible biomarkers.

1.4.2 AD Biomarkers
To date, there is no universally accepted biomarker or set of biomarkers, that has the
level of specificity or sensitivity required for definitive diagnosis of AD (DSM-IV-TR®,
2000; Consensus Report of the Working Group on: “Molecular and Biochemical
Markers of Alzheimer’s Disease”, 1998). Although studies on CSF biomarkers such as
Aβ and tau have shown potential for differentiating between AD, mild cognitive
impairment (MCI), subjective memory complainers (SMC) and healthy controls
(Blennow, 2004; Visser, et al., 2009; Wallin et al., 2006; Herukka et al., 2007), the
invasiveness of CSF collection and high costs of imaging make these techniques
impractical for routine use in clinical practice. Current diagnostic techniques are
largely based on a clinician’s subjective judgement, the quality of which may vary
based on their experience. Knopman et al., 2001, states that the two diagnostic
standards described above have good reliability, with a sensitivity of 81% on average,
but a specificity of only 70%, on average. These figures are based on thirteen studies
which examined the accuracy of clinical diagnostic tools for AD. It is likely, however,
that these figures are not likely to be representative of accuracy in the early stages of
the disease (Frank et al., 2003), and as previously stated, the only way to confirm the
diagnosis of Alzheimer’s at present, is by autopsy examination.
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1.4.3 MCI
Potential Alzheimer’s patients in the very early stages of the disease may be diagnosed
with MCI (Frank et al., 2003). MCI is characterised by memory loss and other cognitive
impairment, without meeting the neuropathologic criteria for dementia (Petersen et
al., 1999). When memory loss is the primary symptom, it is termed “amnestic” MCI,
and is considered to be a particular risk factor for AD. It has been shown that at least
50% of MCI patients do progress to dementia (Schmidtke & Hermeneit, 2008;
Gauthier, et al., 2006), however some MCI patients either go on to develop disorders
other than AD, show no progression of impairment, or even recover, so the ability to
differentiate between these cases is of particular diagnostic importance.

1.4.4 SMC
Individuals with SMC have also been found to have an increased risk for developing
dementia in a number of studies (Obrien, et al., 1992; Geerlings, et al., 1999; Schmand,
et al., 1996). In a recent study, SMC individuals were found to have significantly lower
scores on tests for cognitive impairment, such as the MMSE, compared with controls.
In addition, the APOE ε4 allele was found to be over-represented in this cohort, in a
dose-dependent manner (Laws, et al., 2002). This may indicate that individuals with
subjective memory complaints could be at a higher risk for developing AD, similar to
MCI patients.

1.4.5 The need for better AD biomarkers
One of the problems with current diagnostics is the inability to identify individuals
before or during the early stages of neurodegeneration that lead to clinical dementia.
As mentioned earlier, it would be of enormous benefit to identify one or more
biomarkers to assist AD diagnosis at the earliest possible stages, and preferably prior
to the onset of the irreversible symptoms. This would allow treatment to commence
at a more functional stage for the patient and slow or delay the progression of
symptoms (Borroni, et al., 2006). Quality of life could be maximised for sufferers and
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their families, and economic benefits regarding healthcare would be significant
(Brookmeyer et al., 1998). Recently, recommendations were made by the National
Institute of Ageing (NIH) and Alzheimer’s Association for the revision of current
diagnostic criteria (Jack, et al., 2011). The recommendations from these working
groups were in part to include scientifically validated biomarkers of AD in the
standards that may detect AD at a preclinical stage, namely CSF levels of Aβ, total tau
(T-tau) and phosphorylated tau (P-tau), increased brain amyloid load and reduced
fluorodeoxyglucose uptake determined by positron-emission topography (PET)
imaging (pattern-specific), and brain atrophy determined by structural magnetic
resonance imaging (MRI). Searching for blood biomarkers as well as any biomarkers
that can detect AD at the earliest possible stage is therefore of great importance and
many potential biomarkers are currently in the process of being validated (Hampel, et
al. 2010).

1.4.5.2 The “Ideal Biomarker for AD”
The Working Group on Molecular and Biochemical Markers of Alzheimer’s Disease
(The Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association and
the National Institute on Ageing Working Group, 1998) has suggested that the “ideal
biomarker” for AD should possess a number of features. Firstly it should be related to
a pathological feature of AD, and be validated in confirmed AD cases. It should be
sensitive enough to allow early diagnosis and to differentiate it from other dementias.
In addition, the “ideal biomarker” should be reliable, biomarker screening should be
inexpensive and simple, and should involve relatively non-invasive testing.

The

detection of biomarkers in easily accessible biological fluids is therefore an area of
intense interest. Although CSF is likely to be the most accurate biological fluid for
reflecting pathophysiological changes, as it is in direct contact with the brain (Blennow,
2004), techniques such as lumbar puncture for the analysis of CSF, are highly invasive,
uncomfortable for the patient and often expensive, requiring an expert clinician to
perform the procedure. Therefore, identification of one or more peripheral blood
biomarkers would be highly useful for diagnostic, prognostic and therapeutic purposes.
A variety of different blood biomarkers could potentially be used together to improve
the precision of the screening process. For example, studies have recently been
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focusing on the analysis of protein expression patterns in plasma or serum, with
positive results (Doecke, et al., 2012; Soares, et al., 2012; O’Bryant, et al., 2010; Ray et
al. 2007). In addition, the Aβ42/Aβ40 ratio has been shown in plasma to be potentially a
promising biomarker for identifying persons at risk of developing MCI or AD (Okereke,
et al., 2009; Graff-Radford et al., 2007). However, there is some controversy regarding
the usefulness of plasma Aβ as a reliable, pre-clinical biomarker (Rissman, et al., 2012).
The identification of additional biomarkers that could be used in conjunction with, or
instead of the above potential biomarkers, would be highly beneficial. Regardless, Aβ
and/or proteins that interact with it may be the most useful due to their key roles in
AD pathology. The use of Aβ as a biomarker is discussed in detail below.

1.4.6 Aβ as a Biomarker for AD Diagnosis
1.4.6.1 Aβ and PET Imaging
Fibrillar amyloid deposits in the brain of living persons can be visualised by PET, using
amyloid-imaging

agents

such

as

[18F]1,1-dicyano-2-[6-(dimethylamino)-2-

naphthalenyl]-propene, more commonly known as

18

F-DDNP, and N-methyl-[11C]2-(4'-

methylaminophenyl)-6-hydroxybenzothiazole, known as PiB (Klunk, et al., 2004;
Nordberg, 2004). While PiB only detects amyloid burden (Ikonomovic, et al., 2008),
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F-DDNP is believed to detect both amyloid and NFT (Shin, et al., 2008). Studies have

demonstrated that AD patients in the early stages can be differentiated from healthy
controls by PiB-PET imaging and an inverse correlation has been shown between PiB
retention and glucose metabolism in the brain (Klunk, et al., 2004).

1.4.6.2 Aβ in CSF
Currently, the most promising biomarkers for the diagnosis of early AD appear to be
CSF levels of Aβ42 together with total tau (t-Tau) and hyperphosphorylated tau (tau
phosphorylated at residue 181, P-tau181P), which are clearly linked to the different
pathological hallmarks of AD. This combination of biomarkers has been shown to be
able to differentiate AD from normal ageing and other diagnoses (Blennow, 2004), as
well as identifying which individuals are likely to convert from SMC or MCI to AD
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(Mattson, et al., 2009; Diniz, et al., 2008; Visser, et al., 2009). Nevertheless again, the
value of CSF biomarkers is limited clinically as a routine diagnostic test for AD, as the
collection of CSF is highly invasive and side effects are common (Williams, et al., 2008).
Blood would be preferential for the identification of potential biomarkers as it is
inexpensive and simple to collect, and is not particularly invasive.

1.4.6.3 Aβ in Plasma
A number of studies have focused on the detection of Aβ as a biomarker in blood, yet
with inconsistent results (Graff-Radford, et al., 2007; Fukumoto, et al., 2003).
Although plasma levels of Aβ have been shown to be increased in familial types of AD
(Scheuner, et al., 1996), this trend is less clear in sporadic forms, with considerable
overlap between controls and AD cases. In addition it appears that levels of plasma Aβ
increase with age, which may lend a confounding factor (Mayeux, et al., 1999).
Overall, it appears that plasma Aβ is elevated prior to amyloid deposition, though after
some deposition occurs there is a concomitant, progressive reduction in plasma levels
(Kawarabayashi, et al., 2001; Kuo, et al., 2000; Schupf, et al., 2008). This suggests that
peripheral Aβ may be a source for cerebral accumulation of the peptide, it may also
mean that less cerebral Aβ is reaching the circulation. Longitudinal studies support the
theory that elevated plasma Aβ is a risk factor for AD (Mayeux, et al., 1999; Mayeux, et
al., 2003). The pattern of plasma Aβ levels over time may explain why various crosssectional studies have found such a broad overlap between controls and sporadic
cases (Fukumoto, et al., 2003; Vanderstichele, et al., 2000). It has also been shown
that Aβ can pass from CSF to plasma and vice versa through the blood-brain barrier
(BBB), however there is no correlation between Aβ levels in these biological fluids,
indicating contributions from both CNS and peripheral tissues (Le Bastard, et al., 2009;
Mehta, et al., 2000; GhersiEgea, et al., 1996).
Several studies have investigated the plasma Aβ42/Aβ40 ratio as a possible indicator of
AD risk. In general, it appears that a low Aβ42/Aβ40 ratio may be associated with
increased risk of AD and/or MCI (Graff-Radford, et al., 2007; Abdullah, et al., 2007; Van
Oijen, et al., 2006; and reviewed by Koyama, et al., 2012). Interestingly, it may be an
increase of the Aβ40 species relative to Aβ42 that causes this decrease, as some studies
have not found a change in Aβ42 levels (Van Oijen, et al., 2006; Abdullah, et al., 2007).
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However, a recent meta-analysis showed that there was no change in Aβ40 levels,
while there was a slight reduction in Aβ42 levels, albeit non-significant (Song, et al.,
2011). Furthermore, in longitudinal studies it was shown that baseline levels of Aβ and
the Aβ42/Aβ40 ratio were marginally higher in AD patients but again these results were
non-significant. Another study found that the Aβ42/Aβ40 ratio was not affected by
APOE genotype, contrary to individual concentrations of plasma Aβ40 and Aβ42
(Blennow, et al., 2009). This may indicate that the Aβ42/Aβ40 ratio in plasma could be
more beneficial as a biomarker than individual Aβ42 and Aβ40 levels, or could be used in
conjunction with other biomarkers. In accordance with a number of other studies,
findings from the AIBL study (see Chapter 2, Materials and Methods for details) have
found lower levels of plasma Aβ42, and thus a decrease in the Aβ42/Aβ40 ratio in AD
patients when compared with healthy controls (HC) (Lui, et al., 2010). In addition, it
was found that the levels of Aβ42 as well as the Aβ42/Aβ40 ratio were negatively
correlated with brain Aβ load. These results are consistent with findings from the AIBL
follow-up at 18 months, which also showed a reduction of Aβ42 in MCI individuals and
healthy controls who converted to MCI during this period (Rembach, et al., 2013). This
suggests that although plasma Aβ may have limited usefulness as a single biomarker
for AD, it may have some clinical value for early detection of AD when used in
conjunction with other biomarkers.
Although the current literature on plasma levels of Aβ is inconsistent, this
inconsistency may also be due to methodological difficulties and different techniques.
Results from the AIBL study acknowledged differences in results when using different
commercial kits to measure Aβ levels, as well as various confounding covariates (Lui, et
al., 2010; Rembach, et al., 2013). ELISA-based methods may fail to detect Aβ which is
bound to other proteins or differentiate between Aβ oligomers and free Aβ, resulting
in only a portion of the total peptide being measured (Portelius, et al., 2008; Kuo, et
al., 1999; Abdullah, et al., 2007). In a study by Xia, et al. (2009), using a specially
designed ELISA for the purpose of detecting Aβ oligomers, they found that oligomeric
and monomeric levels of Aβ were strongly associated. In a study by James & Mamo
(2005), they demonstrated that the presence of lipids with Aβ in vitro can alter the
predominant form of Aβ, and sequester it, rendering it unavailable for detection by
commonly used methods. In addition, it has been shown that in gel-based techniques,
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denaturing conditions can liberate these oligomers or bound proteins, increasing total
levels of measurable Aβ (Portelius, et al., 2008). Various other methodological factors
have also been demonstrated to confound results (Vanderstichele, et al., 2000),
indicating a need for a methodological standard for measurement of this protein (and
likely other proteins) in plasma. It is more than likely that one blood protein marker
will not be sufficient to diagnose pre-clinical AD, with adequate specificity and
sensitivity. There are many plasma proteins that are being investigated for their
potential as a biomarker. The following will be a discussion on those that are directly
related to my project, ApoE, insulin and IDE.

1.5 Apolipoprotein E
Apolipoprotein E (ApoE) is a 34 kDa, 299-residue polymorphic protein that has been
strongly implicated in the pathogenesis of AD (Sheng, et al., 1996; Mahley, et al., 2006;
Strittmatter, et al., 1993(a); Corder, et al., 1993). The APOE gene on chromosome 19
that encodes ApoE has three alleles, ε2, ε3 and ε4. The three ApoE protein isoforms
differ by substitutions at residues 112 and 158, with ApoE2 containing cysteine at
these positions, ApoE4 containing arginine at both positions, and ApoE3 having an
arginine substitution at only residue 158 (Bentley, et al., 2002). To date, ε4 is still the
major genetic risk factor for LOAD, being significantly overrepresented in LOAD cases
compared with controls (Kaur & Balgir, 2006; Saunders, et al., 1993; Strittmatter, et al.,
1993(a)). Generally, the ε3 variant of APOE appears to be the “wild-type” allele, with a
frequency of 60-70% in the general population, while the ε4 variant has a frequency of
only 15-20% (Mahley, et al., 2006). The ε2 allele seems to have some protective effect
against AD, however in the general population, its frequency is only 5-10%.

1.5.1 Association of APOE genotype with AD
A number of studies have investigated the association of APOE genotype with AD.
Most have found that the ε4 allele is significantly associated with an increased risk for
developing AD, in a dose-dependent manner (Kaur & Balgir, 2006; Corder, et al., 1993;
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Saunders, et al., 1993). Corder, et al. (1993) found that the risk for AD increased from
20% for individuals without an ε4 allele, to 47% in individuals with one ε4 allele, and to
91% in individuals homozygous for the ε4 allele.
Not only is the risk for developing AD increased by the ε4 allele, but also the age of
disease onset has been shown to be significantly decreased in a dose-dependent
manner (Corder, et al., 1993). Hence, ε4/ε4 homozygotes have been found to develop
AD earlier than their heterozygotic ε4/ε3 and ε4/ε2 counterparts. For individuals
without an ε4 allele, Corder, et al. (1993) found the mean age of onset was 84.3 years,
while the ages of AD onset for ε4 heterozygotes and ε4 homozygotes were 75.5 years
and 68.4 years, respectively. In addition, the ε4 allele has been associated with
accelerated brain atrophy rates, in both cognitively normal individuals and AD patients,
also in a dose-dependent manner (Chen, et al., 2007; Agnosta, et al., 2009). Rebeck, et
al. (1993) also showed that ε4/ε4 AD patients had significantly greater amyloid plaque
deposition when compared with ε3/ε3 AD patients.

1.5.2 Functions of ApoE
The ApoE protein is a normal component of certain lipoproteins, and as such has
functional roles in lipid (including cholesterol and lipid soluble vitamins) transport and
clearance in the body (Mahley, 1988), and in the brain it plays a role in neuronal
growth, maintenance and repair (Ignatius, et al., 1986; Cedazo-Mínguez, 2007). ApoE
functions as a ligand in receptor-mediated endocytosis of lipoprotein particles. In
plasma, ApoE proteins are found on lipoproteins in association with other
apolipoproteins, whereas in the brain ApoE and two other apolipoproteins, ApoJ and
ApoA-1, are predominantly found in high density lipoprotein (HDL)–like particles (Kim,
et al., 2009)
ApoE is generated predominantly in the liver and brain, but also in much smaller
amounts in most other tissues (Bentley, et al., 2002). The isoforms of ApoE have
different affinities for the blood lipoproteins, with ApoE2 and ApoE3 showing
preferential affinity for HDL while ApoE4 binds preferentially to VLDL (Weisgraber &
Mahley, 1996).
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1.5.3 APOE and AD
While the APOE ε4 genotype has been confirmed as a risk factor for AD, the
mechanism of pathogenesis is less clear. The ApoE protein has been localised within
both SP and NFT, indicating a direct interaction with components of these lesions
(Sheng, et al., 1996; Namba, et al., 1991). Many other pathogenic changes observed
in AD have also been associated with ApoE, including NFT formation, oxidative stress,
and dysfunction of lipid regulation, synaptic plasticity and cholinergic function
(reviewed by Cedazo-Mínguez, 2007), indicating how important ApoE may be in AD
pathogenesis.
Abnormal cholesterol and lipid metabolism has been associated with the pathogenesis
of AD, with high total plasma cholesterol suggested as a risk factor (Roher, et al., 1999;
Notkola, et al., 1998), however some studies have shown a decrease in cholesterol and
lipid levels in AD patients compared with controls (Siest, et al., 2000). In addition, it
has been reported that AD patients have higher serum levels of the detrimental LDL
cholesterol, and lower levels of the beneficial HDL cholesterol than control cases
(Roher, et al., 1999; Kuo, et al., 1998). Kuo, et al., (1998) also demonstrated a positive
correlation between total and LDL cholesterol levels, and cerebral levels of Aβ42,
independent of APOE genotype. It is feasible that either low levels or dysfunction of
the ApoE protein may contribute to AD pathology independently of the ε4 allele,
possibly due to abnormal lipid transport or metabolism.
Due to the discovery of ApoE in amyloid plaques and CAA, studies were carried out to
ascertain whether ApoE could bind Aβ directly, and it was found that ApoE can bind to,
and facilitate the fibrillogenesis of Aβ in an isoform-dependent fashion, suggesting a
role as a “pathological chaperone” (Strittmatter, et al., 1993(b); Wisniewski &
Frangione, 1992, p237; Wisniewski, et al., 1994; LaDu, et al., 1994). The differences in
amino acids between ApoE2, ApoE3 and ApoE4 appear to differentially affect the
binding interactions within the protein, as well as to other molecules such as Aβ (LaDu,
et al., 1994; LaDu, et al., 1995), and there was in vitro evidence that ApoE4 could bind
Aβ peptides more avidly than the other two isoforms, potentially explaining why
ApoE4 increases AD risk.
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However, the association of ApoE with lipids is also a determinant of its binding affinity
toward Aβ (Tokuda, et al., 2000). Not only does the binding affinity increase following
lipidation, it also changes the isoform-specific differences (LaDu, et al., 1995). It was
then found that the efficiency of complex formation between lipidated ApoE and Aβ
follows the order of ApoE2 > ApoE3 >> ApoE4 (Tokuda et al., 2000).
Since the binding efficiency of ApoE isoforms to Aβ correlates inversely with the risk of
developing AD, it was then hypothesised that ApoE2 and ApoE3 may enhance the
clearance of Aβ, compared to ApoE4 (Hone, et al., 2003; Yang, et al., 1999). To
complicate the story further, later studies have since also found in AD-model
transgenic mouse studies that a complete lack of ApoE results in no deposition of true
plaques and much less Aβ deposition overall, which would not be expected if ApoE’s
major interaction with Aβ was to facilitate clearance. Other in vivo studies that
involved crossing AD-model mice with ApoE knock-in mice demonstrated a clear
isoform-dependent (E4>E3>E2) effect on Aβ accumulation (Bales et al., 2009; Kim et
al., 2009). Due to such apparently conflicting results, it is still not clear whether
increasing or decreasing brain ApoE levels would be therapeutic against AD
development.
The ApoE isoforms also appear to have different neurotrophic properties, with E3
facilitating, and E4 inhibiting neurite outgrowth, respectively (Nathan, et al., 1994).
Studies have shown that ApoE, and in particular E4, may exacerbate the neurotoxicity
of Aβ (Manelli, et al., 2007), and may also be directly toxic to neurons when not
associated with lipids (Cedazo-Mínguez, et al., 2001). Overall, ApoE appears to be
intimately involved with many of the pathogenic mechanisms which are characteristic
of AD.

1.5.4 ApoE in plasma
As with Aβ, there has been contention regarding the levels of ApoE in plasma.
Although it has been demonstrated that APOE genotype has an effect on serum levels
of the ApoE protein, with ε4 carriers having the lowest levels and ε2 carriers the
highest, it has been suggested that APOE genotype and protein levels may affect AD
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risk independently (Schiele, et al., 2000; Siest, et al., 2000). Indeed, there does not
appear to be consistency between reports on AD diagnosis and plasma ApoE protein
levels. Studies have found both increased levels (Taddei, et al., 1997) and decreased
levels (Siest, et al., 2000), and some have found no difference (Scacchi, et al., 1999;
Slooter, et al., 1998). Preliminary studies of the AIBL cohort have been promising, with
total plasma ApoE levels being able to differentiate SMC and MCI patients from either
HC or AD patients, with the lowest levels occurring in APOE ε4 homozygotes and the
highest in healthy controls (Martins, 2009). Moreover, plasma ApoE4 levels have also
been measured, and could differentiate between AD patients, MCI patients and
controls, with AD patients once again having the lowest levels (AD<MCI<HC). In
addition, as previously mentioned, there was an inverse correlation between ApoE4
levels and Aβ42 levels in the plasma regardless of disease status. These results indicate
that plasma levels of total ApoE and ApoE4 may be good candidates as early diagnostic
biomarkers, particularly together with other blood biomarkers. However, it should be
taken into account that some independent factors may alter levels of plasma ApoE,
such as geographical location (Schiele, et al., 2000), levels of the cholesterol
transporter ABCA1 (Hirsch-Reinshagen, et al., 2009), and other biological factors such
as age, gender and body mass index (BMI) and possibly certain medications (VincentViry, et al., 1998). In addition, methodological differences may have contributed to the
inconsistencies in previous literature.

Similar to the data for plasma Aβ,

standardisation of methodological procedures for the measurement of ApoE in plasma
would be highly beneficial. It has also been demonstrated that expression levels of
ApoE correlate with the formation of SP and levels change with disease progression
(Barger, et al., 2008; Kuo, et al., 2000).

1.6 Aβ Degradation and Clearance
The removal of Aβ from the CNS may occur via several mechanisms. Firstly, according
to the well-characterised “peripheral sink hypothesis”, cerebral Aβ has been shown to
be transported across the blood brain barrier (BBB) and into the peripheral circulation,
facilitated by the LDL receptor-related protein-1 (LRP-1) (Shibata, et al., 2000;
DeMattos, et al., 2001). This efflux appears to be isoform-dependent, with studies
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showing a slower rate of clearance across the BBB of Aβ42 in comparison to Aβ40 (Bell,
et al., 2007). Once in the periphery, Aβ-binding agents may bind to the peptide and
prevent its return to the CNS (Sagare, et al., 2007; Takata, et al., 2007). However, free
peripheral Aβ may enter the CNS due to the BBB’s bi-directional nature, assisted by the
receptor for advanced glycation end products (RAGE) (Deane, et al., 2003). It is
therefore probable that the degradation and/or binding of Aβ to other agents in the
periphery could be of importance to its accumulation in the brain.
Another mechanism for cerebral Aβ clearance is by transport through perivascular
drainage pathways into the CSF, and subsequently into the peripheral circulation via
the blood-CSF barrier (Zlokovic, et al., 2005; Preston, et al., 2003).

Failure of

components of this mechanism may have a role in both vascular and parenchymal
deposits of Aβ, and may be related to the development of CAA.
The elimination of Aβ from the CNS can also potentially occur via proteolytic
degradation. A number of proteases have been shown to degrade Aβ including insulindegrading enzyme (IDE), neprilysin (NEP), endothelin-converting enzyme (ECE),
angiotensin-converting enzyme (ACE), the uPA/tPA-plasmin system, cathepsin D,
gelatinase A, gelatinase B, matrix metalloendopeptidase-9, coagulation factor Xia,
antibody light chain c23.5 and hk14, and α2-macroglobulin complexes (Wang, et al.,
2006; Miners, et al., 2008a). Of these, IDE has attracted considerable interest as a
primary regulator of Aβ levels, and accumulating evidence suggests that it may have a
role in AD pathology via this interaction with Aβ.

1.6.1 Insulin-Degrading Enzyme
Insulin-Degrading Enzyme (IDE) (EC 3.4.24.56, formerly known as EC 3.4.22.11), also
known

as

insulysin,

insulin

protease

and

insulinase,

is

a

110

kDa

thiolmetalloendopeptidase which consists of 1019 amino acid residues (Selkoe, 2001;
Affholter, et al., 1988). The high degree of evolutionary conservation in both exonic
and intronic sequences of IDE suggests an important role in cellular function (Qiu &
Folstein, 2006). It is a multi-functional protein, with some of its identified roles being
1) regulation of peripheral insulin levels, 2) processing of antigenic proteins destined
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for the major histocompatibility complex (MHC) (Parmentier, et al., 2010), 3)
regulating cellular proteasome activity (Bennett, et al., 2000(b)) and 4) playing a role in
cell survival and differentiation (Tundo, et al., 2012; Kayalar & Wong, 1989). It was
also reported by Li and associates (2006) that IDE was a receptor for the varicellazoster virus, however this has since been found to be controversial (Carpenter, et al.,
2010).

Other important functions for IDE include regulation of steroid-related

signalling (Kupfer, et al., 1994), and also notably being responsible for the clearance of
amyloidogenic peptides (Farris, et al., 2003; and reviewed in Authier, et al., 1996(a)).
IDE is expressed in almost all tissues of the body, including the brain, where it is highly
expressed in cerebral neurons (Bernstein, et al., 1999; Kuo, et al., 1993). Studies have
also shown that it is produced and secreted by microglial cells in association with
exosomes (Tamboli, et al., 2010; Qiu, et al., 1997) as well as astrocytes (Jiang, et al.,
2008). IDE has been detected in most peripheral tissues, including the lung, skeletal
muscle, skin, breast, testes and several blood cell types, as well as the liver and kidney
which are believed to be the primary organs responsible for the clearance of
peripheral Aβ (Kuo, et al., 1993; Hone, et al., 2003). In addition, its presence has been
reported in endothelial and smooth muscle cells, and pericytes within cerebral
microvessels; areas of Aβ deposition in cerebral amyloid angiopathy (CAA), which often
co-exists with AD (Morelli, et al., 2004; Gao, et al., 2004). Interestingly, it has also
been detected in AD senile plaques, indicating a role for IDE in plaque pathology
(Bernstein, et al., 1999).
At a subcellular level, IDE is mainly located in the cytosol (Akiyama, et al., 1988;
Authier, et al., 1996(b)), however it has also been localised to peroxisomes (Kuo, et al.,
1994), endosomes (Hamel, et al., 1991), exosomes (Bulloj, et al., 2010), rough
endoplasmic reticulum (RER) (Qiu, et al., 1998), plasma membranes (Seta & Roth, et
al., 1997; Goldfine, et al., 1984) and recently, lipid rafts associated with the plasma
membrane (Bulloj, et al., 2008). In addition, it has been detected within proteasome
complexes (Bennett, et al., 2000(b)), and has also been found secreted into the CSF
(Qiu, et al., 1998). A longer, mitochondrial isoform of IDE has also been confirmed in
vitro, this mitochondrial isoform is generated from an alternative translation start site
41 amino acids upstream of the first Met of cytosolic IDE, and the additional amino
acid sequence forms a mitochondrial targeting sequence (Leissring, et al., 2004). This
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isoform has been shown to exist in the human brain and recently has been
demonstrated to regulate mitAβ (Leal, et al., 2013). It is highly likely that IDE found in
different subcellular locations of IDE controls different pools of Aβ; where
mitochondrial IDE regulates mitAβ, cytosolic IDE regulates intracellular Aβ, and
membrane-bound IDE most likely degrades extracellular Aβ.
Most of the expressed IDE has been reported to be the 110kDa isoform, with the
membrane-bound isoform having a molecular weight of 115kDa (Vekrellis, et al.,
2000). However, some older studies have reported other molecular weights including
80kDa (Burghen, et al., 1972), 150-160kDa (Kolb & Standl, 1980), 135kDa (Yokono et
al., 1981), 170kDa and 60kDa (Camberos, et al., 2001). While these discrepancies may
be due to methodological differences or analyses of different tissues and species, it is
possible that multiple forms exist. A truncated isoform of IDE has also been identified
which has been reported in the National Centre for Biotechnology Information (NCBI)
database

(Reference

sequence

NP_001159418.1,

http://www.ncbi.nlm.nih.gov/protein/NP_001159418.1). This form is identical to the
464 amino acid residues on the C-terminal end of the full-length protein. This may
correspond to the 60kDa protein reported. However, this isoform is unlikely to be
active in degrading Aβ as it does not contain the catalytic site required for catabolism.
In agreement with this, it has been shown experimentally that the C-terminal half of
IDE is not catalytically active (Li, et al., 2006). The molecular weights stated in the
UniProtKB database (http://www.uniprot.org/uniprot/P14735) for the full-length and
the truncated IDE isoforms are 117.968kDa and 54.240kDa, respectively. At the
commencement of this project, there were no published results of IDE in blood or
plasma so it was unknown what isoforms may be present in this biofluid. However, a
paper published very recently is, to our knowledge, the first to detail IDE activity in
human serum in AD and MCI patients (Liu, et al., 2012(a)). The results of this study
suggest that AD and MCI have lower IDE activity levels when compared with healthy
controls (n = 216). However, only 8.7% of this cohort were MCI individuals (n = 19),
and 7.4% were AD patients (n = 16), therefore this study may not have sufficient power
to form a solid conclusion.
Farris and colleagues (2005) identified an alternative full-length human isoform of IDE
which was generated as a result of alternative splicing, which they termed “15b-IDE”.
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This isoform was similar to the canonical isoform (termed “15a-IDE”) with the
exception of exon 15, and was shown to exist in both the cytosol and in the
mitochondria of human brain and liver. The 15b-IDE isoform was demonstrated to
have an impaired ability to degrade insulin and Aβ, when compared with 15a-IDE, and
it was also found that both isoforms could exist intracellularly as either homodimers or
heterodimers. Hence, an increase in the ratio of 15b-IDE:15a-IDE isoforms could
potentially have a negative effect on Aβ and/or insulin degradation.

1.6.1.1 Structure and Function of IDE
IDE was first discovered around 60 years ago due to its ability to degrade the insulin B
chain (Mirsky & Broh-Kahn, 1949), and has since been found to cleave a variety of
other substrates, including amylin (Bennett, et al., 2000(a)), β-endorphin (Safavi, et al.,
2006), insulin-like growth factors I and II (IGF-I and IGF-II) (Roth, et al., 1984), glucagon
(Duckworth & Kitabchi, 1974), atrial natriuretic peptide (ANP) (Müller, et al., 1991),
transforming growth factor-alpha (TGF-α) (Garcia, et al., 1989), bradykinin, kallidin
(Malito, et al., 2008), somatostatin (Ciaccio, et al., 2009) and the APP intracellular
domain (AICD), which is cleaved from APP during Aβ processing by γ-secretase
(Edbauer, et al., 2002; Venugopal, et al., 2007). However, AD researchers suddenly
developed significant interest in this enzyme when it was discovered that IDE was also
found to degrade Aβ (Kurochkin & Goto, 1994; Qiu, et al., 1998; McDermott & Gibson,
1997; Chesneau, et al., 2000) (Figure 1.2). Although IDE is known to bind and degrade
a wide range of substrates, it has a preferential affinity for insulin (Qiu, et al., 1998;
Duckworth, 1988; Edbauer, et al., 2002).

However, unlike most enzymes which

recognise substrates via sequence specificity, IDE appears to have conformational
specificity for its substrates, many of which share a similar secondary structure – can
form beta strands, and have a tendency toward amyloidogenesis (Kurochkin, 1998;
Kurochkin, 2001; Bennett, et al., 2000(a)). It is therefore possible that it may have a
primary function in the prevention of amyloid formation and deposition by degrading
potentially amyloidogenic peptides.
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Figure 1.2 The IDE protein in complex with an
Aβ peptide. (Shen, et al., 2006)
The N-terminal domain of IDE is green, and Cterminal domain is red. The Aβ peptide (blue) is
shown within the degradation chamber of the
IDE protein.

IDE can be divided into two subunits, the N-terminal half and the C-terminal half (IDEN and IDE-C, respectively) of approximately 55 kDa each, which are joined by a loop
comprised of 28 amino acids (Shen, et al., 2006). These subunits interact with each
other to form a triangular crypt which engulfs and binds its substrates to the internal
catalytic site before hydrolysing them at specific residues, favouring smaller substrates
which are less than 6kDa with few positively-charged residues at the C-terminus
(Duckworth, et al., 1998; Shen, et al., 2006). IDE can also be divided further into four
domains, with domains 1 (AA 43-285) and 2 (AA 286-515) comprising IDE-N, and
domains 3 (AA 542-768) and 4 (769-1016) comprising IDE-C (Shen, et al., 2006). The
active catalytic site of IDE is located in domain 1, and residues His108, Glu111, His112
and Glu189, which associate with a zinc ion, have been demonstrated to be crucial for
normal activity of the enzyme (Shen, et al., 2006; Perlman & Rosner, 1994; Song, et al.,
2005).
IDE displays allosteric kinetic properties with evidence suggesting that the enzyme
usually exists in a closed conformation, but shifts to an open conformation when
activated. This has been shown to occur by each half rotating away from each other.
One proposed mechanism responsible for this appears to be a disruption in hydrogen
bonding at the IDE-N and IDE-C interface; it has been confirmed that mutations in this
region which dislocate this interface between domains 1 and 4, promote the open
conformation and hence substantially increase the catalytic activity of the enzyme
(Shen, et al., 2006; Im, et al., 2007). It has also been demonstrated that the open
conformation can be initiated by the binding of nucleotide polyphosphate anion
regulators such as ATP, to a cationic distal exosite located primarily in domain 4, within
the catalytic chamber (Shen, et al., 2006; Im, et al., 2007; Noinaj, et al., 2011).
Although ATP was first reported to be an inhibitor, the regulation of IDE by nucleotide
27

polyphosphates appears to be concentration-dependent, and at physiological
concentrations ATP activates the enzyme to increase hydrolysis of small peptide
substrates (Camberos & Cresto, 2007; Song, et al., 2004). It is possible that other
anions may also regulate IDE in this way (Noinaj, et al., 2011 (b)). IDE’s ability to be
activated selectively through the polyphosphate cationic exosite could be useful in
developing drug targets for this mechanism, and synthetic compounds have been
identified which can activate the enzyme nearly 7-fold in this manner (Cabrol, et al.,
2009).
In addition to the active site in domain 1, a distal site which binds peptide substrates
has been identified in domain 2, also within the catalytic cavity. The binding of small
peptides to this site is also thought to be involved in allosteric kinetics and activation.
This is supported by studies of mutations in this region which have been found to
eradicate these properties (Noinaj, et al., 2011 (a)). However, the distal site appears to
be a distinct site from the anion-binding site, as activation of IDE by the small peptide
bradykinin was largely unaffected by an excess of either ATP or triphosphate (Song, et
al., 2004). Larger IDE substrates such as insulin and Aβ have been demonstrated to
bind to this distal site via their N-terminus, while simultaneously binding to the active
site, inducing a change in substrate conformation toward β-strands. This mechanism
has been proposed as a way of positioning larger substrates for cleavage via the active
site, and in addition may also indicate a means of locking IDE in the closed
conformation due to electrostatic charges (Leissring, et al., 2010). Smaller substrates
less than 12 amino-acids in length are unable to bind to both sites simultaneously,
however may act as heterotropic activators if they have a stronger affinity for the
distal site than the active site, as in the case of bradykinin (Amato, et al., 2009; Song, et
al., 2003; Noinaj, et al., 2011 (a)). Binding to both the active site and distal site
simultaneously by larger peptides such as insulin, has been shown to eliminate both
allosteric behaviour and activation by ATP and small peptide substrates, possibly by
either physical blocking of the cationic binding site/s and/or steric hindrance.
Experimental evidence suggests that via peptide binding to this site, IDE can be
selectively activated toward particular substrates; for example dynorphin B-9 increases
the rate of Aβ1-40 degradation but inhibits insulin degradation (Song, et al., 2003).
Similarly, somatostatin, has been shown to positively regulate the degradation of Aβ
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by IDE (Tundo, et al., 2012; Ciaccio, et al., 2009), and interestingly, reduced levels of
somatostatin have been implicated both in the pathology of AD, and also as part of
normal ageing (Ciaccio, et al., 2009; Gavilán, et al., 2007). This feature of selective
activation by small peptides could offer a potential target for Aβ-reducing therapies for
AD.
As well as activation by small peptides and phosphates, IDE activity has also been
found to be regulated by calcium, manganese, magnesium and zinc ions (Duckworth,
et al., 1990; Ebrahim, et al., 1991) with zinc being essential for its function. It was
demonstrated recently that a single exposure of lead can impair IDE activity in vitro,
and increase the intracellular accumulation of Aβ (Behl, et al., 2009). One theory that
was put forward to explain this mechanism involved lead replacing the zinc ion at the
catalytic site, being a bivalent cation itself. Physiological levels of these cations,
therefore, are likely to be influential in regulating IDE catalytic activity.
IDE also requires free thiol groups for its proteolytic activity and this seems to be
related to its cysteine residues.

Studies have shown that alkylation, oxidation,

nitrosylation or glutathionylation may modify cysteine-related thiols and cause
complete or partial inhibition of the enzyme (Neant-Fery, et al., 2008; Shinall, et al.,
2005; Malito, et al., 2008; Cordes, et al., 2011).

While alkylation of thiols is

irreversible, nitrosylation and glutathionylation appear to be reversible modifications.
Oxidation may inhibit IDE directly, or indirectly via oxidised glutathione. These effects
could therefore provide another mechanism for IDE dysfunction in AD.
The aggregation status of IDE is also important in regulating its function, and IDE has
been found to exist normally as a mixture of monomers, dimers and tetramers in
equilibrium, with dimers and tetramers being the dominant species (Song, et al., 2003;
Song, et al., 2004). The dimer is reportedly the most active form. Evidence suggests
that ATP shifts the aggregation status of IDE towards the monomeric form, and
increases its affinity for degrading smaller peptides such as bradykinin and dynorphin
B-9, without effect on larger peptides like insulin and Aβ (Song, et al., 2004). In
addition, the monomeric variant of IDE does not appear to be activated by small
peptides or ATP, and displays classic Michaelis-Menten kinetics rather than allosteric,
indicating that the association of two or more subunits has a cooperative effect (Song,
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et al., 2010). Thus the balance of these species is important in the overall function and
enzymatic activity of IDE.
As mentioned previously, IDE appears to have many roles in human physiology, as well
as disease pathology, one of them being its association with the development of type 2
diabetes, otherwise known as diabetes mellitus type 2 (DM2) (Furukawa, et al., 2008;
Karamohamed, et al., 2003; Kwak, et al., 2008). Numerous studies have also found an
association between DM2 and AD (Ott, et al., 1996; Ott, et al., 1999; Muller, et al.,
2007). However, the putative mechanisms which may be common to both DM2 and
AD, or mechanisms for DM2 increasing risk of AD have yet to be elucidated. This link
between DM2 and AD will be discussed in more detail below.

1.7 Type 2 Diabetes, Insulin Resistance Syndrome and AD
One of the precursors to DM2 is the insulin resistance syndrome (also called
“Metabolic Syndrome” or “Syndrome X”), which has also been implicated in the
development of AD.
syndrome

include

Characteristics associated with DM2 and insulin resistance
insulin

resistance,

high

peripheral

levels

of

insulin

(hyperinsulinemia), hyperglycaemia and impaired glucose tolerance, obesity,
hypertension, and abnormal peripheral lipid and cholesterol concentrations, among
others (Kuusisto, et al., 1997; Chang, 2008; Wehr, et al., 2006; and reviewed by Craft,
2006 and Mielke & Lyketsos, 2006). Accumulating evidence suggests that in particular,
insulin resistance, hyperinsulinemia and DM2 are significant risk factors for AD (Ott, et
al., 1996; Ott, et al., 1999; Kuusisto, et al., 1997; Muller, et al., 2007).
Cross-sectional studies have demonstrated that DM2 is considerably over-represented
in AD patients in comparison with non-AD controls (Kuusisto, et al., 1997; Ott, et al.,
1996; Stewart & Liolitsa, 1999). In addition, it has been shown in numerous large,
population-based longitudinal studies that DM2 may significantly increase the risk of
AD (Peila, et al., 2002; Ott, et al., 1999; Leibson, et al., 1997; Xu, et al., 2004;
Arvanitakis, et al., 2004). However, some studies have not found an association
between DM2 and risk of AD, or the results may have demonstrated a trend but were
non-significant (Luchsinger, et al., 2001; MacKnight, et al., 2002; Hassing, et al., 2002).
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A study by Peila et al. (2002) found that AD patients with co-morbid diabetes had an
increase in the prevalence of SP, NFT and CAA, and especially in carriers of the APOE ε4
allele. In addition, both AD and DM2 have an increased prevalence with age (von
Strauss, et al., 1999; Davidson, 1979). This may suggest that a common pathological
mechanism related to ageing may be implicated in both DM2 and AD.
Pathological similarities exist between DM2 and AD; cytotoxic amyloid is deposited in
both conditions. While fibrillar Aβ is deposited in particular brain regions in AD
(Glenner & Wong, 1984), most DM2 patients have similar amyloid deposits in the islets
of Langerhans in the pancreas, composed of fibrillar islet amyloid polypeptide (IAPP),
also known as amylin (Cooper, et al., 1987; Westermark, et al., 1987). Studies have
shown that amylin may aggregate intracellularly in the β-cells prior to cell loss, and
subsequently form extracellular deposits after the death of cells (O’Brien, et al., 1995;
O’Brien, et al., 1994). It is possible that AD pathology follows the same pattern. In
fact, several studies have shown that Aβ is produced intracellularly and overproduction or reduced clearance may be significant in AD pathology (Wertkin, et al.,
1993; and reviewed by Gouras, et al., 2010). Interestingly, islet amylin deposits
contain ApoE akin to Aβ deposits, indicating a role for ApoE in amyloid formation in
both conditions (Wisniewski & Frangione, 1992). Further evidence linking DM2 to AD
comes from a study by Janson et al. (2004), which found that AD patients are more
likely to have islet amyloid deposits than non-AD controls. The same study found that
non-AD DM2 patients are not more likely to develop SP, although when diffuse or
neuritic plaques were present, they correlated with the duration of DM2. The results
are different to what has been found in other studies, as their data support the
hypothesis that patients with Alzheimer disease are more vulnerable to DM2 (not the
other way around). The results need to be replicated in other studies, using a larger
cohort.
DM2 patients have been shown to be more susceptible to cognitive impairment, and
to have lower MMSE scores than controls (van den Berg, et al., 2005; Grodstein, et al.,
2001; Sinclair, et al., 2000; Arvanitakis, et al., 2004). Interestingly, it has been reported
that medications that promote the secretion of insulin further increase the risk for AD
in diabetics (Luchsinger, et al., 2001; Ott, et al., 1999; Ott, et al., 1996). It is possible,
therefore, that the link between DM2 and AD may be related to insulin.
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1.7.1 Insulin and AD
Insulin, well known for its role in regulating peripheral glucose levels, is principally
produced and secreted by β-cells in the pancreas, and insulin secretion occurs in
normal physiology in response to elevated plasma glucose (Martini, 1998). It is also
known that insulin plays an important role in the CNS, gaining access from the
periphery by receptor-mediated transport across the BBB (Banks, et al., 1997). It has
been shown that insulin plays a role in long-term potentiation (LTP), a process which
underlies memory formation (Craft, 2006).

In addition, animal studies have

demonstrated that neurons can generate insulin, and insulin receptors have been
found in key areas of the brain involved with AD pathology and cognitive function
(Devaskar, et al., 1994; Schechter, et al., 1988; Craft & Watson, 2004). Due to the role
of insulin in glucose regulation, it is likely that insulin abnormalities impair cerebral
glucose metabolism, a characteristic which has been demonstrated in both AD and
MCI brains (De Santi, et al., 2001). Elevation of peripheral insulin levels has also been
shown to increase insulin concentration in the CNS (Wallum, et al., 1987). However, it
has been shown that insulin levels in the brain are actually lower in AD patients (Craft,
et al., 1998) and evidence suggests this can be caused by the presence of
hyperinsulinemia-related insulin resistance in the periphery, causing a reduction in
brain insulin uptake through the blood-brain barrier (Baura, et al., 1996; Craft, et al.,
1998; Kaiyala, et al., 2000). In addition, insulin resistance in the CNS may be associated
with impairment of several molecules involved in the insulin signalling cascade (Talbot,
et al., 2012). Conversely, hyperinsulinemia could also inhibit Aβ degradation in the
periphery itself through competitive inhibition of IDE, leading to Aβ accumulation both
peripherally and then in the CNS by migration across the BBB.

1.7.1.1 Hyperinsulinemia
Hyperinsulinemia, referring to high peripheral levels of insulin, is an early feature of
DM2 in many individuals, occurring well prior to altered glucose metabolism (Weyer,
et al., 2000). Chronic hyperinsulinemia leads to, correlates with, and therefore is used
as a measure of insulin resistance. It is also used as a predictor of DM2 (Laakso, 1993;
32

Lundgren, et al., 1990; Weyer, et al., 2000). Research suggests that hyperinsulinemia
is also a significant risk factor for AD (Luchsinger, et al., 2004), and in contrast to the
findings that brain insulin levels decrease in AD as mentioned above, numerous studies
have demonstrated elevated serum insulin levels in AD subjects in comparison with
controls (Kuusisto, et al., 1997; Weyer, et al., 2000; Muller, et al., 2007; Carantoni, et
al., 2000; Fujisawa, et al., 1991). This association has been demonstrated in nondiabetic individuals too, suggesting that this feature of DM2 may be more relevant to
AD risk than just DM2 itself (Luchsinger, et al, 2004; Stolk, et al., 1997). In support of
this, other evidence suggests that AD severity also correlates with plasma insulin levels
(Craft, et al., 1998).
Two studies have shown that hyperinsulinemia is a significant risk factor in AD patients
who do not possess the APOE ε4 allele, indicating that these factors may affect risk
independently (Kuusisto, et al., 1997; Craft, et al., 1999). Moreover, Craft et al. (1998)
found that AD subjects with only one APOE ε4 allele or no ε4 alleles had higher plasma
insulin levels than ε4/ε4 homozygotes. Craft et al. (2003) later found that memory
facilitation occurred with peripheral insulin infusions at a similar dose for normal
adults and APOE ε4/ε4 homozygotes with AD, however AD patients with one or less ε4
alleles required much higher doses for the same effect. These results may indicate
that those who are not ε4/ε4 homozygotes may have reduced sensitivity to insulin.
Another large study found no association between diabetes and AD risk overall,
however when stratified for APOE ε4 genotype, this study found an association only in
APOE ε4 negative individuals (Akomolafe, et al., 2006). These results indicate that
insulin metabolism dysfunction may be a relevant pathological mechanism for the
approximate 50% of AD patients who do not possess the ε4 allele, in respect to AD risk.
It may indicate that for those individuals with APOE ε4 alleles, the supposed metabolic
deficiencies caused by the ApoE4 protein are sufficient to increase AD risk, whereas in
non-APOE ε4 individuals, AD may develop after long-term insulin resistance and
associated effects.

1.7.1.2 Insulin and Cognition
Accumulating evidence suggests that insulin is involved in a number of key roles in
cognition and memory. In support of this, insulin has been shown to play a part in
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regulating cerebral levels of neurotransmitters which are involved in memory and
cognition, such as dopamine, acetylcholine and norepinephrine (Craft & Watson,
2004). In vivo studies have shown memory facilitation in rats after insulin was directly
applied to the brain (Park, et al., 2000) and after intravenous insulin infusion in
humans (Craft, et al., 2003). The administration of insulin via nasal pathways has the
effect of elevating levels in the CNS without raising peripheral levels, and several
studies have also demonstrated improvements in memory and cognitive function after
such treatment both in diabetic mice, and in early AD and MCI patients (Craft, et al.,
2012; Francis, et al., 2008; Reger, et al., 2006; Reger, et al., 2008(a); Reger, et al., 2008
(b)). Interestingly, in the study by Reger et al. (2008(a)), memory facilitation only
occurred in APOE ε4 negative subjects while memory was impaired in ε4 carriers. It is
possible that this outcome was dose-related as it is in contrast to previous reports
(Craft, et al., 2003).
Conversely, DM2 and elevated plasma insulin has also been associated with impaired
cognition and memory (Stolk, et al., 1997; Vanhanen, et al., 1998; Marfaing-Jallat, et
al., 1995). The discrepancy in these results may be due to the fact that insulin-induced
memory facilitation is attenuated at higher (and lower) doses, indicating an optimum
level is required for cognitive improvement (Craft, et al., 2003; Reger, et al., 2008 (a)).
In addition, APOE genotype-related differences in insulin sensitivity may have affected
this result. The study by Stolk et al. (1997) excluded diabetics and dementia patients
from the analysis, which may have skewed the results, and significant results were only
obtained for females. Similarly, Vanhanen’s study (1998) was only on elderly glucose
intolerant individuals. Much more likely, however, is that acute hyperinsulinemia may
facilitate memory and cognition, while chronic hyperinsulinemia appears to produce
deleterious effects.

1.7.1.3 Insulin and Aβ
Insulin has been demonstrated to regulate Aβ levels, both in the CNS and peripherally,
although the mechanisms that control Aβ levels are unclear. An in vivo study on
healthy adults found that Aβ levels in the CSF were elevated after intravenous insulin
infusion (Watson, et al., 2003). In vitro studies have found that insulin stimulates Aβ
production via upregulation of APP trafficking and increased secretion of Aβ into the
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extracellular milieu (Gasparini, et al., 2001). The same study showed that insulin also
increased extracellular levels of Aβ by impairing its degradation by IDE. This has been
supported by other studies that have found that hyperinsulinemia has an inhibitory
effect on Aβ degradation (Qiu, et al., 1998; Kulstad, et al., 2006). Moreover, it has
been recently demonstrated that AD patients respond differently to insulin when
compared to healthy controls (Kulstad, et al., 2006). While levels of plasma Aβ
dropped in normal adults after receiving a peripheral insulin infusion at optimal levels,
the AD patients consistently showed an increase in Aβ levels in a dose-dependent
manner. This indicates that AD patients may have impaired insulin clearance which
could be attributable to IDE dysfunction or a reduction in levels of IDE, which then
leads to accumulation of Aβ.

1.7.1.4 Hypercholesterolemia, Insulin and IDE
There are other sources of evidence which link insulin and IDE with Aβ regulation.
Hypercholesterolemia has been associated with AD, MCI and increased levels of Aβ in
some studies (Pappolla, et al., 2003; Kivipelto, et al., 2001), and research has shown
that a high-fat diet in AD-model transgenic Tg2576 mice induces insulin resistance and
subsequently impairs insulin signalling in the brain (Ho, et al., 2004). Concomitantly,
there is a decrease in IDE activity, and an increase in both Aβ40 and Aβ42 levels and
brain plaque load.

The suggested role of insulin signalling in IDE regulation is

supported by a similar study by Zhao et al. (2004). Obesity and elevated free fatty
acids (FFA), features related to hyperinsulinemia, have also been shown to impair
insulin degradation via direct non-competitive inhibition of IDE (Hamel, et al., 2003;
Eckel, et al., 2005).
Insulin potentially affects other aspects of AD pathology. It has been demonstrated
that both insulin and insulin-like growth factor-1 (IGF-1) regulate the phosphorylating
protein kinase, glycogen synthase kinase-3β (GSK-3β) to stimulate transient tau
phosphorylation in vitro and in vivo, which may be involved in the formation of NFT
(Engel, et al., 2006; Lesort, et al., 1999; Lesort & Johnson, 2000; Hong & Lee, 1997; Ho,
et al., 2004). IGF-1 not only has neurotrophic properties and a role in apoptosis, but
also regulates levels of IDE and therefore may modulate Aβ levels, and as mentioned
above may be involved in tau phosphorylation through regulation of GSK-3β (Sharma,
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et al., 2008; Costantini, et al., 2006). Interestingly, IGF-1 is also a substrate for IDE
degradation, and low levels have been found in AD brains (Steen, et al., 2005). In
addition, IGF-1 signalling has an effect on GSK-3α, which has been shown to regulate
APP

processing (Phiel,

et

al.,

2003).

Another

study has shown

that

hypercholesterolemia increases production of Aβ via GSK-3α, and decreases clearance
of Aβ due to a reduction in levels of IDE, through alterations in the IGF-1 signalling
pathway (Sharma, et al., 2008). This association between hypercholesterolemia and
low IDE is supported in another study (Prasanthi, et al., 2008).

Therefore,

hypercholesterolemia may also play an important part in the link between DM2 and
AD.

In addition, hyperinsulinemia has been shown to promote inflammatory

responses in the CNS, a feature associated with AD (Craft, 2005; Aisen, 1997; Fishel, et
al., 2005). Research has found that the degree of chronic inflammation correlates with
both cognitive decline (Parachikova, et al., 2007) and brain atrophy (Cagnin, et al.,
2002) and therefore may exacerbate neuronal degeneration. Increased peripheral
insulin levels have been found to lead to increased cerebral levels of pro-inflammatory
cytokines such as interleukin-1β (IL-1β), interleukin-6 (IL-6) and tumour necrosis factorα (TNF-α), all of which have been reported to be elevated in AD and have been located
in SP and their related glial cells in Alzheimer’s patients (Craft, 2005; Sokolova, et al.,
2009; Griffin, et al., 1989; Bauer, et al., 1991; Fishel, et al., 2005; Dickson, et al., 1993).
Interestingly, anti-inflammatory cytokines have been shown to increase both IDE
expression as well as Aβ degradation (Shimizu, et al., 2008). Inflammation is a known
characteristic of DM2, and there is mounting evidence that chronic inflammation is an
important early stage of AD pathogenesis (reviewed by Bhamra & Ashton, 2012). In
fact, inflammation-linked proteins such as alpha-2 macroglobulin and clusterin
(amongst others) are considered to be good potential biomarkers of early stages of AD
(Thambisetty, et al., 2010; reviewed by Bhamra & Ashton, 2012). Chronic activation of
microglia in neurodegenerative disorders such as AD, Parkinson's disease (PD),
Huntington's disease (HD), amyotrophic lateral sclerosis (ALS) as well as inflammatory
conditions of CNS such as multiple sclerosis (MS) results in overall upregulation of proinflammatory cytokines and chemokines in the brain. As a result, many therapeutic
strategies aim to alleviate neurodegenerative disease progression by reducing
inflammation (Reinhart, et al., 2011; reviewed by Holmes, 2013; Cappellano, et al.,
2013; Rizzo, et al., 2013).
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1.8 Hyperinsulinemia, IDE and AD
Insulin resistance and hyperinsulinemia are related conditions, such that each
condition induces the other (Craft, 2006). Therefore it is plausible that low levels of
plasma IDE may lead to hyperinsulinemia, which leads to insulin resistance and
possibly the development of DM2.

In addition, IDE deficiency-induced

hyperinsulinemia could reasonably lead to the accumulation of Aβ in the periphery,
due to competitive inhibition.
pathology.

This could potentially instigate or exacerbate AD

In accordance with this, it has in fact been demonstrated that

hyperinsulinemia can increase Aβ levels in the periphery, and also in the CSF and brain
(Fishel, et al., 2005). Certain diets may exacerbate this problem too, if they lead to
high peripheral lipid levels and/or chronic insulin release.
In other studies, including studies by our group in the AIBL study, it has been shown
that greater levels of exercise have a protective effect against AD, and also induce
positive effects on AD-related pathological biomarkers (Brown, et al., 2012(a); Brown,
et al., 2012(b); Liang, et al., 2010). This may be, in part at least, associated with
exercise-induced elevation of IDE levels, as a recent study in rats confirmed that IDE
levels increase, causing a decrease in insulin levels, as a result of even short-term
exercise (Kim, et al., 2011).
It has been demonstrated that levels of IDE decline as a result of ageing, in areas of the
brain susceptible to AD pathology (Caccamo, et al., 2005); for example IDE levels were
found to decline in hippocampal regions, an area commonly affected by AD pathology,
but not in the cerebellum, a region of the brain where Aβ deposits are rare. This
ageing-related, regional decline in IDE levels supports the concept that insulin and IDE
levels are relevant in AD pathogenesis.

Insulin resistance and chronic

hyperinsulinemia, as previously mentioned, can also have other effects relevant to AD,
such as reducing insulin transport across the BBB into the CNS (Baura, et al., 1996).
This may lead to reduced levels of insulin in the brain, attenuating the benefits of
insulin on cognition and memory.
If hyperinsulinemia forms the basis for the putative relationship between AD and DM2,
IDE could be a good candidate as a plasma biomarker for AD. Leissring and colleagues
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(2003) examined the effect of genetic over-expression of IDE in APP transgenic mice.
The results showed a significant decrease in both soluble and insoluble cerebral Aβ
levels, with a concomitant prevention or reduction in formation of SP when compared
with APP transgenic controls. In addition, premature death was attenuated in the
mice over-expressing IDE. This result paralleled a previous in vitro IDE over-expression
study, where extracellular levels of both Aβ40 and Aβ42 were also found to be
significantly reduced (Vekrellis, et al., 2000). In this cell culture study, the reduction of
Aβ was inhibited by insulin incubation, highlighting the competition between insulin
and Aβ for IDE, and its preference for insulin. Another over-expression study on
Chinese hamster ovary cells demonstrated a significant reduction in both extracellular
and intracellular Aβ levels (Sudoh, et al., 2002). Interestingly, IDE has been shown to
degrade monomeric but not oligomeric or fibrillar Aβ, indicating that a reduction in
monomeric Aβ may be sufficient to prevent plaque formation, and that IDE may not
recognise/bind aggregated Aβ (Leissring, et al., 2003; Vekrellis, et al., 2000; Mukherjee,
et al., 2000). However, in a more recent study, it was shown that IDE is responsible for
a significant portion of the degradation of fibrillar Aβ in monocyte-derived
macrophages (Yamamoto, et al., 2008). It is likely that protein chaperone-mediated
disassembly of the fibrils may occur before the degradation by IDE. It has also been
suggested that monomeric and polymeric Aβ may exist in equilibrium, where reduction
of monomers may instigate the disassembly of pre-formed fibrillar aggregates
(Leissring, et al., 2003). A study by Lazarov et al. (2002) supports this equilibrium
hypothesis by demonstrating that SP formation is reversible. If this is the case, then
IDE may be ideal as a therapeutic target against AD.
Further support for the concept that IDE is important in Aβ breakdown comes from in
vivo studies which have found that levels of Aβ in the brain elevate as a response to
deletion of the IDE gene, in transgenic knockout mouse models (Farris, et al., 2003;
Miller, et al., 2003). While Miller et al. (2003) found an increase of both Aβ40 and Aβ42,
Farris and colleagues (2003) demonstrated that murine IDE knockouts not only display
chronic elevation of Aβ levels, but also develop hyperinsulinemia and impaired glucose
tolerance, characteristics of DM2. In these experiments, levels of AICD were also
found to be elevated, signifying impaired clearance. The function of AICD is not
precisely known, however it has been suggested that it may have a role in nuclear
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signalling and apoptosis (Edbauer, et al., 2002; Kinoshita, et al., 2002). In addition,
AICD is thought to be neurotoxic and it appears to regulate GSK-3β (Kim, et al., 2003;
Ryan & Pimplikar, 2005).

This suggests a mechanism that is separate from Aβ

accumulation which could be involved in AD pathogenesis.
Farris et al. (2004) demonstrated further evidence for IDE’s possible involvement in the
development of LOAD, in a study on Goto-Kakizaki (GK) rats. The GK rat is a wellcharacterised rat model of DM2, with typical features such as hyperinsulinemia and
postprandial hyperglycaemia, and mutations within the IDE gene (Fakhrai-Rad, et al.,
2000). This study showed that partial IDE hypofunction was sufficient to induce
elevations in neuronal Aβ levels; however increases in steady-state levels of Aβ did not
occur until the age of 14 months, indicating a possible compensatory effect in the early
stages of life. This may reflect possible mechanisms for the development of LOAD. In
addition, the levels of Aβ in this study compared along with knockout and overexpression studies appear to indicate a dose-dependent effect of IDE on Aβ, further
supporting the importance of expression levels on Aβ homeostasis (Farris, et al., 2003).
Overall the results indicate that impaired expression and/or activity of IDE are
sufficient to generate symptoms of AD pathology.
Clinical evidence supports the premise that IDE may be integral to the development
and progression of AD. A study by Perez et al. (2000) found that the activity level of
IDE was significantly lower in AD brains compared with controls. While this study did
not measure the cerebral levels of the full length IDE protein due to detection
difficulties, levels of a 44 kDa fragment of IDE in the cytosolic fraction were shown to
be decreased in AD brains compared with controls. These findings were supported by
a larger-scale study by Cook et al. (2003), who found decreased levels of IDE protein
and mRNA in hippocampal regions of AD brains compared with control brains.
Interestingly, this reduction was only observed in APOE ε4 carriers, which suggests that
the ε4 allele either directly affects IDE expression, or interacts with an independent
process of AD pathology which leads to reduced IDE expression. This finding of
decreased levels of IDE in hippocampal regions was supported in a murine study,
where homozygous triple-transgenic models of AD (Oddo, et al., 2003) showed
significantly lower levels of IDE in the hippocampus compared with wild-type and
hemizygous transgenic mice (Caccamo, et al., 2005).

In accordance with these
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findings, a new transgenic mouse model of AD has been reported to demonstrate
reduced cortical expression of IDE prior to the appearance of SP (Ferretti, et al., 2011).
Conversely, studies have also shown that levels of IDE are increased in certain regions
of the AD brain in comparison with controls, the enzyme can be localised to neurons
and has also been associated with SP (Bernstein, et al., 1999). It is possible that small
sample size, lack of APOE ε4 stratification, and/or region-specific alterations in IDE
levels may be causing these conflicting results. Miners et al. (2008a) demonstrated
that hippocampal IDE expression differs depending on the region examined; with
CA3/4 neurons showing the highest expression and CA1 the lowest, and significantly
lower levels being found in AD patients compared with controls in the CA2 and CA3/4
regions. In this study, the lowest levels were also associated with the most advanced
AD cases. Furthermore, slight differences were found between APOE ε4 carriers and
non-carriers with respect to IDE expression levels; however they failed to reach
significance.

1.8.1 IDE Catalytic Activity
It is plausible that it is a combination of decreased activity and expression levels, or
simply impaired activity alone that leads to decreased Aβ degradation. Although there
have been reports of increased IDE activity in AD individuals compared with healthy
controls in some studies (Miners, et al., 2009), numerous studies have reported
reduced activity levels compared with healthy controls (Kim, et al., 2007; Perez, et al.,
2000; Qin & Jia, 2008; Zhao, et al., 2007; Morelli, et al., 2004). The relatively recent
study by Zhao and colleagues (2007) showed impairment in both IDE levels and activity
in membrane fractions of the hippocampus in MCI patients compared with normal
adults. Moreover, both activity and concentration levels continued to decrease during
the progression from MCI to AD, and were inversely correlated with cerebral Aβ42
levels. This supports the notion that IDE dysfunction and impairment of expression are
present and apparent in the prodromal stages of AD. The importance of IDE activity is
further highlighted in the study by Morelli et al. (2004). This study examined the levels
and activity of IDE in cerebral microvessel fractions, in AD patients with concomitant
CAA, compared with non-AD controls. The results found that although expression
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levels of IDE were markedly comparatively increased in AD/CAA patients, the activity
levels were significantly decreased.
One recent study on familial EOAD patients with a novel PS1 mutation found that
accumulation of extracellular and intracellular Aβ42 was always associated with
decreased activity levels of IDE, both in the cytosol and on the plasma membrane (Qin
& Jia, 2008).

Moreover they discovered that elevated intracellular, but not

extracellular Aβ42, was also associated with decreased expression levels of IDE. This
indicates that intra- and extracellular IDE may function in different ways. It has
recently been shown that cytosolic IDE has a longer half-life than membrane-bound
IDE, which has a considerably faster turnover (Bulloj, et al., 2008). This localisation,
and IDE activity can be modulated by changes in membrane lipid composition, and has
been shown to result in alterations in Aβ degradation. This may explain a mechanism
for an IDE-lipid interaction which impacts on IDE activity levels.

As previously

mentioned, the novel 15b-IDE isoform (Farris, et al., 2005), could also suggest a
mechanism for the reduced activity levels observed in AD, whether it exists
physiologically as a homodimer or with 15a-IDE as a heterodimer.
There are a number of other factors that may contribute to the impairment of IDE
activity. It has been shown that ubiquitin, a regulatory protein which has been
suggested as having a possible role in AD and other neurodegenerative diseases, binds
to and inhibits the activity of IDE, and this interaction was found to be modulated by
insulin (Grasso, et al., 2008; Saric, et al., 2003) indicating it is affected via a competitive
mechanism. This would be likely to affect the degradation of Aβ in the same manner.
Ubiquitin has also recently been found to be a substrate of IDE (Ralat, et al., 2011).
Pathological mechanisms of AD such as oxidative stress or intracellular accumulation of
Aβ could increase the levels of ubiquitin and therefore reduce IDE activity.
IDE activity has also been found to be reduced through impaired insulin signalling due
to diet-induced insulin resistance (Ho, et al., 2004), inhibition through elevation of
FFA’s (Hamel, et al., 2003) and elevated glucocorticoids (Kulstad, et al., 2005; Harada,
et al., 1996). Interestingly, the glucocorticoid cortisol has been found to be elevated in
the periphery of AD patients (Umegaki, et al., 2000; Hartmann, et al., 1997; Davis,
1986). A recent study showed that different types of fatty acids can differentially
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affect the expression of IDE as well, with saturated palmitic acid causing downregulation and polyunsaturated docosahexaenoic acid (DHA) causing the opposite
effect (Du, et al., 2010). Interestingly, saturated dietary fatty acids such as palmitic
acid have been shown to exacerbate AD pathology while unsaturated fatty acids such
as DHA are considered to be protective (Morris, et al., 2003; Patil, et al., 2007; Cole &
Frautschy, 2006). It is possible that this may be due in part to their effects on IDE
expression and activity.
As previously mentioned, the activity of IDE has also been shown to be inhibited by
cysteine-directed modifications such as alkylation, S-nitrosylation by nitric oxide (NO),
and oxidation or glutathionylation (Neant-Fery, et al., 2008; Cordes, et al., 2009;
Malito, et al., 2008; Shinall, et al., 2005). IDE activity has also been reported to be
positively regulated by the peptide hormone somatostatin, which is known to be
reduced in AD (Ciaccio, et al., 2009). In addition, the important discovery that fibrillar
Aβ binds to, and inhibits the activity of IDE, is also a very significant observation
(Chander, et al., 2007).

One or more of these factors may contribute to the

impairment of IDE activity and subsequent development of AD pathology. Overall the
results suggest a need to examine both expression levels and activity in conjunction
with each other to gain a more complete picture of IDE-related AD pathology.

1.8.2 IDE and Aβ Neurotoxicity
Another positive effect of IDE cleavage of Aβ is the subsequent neutralization of the
neurotoxic effects of the fragments produced. An in vitro study by Mukherjee, et al.
(2000) found that IDE reduced the cytotoxicity of both Aβ40 and Aβ42 in a dosedependent manner. However, while only 50 ng of IDE was sufficient to almost
completely eliminate the toxicity of Aβ40, a ten-fold increase in IDE was required to
neutralize Aβ42 to a similar degree. The significance of this difference is not clear,
however may reflect the differing degrees of neurotoxicity and/or propensity to
oligomerise, of each of the species. In addition, this study also showed that these
hydrolysed fragments of Aβ produced by IDE did not deposit on synthetic amyloid in
vitro. This further highlights a possible role for IDE in a therapeutic capacity.
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1.8.3 ApoE and IDE
While it is not known how the ApoE protein contributes to AD pathogenesis, it has
been reported that ApoE is essential for, and may assist with cerebral clearance of Aβ,
via degradation extracellularly by IDE and within microglia by IDE and its related
protease, neprilysin (NEP) (Jiang, et al., 2008). The capacity of ApoE in this degradative
facilitation is determined partly by isoform, with ApoE4 demonstrating a reduced
capability to assist this process, and ApoE2 being most efficient. In addition, this study
demonstrated the importance of ApoE lipidation status in the proteolytic clearance of
Aβ, with unlipidated ApoE also demonstrating a reduced capacity for facilitation
compared with the lipidated protein. This finding supports similar previous reports
that found that lipidation of ApoE is essential for effective Aβ clearance (Cole & Ard,
2000). Defects in the ATP-binding cassette transporter A1 (ABCA1) have been shown
to result in abnormally lipidated ApoE, and lead to a reduction of ApoE levels in the
CNS and plasma (Wahrle, et al., 2004; Hirsch-Reinshagen, et al., 2005). Studies on
ABCA1 deficiency have shown an increase in the levels of both soluble and insoluble
Aβ in murine brains (Wahrle, et al., 2005; Koldamova, et al., 2005), that cannot be
attributed to an increase in Aβ production (Hirsch-Reinshagen, et al., 2005).
Therefore, another possible mechanism for the development of AD pathology may be
related to the interaction between the ApoE and IDE proteins in the clearance of Aβ.
Another recent study by Du and colleagues (2009) demonstrated that IDE mRNA and
protein expression was down-regulated by ApoE4 in comparison to ApoE2 or ApoE3 in
rat primary hippocampal neurons and PC12 cells. The same study showed that ApoE is
required for normal IDE expression levels as APOE knockout mice had significantly
lower IDE levels than wild-type mice. By culturing hippocampal primary neurons from
these APOE knockouts and treating them with ApoE3-containing conditioned medium,
they showed that this IDE deficit could be rescued, however treating with ApoE4
containing medium had no effect. These effects could be attenuated by blocking the
N-methyl-D-aspartic acid receptor (NMDAR); in fact, by inhibiting this receptor they
showed an increase in IDE levels and a corresponding decrease in IDE levels when this
receptor was activated. This indicates that the regulatory effect of ApoE isoforms on
IDE levels is dependent on the NMDA receptor pathway.
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Other interactions appear to occur between IDE and APOE genotype to alter IDE
expression levels. Studies have shown that elderly individuals carrying the ε4 allele
have higher peripheral levels of the glucocorticoid cortisol than non-ε4 individuals
(Peskind, et al., 2001), as do AD patients (Umegaki, et al., 2000; Hartmann, et al., 1997;
Davis, 1986), and in a study of aged macaque monkeys, oral cortisol treatment was
found to cause a decrease in IDE mRNA and protein levels in both the frontal cortex
and the hippocampus (Kulstad, et al., 2005). It has also been reported that other
glucocorticoids interact with IDE to inhibit its capacity for insulin degradation (Harada,
et al., 1996). Overall this could suggest that the increased risk conferred by the ε4
allele may be partly due to an increase in glucocorticoid levels, affecting IDE expression
and activity.

1.9 IDE Levels in Plasma
IDE levels have been studied in regions of the brain, both in cytosolic and membrane
fractions, as well as in brain microvessels. It has been investigated in liver, kidneys,
erythrocytes, skeletal muscle, testes and ovaries, among other tissues, in both rodents
and humans (Miller, et al., 2003; Duckworth, et al., 1988; Morelli, et al., 2004;
Vekrellis, et al., 2000; Farris, et al., 2003; Duckworth, et al., 1990). IDE has also been
detected in extracellular biological fluids such as CSF and wound fluid (Qiu, et al., 1998;
Shearer, et al., 1997). It has been shown that the expression of IDE is ubiquitous (Kuo,
et al., 1993; Weirich, et al., 2008), and evidence also exists for the presence of an
enzyme with insulin-degrading capacity in human serum (Misbin, et al., 1981).
However, although the activity of IDE has been examined in blood in rudimentary
studies with respect to insulin degradation (Ionushas, et al., 1987; Ardy & Pontremoli,
1953), and more recently IDE expression has been detected in blood and all other
tissues examined (Su, et al., 2002), surprisingly it appears that no study at the
commencement of this project, had examined IDE protein or activity in blood, and
certainly not with respect to AD. However as mentioned previously, one very recent
study has been published on serum IDE activity but had low sample numbers in the AD
and MCI groups (Liu, et al., 2012(a)).
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Given the evidence associating hyperinsulinemia, elevated plasma Aβ levels and AD, it
would be highly beneficial to examine the blood concentration and catalytic activity of
this protease in a large cohort.

1.10 Genetic Linkage and Association of IDE
The gene for IDE is located on chromosome 10q23-q25 (Espinosa, et al., 1991;
Affholter, et al., 1990), and in addition to functional evidence supporting IDE as a
putative biomarker for AD, there is accumulating evidence that the region in and/or
around IDE may be genetically associated with both AD (Kehoe, et al., 1999; Myers, et
al., 2000; Bertram, et al., 2000; Ait-Ghezala, et al., 2002; Bian, et al., 2004; Liu, et al,
2007; Hamshere, et al., 2007; Vepsäläinen, et al., 2007; Mueller, et al., 2007; Bjork, et
al., 2006; Zuo & Jia, 2009; Carrasquillo, et al., 2010) and DM2 (Duggirala, et al., 1999;
Wiltshire, et al., 2001; Karamohamed, et al., 2003; Furukawa, et al., 2008; Zeggini, et
al., 2007). Moreover, as with many conditions, various studies on both dizygotic and
monozygotic twins have shown that genetic factors may account for a significant
proportion of the risk of LOAD (Petersen, et al., 2004; Bergem, et al., 1997; Gatz, et al.,
1997). A recent large study demonstrated an association between a novel IDE variant
and lower plasma Aβ40 levels and a reduced risk of LOAD. It was found that this
variation resulted in an increase in IDE mRNA expression (Carrasquillo, et al., 2010).
In addition, IDE has been linked to other quantitative indices (QTL) of AD, such as age
of onset (Li, et al., 2002; Blacker, et al., 2003; Prince, et al., 2003; Dickson, et al., 2008),
plasma Aβ levels (Ertekin-Taner, et al., 2000, Ertekin-Taner, et al., 2004), MMSE score,
memory and cognitive function, CSF levels of tau protein, cerebral Aβ and NFT load
(Prince, et al., 2003; McQueen, et al., 2007; Liu, et al, 2007; Blomqvist, et al., 2005;
Mueller, et al., 2007). Quantitative indices of DM2 such as elevated fasting plasma
glucose levels (Meigs, et al., 2002; Karamohamed, et al., 2003), plasma insulin levels
(Marlowe, et al., 2006; Gu, et al., 2004), and age of onset (Duggirala, et al., 1999) have
also been associated with the region in and/or around the IDE gene. A recent study by
Hong and colleagues (2008) also discovered an association between human life span
and IDE.
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Interestingly, some studies showed genetic association with IDE only in APOE ε4
negative individuals (Feuk, et al., 2005; Edland, et al., 2003; Zuo & Jia, 2009),
supporting findings of insulin resistance and hyperinsulinemia in non-ε4 carriers with
AD (Kuusisto, et al., 1997; Craft, et al., 1999), and an association between AD and DM2
only in non-ε4 carriers (Akomolafe, et al., 2006). This suggests that the effect of the
APOE genotype and IDE might affect risk independently, and may be of significance for
a subset of AD and DM2 sufferers. In addition, this also highlights the importance of
stratifying results by APOE genotype.
Although many studies have reported an association between the IDE gene and AD,
there are also studies that refute this association (Marlowe,et al.,2006; Ozturk, et al.,
2006; Nowotny, et al., 2005). It was suggested that these discrepancies could be due
to a number of factors including allele frequency, linkage disequilibrium and locus
variance in different populations, subject selection bias and genotyping errors.
Another common theme which occurs in some of these genetic analyses is that often
the association is only seen in males (Gu, et al., 2004; Hong, et al., 2008) or the study
only used men in their cohort (Marlowe, et al., 2006). Of course, in addition, it is not
possible to analyse every single nucleotide polymorphism within the limitations of a
single study. This may be another factor to consider when translating the data.
Although disease-causing mutations have not yet been discovered within the coding
region of the IDE gene, it is possible that mutations exist within the non-coding region.
These non-coding region mutations may affect the cap, tail, polyadenylation signal,
promoter or other regulatory sequences which may alter the gene product and/or its
expression or function (Knight, 2003). In accordance with this, a recent meta-analysis
of the literature found a significant positive association between the IDE
polymorphism rs1832196 and AD risk (Zhang, et al., 2013). This polymorphism is
located within an intronic sequence of IDE. Collectively, there is considerable evidence
supporting the genetic involvement of IDE in both AD and DM2 pathology.
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1.11 Summary and Project Hypothesis
For the moment, the only way to ascertain a definite diagnosis of AD is via postmortem analysis, and current diagnostic methods are not sufficient in the early or
prodromal stages of the disease for accurate diagnosis.

With the increasing

prevalence and incidence of AD in the ageing population, the identification of a
suitable biomarker, or set of biomarkers, for prognostic, diagnostic and therapeutic
monitoring purposes is becoming all the more imperative. In particular, a blood
biomarker would be highly beneficial due to the invasive nature, difficulties and
expense associated with current diagnostic procedures. Aβ is widely believed to be
central to the pathogenesis of AD, with increased accumulation as a product of an
imbalance between production and clearance of this peptide. The vast majority of AD
cases are of the non-familial and/or late-onset variety, and increasing evidence
suggests that impairment of Aβ clearance mechanisms may be the more important
factor in LOAD pathogenesis, rather than increased Aβ production.

Enzymes,

receptors and any other proteins involved in the clearance and/or degradation of Aβ
are therefore viable biomarker candidates.
IDE is a protease of interest, due to increasing evidence supporting its mechanistic
involvement in the regulation of Aβ and AD pathology, and genetic studies supporting
the existence of an AD risk locus, and AD QTL loci in the vicinity of the IDE gene on
chromosome 10q. In addition, IDE is associated with hyperinsulinemia and DM2,
which have both been suggested as potential risk factors for AD. IDE has also been
shown to interact with the ApoE protein and can be affected by APOE genotype. Some
gaps in current knowledge include the quantification and activity of IDE in the blood,
and the possible association of IDE expression and/or IDE activity levels with AD risk.
While numerous studies have reported associations between IDE and AD, replication
of these results has been inconsistent, and a number of factors may have led to these
discrepancies. An analysis of these variables in a large population would assist in
determining the associations between IDE and AD pathogenesis, as well as evaluate
the potential of IDE as a functional AD biomarker.
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Therefore, the project hypotheses are as follows:
1. The levels and catalytic activities of IDE in human plasma differ between clinical
classifications of AD, MCI and healthy controls.
2. The levels and catalytic activities of IDE in human plasma are affected by APOE
genotype.

To test these hypotheses, the particular aims of this project are:
1. To measure the levels of plasma IDE protein in a large cohort (n = 1000+).
2. To measure the catalytic activity of plasma IDE in a large cohort.
3. To determine if there is any relationship between IDE levels, catalytic activity, and
other biochemical markers including Aβ, ApoE and insulin in plasma between
AD/MCI affected individuals and healthy controls.
4. To determine if APOE ε4 genotype impacts upon the levels or catalytic activity of
plasma IDE.
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Figure 1.3 Representation of various factors associated with AD or DM2 which may affect IDE function. A number
of physiological conditions may negatively regulate the catalytic activity (yellow), expression levels (pink), or both
levels and activity (purple) of IDE. Low ApoE protein, indicated in blue, regulates the ability of IDE to degrade Aβ
independently of IDE levels or catalytic activity, and this has been shown to be modulated by the lipidation status of
ApoE. Individual factors or a combination of these may lead to an insufficiency of IDE to efficiently degrade Aβ and
lead to its accumulation in the periphery and/or the brain.
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Figure 1.4 Flowchart of how a reduction in IDE levels or activity may lead to the development of both AD and DM2.
Reduction of IDE levels or activity cause an insufficiency in both Aβ and insulin degradation, leading to their
accumulation in plasma. The increased proteins/peptides then compete further for IDE, causing a positive feedback
mechanism. The hyperinsulinemic state is also central to both conditions. This leads to an increase in amyloid
deposition in the brain (Aβ) and pancreas (ProIAPP/IAPP) which subsequently develops into DM2 and/or AD.
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CHAPTER 2 – Materials and Methods.
2.1 Materials
2.1.1 Antibodies
The antibodies used in this project are summarised in Tables 2.1 and 2.2. Figure 2.1
illustrates the epitopes on IDE to which each antibody binds.

Table 2.1 Commercial primary IDE antibodies.
Antibody
Ab 1(a) –
Batch 1
Ab 1(b) –
Batch 2

Catalogue
Number
AB9210

Ab 2

LS-C55007

Ab 3

ab28561

Ab 4

250706

Ab 5

AF2496

(M)Ab 7

H00003416A01
MMS-282R

Ab 8

GTX111664

(M)Ab 9

5282-1

Ab 6

•

PRIMARY IDE ANTIBODIES
Immunogen
Supplier
Host
Source
Chemicon Aust. P/L
(now
Rabbit
Synthetic rat
Merck/Millipore, VIC,
Australia)
LifeSpan Biosciences,
Synthetic
Inc. (Seattle, WA,
Goat
Human
USA)
Abcam (Cambridge,
Synthetic
Rabbit
UK)
Human
™
Abbiotec (San
Synthetic
Mouse
Diego, CA, USA)
Human
®
R&D Systems Inc.
Recombinant
(Minneapolis, MN,
Goat
Human
USA)
Abnova (Taipei,
Synthetic
Mouse
Taiwan)
Human
Covance (MA, USA)
Mouse
Human
GeneTex Inc.
Synthetic
Rabbit
(California, USA)
Human
Synthetic
Epitomics (CA, USA)
Rabbit
Human

Immunogen
Sequence

Formulation

AA200-250

Serum

AA914-924

Purified

AA238-416

Purified

N-terminus
(Not defined)

Purified

AA42-1019

Purified

AA 920-1019

Serum

AA 1-1019

Ascites

AA 349-585

Purified

AA 50-75

Tissue culture
supernatant

(M) denotes monoclonal antibody
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Table 2.2 Additional commercial non-IDE and secondary antibodies.
Antibody
GTX27793
(AL-01) (M)

Supplier
GeneTex Inc. (California,
USA)

Antibody
P0449

Supplier
Dako (VIC, Australia)
Chemicon Australia Pty.
Ltd. (VIC, Australia)
Chemicon Australia Pty.
Ltd. (VIC, Australia)

AP322P
AP326P

•

NON-IDE ANTIBODIES
Host
Immunogen
Human serum
Mouse
albumin
SECONDARY ANTIBODIES
Host
Classes
Goat
All

Epitope

Formulation

Full-length

Purified

Conjugate
HRP

Formulation
Purified

Rabbit

IgG

HRP

Purified

Mouse

IgG

HRP

Purified

(M) denotes monoclonal antibody
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1) Western Immunoblotting
2) Sandwich ELISA (Coating antibody)
3) Fluorometric Activity Assay

Sandwich ELISA (Detection antibody)

Ab 3 (238-416)
Ab 5 (42-1019)

Ab 1 (200-250)
Ab 4 (N-terminus)

AA1

MAb 9 (50-75)

Ab 8 (349-595)

Ab 2 (914-924)

Ab 6 (920-1020)

AA1019

MAb 7 (1-1019)

Figure 2.1

Diagram of IDE epitopes to which commercially-available antibodies bind.

Monoclonal antibodies are indicated by (M).
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2.1.2 Suppliers of Reagents
2.1.2.1 Proteins
The fluorogenic peptide substrate (Mca-R-P-P-G-F-S-A-F-K(Dnp)-OH, also called
Substrate V), ES005, and human recombinant IDE, 2496-ZN were purchased from
R&D Systems, Inc. (Minneapolis, MN, USA).

Recombinant His-tagged rat IDE,

407241, was purchased from Calbiochem/EMD Biosciences, Inc. (Merck KGaA,
Darmstadt, Germany). Lyophilized recombinant Aβ40 and Aβ42 was synthesized and
purchased from W.M. Keck Foundation Biotechnology Research Laboratory (Yale
University, New Haven, CT, USA). The custom-synthesized blocking peptide against
LS-C55007 primary antibody was purchased from Mimotopes Pty. Ltd. (Clayton, VIC,
Australia). The commercial blocking peptide (and immunogen) against antibody
ab28561 was purchased from Abcam (Cambridge, UK).

2.1.2.2 Other reagents
All de-ionized ultra-pure water (MQ H2O) was obtained from the usual laboratory
distilled water system, and filtered through the Sartorius Arium® (611DI) filtration
system (Sartorius AG, Göttingen, Germany).
Polyoxyethylene (20) sorbitan monolaurate (Tween-20), bovine serum albumin
(BSA),

4-(2-hydroxyethyl)-1-piperazineethanesulfonic

acid

(HEPES),

Trizma

Hydrochloride (Tris-HCl) (T-3253) and Ponceau S powder (78376) were all
purchased from Sigma-Aldrich Pty. Ltd. (Castle Hill, NSW, Australia).
NuPage® Novex 10% (NP0316BOX) and 4-12% (NP0336BOX) Bis-Tris 1.5mm x 15well pre-cast gels, NuPage® 4x lithium dodecyl sulfate (LDS) sample buffer (NP0007),
NuPage® 10x Reducing Agent containing 500 mM dithiothreitol (DTT) (NP0009),
NuPage® Antioxidant (NP0005), Novex® Sharp Pre-stained Protein Standard
(LC5800), NuPage® 20x MES SDS Running Buffer (NP0002-02) and NuPage® Transfer
Stacks – Regular Nitrocellulose (IB3010-01) were all purchased from Invitrogen™
Australia Pty. Ltd. (Mulgrave, VIC, Australia).
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Sodium chloride (NaCl), ethylenediaminetetraacetic acid tetra-sodium salt (EDTA),
ethanol absolute was purchased from Merck Pty. Ltd. (Merck KGaA, Darmstadt,
Germany). Fraction V bovine serum albumin (10 735 086 001) was purchased from
Roche Diagnostics Australia Pty. Ltd. (Castle Hill, NSW, Australia). AnalaR sodium
carbonate (Na2CO3) (10240.4H), AnalaR sodium hydrogen carbonate (NaHCO3)
(10247.4V), and sodium dodecysulfate (SDS) were all purchased from BDH
Chemicals Australia Ltd. (VIC, Australia). The Thermo Scientific Micro BCA™ Protein
Assay Kit (23235), Pierce Direct IP Kit (26148), Restore™ Western Blot Stripping
Buffer (21059) and Gelcode Blue Stain Reagent (Coomassie stain) (24592) were all
purchased from Thermo Fisher Scientific (Scoresby, Vic, Australia).
(193996),

1,1,1,3,3,3-hexafluoroisopropanol

[hydroxymethyl]aminomethane

(Tris)

(HFIP)

(152176)

was

Glycerol

(151245)

and

purchased

from

TrisMP

Biomedicals Australia (Formerly ICN Biomedicals Inc., Seven Hills, NSW, Australia).
Amersham ECL™ Western Blotting Detection Reagents (RPN2106), Amersham ECL™
Advance Western Blotting Detection Kit (RPN2135) and Amersham ECL™ Prime
Western Blotting Detection Reagents (RPN2232) were all purchased from GE
Healthcare Australia Pty. Ltd. (Rydalmere, NSW, Australia). Phosphate-buffered
saline (PBS) was purchased from Fisher Biotech International Ltd. (Wembley, WA,
Australia).

Complete Mini Protease Inhibitor Cocktail (11836153001) was

purchased from Roche Australia (Osborne Park, WA, Australia).

3,3’,5,5’-

Tetramethylbenzidine (TMB) Microwell Peroxidase Substrate System (50-76-00)
was purchased from Kirkegaard and Perry Laboratories Inc. (Maryland, USA). Block
Ace (BUF029) was purchased from AbD Serotec (Oxford, UK).
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2.1.3 Suppliers of Equipment
Aβ42 solution concentration was determined using an Implen Nanophotometer
(Version 7122, V2.0.0).

2.1.3.1 Western Immunoblotting
Proteins were resolved by sodium dodecyl sulphate-polyacrylamide gel
electrophoresis (SDS-PAGE) using the Invitrogen™ NuPage® Electrophoresis system,
using the XCell SureLock™ Mini-Cell Electrophoresis Blot Module and the
Invitrogen™ iBlot® Gel Transfer Device, both purchased from Invitrogen™ Australia
Pty. Ltd. (Mulgrave, VIC, Australia). Bands were visualised by densitometric analysis
using the Bio-Rad GS-800 Densitometer (Bio-Rad Laboratories Pty. Ltd., CA, USA).

2.1.3.2 ELISA/Fluorescent and BCA Protein Assay
IDE ELISA kit was purchased from Kamiya Biomedical Company (Seattle, USA). 96well microplates 655900 were purchased from Greiner Bio-One (Frickenhausen,
Germany), U16 MaxiSorp™ Modules 469264 and black F16 MaxiSorp™ Modules
475515 were purchased from Nunc (Rochester, NY, USA).

Microplates were

washed using either the Bio-Rad Immunowash Microplate Washer (Model 1575) or
the BioTek® Select Deep Well Microplate Washer (ELx405™, VT, USA). Proteins
were quantified using the Fluostar Optima Microplate Reader (BMG Labtech GmbH,
Ortenberg, Germany).
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2.2 Methods
2.2.1 The Australian Imaging, Biomarker and Lifestyle Flagship Study
of Ageing (AIBL) Cohort
Plasma samples to be analysed were sourced from the Australian Imaging,
Biomarker

and

Lifestyle

Flagship

Study

of

Ageing

(AIBL)

study

(http://www.aibl.csiro.au/) which has been well characterised (Ellis, et al., 2009).
Launched in November 2006, this longitudinal study includes participants recruited
from Perth, Western Australia (40%) and Melbourne, Victoria (60%). The primary
aim of this study has a focus on early detection, and prevention or delay of
Alzheimer’s disease, by research into a variety of diagnostic markers, biomarkers
and neuroimaging techniques. AIBL is also assessing the role of diet and exercise in
relation to the prevention of AD.
The AIBL cohort consists of 1112 individuals, of which 211 have AD, 133 have MCI
and 768 are healthy controls (HC) (Figure 2.2). Of the 768 HC participants, 396
reported having memory complaints that did not meet the criteria for MCI or
dementia. Using a multidisciplinary approach, all participants underwent extensive
clinical (including blood collection for biomarker analysis), neuropsychological and
lifestyle assessments at baseline, and neuroimaging with PiB-PET and MRI was
performed on approximately one quarter of the cohort. Consenting participants
are subsequently re-assessed at 18 month intervals until death. The exclusion
criteria included comorbid conditions that could affect cognitive function, including
non-AD dementias, uncontrolled diabetes, past serious head injury, current clinical
depression, history of stroke, and alcohol consumption exceeding two standard
drinks per day for women, and four standard drinks per day for men.
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180 NINCDS-ADRDA “Probable AD”
211 AD
31 NINCDS-ADRDA “Possible AD”

49 Single Domain
126 Amnestic
77 Multi Domain
133 MCI
1 Single Domain
7 Non-Amnestic
6 Multi Domain

396 Memory Complainers
768 HEALTHY CONTROLS
372 Non-Memory Complainers

Figure 2.2
(n=1112).

Classification of AIBL cohort subgroups at baseline by diagnosis
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2.2.2 Sample preparation
Blood collection details can be found in Ellis, et al., 2009. In summary, whole blood
from the participants was collected into three types of tubes; lithium-heparin,
serum and EDTA (with prostaglandin E1 added at a concentration of 33.3ng/mL to
EDTA tubes only). The tubes were divided into aliquots and stored in liquid
nitrogen, and after removal samples were subsequently stored at -80°C until use.
Immediately prior to assaying, plasma samples were thawed on ice, and then
centrifuged at 12,000 RPM for 15 minutes, and the supernatant collected. All
plasma samples used in this project were sourced from EDTA tubes unless
otherwise specified. It should be noted that separate subsets of the AIBL cohort
were used to measure full-length IDE levels by Western immunoblotting, total IDE
levels by ELISA, and IDE activity with very few samples in common between each
assay.

2.2.2.1 Methods used for the measurement of biomarkers other
than IDE
Testosterone, estradiol, total cholesterol, LDL/HDL cholesterol and insulin
measurements were collected by clinical pathology services PathWest Laboratory
Medicine WA (Perth) or Melbourne Health (Melbourne). With the exception of
insulin for which measurements were taken using serum samples, the remainder of
the test measurements from the clinical pathology services were taken from blood
plasma collected in Lithium-Heparin tubes or serum samples. Total testosterone
was measured using a chemiluminescent microparticle immunoassay.

Free

testosterone was calculated from total testosterone levels and sex-hormone
binding globulin (SHBG) levels. Estradiol was measured using a chemiluminescent
microparticle immunoassay. Total cholesterol was measured using an enzymatic
assay based on the formulation of Allain, et al., 1974 with modifications of this
procedure by Roeschlau, et al., 1974. HDL cholesterol was measured with an
Accelerator Selective Detergent method. LDL cholesterol was calculated using the
Friedewald formula (Friedewald, et al., 1972) from HDL cholesterol, total
cholesterol and triglyceride measurements (if triglycerides were < 4.5 mmol/L)
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otherwise if triglycerides were ≥ 4.5mmol/L, direct measurements were taken with
a Measured, Liquid Selective Detergent method. Insulin levels were measured
using a chemiluminescent microparticle immunoassay. An in-house sandwich ELISA
was used to measure the Aβ isoforms using EDTA-collected plasma as previously
documented (Mehta, et al., 2000). A commercial sandwich ELISA kit (ApoE4/Pan
ApoE ELISA, MBL International, Woburn, USA) was used to measure the levels of
plasma ApoE and ApoE4 using EDTA-collected plasma as previously documented
(Gupta, et al., 2011). DNA for the APOE genotyping was isolated from whole blood
using a Qiamp DNA blood Midikit (Qiagen) as per manufacturer instructions. APOE
genotyping was performed using either APOE TaqMan® SNP Genotyping Assays
(Life Technologies) for rs7412 (Assay ID: C____904973_10) and rs429358 (Assay ID:
C___3084793_20), or by amplification by polymerase chain reaction with restriction
enzyme digestion as previously detailed (Hixson & Vernier, 1990). Brain Aβ load
was determined by PET imaging using a radioactive imaging agent, Pittsburgh
Compound B (PiB) as previously detailed (Pike, et al., 2007).

2.2.3 Determination of plasma total protein content
The total protein content of human plasma was obtained with the Micro BCA™
Protein Assay kit (Pierce, 23235). To summarise, bovine serum albumin (BSA)
standards were prepared with MQ H2O, in the range of 0 – 80 μg/mL from a stock
concentration of 2.0 mg/mL. 150 μL per well of each standard dilution was loaded
in duplicate onto a standard 96-well microplate (Greiner Bio-One). Plasma was
diluted to 1:100, 1:1000 and 1:2000 with MQ H2O, and 150 μL of the plasma
dilutions were loaded in quadruplicate. A working reagent was prepared with 25
parts Pierce reagent MA, 24 parts reagent MB, and one (1) part reagent MC as per
manufacturer instructions, and 150 μL was added to the wells containing the
standards and plasma dilutions. The plate was agitated for 30 seconds, then
covered and incubated at 37°C for two hours. The plate was then allowed to cool
to room temperature and absorbance was read on a Fluostar Optima microplate
reader (BMG Labtech GmbH, Ortenburg, Germany) at 562 nm. A standard curve
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was generated from the BSA standard dilutions and the plasma total protein
concentration was interpolated from this curve.
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2.2.4 IDE levels in human plasma by Western immunoblotting
2.2.4.1

Sodium

dodecyl

sulfate

polyacrylamide

gel

electrophoresis (SDS-PAGE) separation of proteins
All samples were prepared using NuPage® LDS Sample Buffer and Reducing Agent
(Invitrogen) on 10% Bis-Tris 1.5mm 15 well pre-cast gels with MES SDS running
buffer, unless otherwise specified. Proteins were resolved by SDS-PAGE under
reducing conditions.

Total protein concentration of undiluted pooled control

plasma (PCP) was determined to be 59.503 μg/ul. IDE as a positive control was
prepared from purified recombinant rat IDE (rrIDE) diluted in MQ H2O to a
concentration of 20 ng/μL using a 1 mg/mL stock solution, with the final content
per well being 100 ng. Plasma samples were diluted 1:7 with MQ H2O (1μL per
well), including an internal standard of pooled human plasma (PCP) which was
loaded onto each gel. Total protein content after dilution was calculated to be
59.503 μg per load for PCP. LDS Sample Buffer and reducing agent (Invitrogen™)
were added in the ratio of 8:3:1 (IDE standards or diluted plasma: LDS Sample
buffer: reducing agent). The standards and plasma samples were heated at 70°C
for 10 minutes. Where rat liver, human frontal cortex or zebrafish brain were used
in optimization steps, the samples were heated for 5 mins at 95°C. The samples,
PCP and positive control were loaded onto NuPage® 10% Bis-Tris mini pre-cast gels,
using the XCell SureLock™ Mini-Cell Electrophoresis Blot Module (Invitrogen™), and
NuPage® 1x MES SDS Running Buffer (Invitrogen™) for inner and outer chambers.
500 μL of NuPage® Antioxidant was added to the inner chamber immediately prior
to loading samples. Proteins were separated according to their molecular weight
along with pre-stained molecular weight markers (in the range of 3.5 kDa to 260
kDa; Invitrogen™) by electrophoresis, at 100 V for 1.5 to 3 hours. The semi-dry
transfer of proteins to nitrocellulose membranes by electrophoresis was performed
using the iBlot® Dry Blotting System (Invitrogen™) on programme P3 for 8.5 mins.
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2.2.4.2 LS-C55007 immunoblotting protocol
Following electrophoretic transfer of the proteins, the nitrocellulose membranes
were incubated with tris-buffered saline (TBS, pH 7.4) containing 3% non-fat dairy
milk powder (NFDM) for one hour at room temperature with rocking, to block any
non-specific binding sites. No Tween-20 was included in the blocking buffer at this
stage to avoid the detergent loosely binding to the membrane and displacing the
NFDM, as this may lead to the Tween-20 being removed by subsequent washes in
TBST and leaving spaces for non-specific binding of the antibodies. After washing
twice for 2 mins in TBS containing 0.05% Tween-20 (TBST), the membranes were
then incubated with primary antibody LS-C55007 (LifeSpan Biosciences Inc.) diluted
1:5000 in TBST at 4°C overnight (approximately 18 hours) with rocking. Following
the overnight incubation, the membranes were washed twice for 2 mins, then 4
times for 3 mins each in TBST to remove unbound antibody. The anti-goat HRPconjugated secondary antibody (P0449) was then diluted 1:7500 in TBST and the
membranes were incubated for 1 hour at room temperature (RT) with rocking. This
was followed by washing twice for 2 mins and four times for 3 mins each in TBST to
remove any unbound secondary antibody, then two 3 minute washes in TBS to
remove any traces of Tween-20. The membranes were then incubated with ECL™
detection reagent (for 2 mins) for optimization only, or ECL Advance/Prime
detection reagents (GE Healthcare Australia P/L) prepared as per manufacturer’s
instructions for 5 mins and exposed to film for up to 1.5 hours to obtain the desired
signal intensity.

2.2.4.3 AB9210 immunoblotting protocol
Following electrophoresis, the membranes were incubated in TBS containing 5%
NFDM. Membranes were then incubated overnight with primary antibody AB9210
diluted 1:8000 in TBST containing 0.5% NFDM at 4°C as per the LS-C55007 protocol.
Following the overnight incubation, blots were washed three times for 10 min in
TBST, and then incubated with HRP-conjugated anti-rabbit secondary antibody
(AP322P) for 1 hour at RT as above. A further three 10 min washes in TBST and two
3 min washes in TBS followed. Secondary antibodies were detected by incubation
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in ECL™ detection reagent for 2 mins and exposure to film for up to 20 minutes to
achieve desired signal intensity.

2.2.4.4 ab28561 immunoblotting protocol
After electrophoretic transfer or stripping (stripping protocol detailed below in
section 2.2.4.5), the membranes were incubated in TBS containing 3% NFDM at 4°C
overnight with rocking. After washing twice in TBS, primary antibody ab28561 was
diluted 1:2000 (or 1:1000 for some optimization steps) in TBST containing 0.5%
NFDM and incubated for 2 hours at RT (rocking). Following primary antibody
incubation, membranes were washed as per LS-C55007 protocol and then
incubated in HRP-conjugated anti-rabbit secondary antibody, diluted 1:5000 in TBST
with 0.5% NFDM, for 1 hour at RT. The membranes were then washed and
incubated in ECL™ or ECL™ Prime detection reagent as per the LS-C55007 protocol,
and exposed to film for up to 30 mins to achieve desired signal intensity.

2.2.4.5 Stripping of antibodies from membrane
Membranes were stored between cellulose acetate sheets at RT prior to stripping.
After removing from acetate, blots were re-hydrated in TBS for 15 mins (no
rocking), and then washed in TBS for 7 mins (with rocking for all steps from here
on). Blots were then washed in 20 μL of Restore™ stripping buffer for 10 minutes in
the fumehood to remove all bound antibodies, before washing in TBS for 2 mins.
Following this, blots were washed in TBST four times for 5 mins, and in TBS twice
for 2 mins. For AIBL samples, after stripping, the membranes were stained with
Ponceau S, then destained and immunoblotted using ab28561 antibody.
Alternatively, blots were re-stripped following immunoblotting and Coomassie
stained.

2.2.4.6 Ponceau S and Coomassie staining as a loading control
The freshly stripped membranes were subsequently stained using a 0.1% (W/V)
solution of Ponceau S in 5% acetic acid, for 5 mins, rocking. They then were were
rinsed in MQ H2O twice for 30 seconds to remove excess background staining.
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After scanning, blots were then destained using one 2 min wash in hot TBS, then a
further two washes for 2 mins in cold TBS prior to immunoblotting.
After immunoblotting, membranes were stripped of antibodies as previously
described in Section 2.2.4.5. The freshly stripped membranes were then Coomassie
stained using Pierce GelCode Blue Stain Reagent as per manufacturer instructions.

2.2.4.7 Test of EDTA spiking on IDE levels in lithium-heparin
collected plasma
The approximate concentration of EDTA in the EDTA-collected tubes is 1.8 mg/mL,
and may vary per sample, therefore non-EDTA containing plasma was assessed to
determine if varying amounts of EDTA would affect the detectable levels of IDE via
Western immunoblotting. EDTA was diluted in MQ H2O to a concentration of 10
mg/mL, then spiked into diluted lithium-heparin collected plasma to a final
concentration of 2.0, 1.5 and 1.0 mg of EDTA per mL of (non-diluted) plasma. A
control sample of lithium-heparin plasma containing 0 mg of EDTA was included for
comparison, as well as two positive controls of 50ng and 100ng of rrIDE. Samples
were subsequently analysed by Western blot using the LS-C55007 protocol as
detailed above, with the exception of the washing steps after the antibodies. The
wash steps were twice for 2 mins, one 15 min wash and then three 5min washes.
Two three minute TBS washes were included after the secondary antibody to
remove the Tween-20.
The same membrane was subsequently stripped of antibodies and re-probed using
antibody ab28561 using the protocols described previously.

2.2.4.8 Test of cross-reactivity of LS-C55007 (and ab28561) to
purified BSA and HSA
To test if antibody LS-C55007 or ab28561 detects purified BSA or HSA within the
region of interest in the Western blot, purified BSA and HSA was diluted in MQ H2O
to a final concentration of 30 and 60 μg per well. This represents the lower and
upper limits of albumin levels found in human plasma in normal physiology.

A
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separate HSA sample equivalent to 60 μg per well was also spiked with 175.2 ng of
purified human recombinant IDE (rhIDE) and a separate sample spiked with 8 ng
rrIDE to determine if IDE was sequestered by albumin under denaturing and
reducing conditions. The spiked sample was pre-incubated for 1.5 hours at RT to
allow time for binding.

Samples were then resolved by SDS-PAGE and

immunoblotted using the LS-C55007 or ab28561 protocols as previously described.

2.2.4.9 Test of cross-reactivity of ab28561 to purified BSA and
albumin-free blocking agent
To test if antibody ab28561 detects purified BSA or an albumin-free blocking agent
(ECL™ Advance Blocking Agent) within the region of interest in the Western blot,
purified BSA and ECL™ Advance were both diluted in MQ H2O to a final
concentration of 15, 30 and 60 μg per well. A single lane of rrIDE (7.5 ng/well) was
added as a positive control.

All samples were resolved on a single gel and

immunoblotted as per the previously detailed protocols with antibody ab28561.

2.2.4.10 Pre-incubation with recombinant human IDE blocking
test for AB9210 for specificity
PCP was diluted in MQ H2O (59.503 μg/well), LDS Sample Buffer and Reducing
Agent to a ratio of 6 parts diluted PCP/3 parts Sample Buffer/1 part Reducing Agent
and four lanes of each were loaded onto a single gel (two duplicates). Proteins
were resolved by SDS-PAGE and electrophoretically transferred to a nitrocellulose
membrane as previously described in Section 2.2.4.1. The single membrane was
then cut into two identical pieces, designated membrane A (control) and
membrane B.

The separate membranes were then immunoblotted with IDE

antibody AB9210 as previously described in Section 2.2.4.3, with the exception of a
brief pre-incubation step prior to the primary antibody incubation. This step
involved spiking and pre-incubating the antibody solution with either 0 (membrane
A) or 1.32 μg (membrane B) of rhIDE for 10 minutes prior to adding the respective
membranes before incubating overnight.

The remainder of the protocol was
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identical to previously described, using separate containers to prevent crosscontamination.

2.2.4.11 Pre-incubation with immunizing peptide blocking test
for LS-C55007 for specificity
PCP was diluted in MQ H2O as previously described (59.503 μg/well) as well as rrIDE
(200 ng/well) and five lanes of each were loaded onto a single gel. Proteins were
resolved by SDS-PAGE and electrophoretically transferred to a nitrocellulose
membrane as previously described in Section 2.2.4.1. The single membrane was
then cut to result in 5 identical pieces; each containing one lane of molecular
weight marker (MWM), one lane of PCP, and one lane of rrIDE. The separate pieces
were designated membrane A (control), B, C, D and E. All membranes were then
immunoblotted with IDE antibody LS-C55007 as previously described in Section
2.2.4.2, with the exception of a pre-incubation step prior to the primary antibody
incubation. This step involved spiking the antibody solution with 0 μg (A), 5 μg (B),
10 μg (C), 15 μg (D) and 20 μg (E) of a custom-synthesized peptide matching the
immunogen to antibody LS-C55007. The five tubes were then incubated at RT for
30 mins prior to incubating the membranes. The remainder of the protocol was
identical to previously described, using separate containers to prevent crosscontamination.
The test was repeated twice more using increasing amounts of blocking peptide up
to 500 μg, to ensure validity of results.

2.2.4.12 Pre-incubation with immunizing peptide blocking test
for ab28561 for specificity
PCP (59.503 μg/well) and rrIDE (25 ng/well) were diluted in MQ H2O, prepared with
sample buffer and reducing agent prior to SDS-PAGE and stored at -80°C until use.
Rat liver (1 μL/well) was pre-homogenized, centrifuged for 10 mins at 12,000 RPM
and the supernatant pre-prepared in tris-tricine sample buffer (1M Tris-HCl
containing 2% (W/V) SDS, 4% (W/V) glycine, 0.05% (W/V) phenol red). Liver was
then stored at -80°C until use. Zebrafish brains (25 ng/well) were pre-homogenized
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in PBS containing a protease inhibitor cocktail (PI), and centrifuged at 6,000 RPM
for 10 mins at 4°C. The supernatant was collected and the total protein content
determined by a BCA Protein Assay.
Samples were all heated for 70°C for 10 mins, with the exception of rat liver which
was heated at 95°C. Three lanes of each sample were loaded onto a single gel
(NuPage® 4-12% Bis-Tris 1.5mm 15 well pre-cast) and resolved by SDS-PAGE for 2
hours at 100V. After semi-dry transfer as previously described, the membrane was
cut into three identical pieces, each with one lane of molecular weight marker and
one lane of each sample. The separate pieces were designated membrane A
(control), B and C. All membranes were then immunoblotted with ab28561 as
previously described, with the exception of a pre-incubation step prior to the
primary antibody incubation. This step involved spiking the antibody solution
(diluted 1:1000) with 0 μg (A), 5 μg (B) and 40 μg (C) of a commercially available
peptide matching the immunogen to antibody ab28561. The three tubes were then
incubated at RT for 30 mins prior to incubating the membranes. The remainder of
the protocol was identical to previously, using separate containers to prevent crosscontamination.

2.2.4.13 Pre-clearing IgG from plasma
PCP was diluted 1:3 in PBS containing PI, and pre-cleared using the Pierce Direct IP
kit, as per manufacturer instructions, to remove any immunoglobulins which may
bind non-specifically to the beads.

2.2.4.14 Pre-clearing albumin from plasma
To clear some of the albumin from the PCP, the Pierce Direct IP kit was used as per
manufacturer instructions. Briefly, 20 μL of a 50% agarose bead slurry was added
to a spin column and equilibriated with a coupling buffer. 10 μg of purified antialbumin antibody GTX27793 was then covalently bound to the beads for 2 hours.
After washing with tris buffer, the pre-cleared (see above) PCP sample was diluted
to a volume of 300 μL in PBS containing PI and added to the column. The column
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was then sealed and incubated overnight on a rotating mixer at 4°C. The column
was centrifuged and the flow-through collected.

2.2.4.15 Preparation of Aβ42
To prepare a stock solution of purified Aβ42 from lyophilized stock, 100 μL of
hexafluoroisopropanol (HFIP) was added per 1mg of lyophilized peptide into a tube,
and allowed to sit open for 15 mins in the fumehood to assist with solubilization.
After removing the HFIP by vacuum, and sitting for a further 10 mins, 1 mL of MQ
H2O was added to the tube, vortexed and allowed to sit a further 5 mins. The
solution was then centrifuged for 10 mins at 10,000 RPM and the supernatant
transferred into a low protein-binding tube. The concentration was subsequently
determined using an Implen Nanophotometer at a wavelength of 214nm.
Purified Aβ was subsequently incubated with rhIDE (9ug Aβ to 100ng rhIDE)
overnight at 4°C with end-over-end mixing, then resolved by SDS-PAGE and probed
with an IDE antibody (LS-C55007 or ab28561) as previously described. This was to
determine if IDE and Aβ denaturant-resistant binding occurs, leading to a shift in
molecular weight. Purified Aβ was also used as an IDE inhibitor for the fluorometric
activity assay as detailed in Section 2.2.6.3.

2.2.4.16 Immunoprecipitation of IDE from plasma
To assist with determining the band/s of interest on Western blot, PCP and precleared/albumin-depleted PCP (AD-PCP), as well as rrIDE and rhIDE were used in an
immunoprecipitation (IP) procedure for enrichment of the target protein (IDE).
rhIDE was also spiked with Aβ42 and included in the immunoprecipitation
experiment,

to

determine

if

IDE-Aβ

binding

was

resistant

to

the

immunoprecipitation method and subsequently denaturing and reducing
conditions, leading to an increased molecular weight determined by Western
blotting. All dilutions and washes were done using TBS containing a protease
inhibitor cocktail (TBS/PI). IDE antibody 250706 or AF2496 was diluted 1:120 in
TBS/PI (per tube) and bound to Protein G-coupled Magnetic Sepharose beads (20%
slurry) as per manufacturer instructions, using the Classic Protocol. 4-8 μL each of
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PCP and AD-PCP, and 100 ng of rrIDE was diluted to 500 μL with TBS/PI, and
incubated in separate tubes with the antibody-bound beads for 1 hour with endover-end mixing. The supernatant was then discarded and after washing the beads,
the proteins were eluted from the beads by adding NuPage® LDS sample buffer and
reducing agent, and then heating the tubes for 5 mins at 95°C. The supernatant
was then separated from the beads and the samples stored at -80°C until resolved
by SDS-PAGE.

2.2.4.17 Western Blotting image analysis and quantitation
Films were scanned using a Bio-Rad GS-800 Calibrated Densitometer, and Quantity
One software (version 4.5.1). Images were acquired using high-resolution settings
of 36.3 x 36.3 microns. Quantity One software was used to measure the density of
the scanned IDE bands, and the data was then exported to Microsoft® Excel 2007 for
normalization to adjust for gel to gel variation using the internal control sample
included on every gel.

Background density for each band was determined

separately by measuring an area close to the band that did not contain any protein;
and was then removed from the density of the band.

Duplicates having a

coefficient of variation of < 15% were omitted from the analysis. The data was
analysed using IBM® Statistical Package for the Social Sciences (SPSS®) Version
19.0.0 (Section 2.2.6).
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2.2.5 IDE levels in human plasma by enzyme-linked immunosorbent
assay (ELISA)
All loading volumes are 100 μL per well and all wells were loaded in duplicate unless
otherwise stated.

2.2.5.1 Kamiya IDE ELISA commercial kit
To determine if the Kamiya IDE ELISA commercial kit would be suitable for
measuring IDE in plasma samples, IDE standards were prepared as per
manufacturer instructions to concentrations of 0.78 to 50 ng/mL, and human
plasma samples were applied neat and diluted from 1:1 up to 1:1000 using the
buffer supplied with the kit. The remainder of the protocol was performed as per
manufacturer instructions and absorbance was measured using a Bio-Rad Fluostar
Optima microplate reader at a wavelength of 450nm.

2.2.5.2 Indirect In-house ELISA for IDE
To test if various antibodies would be suitable for use in an indirect in-house ELISA,
a screening test was performed using various commercially-available monoclonal
(MMS-282R and 5282-1) and polyclonal (GTX111664, AB9210, 250706, H00003416A01, LS-C55007 and ab28561) IDE antibodies (see Section 2.1.1 for antibody
details). 96-well Nunc Maxisorp microplates (modules) were coated with purified
rrIDE standards at concentrations of 78.12 to 5000 ng/mL, diluted in 50 mM
carbonate/bicarbonate buffer (pH 8.6). PCP was coated neat (undiluted) and at
several dilutions of 1:1 up to 1:20 in the same buffer. All samples were applied in
duplicate. The plates were incubated O/N at 4°C with shaking. Following the O/N
incubation, plates were washed with a microplate washer four times in PBS (pH 7.4)
and then incubated in a PBS solution containing 2% bovine serum albumin (BSA) to
block any unbound sites on the plate (200 μL per well), for 1.5 hours at 4°C with
shaking. No Tween-20 was included in the blocking buffer at this stage to avoid the
detergent loosely binding to the plate and displacing the BSA, as this may lead to
the Tween-20 being removed by subsequent washes with PBS containing 0.05%
Tween-20 (PBST) and leaving spaces for non-specific binding of the antibodies. The
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plates were then loaded with the primary antibody diluted 1:1000 in PBST
containing 1% BSA (1% BSA/PBST), and incubated for either 2 hours at RT or 4°C
O/N with shaking. Washing was then performed four times with PBST to remove
any unbound antibodies.

The HRP-conjugated anti-rabbit (AP322P), anti-goat

(P0449) or anti-mouse (AP326P) secondary antibodies were then diluted 1:10000 in
1% BSA/PBST, loaded onto the respective plates, and incubated for 2 hours at 4°C
with shaking.

After washing another four times with PBST, 3,3′,5,5′-

tetramethylbenzidine (TMB) was prepared as per manufacturer instructions and
applied to each well while protecting from light. The substrate was incubated for
30 minutes in darkness and the reaction stopped with the addition of 1M
phosphoric acid (H3PO4). The absorbance was then quantified using a microplate
reader at a wavelength of 450nm to determine optical density.

2.2.5.3 Sandwich ELISA for IDE
96-well Nunc Maxisorp microplates (modules) were coated with an inactive domain
IDE antibody (ab28561) at 2.5 μg/mL diluted in 50 mM carbonate/bicarbonate
buffer (pH 9.6, or 8.6 for some optimisations). The plates were then incubated O/N
(18 hours) at 4°C with shaking. Following the O/N incubation, the plates were
washed four times with PBS (pH 7.4) to remove unbound antibodies, on a
microplate washer. After washing, wells were incubated (200 μL per well) with 3%
BSA/PBS for 1 hour at RT with shaking, to block any unbound sites on the plate. No
Tween-20 was included in the washing or blocking buffer prior to this stage to avoid
the detergent loosely binding to the plate and displacing the BSA, as this may lead
to the Tween-20 being removed by subsequent washes with PBST and leaving
spaces for non-specific binding of the antibodies. IDE protein standards were then
prepared from rrIDE, serially diluted to concentrations of 50 to 16000 ng/mL, and
plasma samples were each diluted 1:2 in PBST (pH 7.4). For some optimisations 1%
BSA was added to the diluent. An internal standard of human plasma (PCP) was
also included (1:2). IDE standard and plasma samples were loaded in each well in
duplicate, and the plates were incubated for 1 hour at RT with shaking. Following
this incubation, the plates were further incubated O/N (18 hours) at 4°C with
shaking. After the O/N incubation, any unbound protein was removed by washing
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four times with a microplate washer.

The detection antibody LS-C55007 (or

H00003416-A01 for optimisation) was then diluted 1:750 in PBST, loaded into each
well and the plates were incubated O/N at 4°C with shaking. Following the O/N
incubation, plates were washed four times with PBST. The anti-goat (or anti-mouse
for A01 antibody, AP326P) HRP-conjugated secondary antibody (P0449) was then
diluted 1:7500 in PBST, loaded into each well, and plates were incubated for two
hours at RT with shaking. The plates were then washed again four times in PBST,
and TMB was loaded to each well, protected from light. The plates were then
incubated in darkness for 15 – 25 minutes. The reaction was stopped by applying
1M H3PO4 to each well and the absorbance was measured at a wavelength of 450
nm on a microplate reader to determine optical density.

2.2.5.3.1 Preparation of human (HSA) and bovine (BSA) serum
albumin
Lyophilized preparations of purified BSA, Fraction V BSA, and HSA were diluted to
60 and 30 mg/mL in PBST. Solutions were then diluted 1:2 as per plasma dilutions
and assayed using the IDE sandwich ELISA protocol as detailed previously in section
2.2.5.3. The diluted solutions of purified BSA and HSA were also diluted as detailed
in Section 2.2.6.7 and assayed using the IDE fluorometric activity assay.

2.2.5.4 Low-level data analysis
Blank (background) optical density values were subtracted from the sample optical
density values obtained, and were normalised to the internal standard sample value
included on each plate to control for plate-to-plate variation. Values less than the
mean plus three times the standard deviation of the blanks were considered below
the detection limit. Duplicates with a coefficient of variation (CV) >15% were
omitted from the analysis; if PCP (internal standard) values exceeded this CV the
whole plate was omitted.
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2.2.6 Catalytic activity of plasma IDE by immunocapture-based IDEspecific fluorometric assay
The fluorometric assay used was adapted from Miners, et al., 2008(b) and Wang, et
al., 2010. All well volumes are 100 μL per well unless otherwise specified. All
assays used PBST for dilutions and washing with the exception of the test between
PBST and TBST where TBST was included as a sample buffer.

2.2.6.1 Immunocapture-based IDE specific fluorometric assay
96-well Nunc MaxiSorp™ Black Microplates (modules) were coated with an inactive
domain IDE antibody ab28561 diluted at 2.5 μg/mL in 50 mM carbonate buffer (pH
8.6), and incubated O/N at 4°C, with shaking. Following the O/N incubation, the
plate was washed 4 times in PBST using a plate washer, then blocked for 30 mins at
RT (with shaking) with a 2% BSA/PBST solution (or 3% ECL Advance Blocking Agent
in PBST for one optimisation step). The blocking solution was not removed from
the wells after incubation. IDE protein standards were prepared from rrIDE diluted
in PBST, at concentrations from 312.5 to 7500 ng/mL (for the AIBL samples,
otherwise as specified) and 50 μL per well was added to the plates in duplicate.
Plasma samples including an internal standard of PCP, were diluted in PBST to a
concentration of approximately 19 μg/μL total protein (for the AIBL samples,
otherwise as specified), and 50 μL per well was added to the plates in duplicate.
The plates were then incubated O/N at 4°C with shaking. After the O/N incubation,
plates were washed 4 times with PBST, and the internally-quenched fluorogenic
peptide substrate (Mca-R-P-P-G-F-S-A-F-K(Dnp)-OH) was diluted in 50 mM HEPES to
a concentration of 2.5 μL/mL (10 μM) and applied to each well while protecting
from direct light. The fluorescence generated by the cleavage of the fluorogenic
substrate was incubated and measured in a microplate reader (in darkness) with
excitation at 320 nm and emission at 405 nm (at 31°C), immediately (baseline) and
then hourly for 6 hours (for AIBL samples, otherwise as specified). The cut off point
of 6 hours was used as maximum activity was reached after 5 hours in the original
study (Miners, et al., 2008(b)) and it was considered important to measure the
highest reading possible within the linear range to maximise the chances of
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detecting any differences between the groups. The gain adjustment setting for
early optimisation experiments using Ab 3 (Batch 1) was variable (as specified),
however for Batch 2 the gain adjustment was set to 1487 for all assays. The data
values were interpolated from the standard curve of rrIDE as a measure of the
equivalent amount of recombinant rat IDE (ng/mL).

2.2.6.2 Inhibition of catalytic activity of IDE by IDE-specific
antibodies and Aβ40
To determine the specificity of the assay, four tubes containing PCP (1180 μg total
protein each) were diluted in PBST to a volume of 125 μL, including no inhibitor
(control), or either 20 μL of IDE antibodies AB9210 (A), LS-C55007 (B), or 20.5 μg of
Aβ40 (C). Antibody AB9210 binds to residues 200-250 of IDE which contains part of
the catalytic site, while LS-C55007 binds close to the C-terminus of IDE in a domain
which is distinct from the catalytic site. Aβ40 was prepared as per Aβ42 as previously
described in section 2.2.4.15. The four tubes were then pre-incubated for 2 hours
at RT on a rolling mixer, prior to adding these samples to the plates. The assay was
otherwise conducted as described above in section 2.2.6.1.

Specificity was

determined by comparing the fluorescence generated by PCP in the presence or
absence of each inhibitor.

2.2.6.3 Inhibition of catalytic activity of IDE by Aβ42
To assist with the determination of the assay specificity, 50 μL per well of 50 mM
HEPES containing 0, 10 and 100 μM Aβ42 (prepared as detailed in Section 2.2.4.15)
was added to the immunocaptured IDE (from PCP), and incubated for 2 hours at RT,
with shaking, prior to the addition of 50 μL per well of 20 μM fluorogenic substrate.
The assay was otherwise conducted as described in Section 2.2.6.1. Specificity was
determined by comparing the fluorescence generated by PCP in the presence or
absence of each concentration of Aβ42.
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2.2.6.4 Preparation of insulin
Lyophilized insulin was dissolved in 0.01 M hydrochloric acid (HCl, pH 2.0) to a
concentration of 10 mg/mL and then sterile-filtered through a 0.2 μm pore size
filter. The insulin solution was then diluted with HEPES (pH of approximately 8.0 to
counteract low pH of HCl) to a concentration of 1 mM. Serial dilutions of insulin
were then made to 0.5 and 0.25 mM in HEPES (pH 7.5).

2.2.6.5 Inhibition of catalytic activity of IDE by insulin
50 μL per well of 50 mM HEPES containing 0, 0.25, 0.5 and 1.0 mM of insulin was
added to the immunocaptured IDE (from PCP), and incubated for 2 hours at RT,
with shaking. 50 μL per well of 10 μM fluorogenic substrate diluted in HEPES was
then added to each well, and the assay was otherwise conducted as described in
section 2.2.6.1.

Specificity was determined by comparing the fluorescence

generated by PCP in the presence or absence of each concentration of insulin.

2.2.6.6

Determination of fluorometric activity assay cross-

reactivity with human (HSA) and bovine (BSA) serum albumin
HSA and BSA (Sigma) was prepared as described in section 2.2.5.3.1 to
concentrations of 60 and 30 mg/mL each, diluted in PBST. Each dilution was further
diluted as per plasma samples (40 μl + 85 μL PBST), and then assayed in duplicate
using the fluorometric activity assay protocol as detailed in Section 2.2.6.1. Crossreactivity was determined to be fluorescence generated above the value of the
(PBST only) blank. Results are shown in the Appendix.

2.2.6.7 Comparison of IDE activity from EDTA collected plasma
and Lithium-Heparin (Li-Hep) collected plasma
EDTA plasma and Li-Hep plasma were diluted in PBST to contain 960 ug total
protein per well (50 μL) and IDE activity was measured with the activity assay as
detailed in Section 2.2.6.1.
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2.2.6.8 Low-level data analysis
Duplicate values with a coefficient of variation (CV) of >15%, and assays where the
standard curve values were > 2x standard deviation of the mean of each
concentration were removed from the analysis. Values were then interpolated
from the standard curve included on each plate.
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2.2.7 Statistical Analysis
All data was analysed using IBM® Statistical Package for the Social Sciences (SPSS®)
Version 19.0.0 (for Windows).

Normality of the frequency distribution was

determined using z-scores for skewness and kurtosis, the Kolmogorov-Smirnoff and
Shapiro-Wilk tests, histograms, boxplots and normal Q-Q plots. Levene’s test was
used to determine homogeneity of variance.
Data was determined to have a non-normal distribution if z-scores for skewness
and kurtosis were outside the range of ± 1.96, and Kolmogorov-Smirnoff/ShapiroWilk tests produced a significance value of p ≤0.05. Histograms, boxplots and
normal Q-Q plots were also visualised for normal shape of the distribution and
outliers.

A significance of p ≥0.05 for Levene’s test was used to determine

homogeneity of variances.

Data found to be not normally distributed was

subsequently transformed if possible.
Data that satisfied the normality criteria following transformation was then
analysed with the parametric Student’s T-test, one-way analysis of variance
(ANOVA) or analysis of covariance (ANCOVA) using Tukey Post-Hoc analyses
(independent samples, two-tailed analysis). Correlations were determined using
Spearman’s Rho, with Bonferroni-Holm correction applied to correct for multiple
testing, which is a slightly less stringent correction method than the Bonferroni
method (Holm, 1979).
Data that still displayed non-normal distribution after transformation was analysed
with the non-parametric Mann-Whitney and Kruskall-Wallis tests. Mann-Whitney
tests were used as Post-Hoc tests for the Kruskall-Wallis test with Bonferroni
correction applied to correct for multiple testing. The Monte Carlo method was
used to determine the estimate of significance which is more accurate than the
Asymptotic Method when data is poorly distributed. Significance was considered to
be p≤0.05. Correlations were determined using Spearman’s Rho, with BonferroniHolm correction applied to correct for multiple testing.
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CHAPTER 3 – Full-length plasma IDE Levels are higher
in MCI in comparison to healthy controls or AD, as
measured by Western Immunoblotting.
3.1 Introduction
Beta-amyloid (Aβ) is believed to be a key peptide involved in the pathogenesis of
Alzheimer’s disease (AD), and higher than normal levels of Aβ peptides in the brain
lead to Aβ aggregation and neurotoxicity, and appear to instigate the development
of extracellular senile plaques (SP) and subsequently the formation of intracellular
neurofibrillary tangles (NFT) which are the primary lesions found in the brains of
AD patients. It has been demonstrated that Aβ is produced within brain cells as
well as within the cerebrovasculature (Reviewed by Wilson, et al., 1999; Kalaria, et
al., 1996), and can be transported out into the periphery. However free Aβ can
also be transported into the brain, across the blood-brain barrier from the
peripheral circulation (Deane, et al., 2003). It has been shown that plasma levels
of Aβ increase in AD patients prior to the formation of SP, but decrease
considerably as levels of brain Aβ increase and begin forming insoluble fibrillar
deposits of amyloid (Kawarabayashi, et al., 2001; Schupf, et al., 2008). This
suggests that peripheral Aβ may be a source for the Aβ that accumulates in the
brain, and it is likely that regulation of Aβ levels in the periphery may be of
importance in the pathogenesis of AD.
Insulin-degrading enzyme (IDE) has been demonstrated to be a primary
metalloprotease responsible for the regulation of monomeric Aβ levels in the brain,
but not oligomeric or fibrillar forms (Leissring, et al., 2003; Farris, et al., 2003). It
has also been shown that overexpression of IDE not only reduces the soluble levels
of brain Aβ, but also attenuates the formation of SP and prevents early death in
transgenic mouse models. These results suggest that the reduction of monomeric
Aβ levels is sufficient to prevent SP formation. In accordance with this, recent work
has shown that the formation of Aβ fibrils is critically influenced by the oligomeric
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state of soluble Aβ, as well as the balance of monomeric to aggregated forms of
Aβ42, revealing more about the role of Aβ42 in the amyloidogenic pathway (Jeong, et
al., 2013). It has also been shown that amyloid formation is reversible (Lazerov, et
al., 2002). It is possible then that reducing monomeric Aβ in the periphery by way
of IDE clearance may have some impact on preventing cerebral accumulation of the
peptide, as well as its oligomerisation and fibrillisation,

and hence the

development of AD. Therefore, the levels of IDE in human plasma could be integral
in regulating not only plasma Aβ, but also Aβ in the brain. Furthermore, plasma IDE
levels may also reflect cerebral levels of Aβ, and thus provide a useful biomarker for
the assessment and monitoring of brain Aβ levels and/or early pathological
processes that lead to neurodegeneration. Plasma IDE levels could also potentially
be utilised as a biomarker in clinical trials for determining the efficacy of drugs,
preventative interventions and other relevant treatments for AD.
It has been shown that truncated isoforms of IDE have little or no activity (Li, et al.,
2006), therefore the first aim of this project was to determine if full-length IDE was
present in human plasma.

Western immunoblotting was employed for this

purpose, and a number of IDE antibodies were screened for suitability. Once the
presence of full-length IDE was confirmed, the levels of plasma IDE in AD patients
and MCI individuals were measured against the levels in healthy controls (HC), to
see if they were altered in the prodromal period of AD (MCI) or in the disease state.
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3.1.1 Aims

1. To use Western immunoblotting techniques to characterise commercial IDE
antibodies and to determine whether full-length IDE is present in human
plasma.
2. To measure levels of plasma IDE using a well-characterised Western
immunoblotting technique to determine if plasma IDE levels can
differentiate between classifications of AD, MCI and HC.
3. To determine if the presence of the APOE4 allele has any impact on the levels of
full-length plasma IDE.
4. To identify any relationships between full-length plasma IDE and other
biochemical data obtained from the AIBL study.
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3.2 Experimental Summary
3.2.1 Antibody characterisation: Pre-incubation of polyclonal IDE
antibody Ab 1 with recombinant human IDE to check specificity for
human plasma IDE.
Experiments were carried out to test if IDE antibody AB9210 (Ab 1(a) (Batch 1) –
refer to Table 2.1 for details) detects full-length IDE in human plasma, and to
determine if the bands seen are specific. SDS-PAGE and Western immunoblotting
were performed as previously outlined in Sections 2.2.4.1 and 2.2.4.3, including a
pre-incubation blocking step prior to the primary antibody incubation as outlined in
Section 2.2.4.10.

3.2.2 Testing the batch-to-batch variability of IDE antibody Ab 1 on
human plasma and rrIDE.
Experiments were carried out to test if a second batch of IDE antibody AB9210 (Ab
1(b)- refer to Table 2.1 for details) could detect full-length IDE in human plasma as
efficiently as the previous batch (Ab 1(a)). Recombinant rat IDE (rrIDE) was used as
a positive control, and SDS-PAGE and Western immunoblotting were performed as
outlined in Sections 2.2.4.1 and 2.2.4.3.

3.2.3 Test of alternate polyclonal IDE antibody Ab 2: comparison with
IDE antibody Ab 1.
SDS-PAGE and Western immunoblotting were performed as outlined in Sections
2.2.4.1, 2.2.4.2 and 2.2.4.3, to determine if an alternate IDE antibody LS-C55007 (Ab
2 – refer to table 2.1 for details) could detect full-length IDE in human plasma and
rrIDE as efficiently as IDE antibody AB9210 (Ab 1(a) (Batch 1)). Subsequent
experiments showed that an extended development time of one hour was required
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to adequately visualise the band of interest in the region of 115-120 kDa, however
background was also amplified. Consequently ECL Advance/Prime detection agents
were used along with additional washing steps in order to increase the sensitivity of
the method for the detection of full-length IDE in human plasma while minimizing
the background generated.

3.2.4 Determination of the effect of EDTA in blood collection tubes on
levels of human plasma IDE detected with IDE antibody Ab 2.
As EDTA is a chelating agent and IDE is a metalloprotease, an experiment was
conducted to analyse whether the EDTA in the blood collection tubes has an effect
on the amounts of full-length plasma IDE that are detected using IDE antibody LSC55007 (Ab2). SDS-PAGE and Western immunoblotting were performed as outlined
in Sections 2.2.4.1, 2.2.4.2 and 2.2.4.7.

3.2.5 Investigating potential cross-reactivity of IDE antibody Ab 2 with
purified human and bovine albumin.
Human plasma contains diverse components including many proteins, and the most
abundant of these is albumin. Cross-reactivity occurring between plasma albumin
and a specific antibody of interest could therefore potentially mask the detection of
other less abundant proteins by the antibody in question. In addition, bovine
serum albumin is often used as a blocking agent in various immune-based protein
detection methods, and sometimes cross-reacts with antibodies raised in goats due
to species similarity. Therefore purified human (HSA) and bovine (BSA) serum
albumin was analysed by SDS-PAGE and Western immunoblotting (as described in
Sections 2.2.4.1, 2.2.4.2 and 2.2.4.8 with IDE antibody LS-C55007 (Ab 2) to
determine if either of these albumins could be detected in the region of interest.
The concentrations of albumin used reflected physiological levels found in plasma
in normal human physiology. In addition, HSA was spiked with recombinant human
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IDE to determine if any interactions between IDE and HSA occur under denaturing
and reducing conditions.

3.2.6

Pre-incubation of IDE antibody Ab 2 with a synthesised

immunogen peptide to assess specificity of antibody to IDE in human
plasma.
To determine if the bands detected by IDE antibody LS-C55007 (Ab 2) are specific
for IDE in human plasma and specific for rrIDE, SDS-PAGE and Western
immunoblotting were performed as outlined in Sections 2.2.4.1 and 2.2.4.2. The
experiment included a pre-incubation blocking step using a custom-synthesised
peptide identical to the Ab 2 immunogen. This step was carried out prior to the
primary antibody incubation, as outlined in Section 2.2.4.11.

3.2.7 Test of alternate polyclonal IDE antibody Ab 3: assessment of its
detection of rrIDE as well as full-length IDE in human plasma.
To determine if an alternative polyclonal IDE antibody ab28561 (Ab 3 - refer to
Table 2.1 for details) can detect full-length IDE in human plasma, as well as purified
rrIDE used as a positive control, SDS-PAGE and Western immunoblotting were
performed as outlined in Sections 2.2.4.1 and 2.2.4.4. Homogenised rat liver,
human frontal cortex and purified recombinant human IDE were also included as
further positive controls.

3.2.8 Determination of the effect of EDTA in blood collection tubes on
the detection of human plasma IDE using IDE antibody Ab 3.
To determine the effect, if any, of EDTA’s presence in human blood samples on the
detection of full-length IDE by IDE antibody ab28561 (Ab 3), membranes previously
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analysed by IDE antibody LS-C55007 were stripped of antibodies and re-probed (as
described in Sections 2.2.4.7 and 2.2.4.5).

3.2.9 Testing IDE antibody Ab 3 for cross-reactivity with BSA, HSA
and a non-albumin containing blocking agent.
As IDE antibody LS-C55007 was found to cross-react with albumin, an experiment
was conducted to identify any cross-reactivity between polyclonal IDE antibody
ab28561 (Ab 3) and purified BSA or an alternative, commonly used blocking agent
which contains no albumin (ECL™ Advance Blocking Reagent).

SDS-PAGE and

Western immunoblotting were performed as described in Sections 2.2.4.1 and
2.2.4.4.

The concentrations of albumin (or non-albumin blocking agent) used

reflected physiological levels of albumin found in plasma in normal human
physiology. The same experiment was subsequently repeated to include HSA and
BSA, as well as rrIDE/rhIDE-spiked HSA as outlined in Sections 2.2.4.8 and 3.2.5.

3.2.10 Pre-clearing and albumin-removal from human plasma.
As immunoglobulins and albumin may be interfering factors in antibody-based
detection and immunoprecipitation methods, it was considered that it would be
beneficial to reduce the immunoglobulin and albumin content of human plasma. A
pre-clearing step was performed as described in Section 2.2.4.13 to remove
immunoglobulins that may non-specifically bind to the beads used in the
immunoprecipitation protocols. The pre-cleared plasma was then also depleted of
albumin content using the immunoaffinity-based protocol described in Section
2.2.4.14, using a monoclonal antibody to human albumin GTX27793 (AL-01).
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3.2.11 Immunoprecipitation (IP) of IDE from human plasma with
polyclonal IDE antibodies Ab 4 and Ab 5.
IDE immunoprecipitation experiments were carried out on untreated human
plasma, and to investigate whether there are any non-specific contaminating
factors, immunoprecipitation was also carried out on human plasma which had
been pre-cleared of immunoglobulins and depleted of albumin prior to IP. RrIDE
and rhIDE (AF2496 only) were immunoprecipitated to be included as positive
controls. A sample of rhIDE pre-incubated with Aβ42 (Aβ42 preparation is detailed in
Section 2.2.4.15) was also included in the IP experiment, to determine if IDE-Aβ
interactions were resistant to the IP method as well as to the denaturing and
reducing conditions of the subsequent Western immunoblotting step, leading to an
increased molecular weight. The IP experiment was performed as described in
Section 2.2.4.16, using polyclonal IDE antibodies 250706 (Ab 4) or AF2496 (Ab
5)(refer to Table 2.1 for details). The immunoprecipitated samples were then
resolved by SDS-PAGE and Western immunoblotting with IDE antibody ab28561 (Ab
3) as described in Sections 2.2.4.1 and 2.2.4.4.

3.2.12 Testing the specificity of IDE antibody Ab 3 for IDE in human
plasma by pre-incubation with a commercial blocking peptide.
To determine if the bands detected from human plasma samples by IDE antibody
ab28561 (Ab 3) were specific, SDS-PAGE and Western immunoblotting were
performed as outlined in Sections 2.2.4.1 and 2.2.4.4, including a pre-incubation
blocking step with peptide, that was used as the immunogen, prior to the primary
antibody incubation, as outlined in Section 2.2.4.12. rrIDE, rat liver and zebrafish
brain homogenates were included as positive controls.
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3.2.13 Determination of full-length IDE levels in the plasma samples
of the AIBL cohort by SDS-PAGE and Western immunoblotting, using
IDE antibody Ab 3.
Samples which had been collected using the methods described in Section 2.2.2
from the AIBL cohort were tested to measure full-length IDE levels. These
investigations used SDS-PAGE and Western immunoblotting, and IDE antibody
ab28561 (Ab 3), as outlined in Sections 2.2.4.1 and 2.2.4.4. An internal control
sample of pooled control plasma (PCP) and a positive control of rrIDE were included
on each gel. Ponceau S staining of the antibody stripped membrane prior to
immunoblotting, was performed as previously described in Section 2.2.4.6, to
ensure complete transfer of proteins as well as providing a gel loading control.
Alternatively, blots were re-stripped following immunoblotting and Coomassie
stained. Following ECL detection of bands, levels of full-length plasma IDE were
quantified by scanning on a Bio-Rad densitometer GS-800 and images were
analysed using Quantity-One software (V4.5.1).
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3.3 Results
3.3.1 Bands detected by IDE antibody Ab 1(a) (Batch 1) in human
plasma are IDE.
When using immunoaffinity methods such as Western immunoblotting, it is
common to detect several bands, particularly when using polyclonal antibody sera
which may detect multiple epitopes on the protein of interest, and which may also
contain antibodies to other proteins. Although the bands detected may be specific
and represent multiple isoforms of the protein, it is also common to have nonspecific binding occur. Therefore it is important to identify which of the detected
bands (if any) is the target protein.
One commonly used technique is to absorb antibody activity by pre-incubation with
the immunising peptide, thus blocking the antibody binding sites (also called
peptide competition assay); the blocked antibody is then used in immunoblotting.
Briefly, the antibody is pre-incubated with an excess of the immunising peptide
used to raise the antibody, or a peptide or protein that contains the matching
epitope of interest, prior to adding to the membrane. The peptide binds to the
antibody, effectively blocking it from binding to the target epitope. The resulting
blot will show that the specific bands are significantly reduced in intensity or
absent, while non-specific bands remain. While this technique is generally more
effective on monoclonal antibodies, which usually recognise just one epitope on the
protein of interest, it can also be useful for determining the specificity of polyclonal
antibodies.
An immunising peptide blocking experiment was performed on Ab 1(a) (AB9210) to
determine if the single band detected at 105 kDa in human plasma is IDE (Figure
3.1). This antibody was raised against a synthetic peptide of rat IDE spanning from
amino acids 200 to 250. As this sequence shows 96.1% homology with the human
IDE peptide it would be expected to detect IDE in human plasma. Results show that
the band density was reduced by more than 50% after using full-length human IDE
to neutralise the antibody. This indicates that the band seen is likely to be IDE,
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despite a slightly lower estimated molecular weight when compared to most
published studies. A limitation of this test was that it was only performed once and
should have been repeated twice to ensure validity of the results. In addition, it
would have been useful to include increasing doses of IDE to observe a dose-curve
effect. However, as the subsequent batches of this antibody performed differently,
it was decided not to continue with this antibody (discussed in Section 3.3.2) so
further testing was considered unnecessary.

Figure 3.1 Immunising peptide (protein) blocking experiment on IDE antibody
AB9210 (Ab 1(a)). Western immunoblot probed with polyclonal IDE antibody
AB9210 (1:8000) after pre-incubating primary antibody solution without human IDE
protein (membrane A.) or with 1.32 μg recombinant human IDE as detailed in
Sections 2.2.4.1 and 2.2.4.3 and 2.2.4.10. Sample is 1 μL pooled control plasma
(PCP) per lane in duplicate. Results show signal is reduced by approximately 50% in
B. as compared with the control. Coomassie stain of membrane was included as a
loading control. Error bars indicate ±SD.

3.3.2 Subsequent batches of polyclonal IDE antibody Ab 1 are unable
to detect full-length IDE in human plasma.
While monoclonal antibodies are known to be more specific than polyclonal
antibodies, there are nevertheless certain advantages to using polyclonal
antibodies. These include reduced cost, and they can also be more sensitive than
monoclonals in detecting the protein. One drawback, however, is the possibility of
batch-to-batch variation in polyclonal antibodies. It is important to compare each
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new batch of polyclonal antibody with the previous batch to ensure consistency,
and it is essential to use the same batch when conducting studies on a cohort
where samples need to be compared to each other.
The initial batch of IDE antibody AB9210 (Ab 1(a) (Batch 1)) was compared with a
subsequent batch (Ab 1(b) (Batch 2)) to determine if results were comparable
(Figure 3.2). The results show that Batch 2 was unable to detect IDE in human
plasma, even at double the original concentration used for Batch 1.

It was

concluded that Batch 2 was unsuitable for measuring IDE in human plasma. As
supplies of Batch 1 were no longer available, an alternative antibody needed to be
screened.

Figure 3.2 Comparison of original batch of IDE antibody AB9210 (Ab 1(a) (Batch
1)) with a subsequent batch of AB9210 (Ab 1(b) (Batch 2)) on human plasma and
rrIDE. Western immunoblot of human plasma and rrIDE probed with IDE antibody
Ab 1(a) (Batch 1) (membrane A.) compared with Ab 1(b) (Batch 2) (membranes B.
and C.) as detailed in Sections 2.2.4.1 and 2.2.4.3. Samples are 1 μL/lane of pooled
control plasma (PCP) and 50 ng/lane rrIDE in duplicate. Results show that Ab 1(b)
(Batch 2) is unable to detect IDE in human plasma at concentrations of 1:8000 or
1:4000. Ab 1(b) (Batch 2) is capable of detecting purified rrIDE, however appears to
be less sensitive than Ab 1(a) (Batch 1). Once past the primary antibody step, the 3
blots were processed together.
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3.3.3 Comparison of IDE antibody Ab 1 (AB9210, Batch 1) and IDE
antibody Ab 2 (LS-C55007).
A comparison was made between Ab 1(a) (Batch 1) (AB9210 original batch) and
another polyclonal IDE antibody Ab 2 (LS-C55007) (Figure 3.3(A) and (B)). Ab 2 was
raised against a synthetic peptide of human IDE, spanning amino acids 914-924,
targeting the C-terminal end of the IDE protein. The reported truncated isoform of
IDE contains this region, therefore Ab 2 would be expected to detect both the
truncated plus the full-length isoforms of IDE. The initial results show that at a
concentration of 1:8000 for Ab 1(a) (Batch 1), and 1:5000 for Ab 2, both are able to
detect rrIDE at 200-400 ng/well, however Ab 2 appears to have less affinity for
recombinant rat IDE. This may be because Ab 2 was raised against a human IDE
sequence, whereas Ab 1 was raised against a rat IDE sequence. However these
antibodies are difficult to compare in this test. Firstly, Ab 1 is in the form of
antiserum, therefore the exact concentration of IDE-specific immunoglobulins
cannot be determined (total IgG is estimated to be between 1-2 mg/mL), whereas
Ab 2 is purified and the concentration determined to be 0.5 mg/mL. In addition,
these antibodies require different secondary antibodies (anti-Rabbit versus antiGoat), and different concentrations were used [Ab 2 (1:7500), Ab 1 (1:5000)], these
issues would also have contributed to the observed differences in signal. In human
plasma, no bands were seen under the conditions used with Ab 2 in the range of
100-120 kDa, which is the expected molecular weight for full-length IDE. However a
signal was detected at approximately 45 kDa which may correspond to the
truncated form that has been reported.
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Figure 3.3 (A) and (B) Comparison of polyclonal IDE antibody AB9210 (Ab 1(a)
(Batch 1)) with LS-C55007 (Ab 2) on human plasma and rrIDE. Western
immunoblot of human plasma and rrIDE probed with IDE antibodies Ab 1(a) (Batch
1) (membrane A) compared with Ab 2 (membrane B) as detailed in Sections 2.2.4.1,
2.2.4.2 and 2.2.4.3. Samples are 1 μL/lane of pooled control plasma (PCP) and 400
and 200 ng/lane of rrIDE in duplicate. Results show Ab 2 detects a band at
approximately 45 kDa, but not within the range of full-length IDE (100-120 kDa)
under these conditions.
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The Western blotting methods were modified slightly to try to improve the
detection of full-length IDE in human plasma by Ab 2. Three individual plasma
samples (including PCP) and rrIDE were resolved by SDS-PAGE and probed with Ab
2, using an extended exposure time when developing the film (Figure 3.4). Results
show that after a one hour exposure, additional bands to the 45 kDa bands
previously demonstrated appeared at approximately 160 (ghost bands), 115-120,
80 and 60 kDa. The band at 115-120 kDa corresponded to various previous reports
of the molecular weight of IDE, however differed from the molecular weight of the
band seen using Ab 1 (105 kDa). Cross-reactivity with the molecular weight marker
(MWM) proteins at 80 and 60 kDa demonstrates some non-specific binding.
To reduce the exposure time required and to retain sufficient visualisation of the
bands within the region of interest (specifically the 115-120 kDa band), ECL™
Advance Detection Reagent was tested in this application (Figure 3.5) with five
individual plasma samples including PCP, and rrIDE (previously ECL™ Detection
Reagent was used).

ECL™ Advance is reported to be a more sensitive

chemiluminescent reagent than ECL™, increasing the sensitivity of detection by up
to ten times compared to standard ECL™. Results show that ECL™ Advance did
improve the detection of bands at 115-120, 80, 70 and 45 kDa, although the
background was also significantly enhanced. The previously observed “ghost”
bands at 160 kDa (Figure 3.4) were not apparent.
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Figure 3.4 Investigating the effect of extended ECL development time on the
detection of full-length human plasma IDE with Ab 2. Pooled control plasma
(PCP), and two individual plasma samples (S1 and S2) were run in triplicate (1
µl/lane) as detailed in Sections 2.2.4.1 and 2.2.4.2. The rrIDE sample contained 100
ng. After transfer, the immunoblot was probed with primary antibody Ab 2 (LSC55007) and developed for 1 hr. Results show that multiple bands are detected in
plasma after exposing for one hr, at approximate molecular weights of 160, 115120 (close to expected size), 80, and 70 kDa, and strong bands at approximately 45
kDa. Cross-reactivity is apparent with the MWM at 80 and 60 kDa. Differences in
intensity of the plasma bands between individual samples at 115-120 kDa are
apparent, although intra-sample variation is also apparent.

Differences in intensity of the 115-120 kDa band were apparent between individual
samples. The development time was reduced from 60 min with standard ECL™ to 1
min using ECL™ Advance. It should be noted that the last lane was markedly lighter
than its duplicate; this was unlikely to be due to imprecise pipetting, as this
phenomenon was observed consistently. As it was only a positive control loaded in
this lane in all gels, and not used for quantification, it was not considered to be an
issue in this instance.
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Figure 3.5 Plasma samples probed with Ab 2 (LS-C55007), using rrIDE as positive
control, and developed using ECL™ Advance. Pooled plasma (PCP), and four
individual plasma samples (S1, S2, S3 and S4) all at 1 μL plasma per lane, were run
in duplicate as detailed in Sections 2.2.4.1 and 2.2.4.2. The rrIDE sample contains
100 ng. Results show that multiple bands are detected in the plasma samples after
exposing for 1 min, at approximate molecular weights of 115-120 (close to
expected), 80, and 70 kDa, and strong bands at approximately 45kDa. Crossreactivity is apparent with the MWM at 80 and 60kDa. Differences in intensity of
the plasma bands between individual samples at 115-120 kDa are apparent. The
background is considerably darker with this developer.

3.3.4 EDTA has no effect on the intensity of the 115-120 kDa band
detected with IDE Ab 2.
EDTA is a common anticoagulant used in blood collection tubes to prevent the
clotting cascade, when separating plasma out of whole blood. Final concentrations
of EDTA in blood after collection range from approximately 1.2 to 2.0 mg/mL, and
as EDTA is water-soluble, it is most likely that a majority of this would remain in the
plasma following red blood cell removal.

EDTA functions as a chelating agent,

sequestering metal ions from proteins, and this may have an effect on the
antibody-antigen interaction in immunoblotting techniques when detecting metal99

dependent enzymes such as IDE. To determine whether IDE detection is influenced
by EDTA in the blood samples, plasma which was collected in non-EDTA collection
tubes (using Lithium-heparin as anticoagulant) was spiked with EDTA to give final
concentrations from 0 to 2.0 mg/mL. SDS-PAGE and Western immunoblotting were
then performed on these samples with IDE Ab 2 (Figure 3.6). Results show there
was no difference in the levels of IDE detected when comparing the control plasma
(0 mg/mL of EDTA) with the plasma samples containing concentrations of EDTA up
to 2.0 mg/mL.

Figure 3.6: Investigating the effect of EDTA on IDE detection. Western blot of an
individual plasma sample collected in lithium-heparin collection tube subsequently
spiked with EDTA to final concentrations of 1.0, 1.5 and 2.0 mg/mL as detailed in
Sections 2.2.4.7, 2.2.4.1 and 2.2.4.2. The blot contained rrIDE as a positive control,
and was probed with IDE Ab 2 (LS-C55007). Duplicate aliquots of plasma sample S1
(1 μL/lane) were loaded. The rrIDE lane contained 50 ng protein. Results show no
significant differences between IDE band intensities for EDTA concentrations from 0
to 2.0 mg/mL.
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3.3.5 IDE Ab 2 cross-reacts with HSA strongly, and BSA weakly, in
Western immunoblotting.
Albumin is the most abundant plasma protein and therefore cross-reactivity
between albumin and a detecting antibody may potentially mask true levels of a
less abundant protein. The plasma levels of albumin in the AIBL cohort range from
approximately 30 to 60 mg/mL (which would equate to 30-60 µg/lane in the 1 µl
plasma aliquots/lane).

Therefore Western immunoblotting experiments were

carried out to determine whether IDE Ab 2 (LS-C55007) cross-reacts with purified
bovine (BSA) and/or human (HSA) serum albumin at concentrations within the
physiological range in AIBL participants (Figure 3.7). HSA was also spiked with
purified recombinant human IDE (rhIDE) to determine if any interaction occurs
between the proteins that would produce additional bands in Western
immunoblotting. The results show that Ab 2 cross-reacted with purified HSA
strongly at both 30 and 60 µg/lane, with two close bands detected at approximately
45 kDa. Very slight cross-reactivity was also observed between Ab 2 and BSA at
both concentrations. The bands observed did not appear to be dose-responsive for
either HSA or BSA, although a lower exposure time may have shown band intensity
differences. No other bands were observed when HSA was spiked with rhIDE. It
was concluded that the cross-reactivity between Ab 2 and albumin was of little
significance in the Western immunoblotting method as no bands were seen in the
region of interest (100-120 kDa). Interestingly the molecular weight of human
albumin is 66 kDa and no bands were observed in this region.
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Figure 3.7 Test of cross-reactivity between Ab 2 (LS-C55007) and HSA or BSA.
Purified human serum albumin (HSA), bovine serum albumin (BSA), and HSA spiked
with recombinant human IDE (rhIDE) were probed with IDE Ab 2 as detailed in
Sections 2.2.4.8, 2.2.4.1 and 2.2.4.2. HSA and BSA lanes contain 60 and 30 μg
protein per lane in duplicate. HSA + rhIDE contains 30 μg HSA and 175.2 ng rhIDE in
duplicate. Results show that the antibody cross-reacts with HSA, with strong bands
appearing at approximately 45-50 kDa. Detection appears to be non-dose
responsive. BSA also appeared to be detected weakly at approximately 50kDa, also
in a non-dose responsive fashion.

3.3.6 Testing the specificity of IDE Ab 2 by pre-incubation blocking of
the antibody with the immunising peptide.
To determine which of the bands (if any) observed in human plasma by Western
immunoblotting with Ab 2 are IDE, a pre-incubation step with the immunising
peptide was performed on Ab 2 (refer to Section 3.3.1 for overview). Such a preincubation should block the antibody binding sites. The peptide was customsynthesised to be identical to the immunogen used to raise Ab 2. The test was
carried out in 3 slightly different ways, to ensure accuracy of the results (Figures
3.8(A)(B)(C)). Results showed that the 118 kDa bands observed in rrIDE and rhIDE
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lanes were absent after pre-incubating Ab 2 with the blocking peptide, however no
differences were seen between any of the bands from human plasma in the
molecular weight region of interest. The results indicate that Ab 2 is specifically
detecting the purified recombinant IDE, however also indicate that the bands seen
in human plasma are most likely non-specific.

Figure 3.8(A) Pre-incubation of IDE Ab 2(LS-C55007) with the immunising peptide
to test antibody specificity (Test 1). Pooled control plasma (PCP) and recombinant
rat IDE (rrIDE - positive control) were probed with IDE Ab 2, some antibody aliquots
of Ab 2 were blocked (prior to adding to immunoblots) with a custom-made peptide
identical to the immunogen (20, 40, 80 and 180 μg peptide/blot) as detailed in
Sections 2.2.4.11, 2.2.4.1 and 2.2.4.2. PCP lanes contain 1 μL plasma per lane.
rrIDE lanes contain 200 ng per lane. Results show rrIDE bands (118 kDa) absent at
all concentrations of blocking peptide, however no differences can be seen in PCP
lanes in the region of interest.
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Figure 3.8(B) Pre-incubation of IDE Ab 2(LS-C55007) with the immunising peptide
to test antibody specificity (Test 2). Pooled control plasma (PCP) and recombinant
rat IDE (rrIDE - positive control) were probed with IDE Ab 2, which had been
neutralised/blocked prior to incubation with the custom peptide identical to the
immunogen (250 and 500 μg peptide/blot - higher amount/sample than in previous
experiment) as detailed in Sections 2.2.4.11, 2.2.4.1 and 2.2.4.2. PCP lanes contain
1 μL plasma per lane in duplicate. rrIDE lanes contain 200 ng per lane in duplicate.
Results show that the rrIDE bands (118 kDa) are absent at all concentrations of
blocking peptide, however no difference can be seen in PCP bands.
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Figure 3.8(C) Pre-incubation of IDE Ab 2 (LS-C55007) with the immunising
peptide to test antibody specificity (Test 3). Pooled control plasma (PCP),
recombinant rat IDE (rrIDE), recombinant human IDE (rhIDE) and human brain
frontal cortex (FC) were probed with IDE Ab 2, with some antibody samples having
been blocked prior to incubation with a custom peptide identical to the immunogen
(50 and 500 μg peptide/blot) as detailed in Sections 2.2.4.11, 2.2.4.1 and 2.2.4.2.
PCP lanes contain 1 μL plasma/lane, rrIDE lanes contain 200 ng/lane, rhIDE lanes
contain 127 ng/lane and FC lanes contain 1µL brain homogenate/lane (15.2 µg total
protein). Results show rrIDE and rhIDE bands (118 kDa) are absent at all
concentrations of blocking peptide, however no difference can be seen in the PCP
or FC bands. The immunoblotting results had been transformed with Quantity One
software to aid visualisation of bands.

3.3.7 Test of IDE antibody ab28561 (Ab 3).
An alternate IDE antibody (ab28561), which binds to an epitope encompassing an
area that is not part of the active site of IDE, was tested for its ability to detect
plasma IDE by Western immunoblotting (Figure 3.9). The antibody (designated Ab
3) was tested using both ECL™ (standard) and ECL™ Prime Detection Reagents.
ECL™ Prime is a replacement product for ECL™ Advance (now discontinued),
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therefore has greater sensitivity than standard ECL™. Samples of rrIDE, rhIDE, rat
liver homogenate and human frontal cortex (FC) were also included on the Western
blots. The results showed that Ab 3 can detect rrIDE and rhIDE as a single band at
118 kDa, similar to Ab 1 and 2. Using standard ECL™, several bands were detected
at approximately 50, 70, 80 and 120-130 kDa in human plasma, as well as a single
band at 110 kDa in rat liver and single bands for recombinant IDE (rat and human –
rrIDE/rhIDE, respectively). No bands were detected in the FC sample using standard
ECL™ under these conditions.

When ECL™ Prime was used as the detection

reagent, multiple other bands became visible in all samples, including the rrIDE,
rhIDE and FC.

In plasma, an additional band at approximately 160 kDa was

observed. These results indicated that Ab 3 may be suitable for detecting IDE in
human plasma, however specificity needed to be checked.
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Figure 3.9 Test of Ab 3 (ab28561) on human plasma, rat liver, human frontal
cortex and recombinant IDE (rat and human). Pooled plasma (PCP), recombinant
rat IDE (rrIDE), rat liver homogenate, human brain frontal cortex (FC and
recombinant human IDE (rhIDE) were probed with IDE Ab 3 (ab28561), and
developed with either ECL (membrane A) or ECL Prime (membrane B) as detailed in
Sections 2.2.4.1 and 2.2.4.4. PCP lanes contain 1 μL plasma per lane. The rrIDE
samples contained 100 ng per lane, rat liver samples: 47.4 μg total protein per lane,
human FC samples: 15.2 μg total protein per lane and rhIDE samples: 127 ng per
lane. Single bands were observed for rrIDE, rat liver and rhIDE at 110-118 kDa using
ECL Normal. For PCP, bands appear at approximately 120-130, 80, 70 and 50 kDa.
No band was apparent for human FC (Membrane A). With ECL Prime, an extra band
was seen in the PCP at just over 160 kDa and several extra bands in rat liver (two at
around 80 kDa, one at 55-60 kDa and one at 50 kDa). For human FC, three bands
were detected using ECL Prime in the region of interest (approximately 125, 115
and 100 kDa) as well as two strong bands at approximately 55 and 50 kDa.
Membrane B has been transformed with Quantity One software to aid visualisation
of bands.
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3.3.8 EDTA has no effect on the intensity of the 120-130 kDa band
detected with IDE Ab 3 (ab28561).
As previously described in Section 3.3.4, Ab 3 was tested to determine if the EDTA
in the plasma samples influences the binding of Ab 3 to IDE. The immunoblot which
had been used for this purpose to test IDE Ab 2 was stripped of antibodies, and reprobed using Ab 3 (Figure 3.10). Results showed that there was no difference in
protein band intensities between the control plasma sample and the samples
containing EDTA up to 2.0 mg/mL.

Figure 3.10 Investigating whether EDTA in blood samples interferes with Ab 3
(Ab28561) detection of putative IDE protein bands. The Western blot run for the
purpose of investigating Ab 2 in the same manner (see Fig. 3.6) was stripped and reprobed with IDE antibody Ab 3 (ab28561) as detailed in Sections 2.2.4.5 and 2.2.4.4.
Plasma sample (S1) contains 1μL plasma/lane in duplicate. The rrIDE lane contains
50ng protein. The plasma samples had been spiked with EDTA to 1.0, 1.5 and
2.0mg/mL. Results show no significant difference between band intensities of
control plasma samples and samples spiked with EDTA, when detected with Ab 3.
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3.3.9 Ab 3 (ab28561) cross-reacts with BSA, HSA and a non-albumin
containing blocking agent.
As both monoclonal and polyclonal IDE antibodies have previously been reported to
cross-react with other proteins (Yfanti, et al., 2008), and results on Ab 2 (LS-C55007)
from the current project show cross-reactivity with HSA and BSA (refer to Section
3.3.5), Ab 3 (ab28561) was also tested (Figure 3.11(A)). The amounts loaded onto
the gel were 30 µg and 60 µg which reflected physiological albumin levels found in
the plasma volumes normally loaded onto the gels (1 µL/lane). The results showed
that Ab 3 strongly cross-reacts with BSA in a dose-dependent manner, with bands
visible at 40, 38 and 20 kDa in the 60 µg lane, and only the 40 and 20 kDa bands
visible in the 30 µg BSA lane. With HSA, weak signals were detected at ~ 50 and 36
kDa at 60 µg HSA, but not at 36 kDa in the 30 µg HSA lane. In addition, no extra
bands were observed when 60 µg HSA was spiked with either rrIDE or rhIDE. It
should be noted that the quantity of rhIDE used was approximately 20-fold the
rrIDE quantity; as the rhIDE was past its expiry date, it was used in excess in case
there had been significant protein degradation. As this was not a test requiring
quantification of the IDE, this excessive use of rhIDE was determined to be of no
consequence.
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Figure 3.11(A) Test of cross-reactivity of IDE Ab 3 with HSA and BSA. Purified HSA,
BSA, and HSA spiked with recombinant rat (rrIDE) or human IDE (rhIDE) were
resolved by SDS-PAGE and probed with primary antibody (Ab 3) ab28561 as
detailed in Sections 2.2.4.8, 2.2.4.1 and 2.2.4.4. HSA and BSA lanes contained 30 or
60 μg protein, in duplicate. HSA + rrIDE, or rhIDE, contained 60 μg HSA + 8 ng rrIDE,
or 175.2ng rhIDE, respectively, in duplicate. Results show that the antibody crossreacts with BSA at levels that would be found in plasma volumes frequently loaded
onto gels, with strong bands appearing at ~ 40 and 20kDa and light bands at ~
38kDa only in 60μg lanes. Signals appear to be dose responsive. HSA also appeared
to be detected weakly at ~ 50 and 36kDa.

To investigate further whether IDE Ab 3 may cross-react with other blocking agents
which did not contain albumin, ECL™ Advance Blocking Reagent was tested. Due to
proprietary restrictions, it was not possible to determine the components present
in the ECL™ blocking agent or their respective physiological concentrations;
however it was stated by the manufacturer that the preparation should not contain
albumin or globulin. The preparation was primarily produced from bovine milk
powder and therefore would be expected to contain milk proteins such as casein
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and other whey proteins. The ECL™ blocking agent was tested for Ab 3 crossreactivity at concentrations up to 60 mg/mL (Figure 3.11(B)). The results show that
Ab 3 can cross-react with ECL™ blocking agent at 30-60 mg/mL, with bands at
approximately 55 kDa, however no bands were visible at 15 mg/mL. The signal
detected was dose-responsive.

Figure 3.11(B) Test of cross-reactivity of IDE antibody Ab 3 with BSA and ECL™
Advance Blocking Reagent. BSA and ECL lanes contain 15, 30 and 60 μg protein
each in duplicate. The recombinant rat IDE (rrIDE) lane contains 7.5 ng. Experiment
was performed as detailed in Sections 2.2.4.9, 2.2.4.1 and 2.2.4.4. Results show
that the antibody cross-reacts with BSA at levels equivalent to albumin in the
physiological range of human plasma, with bands at 40kDa (30-60 μg) and 20kDa
(60 μg). The signal appears to be dose-responsive. Similarly, the ECL block is also
cross-reactive with bands appearing at 55kDa (for 30-60 μg). No signal was
detected for either BSA or ECL at 15 μg at this exposure.

As there was no signal present in the expected 100-130 kDa range for HSA, BSA or
ECL™ Blocking Reagent, it was concluded that Ab 3 may still be suitable for the
measurement of plasma IDE by Western immunoblotting. However, the crossreactivity observed may have implications for the detection of IDE in other
immunoaffinity-based applications.
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3.3.10 Immunoprecipitation of IDE from human plasma.
As IDE Ab 3 (ab28561) binds non-specifically with other proteins in human plasma,
it is likely that one or more of the bands seen in Western immunoblotting are nonspecific. To reduce the number of confounding factors in the sample, and to
improve determination of the bands of interest, an immunoprecipitation (IP)
method was trialled using Protein G-coupled magnetic sepharose beads, with yet
another polyclonal IDE antibody (Figure 3.12(A)). The IP antibody was raised in
mouse against a synthetic peptide derived from the N-terminus of human IDE, and
designated Ab 4 (250706). As such, Ab 4 would not be expected to capture the
truncated isoform of IDE as it does not contain the N-terminal half.

The

immunoprecipitated samples were resolved by SDS-PAGE and detected on Western
blots using Ab 3 (ab28561). Results showed that the recovery of purified rrIDE was
poor (under the conditions employed) with only approximately 14% of the protein
recovered after immunoprecipitation with this protocol and antibody. Numerous
bands were still observed after both albumin depletion (including pre-clearing of
immunoglobulins) and immunoprecipitation of plasma. However, in the region of
interest (approximately 100-130 kDa) only one band was clearly visible after either
albumin depletion and/or immunoprecipitation, although this band was less intense
than in the plasma control which had only 25% of the plasma content used in the
IP. This band was determined to be approximately 120-130 kDa. In addition, the
band at 160 kDa in plasma was not observed after IP, and the 70 kDa band was
significantly reduced. The 80 kDa band observed in plasma however, was still
present after albumin depletion and/or IP. It was concluded that the 160 and 70
kDa bands were non-specific, whereas the 120-130 kDa band appears to be specific.
Interestingly, the 80 kDa band also appears to be specific, however analysis of this
band is outside the scope of this project. Nevertheless, it may be worth
characterising this 80 kDa band in future studies.
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Figure 3.12(A) Immunoprecipitation of IDE from human plasma using IDE mouse
polyclonal Ab 4 (250706). IDE was immunoprecipitated from pooled plasma (PCP),
albumin-depleted PCP (AD) and recombinant rat IDE (rrIDE) samples, using IDE Ab 4
(250706) and probed with IDE Ab 3 (ab28561) as detailed in Sections 2.2.4.16,
2.2.4.1 and 2.2.4.4. PCP was pre-cleared of IgG, and albumin-depleted with
antibody AL-01, prior to IP (see Sections 2.2.4.13 and 2.2.4.14). PCP lanes contain 1
μL/lane in duplicate. IP from PCP used 4μL of plasma/sample (per lane), run in
duplicate, and rrIDE lanes contain 50ng or equivalent/lane in duplicate. AD lanes
contain 1, 0.5, and 0.25 μL plasma/lane as indicated. An extra band appears at just
over 50kDa in the rrIDE IP, suggesting cross-reactivity of Ab 3 or the secondary
antibody to the heavy chain of the eluted IP antibody. Blot A. (lower image) has
been transformed with Quantity One software to aid visualisation of upper band.

A further IP experiment was performed using the same protocol, to test a second
polyclonal IDE antibody designated Ab 5 (AF2496) (Figure 3.12(B)). Ab 5 was raised
in goat against full-length human recombinant IDE. Using a full-length protein as an
immunogen for generating an antibody is likely to result in conformational
epitopes, thus the antibody is more likely to recognise the native protein, and may
be more sensitive in an IP in which IDE has not been denatured or reduced. One
rhIDE sample was pre-incubated with Aβ42, and immunoprecipitated, to determine
if binding between these proteins was resistant to the IP procedure (as well as the
denaturing and reducing conditions) which would lead to an upward shift in
molecular weight. Immunoprecipitated samples were subsequently resolved by
SDS-PAGE and immunoblotted using Ab 3 (ab28561). Results showed that Ab 5
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produced similar results to those obtained using Ab 4, with clear bands apparent at
120-130 and 80 kDa. No bands were observed at 160 kDa, and the 70 kDa band
previously observed with Ab 4 was very faint and only seen in PCP, and not in the
AD PCP. Ab 5 detected very weak bands in the rrIDE lanes compared with rhIDE
lanes.

No shift in molecular weight was observed in the Aβ42-spiked rhIDE

compared with rhIDE alone, however the bands were fainter. AD PCP IP bands at
120-130 kDa were also fainter than PCP IP bands. Overall it appears that the 120130 kDa and the 80 kDa bands in human plasma are specific, while it is unlikely that
the 160 kDa or 70 kDa bands are IDE.

Figure 3.12(B) Immunoprecipitation of IDE from human plasma using IDE
antibody Ab 5 (AF2496). IDE immunoprecipitation was carried out from pooled
plasma (PCP), albumin-depleted PCP (AD), recombinant rat IDE (rrIDE) and
recombinant human IDE (rhIDE) using polyclonal IDE AF2496 as detailed in Sections
2.2.4.16, 2.2.4.1 and 2.2.4.4. Following SDS-PAGE and Western blotting, blots were
probed with IDE ab28561 (Ab 3). Image A(2) is a longer exposure of Blot A. The
two right lanes contain 50ng rhIDE + 9μg beta-amyloid 42 (Aβ42). For AD, PCP
samples were pre-cleared of IgG and albumin-depleted with antibody AL-01, prior
to IP (see Sections 2.2.4.13 and 2.2.4.14). IP PCP and AD samples originally used
2μL of plasma per lane in duplicate, and rrIDE/rhIDE and rhIDE+Aβ42 lanes contain
50ng or equivalent of IDE per lane in duplicate. Bands lower than 60kDa in all lanes
are contaminated with the immunoprecipitating antibody fragments which were
eluted with the sample. At 3 min exposure, rhIDE is detected at 118kDa, no visible
bands for rrIDE (Blot A). At 10 min exposure, the rrIDE bands are faintly visible at
118kDa (Blot A(2)).
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3.3.11

Pre-incubation immunising peptide blocking test on IDE

antibody Ab 3 (ab28561) for specificity.
To determine the specificity of the bands detected by Western immunoblotting
with Ab 3, a blocking test involving pre-incubation with the immunising peptide was
performed (similar to the test performed with Ab 1 and 2, in Sections 3.3.1 and
3.3.6) using a commercial peptide which was the Ab 3 immunogen (Figure 3.13).
The results were difficult to interpret as the immunising peptide increased the
background of the immunoblot and this caused difficulties in visualisation of the
bands. However, despite this issue, it was still possible to observe a reduction in
band intensity for rrIDE, the major band in rat liver at 115 kDa and an 80 kDa band
in zebrafish brain.

It also appeared that the upper two bands in plasma

disappeared with the peptide pre-immunisation (120-30 and 160 kDa), as did the 95
and 50 kDa bands in zebrafish brain. Figure 3.13 was transformed by Quantity One
software to maximise the signal to noise ratio and shows no bands visible in these
regions. Densitometric analysis of the 120-130 kDa band shows a reduction of 97%
in the absorbed sample (antibody neutralised with 5 μg peptide). The band in
plasma at 115 kDa conversely, appears to be stronger after peptide preimmunisation. These results support the results obtained by the IP experiments
which suggest that the band observed at 120-130 kDa after immunoblotting with
Ab 3 is IDE. In addition, IDE has been demonstrated to be 110 kDa in rat liver in
previous studies, and Ab 3 specifically detects a band at a similar molecular weight,
lending further support to the likelihood that this antibody detects full-length IDE in
human plasma.

Interestingly, Ab 3 also appeared to detect IDE at different

molecular weights in zebrafish brain (50, 80 and 95 kDa) indicating different
isoforms may be present in this species, however further characterisation of these
bands is outside the scope of this project.
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Figure 3.13 Testing IDE Ab 3 (ab28561) specificity by blocking with the
immunising peptide prior to adding to Western blots. Pooled plasma (PCP),
recombinant rat IDE (rrIDE), rat liver and zebrafish brain (ZF) samples were run on
SDS-PAGE and transferred to Western prior to being probed with IDE ab28561,
some of which had been blocked prior to incubation with a commercial peptide
identical to the immunogen (0, 5 and 40μg peptide/blot). The test was performed
as detailed in Sections 2.2.4.12, 2.2.4.1 and 2.2.4.4. PCP: 1 μL plasma per lane.
rrIDE: 25 ng per lane. Rat liver: 31.6 μg total protein/lane and ZF brain: 25 μg total
protein/lane. Due to high background, the images were enhanced to optimize the
signal to noise ratio, to assist in visualising bands.

3.3.12 Measurement of the 120-130 kDa band in plasma samples
obtained from the AIBL cohort at baseline
The samples were resolved by SDS-PAGE (under reducing conditions), transferred
to Western blots, and immunoblotting was performed using Ab 2 (LS-C55007).
However, as this antibody subsequently failed the immunising peptide blocking
test, it could not be determined if the bands seen with this IDE antibody were
specific (Section 3.3.6). Therefore, the immunoblots were stripped and re-probed
using Ab 3 (ab28561) (example Figure 3.14). The band observed at 120-130 kDa
was determined to be IDE and quantified using Quantity One software. Pooled
control plasma (PCP) was used as an internal standard on each gel to control for
gel-to-gel and blot-to-blot variation. The blots were Ponceau S stained after re116

stripping and prior to immunoblotting (or Coomassie stained following
immunoblotting and subsequent re-stripping) to ensure equal loading.

Figure 3.14 120-130 kDa band measured in human plasma samples obtained from
the AIBL cohort (Ab 3). Example Western blot of 5 individual AIBL samples,
including pooled control plasma as an internal standard (PCP) and recombinant rat
IDE (rrIDE) as a positive control (Figure A.). SDS-PAGE and immunoblotting were
performed as detailed in Sections 2.2.4.1 and 2.2.4.4. Plasma samples including
PCP (1 μL/lane) were loaded in duplicate, rrIDE (100 ng/lane) was also loaded in
duplicate as a positive control. Antibody used here was Ab 3, (ab 28561). Results
show differences in band intensities between individual samples. Figure B.
Coomassie stain of membrane as loading control.

3.3.13 Low-level data analysis.
Results were considered to be semi-quantitative. Raw data were normalised for
inter-gel variation by adjusting to the PCP internal control included on each gel.
Coefficient of variation (CV) values of duplicates which were >15% were excluded
from the analysis. If the CV of the PCP duplicates was >15%, the entire gel was
excluded from the analysis. Data points determined to be outliers were removed
from the analysis (n = 2).
The overall data were observed to have a non-normal distribution (Figure 3.15(A),
Table 3.1), therefore it was transformed by square root (Figure 3.15(B), Table 3.1).
The transformation improved the normality issues, determined by inspecting the
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frequency histogram, and with the z-score for skewness being <1.96. There were
still some normality issues after transformation determined by the z-score for
kurtosis of 2.189 (absolute value), and significant p-values for the KolmogorovSmirnoff (K-S) and Shapiro-Wilk (S-W) tests. However the z-score was very close to
the cut-off point of 1.96 indicating that the normality issues were minimal. In
addition, the K-S and S-W tests are very sensitive to sample size, and as it was
reasonably large, it would be expected to show significance even with minimal
normality issues. Furthermore, when the data was stratified by classification, the
healthy control group particularly, demonstrated non-normal distribution prior to
transformation (Figures 3.16(A)(B)(C), Table 3.2), while after transformation the zscores for both skewness and kurtosis were below the cut-off point of 1.96 for all
classifications, indicating normality (Figures 3.17(A)(B)(C), Table 3.3). While there
still seemed to be minor normality issues for healthy controls only, as evidenced by
significant K-S and S-W tests, the frequency histogram was a normal shape after
transformation.

Therefore the normality issues after transformation were

determined to be within acceptable limits and parametric tests were used to
analyse the data for differences between classification and APOE4 genotype status
(ANOVA (with Tukey HSD post-hoc tests) and Student’s t-tests). However, as
existing biochemical data had non-normal distribution also, the non-parametric
Spearman’s Rho test was used to analyse correlations.
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Figure 3.15(A) Frequency histogram of overall data (IDE levels measured by
Western immunoblotting) before transformation. Band intensity results for the
IDE Western blot (WB) results (untransformed). Histogram shows a positive skew of
the data, indicating non-normal distribution (n = 157).
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Figure 3.15(B) Frequency histogram of overall data (IDE levels measured by
Western immunoblotting) after square root transformation. Band intensity
results for the IDE Western blot (WB) results transformed to square root, outliers
removed (n = 2). Histogram shows the data is improved after transformation by
square root and following the removal of two outliers (n = 155), indicating a more
normal distribution.
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Table 3.1 Values of skewness, kurtosis, Kolmogorov-Smirnoff (K-S) and ShapiroWilk (S-W) tests of distribution normality in the overall data before and after
square root transformation. Values prior to transformation indicate non-normal
distribution; after transformation skewness and kurtosis values are within
acceptable limits regardless of significant p-values for the K-S and S-W tests (n =
157/155).
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A.

B.

C.

Figures 3.16 (A)(B)(C) Frequency histograms of data (IDE levels measured by Western immunoblotting (WB)) stratified by classification (HC,
MCI, AD, respectively) before transformation. Histograms show the data is positively skewed in all classifications, indicating a deviation from
normal distribution.
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Table 3.2 Values of skewness, kurtosis, Kolmogorov-Smirnoff (K-S) and ShapiroWilk (S-W) tests of distribution normality in the data before transformation.
Values prior to transformation indicate non-normal distribution in the HC and AD
data, MCI data is within acceptable limits.

Table 3.3 Values of skewness, kurtosis, Kolmogorov-Smirnoff (K-S) and ShapiroWilk (S-W) tests of distribution normality in the data after transformation by
square root. Values after transformation by square root and removal of 2 outliers
indicate normal distribution in the MCI and AD data. Values for skewness and
kurtosis for HC data indicate normality, however the K-S and S-W tests still indicate
some deviation from normality.
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A.

B.

C.

Figures 3.17 (A)(B)(C) Frequency histograms of data (IDE levels measured by Western immunoblotting) stratified by classification (HC, MCI,
AD, respectively) after transformation by square root. Histograms show the data is improved after transformation (and removal of 2 outliers)
in all classifications, particularly in the HC data, indicating a more normal distribution.
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3.3.14 Full-length plasma IDE levels are increased in MCI compared with
HC in the total cohort.
To determine IDE levels according to cognitive status, the cohort was divided into the
clinically classified groups, healthy controls (HC - including subjective memory
complainers), mild cognitive impairment (MCI) and probable AD (AD). As only a subset
of the cohort was used, the HC and SMC groups were combined to form the healthy
control group. Mean age was significantly different between the groups. It should be
noted that the subset of samples used to measure IDE levels by Western
immunoblotting was different from the subsets subsequently used to measure IDE
levels by ELISA and IDE activity (detailed in Chapters 4 and 5, respectively). This is
because all samples in the cohort were initially going to be assayed, however due to
the time-frame required for optimisation of the procedures, the whole cohort was not
able to be completed.
The demographics for this subset of the AIBL cohort are shown in Table 3.4. AD and
MCI patients were significantly older than the HC group. As expected, AD patients had
a significantly higher percentage of APOE ε4 carriers and brain Aβ load than the control
or MCI groups. Plasma Aβ1-42 was significantly decreased in the AD group compared
with MCI and HC groups. For Aβx-40, the MCI group had significantly higher levels
compared with controls, with the AD group having levels in between MCI and HC
groups. Levels of ApoE4 were significantly decreased in the MCI group compared with
HC and AD, and estradiol was significantly reduced in MCI and AD groups
(HC>MCI>AD).

All other variables were not significantly different between

classifications.
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Table 3.4 Demographics of the AIBL cohort subset used for the Western
immunoblotting IDE analysis. Plasma samples (1.0 μL per well in duplicate) from the
AIBL cohort were measured by Western immunoblotting as detailed in Sections 2.2.4.1
and 2.2.4.4. Other variables were measured as outlined in Section 2.2.2.1. Full-length
plasma IDE level data underwent square root transformation; the remainder of the
variables are not transformed. Continuous variables are expressed as mean (median) ±
standard deviation. P values determined by Kruskall-Wallis tests using the Monte
Carlo method (untransformed) or one-way analysis of variance (transformed). As only
a subset of the cohort was tested, the HC and subjective memory (SMC) groups were
combined to provide the healthy controls for this assay. As ApoE4 is only expressed in
individuals carrying the APOE ε4 allele, the n-values are reduced for this variable. As
only a subset of the cohort were measured with Pib-PET (for Neocortical SUVR – Brain
Aβ load), n-values are reduced for this variable.
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Full-length IDE levels as determined by Western immunoblotting (Figure 3.18) were
found to be significantly higher in MCI individuals when compared with HC subjects (p
= 0.037). IDE levels in MCI individuals were also higher than in AD patients, however
this did not reach significance (p = 0.054 – a significant difference for all results
requires p ≤ 0.05). There was no significant difference between the HC and AD groups.

Figure 3.18 Levels of full-length plasma IDE are increased in MCI compared with HC
and AD. Plasma samples (60 μg/ lane total protein in duplicate) from the AIBL cohort
were resolved by 10% SDS-PAGE, transferred to Western blots and probed for fulllength IDE as described in Sections 2.2.4.1 and 2.2.4.4, the antibody used was Ab 3 (Ab
28561). The average optical density of the duplicate bands was obtained for each
sample, and the mean of these values was compared by ANOVA with Tukey post-hoc
analysis. Data represents mean ± SEM ,n = 155 (90 HC/25 MCI/40 AD). Results show
IDE levels in MCI are significantly increased compared with HC (p = 0.037) and trended
towards an increase in levels compared with AD (p = 0.054).
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3.3.15 Full-length plasma IDE levels are increased in females with MCI
compared with HC and AD
Further analysis revealed a significant difference in IDE levels between males and
females (p = 0.000), with females having higher levels of full-length IDE than males
(Figure 3.19).

Therefore, the data was subsequently analysed by classification

separately for males and females (Figure 3.20). The results show that the significant
difference seen in the MCI group compared with the HC group is only demonstrated in
females (p = 0.014). In addition, the difference between the female MCI and AD
groups was also highly significant (p = 0.008). When analysing the data for the male
participants only, no significant difference between classifications was observed.

Figure 3.19 Full-length plasma IDE is higher in females compared with males. Plasma
samples (60 μg/lane total protein in duplicate) were resolved by 10% SDS-PAGE,
transferred to Western blots and probed for IDE as described in Sections 2.2.4.1 and
2.2.4.4, the antibody used was Ab 3, (Ab 28561). The average optical density of
duplicate bands was obtained for each sample, and the mean of these values was
compared by Students T-test. Data represents mean ± SEM, n = 155 (62 M/93 F).
Results show that full-length plasma IDE is significantly higher in females compared
with males (p = 0.000).
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Figure 3.20 Full-length plasma IDE levels are increased in MCI compared with HC and
AD in females only. Plasma samples (60 μg/lane total protein in duplicate) were
resolved by 10% SDS-PAGE, transferred to Western blots and probed for full-length IDE
as described in Sections 2.2.4.1 and 2.2.4.4, using Ab 3. The average optical density of
the duplicate bands was obtained for each sample, and the mean of these values was
compared by ANOVA with Tukey post-hoc analysis. Data represents mean ± SEM, n =
155 (HC-38 M/52 F, MCI-13 M/12 F, AD-11 M/29 F). Results show that full-length
plasma IDE is significantly increased in female MCI individuals compared with both
female HC (p = 0.014) and female AD (p = 0.008) participants. In addition, IDE is
significantly higher in females compared with males in both the HC (p = 0.008) and the
MCI (p = 0.001) groups but not in the AD group (p = 0.190).

3.3.16 Levels of full-length plasma IDE do not differ in APOE ε4 carriers
compared with non-carriers.
As the APOE ε4 genotype is considered a risk factor for AD, and it has been reported
that levels of IDE are reduced in neurons exposed to the ApoE4 protein in vitro (Du, et
al., 2009), the data was analysed to see if there was any difference between full-length
plasma IDE in individuals carrying the ε4 allele compared to non-carriers (Figure 3.21
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(A)). The results show that there was no significant difference in plasma full-length IDE
levels between ε4 carriers and non-carriers, for the data overall (p = 0.183) When
stratified by ε4 status, a similar pattern was seen by classification as in the overall
subset, however the increase in IDE levels in the MCI group was no longer significant
for either ε4 carriers (p = 0.128) or non-carriers (p = 0.271)(Figure 3.21(B) and (C),
respectively).

Figure 3.21(A) Full-length plasma IDE levels are no different in ε4 non-carriers
compared with carriers. Plasma samples (60 μg/lane total protein in duplicate) were
resolved by 10% SDS-PAGE, transferred to Western blots and probed for full-length IDE
as described in Sections 2.2.4.1 and 2.2.4.4, using Ab 3. The average optical density of
the duplicate bands was obtained for each sample, and the mean of these values was
compared by Students T-test. Data represents mean ± SEM ,n = 152 (54 ε4/98 nonε4). Results show that there is no significant difference in full-length plasma IDE levels
for ε4 non-carriers compared with carriers (p = 0.183).
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Figure 3.21(B) and (C) Full-length plasma IDE levels are not significantly different by
clinical classification for ε4 non-carriers or carriers. Plasma samples (60 μg/lane total
protein in duplicate) were resolved by 10% SDS-PAGE, transferred to Western blots
and probed for full-length IDE as described in Sections 2.2.4.1 and 2.2.4.4, using Ab 3.
The average optical density of the duplicate bands was obtained for each sample, and
the mean of these values was compared by Students T-test. Data represents mean ±
SEM, (ε4 carriers) n = 54 (25 HC/10 MCI/19AD), (non-carriers) n = 98 (64 HC/15 MCI/19
AD). Results show that there is no significant difference in full-length plasma IDE levels
by clinical classification for either ε4 carriers (p = 0.128) or non-carriers (p = 0.271).
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When the overall data is controlled for gender, similar results are observed between
classifications, with the MCI group having significantly higher full-length IDE levels than
controls (p = 0.026), but with levels in the MCI group being significantly higher than the
AD group as well (p = 0.040). As age has also been shown to be significantly different
between the groups in this subset (p = 0.013), this was also controlled for along with
gender, and results showed the same trend: MCI subjects have significantly higher IDE
levels than both HC (p = 0.010) and AD (p = 0.014). Even though there were no
significant differences in IDE levels in ε4 carriers versus non-carriers, the ε4 status has
the potential to affect the levels of IDE in plasma, and controlling for this as well as
gender and age strengthened this trend with the MCI group again having significantly
higher levels than both HC (p =0.004) and AD (p = 0.006) (Figure 3.22). Conversely
when analysing full-length IDE levels by ε4 status, no effect of covariates was observed
demonstrating no significant differences between carriers and non-carriers (data not
shown).

136

Figure 3.22 Full-length plasma IDE levels are significantly increased in MCI compared
with HC and AD. Plasma samples (60 μg/lane total protein in duplicate) were resolved
by 10% SDS-PAGE, transferred to Western blots and probed for full-length IDE as
described in Sections 2.2.4.1 and 2.2.4.4, using Ab 3. The average optical density of
the duplicate bands was obtained for each sample, and the mean of these values was
compared by ANCOVA. Data represents mean ± SEM, n = 152 (89 HC/25 MCI/38 AD).
Data is controlled for gender, age and APOE ε4 status. Results show that full-length
plasma IDE levels are significantly higher in the MCI group compared with the HC (p =
0.004) and AD (p = 0.006) groups.

3.3.17

Relationships between total plasma IDE levels and other

biochemical data collected in the AIBL study.
To determine if there were any relationships between plasma levels of full-length IDE
and other biochemical data collected as part of the AIBL study, correlation analyses
were performed. Details of the methods used to measure the variables other than IDE
are outlined in Section 2.2.2.1. As full-length IDE was shown to differ by gender in the
current study, it was included in the correlation analyses.

Plasma IDE was also

analysed for any correlation with age as it has been reported that expression of IDE
shows an age-dependent reduction in the brain (Caccamo, et al., 2005). Plasma
insulin, Aβ40 and Aβ42 (and N-terminally truncated fragments), and total ApoE and
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ApoE4 were analysed for correlations with IDE, as both insulin and Aβ are substrates of
IDE and ApoE has been associated with reduced IDE expression (Cook, et al., 2003; Du,
et al., 2009). The levels of testosterone, estradiol and cholesterol (plus LDL/HDL
subfractions) were also examined for correlation with full-length IDE levels, as these
have also been associated with changes in IDE expression (Udrisar, et al., 2005;
Sharma, et al., 2008). Furthermore, full-length plasma IDE levels were also compared
with brain Aβ load to see if any correlation exists between these two variables.
Results showed that in the whole subset (Table 3.2), and in addition to a positive
correlation with gender (rs = .282, p = 0.000), only total and free testosterone
negatively correlated with full-length plasma IDE, however these associations were
weak [(rs = -.235, p = 0.004) and (rs = -.255, p = 0.001), respectively]. Oestradiol, the
predominant female sex hormone, almost reached significance (rs = -.173, p = 0.053),
however the association was again weak. No other variables correlated with plasma
full-length IDE. After Bonferroni-Holm correction for multiple testing (Holm, 1979),
only gender (p = 0.000) and free testosterone (p = 0.017) were still significant although
total testosterone also showed a trend towards significance (p = 0.064).
As both testosterone and oestradiol both significantly correlate with gender and with
each other, males and females were analysed separately to see if the relationship
between full-length plasma IDE with these variables was due to the effect of gender
(Tables 3.3(A) and (B)). The results showed that these correlations were not significant
when males and females were analysed separately. No correlations between plasma
IDE and the remaining biochemical variables were observed when the genders were
analysed separately, however in males insulin approached significance for a negative
association (rs = -.239, p = 0.064).
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Table 3.2 Correlation matrix of full-length plasma IDE levels with other variables.
Plasma levels of full-length IDE were analysed for relationships with sex, age, and
plasma insulin, Aβ species, ApoE species, testosterone, oestradiol, lipids and brain Aβ
load (two tailed) (methods of data collection are outlined in Section 2.2.2.1). n values
vary due to missing values for some data or in the case of brain Aβ load only a subset
of the cohort underwent PiB-PET scans. For ApoE4, n value is lower as only the APOE
ε4 carriers express this isoform. Results show a significant but weak correlation exists
between IDE levels and both sex (rs = .282, p = .000), total testosterone (rs = -.235, p =
.004) and free testosterone (rs = -.282, p = 0.001). Oestradiol approached a weak
correlation however did not reach significance (rs = -.173, p = 0.053). Only sex (gender)
and free testosterone remained significant following Bonferroni-Holm correction for
multiple testing. * indicates significance at the 0.05 level, ** indicates significance at
the 0.01 level. (“unadj.” = unadjusted, prior to Bonferroni-Holm correction, “adj.” =
adjusted by Bonferroni-Holm correction).
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Tables 3.3 (A) Correlation matrix of full-length plasma IDE levels with other
biochemical variables (males only). Table 3.3 (A) shows correlation analysis of fulllength plasma IDE with age, and plasma insulin, Aβ species, ApoE species,
testosterone, oestradiol, lipids and brain Aβ load (two tailed). Methods of data
collection are outlined in Section 2.2.2.1. n values vary due to missing values for some
data or in the case of brain Aβ load only a subset of the cohort underwent PiB-PET
scans. For ApoE4, n value is lower as only the APOE ε4 carriers express this isoform.
Results show that insulin demonstrates a trend toward a negative correlation (rs = .239, p = 0.064), however there were no other significant correlations or trends in
males.
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Tables 3.3 (B) Correlation matrix of full-length plasma IDE levels with other
biochemical variables (females only). Table 3.3 (B) shows correlation analysis of fulllength plasma IDE with age, and plasma insulin, Aβ species, ApoE species,
testosterone, oestradiol, lipids and brain Aβ load (two tailed). Methods of data
collection are outlined in Section 2.2.2.1. n values vary due to missing values for some
data or in the case of brain Aβ load only a subset of the cohort underwent PiB-PET
scans. For ApoE4, n value is lower as only the APOE ε4 carriers express this isoform.
Results show no significant correlations or trends in females.
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When stratified by APOE ε4 status (Tables 3.4 (A) and (B)), for the non- ε4 carriers
there were positive correlations observed between full-length IDE levels and sex (rs =
.314, p = 0.002) and total ApoE (rs = .232, p = 0.021), and inverse correlations with Aβ140

(rs = -.230, p = 0.023), total testosterone (rs = -.282, p = 0.006), free testosterone (rs =

-.306, p = 0.002), oestradiol (rs = -.242, p = 0.034) and brain Aβ load (rs = -.401, p =
0.019). Following Bonferroni-Holm correction however, only gender (p = 0.036) and
free testosterone (p = 0.034) remained significant. For the ε4 carriers, no significant
correlations were seen between full-length IDE and any of the variables tested.
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Table 3.4 (A) Correlation matrix of full-length plasma IDE levels with other variables
for APOE ε4 non-carriers only. Plasma levels of full-length IDE were analysed for
relationships with sex, age, and plasma insulin, Aβ species, ApoE species, testosterone,
oestradiol, lipids and brain Aβ load (two tailed) after stratifying data by APOE ε4 status
(methods of data collection are outlined in Section 2.2.2.1). n values vary due to
missing values for some data or in the case of brain Aβ load only a subset of the cohort
underwent PiB-PET scans. For ApoE4, no values are shown as only the APOE ε4
carriers express this isoform. Results show significant positive correlations between
IDE levels and sex (rs = .314, p = 0.002) and total ApoE (rs = .232, p = 0.021), and inverse
correlations with Aβ1-40 (rs = -.230, p = 0.023), total testosterone (rs = -.282, p = 0.006),
free testosterone (rs = -.306, p = 0.002), oestradiol (rs = -.242, p = 0.034) and brain Aβ
load (rs = -.401, p = 0.019). Only gender (p = 0.036) and free testosterone (0.034)
remained significant following Bonferroni-Holm correction for multiple testing. *
indicates significance at the 0.05 level, ** indicates significance at the 0.01 level.
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Table 3.4 (B) Correlation matrix of full-length plasma IDE levels with other variables
for APOE ε4 carriers only. Plasma levels of full-length IDE were analysed for
relationships with sex, age, and plasma insulin, Aβ species, ApoE species, testosterone,
oestradiol, lipids and brain Aβ load (two tailed) after stratifying data by APOE ε4 status
(methods of data collection are outlined in Section 2.2.2.1). n values vary due to
missing values for some data or in the case of brain Aβ load only a subset of the cohort
underwent PiB-PET scans. Results show no significant correlations between full-length
plasma IDE and any other variables tested.
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3.3.17.1 The ratio of full-length IDE to insulin is not significantly
different between classifications.
IDE has a high affinity for both insulin and Aβ and as a result they may compete for the
enzyme in the circulation. This does depend on a plethora of other factors such as
binding affinities of these peptides (and other IDE substrates) for IDE, plasma levels of
the free peptides (as opposed to those bound to other proteins), levels of other IDE
substrates, levels of other enzymes that degrade one or both of these peptides (for
example neprilysin, amongst others, can also degrade Aβ), binding/clearance by other
tissues, and conformation of the peptides. For many reasons, it is possible that the
ratio of IDE to insulin in plasma may help to differentiate between HC and MCI and/or
AD. Therefore a ratio was calculated between the untransformed measurements of
full-length plasma IDE and plasma insulin levels and compared between clinical
classifications (Figure 3.23(A)). The results showed no significant differences in the
ratio of full-length IDE to insulin (p = 0.092), although the ratio tended to be a little
higher in MCI compared with HC group. It was concluded that there was no overall
improvement when considering full-length IDE levels relative to insulin for
differentiating between clinical classifications, compared with IDE alone.
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Figure 3.23(A) The ratio of full-length IDE to insulin is not significantly different
between classifications. Insulin levels were measured as outlined in Section 2.2.2.1.
Plasma samples (60 μg/lane total protein in duplicate) were resolved by 10% SDSPAGE, transferred to Western blots and probed for full-length IDE as described in
Sections 2.2.4.1 and 2.2.4.4, using Ab 3. The average optical density of the duplicate
bands was obtained for each sample, and a ratio was calculated of (untransformed)
full-length plasma IDE to plasma insulin (IDE/Insulin ratio). The median of these values
were compared between classifications by a Kruskall-Wallis test. Data represents
medians with 95% confidence interval (CI), n = 153 (89 HC/25 MCI/39 AD). Results
show no significant differences in the IDE/insulin ratio between classifications (p =
0.092).
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3.3.17.2 The ratio of full-length IDE to total Aβ (42+40) tends to be
higher in MCI compared with HC.
Similarly to the IDE/insulin ratio, the levels of full-length IDE relative to the levels of
Aβ1-42 and Aβ1-40 may be more informative with respect to differentiating between
clinical classifications of AD and MCI with controls, than levels of IDE alone. It has been
demonstrated that plasma Aβ is generally elevated in early AD compared with controls
and reduces as Aβ is deposited into SP in the brain (Kawarabayashi, et al., 2001;
Schupf, et al., 2008), therefore the ratio of plasma IDE/Aβ levels may be pertinent in
the prodromal stages of AD with respect to the regulation of plasma Aβ levels. This
may be reflected in the MCI group, which represents the pre-symptomatic period prior
to full-blown AD symptoms becoming apparent. Therefore, a ratio of plasma fulllength IDE with total levels of Aβ1-42 + Aβ1-40 were calculated and compared between
clinical classifications (Figure 3.23(B)). Results showed that the ratio of full-length
IDE/Aβ42+40 demonstrated a trend toward an increase in MCI compared with HC,
however did not quite reach significance (p = 0.052). Similar to the IDE/insulin ratio, it
was concluded that there were no benefits in considering IDE relative to Aβ42+40
compared with IDE alone, for differentiating between clinical classifications.
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Figure 3.23(B) The ratio of full-length IDE to Aβ42+40 is not significantly different
between classifications. Aβ1-42 and Aβ1-40 levels were measured as outlined in Section
2.2.2.1. Plasma samples (60 μg/lane total protein in duplicate) were resolved by 10%
SDS-PAGE, transferred to Western blots and probed for full-length IDE as described in
Sections 2.2.4.1 and 2.2.4.4, using Ab 3. The average optical density of the duplicate
bands was obtained for each sample, and a ratio was calculated of (untransformed)
full-length plasma IDE to plasma Aβ1-42 + Aβ1-40 (IDE/Aβ42+40 ratio). The median of
these values were compared between classifications by a Kruskall-Wallis test. Data
represents medians with 95% confidence interval (CI), n = 154 (90 HC/24 MCI/40 AD).
Results show a trend towards MCI having higher full-length IDE/Aβ42+40 ratios than HC,
however this did not reach significance (p = 0.052).
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3.3.17.3 The ratio of full-length IDE to insulin + total Aβ42+40 is not
different between clinical classifications.
As both insulin and Aβ are competing substrates of IDE, it is possible that there is a
combined effect of these which may affect their relationship with levels of full-length
IDE. The total levels of these substrates relative to IDE may therefore be able to
differentiate between HC, MCI and AD better than the IDE/insulin or IDE/Aβ42+40 ratios
alone. Thus, to investigate this possibility, the values of plasma insulin (in mU/L) were
converted to pg/mL and added to the values of Aβ1-42 + Aβ1-40, to give a total value of
insulin+Aβ42+40 in pg/mL. The ratio of full-length IDE to insulin+ Aβ42+40 was then
analysed by clinical classification to determine if they could differentiate between MCI,
AD and controls better than either IDE alone, the IDE/insulin ratio or the IDE/ Aβ42+40
ratio (Figure 3.23(C)). Results showed no significant differences in IDE/insulin+Aβ42+40
ratio between clinical classifications (p = 0.171). Hence, it was concluded that the ratio
of full-length IDE with the combination of insulin and Aβ42+40 provided no additional
benefits for differentiating between clinical classifications than levels of full-length IDE
alone, the IDE/insulin ratio or the IDE/Aβ42+40 ratio.
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Figure 3.23(C) The ratio of full-length IDE to insulin + Aβ42+40 is not significantly
different between classifications. Aβ1-42 and Aβ1-40 levels were measured as outlined
in Section 2.2.2.1. Plasma samples (60 μg/lane total protein in duplicate) were
resolved by 10% SDS-PAGE, transferred to Western blots and probed for full-length IDE
as described in Sections 2.2.4.1 and 2.2.4.4, using Ab 3. The average optical density of
the duplicate bands was obtained for each sample, and a ratio was calculated of
(untransformed) full-length plasma IDE to the combined values of plasma insulin + Aβ142 + Aβ1-40 (IDE/insulin + Aβ42+40 ratio). The median of these values were compared
between classifications by a Kruskall-Wallis test. Data represents medians with 95%
confidence interval (CI), n = 154 (89 HC/24 MCI/39 AD). Results show no difference
between clinical classifications for the full-length IDE/insulin + Aβ42+40 ratio (p = 0.171).

150

3.4 Discussion
The aim of this chapter was to optimise a Western immunoblotting protocol to be able
to quantitate levels of full-length IDE in human plasma. Using blood samples obtained
from AIBL study participants, the test was used to determine if IDE levels differed in AD
patients and MCI individuals compared with HC individuals, and to determine whether
IDE levels were related to other AD-related genetic and biochemical factors.
While most studies of IDE involve generating in-house antibodies for use, there are a
number of commercially-available antibodies which have been used in the published
literature. At the commencement of this project, no other study had been undertaken
on determining the levels of IDE in human plasma, therefore a number of
commercially-available antibodies were screened for their suitability for this purpose.
It was also important that the antibody used was able to measure levels of full-length
IDE specifically, as truncated forms of IDE are not catalytically active.
Human blood plasma is a complex mixture with many constituents, and as such can
present difficulties when attempting to detect low-abundance proteins. Non-specific
cross-reactions may occur between the antibodies used and other proteins in the
plasma, leading to false-positive results, or banding which is inconsistent with the
published molecular weight of the protein of interest. Non-specific binding of the
antibody to other proteins may also reduce the availability of the antibody to bind to
the target protein, therefore leading to reduced detection. As such, it is necessary to
determine specificity of the immune reaction when using methods such as Western
immunoblotting to detect proteins in complex samples. Data was collected in the
current study on three polyclonal IDE antibodies (Ab 1, Ab 2 and Ab 3) to determine if
bands observed in the region of interest are in fact IDE. At the start of this study, there
were no publications which had used these antibodies specifically for Western
immunoblotting. It was demonstrated that for the single band detected with Ab 1(a),
approximately 50% of the immunoreactivity could be blocked by pre-incubation of the
antibody with full-length recombinant IDE (not the immunizing peptide), suggesting
that some of the signal observed was specific, and the single band observed at 105 kDa
was of a molecular weight similar to that previously reported in numerous
publications. Therefore, it was likely that this band was indeed IDE. However, only a
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small quantity of full-length recombinant IDE was used as the blocking protein, rather
than a peptide specific to the epitope to which the antibody binds, and this may be
why the band was not completely absent. In addition, 1.32 μg of full-length protein
would have considerably fewer epitopes to block the binding sites of the IDE antibody
than 1.32 μg of peptide specific to the paratope of the antibody. It may be that
prohibitively large quantities of full-length IDE are required to block all the paratopes
to prevent binding to the band on the immunoblot. However, it cannot be ruled out
that another protein can be detected non-specifically by Ab 1 at the same molecular
weight.
Subsequent batches of Ab 1 were unable to detect the same band in the plasma, and
this may have been due to the antibody being sourced from a different bleed of the
immunised animal, or even a different animal altogether. Polyclonal antibodies are
essentially a mixture of antibodies which bind to different epitopes within the region
of the immunogen, and sometimes to other proteins altogether. Batch to batch as
well as bleed to bleed variation is not uncommon. As the immunogen for Ab 1 was
derived from rat, the antibody would be expected to detect the recombinant rat IDE.
However, it is possible that Ab 1(b) (Batch 2) did not contain one or more of the
antibodies that were present in Ab 1(a) (Batch 1) and part of the epitope in human IDE
was altered enough to resist binding of the antibodies from Batch 2, either from an
alteration in the sequence or some post-translational modification that may occur in
the plasma (refer to Figure 3.20 - diagram of hypothetical mechanism). Regardless, it
was concluded that this antibody was unsuitable.
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Figure 3.24 Hypothetical representation of potential mechanism of batch-to-batch variability in polyclonal antibodies. Antibodies in
different batches may recognise different epitopes within the same region of the antigenic protein. Due to batch-to-batch variation in
antibody generation, the presence of post-translational modifications can cause non-recognition of the protein leading to loss of binding by
the antibody.
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Ab 2 initially did not show immunoreactivity in the region of interest for IDE in
plasma, but detected a large, band at approximately 45 kDa. This band was excised
and sent for mass-spectrometry analysis, however was not able to be identified due
to albumin contamination (data not shown). When testing purified rat IDE, the
antibody detected a band at 118 kDa, which corresponds to the published
molecular weight of full-length IDE in the UniProtKB database of 117.968 kDa. This
is slightly higher than most published studies which report IDE at 110 kDa. After
using extended development times or a more sensitive detection system, a band at
115-120 kDa was observed as well as other bands at lower molecular weights of
approximately 80, 70 and 45 kDa. It was difficult to determine the exact molecular
weight of the 115-120 kDa band as the difference between the 110 kDa and the 160
kDa marker was only several millimetres wide. Ideally, it would have been useful to
run the gel for considerably longer to allow better resolution of the bands to
improve the estimation of the molecular weight, or to use lower acrylamide
content (8.5% gels, for example).

Alternatively, a different molecular weight

marker could have been used which was more specific to the region of interest.
Using the enhanced detection system (ECL™ Prime) with Ab 2 dramatically
enhanced the background of the blots, although not enough to impair visualisation
of the bands. The background was subsequently minimised to an acceptable level
by increasing the number of washing steps performed after the primary and
secondary antibody incubations. Although the 115-120 kDa band was slightly
higher than the published molecular weight for IDE, it is possible that some posttranslational modifications may occur in plasma. Another possibility considered
was that IDE-Aβ binding was resistant to the denaturing and reducing conditions
used in the SDS-PAGE (as suggested by Llovera, et al., 2008), increasing the
molecular weight of the band by 4 kDa. However, pre-incubation of purified Aβ and
purified rat IDE did not produce an upward shift in molecular weight for Ab 3,
suggesting that the denaturing and reducing conditions of SDS-PAGE was sufficient
to dissociate any binding. It should be noted that while this result was observed
with purified protein, it cannot be ruled out that in a complex matrix such as
plasma, other factors may affect the binding affinity of IDE to Aβ and the results
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may not reflect what occurs in human plasma. Plasma IDE may also bind to
another, as yet unknown, peptide or protein.
Strong cross-reactivity was noted with human serum albumin (HSA) and weakly
with bovine serum albumin (BSA) using Ab 2, as well as with some of the molecular
weight marker proteins. However, none of these proteins were in the molecular
weight region of interest, suggesting that Ab 2 may still be a valid antibody for the
measurement of IDE in human plasma. A blocking test using the immunising
peptide was therefore performed to check specificity. The results showed that Ab 2
can detect purified IDE, as the purified IDE band disappeared from the Western blot
when the primary antibody Ab 2 was blocked. However this was not the case with
the bands seen in the plasma samples: the non-specific binding of Ab 2 to other
bands in the molecular weight region of interest indicated this antibody was not
going to be suitable for the assay.
A third IDE antibody was therefore screened for its suitability for measuring plasma
IDE (Ab 3). This purified rabbit polyclonal detected a band at approximately 110
kDa in rat liver and human frontal cortex, as well as a band at 118 kDa for both
purified rat and human IDE. In human plasma, Ab 3 detected several bands of
similar molecular weight to those detected by Ab 2; 120-130, 80 and 70 kDa, as well
as the characteristic wide band at 50 kDa. Using the enhanced detection system,
other bands also became apparent in the plasma around the region of interest, at
160 and 115 kDa, as well as several others in rat liver and human frontal cortex.
While it is possible that these extra bands are simply due to non-specific binding, it
is also possible that multiple isoforms of human IDE exist in plasma.
Further analysis of Ab 3 showed strong cross-reactivity with BSA, and weak crossreactivity with HSA, however the bands were not in the region of interest and not
likely to impair visualisation of full-length IDE. With BSA, the bands were visible at
40 and 20 kDa, thus smaller than the reported molecular weight of BSA
(approximately 66-67 kDa). It is possible that these bands represent degraded
fragments of BSA, as a BLAST (NCBI) protein search showed three regions of BSA
which share sequence similarity with regions of the immunogen for Ab 3
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(http://blast.ncbi.nlm.nih.gov/Blast.cgi,

accessed

18th

February,

2014).

Interestingly, a study on BSA degradation demonstrated bands at 40 and 20 kDa (as
well as some others) which correspond to the molecular weights observed in the
current study (Estey, et al., 2006), however it should be noted that this degradation
occurred as a result of acidic conditions and may not be relevant to our study. Two
regions in HSA also share sequence similarity with regions of the immunogen for Ab
3, which may explain the cross-reactivity with HSA. Alternatively, the bands seen
may also represent contaminants of the BSA/HSA preparations. Furthermore,
when testing a commercial blocking agent composed primarily of bovine milk
powder, Ab 3 again showed some cross-reactivity. The company which produced
this blocking agent stated that the blocking agent was unlikely to contain BSA or
globulin, but instead contained milk proteins. Interestingly, two other unrelated
IDE antibodies have been reported to cross-react with fibrinogen, casein and
thrombin, all of which are found in bovine milk (Yfanti, et al., 2008). A BLAST
comparison of sequences revealed one region of sequence similarity (to the
immunogen used to produce Ab 3) with bovine fibrinogen (gamma chain), three
regions

in

the

alpha

chain,

(http://blast.ncbi.nlm.nih.gov/Blast.cgi,

and

two

accessed

in
18th

the

beta

February,

chain
2014).

Furthermore, three regions of bovine beta-casein, and one region of bovine
prothrombin also showed sequence similarity. However, human fibrinogen and
beta-casein had no sequence similarity with the immunogen for Ab 3 but there
were still two regions of similarity with human prothrombin. Regardless, the bands
observed were not in the region of interest and therefore would not interfere with
the detection of full-length plasma IDE.
As mentioned, co-incubation of purified recombinant Aβ with both purified
recombinant rat and human IDE showed no shift in molecular weight of IDE
detected with Ab 3 indicating that any binding between recombinant IDE and Aβ
was dissociated by the denaturing and reducing conditions of the SDS-PAGE.
However, it cannot be excluded that such binding observed with purified proteins
and peptides may be quite different to that which occurs when the proteins are in

156

native form, and in their normal more complex environment, in this case – in
plasma (Cavalcante Braga, et al., 2013).
To remove some of the components of plasma which may be causing non-specific
cross-reactivity with the antibody, and to clarify the band of interest, an
immunoprecipitation (IP) procedure was performed with two separate IDE
antibodies (Ab 4 and Ab 5). The IP was performed with both unprocessed plasma
and also plasma which had been pre-cleared of immunoglobulins and depleted of
albumin. The two antibodies produced a similar reaction pattern, with only one
band remaining in the region of interest at 120-130 kDa. Interestingly, the 80 kDa
band persisted following IP, and it would be of value to investigate this band in the
future. However, within the scope of this project only the full-length isoform of IDE
being the 120-130 kDa band was determined to be relevant.
To investigate further the specificity of the 120-130 kDa band, an antibody blocking
test using the immunising peptide was performed. However, the blocking peptide
significantly increased the background of the immunoblot; nevertheless, it could be
seen that the band at 118 kDa from recombinant rat IDE was reduced dosedependently, as was the 115 kDa band in rat liver, and the 95 kDa band observed in
zebrafish disappeared. This indicated that the bands observed close to the region
of interest in several different species and tissues were most likely IDE. In plasma,
the 160 and 120-30 kDa bands were not visible after peptide treatment, however
the band at 115 kDa appeared to be stronger. This would suggest that the band at
120-130 was specifically IDE, in accordance with this band also persisting after IP
with a different IDE antibody. However, as the 115 kDa persisted after peptide
blocking it could suggest that this band is not specific.

Interestingly, the

observation that the 160 kDa band also was not visible after peptide blocking was
not what was expected, as this band seemed to be absent following
immunoprecipitation. This would indicate that the band seen is specifically IDE. As
this band was considerably higher than the expected molecular weight of IDE, it
may be part of a complex of proteins including IDE, which is resistant to denaturing
and reducing conditions. Unfortunately, investigating this band was outside of the
scope of this project.
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Our studies and other studies have found that different IDE antibodies detect
different bands by Western blotting (Yfanti, et al., 2008). There are a number of
possible explanations for this. Firstly, each of the three antibodies used were raised
against a different size epitope of IDE, for example Ab 2 was raised to an 11 amino
acid peptide, whereas Ab 3 was raised to an IDE sequence of over 150 amino acids,
and secondly, the regions of the IDE sequence used were all different. Thirdly, the
immunogens were all synthetic, and it is not known how much of the immunogen
sequences were in a secondary structure that would be similar to native or
denatured IDE. Fourthly, synthetic proteins do not contain post-translational
modifications which may be present on the native protein.
Yet another factor which may have an effect on the reaction patterns seen in
Western immunoblotting is the species from which the immunogen was sourced:
the Ab 1 immunogen was a rat IDE sequence, whereas Ab 2 and 3 were raised
against human IDE sequences. The host in which the antibodies are raised can also
be an issue; Ab 1 and 3 were raised in rabbits, whereas Ab 2 was raised in a goat.
Regardless of this, however, even antibodies raised in the same type of host can
vary from animal to animal and even from bleed to bleed, which is one major
drawback of using polyclonal antibodies. A recent study demonstrated that even
the method of immunisation can produce highly variable results when it comes to
antibody production (Brown, et al., 2011).
Following preliminary testing, Ab 3 was chosen for the measurement of full-length
IDE in human plasma: the antibody has a high affinity for recombinant human IDE,
and it showed specificity on a number of different tissues from different species,
including

the

120-130

kDa

band

in

human

plasma.

Importantly,

immunoprecipitation methods using two alternative IDE antibodies (Ab 4 and Ab 5)
showed almost identical reaction patterns with the band at 120-130 kDa being the
only remaining band to persist after IP in the region of interest. Although results
are not shown in this chapter, Ab 3 also showed specificity in an IDE activity assay
using several inhibitors which will be discussed in Chapter 5. Results from our
group also previously demonstrated a reduction of the 110 and 80 kDa bands in an
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IDE knock-down experiment in zebrafish, using Ab 3 for the immunoblotting (Chen,
et al., 2012).
IDE is widely reported as being 110 kDa in a number of tissues and species,
therefore the band at 120-130 kDa seen with Ab 3 is larger than expected. A
number of factors could be responsible for this difference. It is possible that IDE
undergoes post-translational modifications in plasma such as phosphorylation,
acetylation, ubiquitination and/or glycosylation. Sequence analysis of IDE using
prediction programs shows that the protein contains numerous motifs and sites
that may be modified by such processes (Prasad, et al., 2009; Li, et al., 2006; Hastie,
et al., 2001; Gupta & Brunak, 2002). Therefore it is possible that the increased
molecular weight may be due to post-translational modifications.

Another

possibility is that a larger isoform may be found in human blood, however there
have been no reports to date of a larger isoform existing in any other tissues, with
the exception of the 115 kDa membrane-bound form of IDE and the mitochondrial
isoform of IDE (Vekrellis, et al., 2000; Leissring, et al., 2004). However, these
isoforms are unlikely to be in the peripheral circulation. It may be simply that our
estimation of IDE molecular weight is different due to the lack of protein separation
on the 10% acrylamide gels – the 110 kDa and 160 kDa weight markers were very
close. However, the band for recombinant rat IDE was consistently observed to be
higher than the 110 kDa marker, and the plasma band (estimated to be
approximately 120-130 kDa) was consistently observed to be higher than that. In
addition and as mentioned previously, the predicted molecular weight of the fulllength isoform as determined from the UniProtKB database is 117.968 kDa, and this
is similar to the molecular weight observed in the current study. In addition, this
antibody detected a band in rat liver of 110 kDa which is consistent with previous
reports, suggesting that it is unlikely that this is an estimation error.
It has been reported in the literature that IDE levels in the brain tend to be lower in
AD patients and MCI individuals (Zhao, et al., 2007; Qin & Jia, 2008; Cook, et al.,
2003; Perez,et al., 2000), and that this drop in IDE levels has been associated with
higher levels of soluble cerebral Aβ. A large body of evidence indicates that the
levels of soluble Aβ in the brain are integral to the process of AD pathogenesis. It is
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also known that brain Aβ can originate from the periphery, such that levels of
soluble Aβ in the blood may influence brain levels of the peptide. Furthermore, it is
highly likely that levels of Aβ-degrading enzymes in the blood play an important
part in regulating the peripheral Aβ content. As IDE has been found to be one of
the primary Aβ-degrading enzymes, its blood concentration may be related to the
accumulation of both peripheral, and subsequently brain Aβ.
The levels of full-length IDE measured by Western immunoblotting in this project
were found to be similar in healthy controls and AD patients. However, a significant
increase in full-length IDE was observed in the MCI group compared with both
controls and AD patients. Upon further analysis this observation was determined to
be significant only in females, however a similar pattern existed in males. This
increase in IDE levels in the MCI group is contrary to what would be expected;
genetic polymorphisms in IDE have been associated with increased levels of plasma
Aβ in individuals at risk of LOAD (Ertekin-Taner, et al., 2004; Ertekin-Taner, et al.,
2008) and if IDE is primarily responsible for regulating the levels of plasma Aβ, as is
seen in the CNS, then it might be expected that early deficits in the levels of plasma
IDE could feasibly be a contributing factor to increased circulating Aβ. Based on the
results of the current study, it is possible then that any potential reductions in levels
of plasma IDE occur well before the onset of cognitive deficits which are observable
in the MCI participants. Furthermore, it is therefore possible that the increase in
IDE levels in MCI individuals may be indicative of a compensatory mechanism
comprising the upregulation of full-length (active isoform) IDE, perhaps in response
to increased levels of IDE substrates such as Aβ and insulin in plasma. It may be
that increased Aβ species and/or an increase in insulin may be a very early event in
AD pathogenesis which saturates all available IDE in the plasma and thus triggers its
upregulation. However, in this subset of the AIBL cohort there was no significant
increase observed in either Aβ or insulin for the MCI participants overall, and there
was no correlation observed between any of the Aβ species or insulin and levels of
full-length IDE overall. In addition, there were no significant differences between
clinical classifications for any of the calculated ratios of IDE with insulin or Aβ (or
the combination), although a trend toward a higher IDE/Aβ42+40 ratio was observed
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in MCI participants compared with controls (but not in AD), which would be
primarily due to the increase seen in full-length IDE levels. However, as pathogenic
processes have already commenced by the MCI stage, an increase in IDE substrates
may occur much earlier than this prodromal period which may return to more
normal levels following the upregulation of IDE.
Alternatively, any potential deficit in IDE function may not be necessarily related to
a reduction in IDE levels but possibly a reduction in IDE catalytic activity. A previous
study reported increased levels of IDE concomitantly with reduced IDE activity in
brain microvessels of AD/CAA patients compared with controls, and this may be
related to the increase in full-length IDE levels found in the circulation in the
current study (Morelli, et al., 2004). The high variation evident in the MCI group
also highlights heterogeneity in the group itself; not all MCI individuals will convert
to AD and some will even revert to normal, therefore this is likely to be a
confounding factor. It is not clear why the increase in MCI seems to be more
pronounced in females than in males, however may be reflective of hormonal
differences.
It is possible that levels of both Aβ and IDE in the plasma negatively reflect the
levels in the brain. Thus high levels of IDE in the plasma may indicate low levels of
IDE in the brain, and concomitantly low levels of Aβ in the plasma may reflect high
cerebral Aβ levels. One group has shown this to be the case for Aβ42 after
glucocorticoid treatment, with increasing levels of Aβ42 observed in the brain and a
corresponding decrease observed in plasma Aβ42 (Kulstad, et al., 2005). This was
also accompanied by a reduction of IDE in the brain, and did not appear to affect
Aβ40 levels.

This would be consistent with Aβ42 being the primary species

implicated in AD. Unfortunately plasma IDE was not measured in the same study so
it is unknown if a corresponding increase occurs in the plasma. Another study
supporting the hypothesis that IDE is primarily responsible for regulating the levels
of Aβ showed that increases in cerebral Aβ42 (both intracellular and extracellular)
were consistently associated with a reduction in IDE levels (both membrane-bound
and cytosolic) in patients with a PS1 mutation (Qin & Jia, 2008). It must be noted
though that early-onset familial AD may not have the same pathogenic processes as
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sporadic AD.

However, as previously mentioned, genetic studies have

demonstrated association between IDE variants and plasma Aβ42 levels in LOAD
families (Ertekin-Taner, et al., 2004; Ertekin-Taner, et al., 2008).
Accumulating evidence appears to support the notion that during the development
of AD pathology, plasma Aβ42 levels decline as plaques develop in the brain
(Kwarabayashi, et al., 2001; Kuo, et al., 2000; Schupf, et al., 2008). One of these
investigations was a large study examining both Aβ42 and Aβ40, and demonstrated
that only Aβ42 levels in plasma were affected during the conversion to AD, with high
initial levels followed by a decline during the onset of AD (Schupf, et al., 2008),
reflecting the deposition of Aβ in the brain.

Another study showed that

intraperitoneal inoculation of Aβ can also trigger amyloid formation in the brains of
transgenic mice (Eisele, et al., 2010). This is supportive of the theory that the
elevated Aβ levels in the brain originate, at least in part, from the peripheral blood
supply. However, it should be noted that previous work by Eisele and colleagues
(2009) showed no initiation of Aβ deposition when injected intravenously, although
soluble levels of brain Aβ were not monitored in that study.
A recent study using AD transgenic mice demonstrated that an increase in plasma
Aβ levels occur concurrently with a reduction in intracellular Aβ in the brain, after
treatment with a γ-secretase inhibitor which also acts on microglial activation
(Sivilia, et al., 2013). This study also reported cognitive improvement and reduced
amyloid deposition in the mice. It is believed that a potential therapeutic pathway
involves reducing levels of soluble Aβ in the brain by increasing its efflux across the
BBB into the plasma, where it may be degraded by IDE and other Aβ-degrading
pathways (Deane, et al., 2009). Recent studies support this concept, as it has been
demonstrated that a reduction in plasma Aβ leads to a reduction in cerebral Aβ in
AD transgenic mice (Guan, et al., 2009; Liu, et al., 2010; Sutcliffe, et al., 2011),
although another recent study refutes these findings (Walker, et al., 2013).
However, as IDE is the primary enzyme responsible for insulin degradation in the
periphery, the challenge would be to increase the degradation of Aβ selectively
without disturbing the degradation of insulin by IDE (and other substrates). As it
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has been established that IDE may be regulated selectively in this fashion by small
peptide activators, and other regulatory factors, this may prove possible.
It is important to note that IDE is too large to cross the blood-brain barrier (BBB),
therefore separate pools are likely to exist in the periphery and the brain. It would
be unlikely that IDE would move from the brain to the periphery. Therefore it is
more likely that IDE would be independently upregulated in the periphery, possibly
in response to increased plasma Aβ or insulin. Upregulation of IDE has been
reported previously, in response to Aβ, insulin and also various cellular stressors
(Vepsalainen, et al., 2008; Zhao, et al., 2004; Tundo, et al., 2013).
Furthermore, it can be speculated that reduced brain IDE may initiate the increase
of cerebral Aβ that many studies have documented, and this excess may increase
transfer of Aβ across the BBB into the periphery. This could subsequently instigate
the upregulation of plasma IDE also, however if the enzyme is unable to control the
levels of peripheral Aβ sufficiently, the peptide may reach a critical level,
disruptions to insulin metabolism may occur, both of which may then cause
alterations to BBB permeability. This would probably lead to increased Aβ influx
back into the brain and a reduction in efflux to the periphery. In support of this
theory, it has been demonstrated that increased levels of brain Aβ are capable of
upregulating IDE levels and therefore it is possible that this also occurs in the
periphery (Vepsalainen, et al., 2008). The increased transport of peripheral Aβ to
the brain, as well as the reduction in efflux (partly due to greater aggregation and
deposition of Aβ in Aβ fibrillar deposits and plaques), in conjunction with the
increased plasma Aβ degradation via elevated levels of plasma IDE may then lead to
the characteristic reduction in plasma Aβ during Aβ deposition which is seen later in
AD patients. The drop in Aβ may then lead to the subsequent down-regulation of
plasma IDE as less would be required, and this is reflected in the results of the
current study.
When the cohort was split into carriers and non-carriers of APOE ε4 alleles, no
significant difference in full-length plasma IDE levels was observed. This is an
interesting finding as it has been reported that carriers of the ε4 allele have lower
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levels of brain IDE compared with non-carriers or controls (Cook, et al., 2003). This
does not support the hypothesis that plasma levels of IDE negatively reflect the
levels in the brain, and instead supports the notion that brain and plasma IDE
function independently. However, it would be of value to examine the results more
thoroughly by way of specific APOE genotypes rather than just ε4 carriers versus
non-carriers, as it has been shown that the different genotypes confer different
risks for developing AD (Farrer, et al., 1997). To characterise properly the effect of
APOE genotype on IDE levels, the results should ideally be analysed after dividing
according to the 6 possible APOE genotypes. Unfortunately the small sample size
precluded this analysis due to a lack of power.
One limitation of this study is that it was not possible to analyse potential effects of
medications on plasma IDE levels, due to the size of the cohort, and the fact that
only a small number of participants were not taking medication. A number of
compounds and medications have been implicated in the regulation of IDE (this will
be discussed in more detail in Chapter 6). Therefore, as a substantial proportion of
the AIBL cohort were taking at least one, or a combination of these medications at
the time blood samples were taken, it is likely that these will have influenced the
measured levels of plasma IDE. A significant correlation was observed between
testosterone and IDE in the whole cohort, although this disappeared when
analysing male and female participants separately. Oestradiol showed a trend
toward association with IDE however this also disappeared when data was split by
gender. This suggests that the potential relationship between IDE and these sex
hormones is not necessarily gender specific. Larger cohorts and additional analysis
will be required to determine if such hormones and medications influence plasma
IDE levels in humans.
Another limitation which should be mentioned is the method of Western
immunoblotting itself. As there were a large number of samples, and only five
samples could be run on each gel in duplicate, a large number of gels were needed.
An internal standard of pooled control plasma was included in each gel, to which
sample results were normalised to control for inter-gel variation. However, the
large number of gels would have increased the chance that errors were going to
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occur when normalising to correct for inter-gel variation.

Another source of

variation in the experiment was due to the step in which the blots were stripped of
antibodies following the initial immunoblotting procedure, and re-probed with a
different primary antibody; although this is generally considered an acceptable
practice.
Western immunoblotting is considered to be a semi-quantitative procedure, and
subject to variation even through such things as the method of quantification
(Gassmann, et al., 2009). Therefore, even a small degree of imprecision may affect
the means or medians, and as such it cannot be excluded that during normalisation
procedures the trend of this data may have been affected by these factors.

3.4.1 Summary
The results in this chapter demonstrate that levels of plasma full-length IDE are
elevated in MCI individuals in comparison to healthy controls as well as AD patients,
and that no difference is observed between healthy controls and AD. In addition,
no difference in plasma IDE levels was seen in APOE ε4 carriers versus non-carriers.
These results for full-length plasma IDE were contrary to what was expected, as it
conflicts with the hypothesis that low plasma IDE levels are an initiating factor in
the development of AD. However, one could argue that AD pathogenesis starts
well before MCI stages, as AD-related early memory loss often indicated by MCI
indicates that synaptic and neuronal loss have already occurred to an extent.
Based on these results and others from the AIBL study, an alternative chain of
events may be occurring. Firstly, it is possible that a trigger such as high plasma Aβ
and/or insulin initiate an upregulation of plasma IDE. Although within this subset of
the AIBL cohort there was no significant increase of either Aβ1-40, Aβ1-42 or insulin
observed in MCI, potentially this may have occurred well prior to the MCI stage.
However, recent results from the AIBL study have shown that individuals who
convert from healthy to MCI have a reduction in plasma Aβ42, while an increase is
seen with Aβ40 in MCI and AD participants after controlling for various factors such
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as gender and APOE status, among others (Rembach, et al., 2014).

As Aβ40

encompasses the majority of the Aβ species, this alone may be adequate for the
saturation of IDE, which may potentially lead to its upregulation in the plasma.
Furthermore, even though the full-length Aβ40 and Aβ42 peptides were not
significantly increased, a significant increase in Aβx-40 (but not Aβx-42) was observed
within this subset. This also highlights the need to consider Aβ42, Aβ40 and Aβ
fragments separately in addition to as a single species of peptide. BBB damage may
then contribute to increased influx and decreased efflux of excess Aβ to/from the
brain, respectively, and lead to the characteristic accumulation of cerebral Aβ seen
in AD. The subsequent decrease in plasma Aβ that has been documented may then
be a result of both Aβ trafficking to the brain and increased plasma degradation of
Aβ due to elevated plasma IDE. Reports from another recent study have shown
that alterations of plasma insulin can occur at the MCI stage, but again appear to be
influenced by gender and APOE status (Cholerton, et al., 2012). Collectively, these
results outline the complexity of the mechanisms surrounding AD pathology and
highlight the need to take into account various factors such as gender, APOE
genotype and differentiating between Aβ species when translating the data. It
would be useful in future studies to examine blood IDE at regular intervals in AD
transgenic animals from a very early age to see if the decrease in plasma Aβ that
has been documented occurs prior to or concurrently with an increase in plasma
IDE, or alternatively if the decrease occurs following an increase in plasma IDE, as
well as monitoring plasma insulin levels.
The overall results though suggest that the differences observed in plasma fulllength IDE levels measured with Western immunoblotting could be reflective of
biochemical changes in the prodromal period of AD, and that IDE may be a suitable
biomarker candidate to include in a panel of biomarkers for early detection.
Various limitations, however, such as the effects of medications, sex hormones,
gender and APOE status among others, on plasma IDE must be acknowledged and
need further investigation before any conclusions may be formed from these
results. In addition, studies that progressively monitor levels of IDE from a nonpathological state through the conversion to AD would provide more information to
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the comparison of MCI and AD with controls and would be of considerable value as
a future direction.
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CHAPTER 4 – Total plasma IDE Levels measured by
enzyme-linked immunosorbent assay (ELISA) are
decreased in MCI in comparison to healthy controls or
AD.
4.1 Introduction
Western blotting techniques are widely used in research and have several
advantages over other immunoaffinity applications for the detection of proteins;
one being good sensitivity to detect low-abundance proteins in a complex sample
such as plasma, and also the specificity to differentiate between proteins based on
molecular weight.

However, there are some limitations to Western

immunoblotting; firstly it is considered a semi-quantitative application, and
secondly it is not ideal for use when measuring a large number of samples due to
the inter-assay variation. In addition, the proteins in Western blotting are usually in
a denatured and reduced conformation compared to the native protein. Hence
some antibodies may not detect specific proteins as they bind to conformational
epitopes and this generally occurs when using antibodies that are raised against the
full-length protein. There are other immunoaffinity applications which are more
suited to protein quantification and also more suited to processing large numbers
of samples, such as the enzyme-linked immunosorbent assay, or ELISA. Using a 96well plate, this application permits the simultaneous measurement of up to 40
samples in duplicate per assay, including an 8-point standard curve (in duplicate).
One common limitation of ELISA-based detection of proteins is the inability to
differentiate between different isoforms of a protein.

However, several

publications have reported total levels of IDE (primarily in brain), and it would be
useful to characterise IDE in human plasma by ELISA and compare with the results
from these other studies. The measurement of total plasma IDE using an ELISA may
also uncover differences compared to measuring with Western immunoblotting:
ELISAs may prove more suitable for measuring IDE as a clinical biomarker. There is
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one commercially available ELISA kit for the measurement of IDE, however it was
found to be unsuitable for our purposes.

Therefore an in-house ELISA was

developed for the purpose of measuring total IDE in human plasma from the AIBL
cohort.

4.1.1 Aims

1. To develop an in-house ELISA for the purpose of measuring total IDE levels in
human plasma.
2. To determine if levels of total IDE differ between HC, MCI and AD participants.
3. To determine if the presence of the APOE4 allele has any impact on levels of
total plasma IDE.
4. To identify any relationships between total plasma IDE, full-length IDE and other
biochemical data obtained from the AIBL study.
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4.2 Experimental Summary
4.2.1 Test of commercial IDE ELISA kit for suitability in testing human
plasma.
To screen a commercial ELISA kit to determine its suitability for the measurement
of IDE in human plasma, the assay was performed twice (Run 1 and Run 2) as per
manufacturer instructions, as described in Section 2.2.5.1.

4.2.2 Screening of eight commercial IDE antibodies to determine
suitability for an in-house, indirect IDE ELISA for use on human plasma
samples.
Antibodies that were screened for their suitability to be used in an indirect ELISA for
plasma IDE are listed in Section 2.1.1 and in Table 2.1. An indirect ELISA was
performed using each of the antibodies as described in Section 2.2.5.2 using
purified rat IDE as a standard, and plasma, both neat and diluted.

4.2.3

Test of the three most suitable IDE antibodies for an IDE

sandwich ELISA.
Using IDE antibody ab28561 (Ab 3) as the coating antibody, a sandwich ELISA was
performed using either H00003416-A01 (Ab 6) or LS-C55007 (Ab 2) as detection
antibody, as described in Section 2.2.5.3. Purified rat IDE was used as a standard,
and both neat and diluted plasma samples were tested.

4.2.4 Assay control tests.
Using IDE antibody ab28561 (Ab 3) as coating antibody, and LS-C55007 (Ab 2) as
detection antibody, a sandwich ELISA was performed as described in Section
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2.2.5.3, with minor changes. The coating buffer was at a pH of 8.6 rather than 9.6;
and no Tween detergent was present in the PBS used for the washing steps, with
the exception of the wash following the secondary antibody incubation. The
blocking agent used in this protocol was Fraction V BSA. Omission of the capture
and detection antibodies, and the blocking agent was tested to ensure there was no
interference by any of these components in the assay, and these controls used
recombinant rat IDE at a concentration of 625 ng/mL as the control sample.

4.2.5 Optimisation of coating conditions for the IDE sandwich ELISA.
Using IDE antibody ab28561 (Ab 3) as coating antibody, and LS-C55007 (Ab 2) as
detection antibody, a sandwich ELISA was performed as described in Section
2.2.5.3. The conditions of coating overnight at 4°C was compared with coating for 2
hr at room temperature, as well as the effect of the buffer pH of 9.6 compared with
8.6. Purified rat IDE was used for the standard, and plasma was tested, both neat
and diluted.

4.2.6 Optimisation of sample and antibody diluents in the IDE ELISA.
For this purpose, the assay was performed as described in Section 2.2.5.3, using
PBST alone for diluting the samples, detection antibody and secondary antibody,
compared with adding 1% bovine serum albumin (BSA) to the sample diluents, or
adding 2% polyethylene glycol (6000) to the detection antibody diluent. Purified rat
IDE was used for the standard, and plasma was tested, diluted 1:1 and 1:2.

4.2.7 Optimisation of detection antibody incubation in the IDE ELISA.
To determine if overnight incubations of the detection antibody at 4°C can improve
the signal obtained in the sandwich ELISA, the ELISA was performed as described in
Section 2.2.5.3 (Ab 3 and 2), using a 2 hr incubation at room temperature for the
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detection antibody, compared with an overnight incubation at 4°C. Purified rat IDE
was used for the standard, and five individual plasma samples were used diluted
1:2.

4.2.8 Investigation of the upper detection limit of the IDE sandwich
ELISA.
For this purpose, the experiment was performed as described in Section 2.2.5.3. An
11-point standard curve of recombinant rat IDE ranging from 50 to 64000 ng/mL
and five individual plasma samples (1:2) were included in the assay.

4.2.9 Optimisation of coating antibody concentration and extension
of standard curve for upper detection limit analysis in the IDE
sandwich ELISA.
The ELISA was performed as previously described in Section 2.2.5.3.

Three

concentrations of coating antibody (Ab 3) were used on a standard curve of
recombinant rat IDE to determine the optimal concentration (5, 1 and 0.1 μg/mL).
The IDE concentrations ranged from 50 to 160000 ng/mL.

4.2.10

Test of non-albumin containing blocking agent to reduce

background in the IDE sandwich ELISA.
To try and decrease the elevated background absorbance, the ELISA was performed
as described in Section 2.2.5.3, substituting 3% ECL™ Blocking agent in the blocking
buffer. Recombinant rat IDE was used for the standard curve ranging from 500 to
16000 ng/mL, and PCP was diluted 1:2.
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4.2.11 Measurement of total plasma IDE levels in a subset of the AIBL
cohort.
Total IDE levels of 177 samples from the AIBL cohort (57 HC/50 MCI/70 AD) were
measured with the in-house sandwich ELISA as detailed in Section 2.2.5.3.
Recombinant rat IDE was used for the standard curve ranging from 50 to 16000
ng/mL and an internal standard of pooled control plasma (PCP) was included on
each plate for normalisation of inter-assay variance (all in duplicate). AIBL samples
were all assayed in duplicate.

4.2.12 Testing for potential cross-reactivity of BSA (standard and
Fraction V) and HSA in the IDE sandwich ELISA.
The IDE sandwich ELISA was performed as described in Section 2.2.5.3.

BSA

(standard and Fraction V) and HSA were prepared as outlined in Section 2.2.5.3.1 at
concentrations equivalent to the lowest and highest levels of albumin likely to be
found in human serum, then diluted as per PCP. PCP was diluted 1:2. Fraction V
BSA was used for the blocking step.

4.2.13 Spike and recovery assessment of IDE sandwich ELISA.
To assess the effect of plasma proteins and other plasma constituents on the
detection of IDE, recombinant rat IDE was diluted 1) in PBST (control), and 2) in
PBST-diluted plasma (1:2) to provide matching standard curves ranging from 1250
to 10000 ng/mL IDE. The IDE ELISA was performed as outlined in Section 2.2.5.3.
Absorbance value of the diluted plasma blank (no spike) was subtracted from the
plasma diluted standard curve to account for the signal from the plasma itself.
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4.3 Results
4.3.1 The commercial IDE ELISA kit is unsuitable for the testing of
human plasma samples.
When using commercial kits to measure proteins in a complex mixture, it is
important to test the kit to determine if it produces expected results. Therefore,
the commercial IDE ELISA kit that was available at the time was trialled using two
human plasma samples at various dilutions. The test was carried out twice to
ensure the results were accurate. The results showed that goodness of fit of the
standard curve was r2 = 0.8674 (Run 1) and r2 = 0.9858 (Run 2) (Figure 4.1(A)).
There was considerable difference in the absorbance values of the standard curve
for each Run; the maximum absorbance (50 ng/mL) for Run 1 was 1.77 compared
with Run 2 which was only 1.04. In addition, there was little or no correlation
between plasma sample dilution levels and measured levels of IDE for either run,
with high inconsistency between Run 1 and Run 2 (Figure 4.1(B)).
To address the possibility that the poor standard curve in Run 1 may have affected
the interpolated plasma values and therefore contributed to the variation
observed, raw absorbance values of the plasma dilutions were normalised to the
mean of the blanks and compared between Run 1 and Run 2 (Figure 4.1 (C)).
Results demonstrated that the plasma dilutions showed considerable variation
independently of the standard curve. Inter-assay variation was up to 56%, while
intra-assay variation was up to 30%. It was considered to be particularly important
to have consistency between assays due to the fact that the sample size was large,
requiring more than one plate, and therefore plates needed to be compared.
Although some assay-to-assay and within-assay variation is expected (preferably
<15%), these results demonstrated that there was excessive inter- and intra-assay
variation with this commercial ELISA kit.

175

Figure 4.1 (A) Comparison of standard curves from Run 1 and Run 2, using the
commercial IDE ELISA kit. Assay was performed as detailed in Section 2.2.5.1.
Standards were prepared in a range of 0.78 ng/mL to 50 ng/mL as per manufacturer
instructions. Results showed considerable differences in the standard curves for
each Run; goodness of fit was r2 = 0.8674 with a maximum absorbance value of 1.77
for Run 1 compared with r2 = 0.9858 and a maximum absorbance value of 1.04 for
Run 2.
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Figure 4.1 (B) Test of commercial IDE ELISA kit with human plasma (Run 1 versus
Run 2). Assay was conducted as detailed in Section 2.2.5.1. Individual human
plasma samples (2) were prepared as per manufacturer instructions and diluted up
to 1:10 (4 dilutions). Results show that the interpolated concentrations from the
plasma dilutions were not dose-responsive for the plasma in either run. In addition,
concentrations for the plasma samples were inconsistent between Run 1 and Run 2.
The interpolated concentration of undiluted plasma for sample 1 in Run 1 was
below the limit of detection compared with 5.06 ng/mL in Run 2. The interpolated
concentration for undiluted sample 2 was below the limit of detection in Run 1 and
16.85 ng/mL in Run 2. The results indicate that this kit has high inter-assay variation
and poor linearity of dilution.
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Figure 4.1 (C) Test of commercial IDE ELISA kit with human plasma – raw values
(Run 1 versus Run 2). Individual human plasma samples (2) were prepared as per
manufacturer instructions and diluted up to 1:10 (4 dilutions). The dashed (black)
line indicates background absorbance (blank). Results showed no linearity of
dilution and poor concordance between runs.

4.3.2 Indirect ELISA detection is effective for purified rat IDE, but not
for IDE in human plasma.
As the commercial IDE ELISA kit was determined to be unsuitable for measurement
of plasma IDE in the AIBL study, development of an in-house ELISA assay was
required. As a result, there were a number of important factors to consider. Two
options were available – an indirect ELISA and a sandwich ELISA. As an indirect
ELISA is simpler, requiring only one detection antibody, this was trialled first. With
an indirect ELISA, the antigen or sample is directly adsorbed to a surface
(microplate well) and the protein of interest is detected by the addition of a specific
antibody to which a labelled secondary antibody is used to quantify the protein
present. An ideal antibody would have low background, produce a high dynamic
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range of the standard curve, and demonstrate good linearity of dilution. Not all
antibodies are effective for use in ELISA, especially if the antibody has been raised
against a small peptide.

This may produce antibodies which prefer a linear

conformation of the antigen, which may be buried in the structure of the nativelyfolded protein. However, this is not always the case, as some linear epitopes are
presented on the surface of the native enzyme. In addition, it is important to
determine if there is any cross-reactivity of the antibodies (primary and secondary)
to non-specific components of the sample matrix.
Eight commercially-available antibodies were selected for screening for the
development of an in-house indirect IDE ELISA; A-MMS-282R (monoclonal), BGTX111664, C-AB9210, D-250706, E-5282-1 (monoclonal), F-H00003416-A01, G-LSC55007 and H-ab28561; designated Abs 1-4 and Abs 6-9 as summarised in Table 2.1
(Figure 4.2, A-H). The screening tests used purified rat IDE for the standard curve
and pooled control plasma (PCP) both undiluted and using a range of dilutions.
Results showed that all antibodies detected the purified IDE dose-dependently,
although the dynamic range varied considerably. The three antibodies with the
highest dynamic range were MAb 9 (Graph set E), Ab 8 (Graph set B) and Ab 3
(Graph set H), respectively. However, the results for the plasma samples varied
considerably, with a majority of the antibodies demonstrating a dose-dependent
signal in the reverse direction. For monoclonal MAb 7, the plasma signals fell below
the background signal (Graph set A). With antibodies Ab 8, Ab 1 (Graph set C) and
Ab 4 (Graph set D) the plasma signals observed were not dose-dependent and were
situated toward the lower end of the standard curve. When testing MAb 9 (Graph
set E), plasma samples showed very little difference in signal between the undiluted
samples and those diluted 1:5, and OD readings were almost as low as the
background signal. Of the three remaining antibodies; Ab 6, Ab 2 and Ab 3 (Graph
sets F-H, respectively), all showed good dynamic range of the standard curve with
the highest being for Ab 3. For the plasma (neat and diluted) samples, all three
antibodies showed a similar reverse trend, however for Ab 6 and Ab 2, the dynamic
range of the plasma dilutions was much lower than Ab 3.
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Figures 4.2 A (A) and (B) Screening of monoclonal IDE antibody MMS-282R (MAb
7). Test of indirect ELISA using mouse antibody MAb 7 (Clone 9B12) at a dilution of
1:1000, with a recombinant rat IDE (rrIDE) standard curve (Graph A.) and pooled
control plasma (PCP) dilutions (Graph B.). Assay was performed as detailed in
Section 2.2.5.2. The dashed line indicates the OD of the blank. The standard curve
ranged from 78ng/mL to 5000ng/mL with each concentration in duplicate. PCP was
neat (PCP1), diluted 1:1 (PCP2), 1:2 (PCP3) and 1:3 (PCP4) in duplicate. Results
show that while the assay works for rrIDE with the highest OD reading of almost
1.000, the background is very high (~0.250) and all PCP OD readings fell below the
OD of the blank.
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Figures 4.2 B (A) and (B) Screening of polyclonal IDE antibody GTX111664 (Ab 8).
Test of indirect ELISA using polyclonal rabbit Ab 8 at a dilution of 1:1000, with a
recombinant rat IDE (rrIDE) standard curve (Graph A.) and pooled control plasma
(PCP) dilutions (Graph B.). Assay was performed as detailed in Section 2.2.5.2. The
dashed line indicates the OD of the blank. The standard curve ranged from
78ng/mL to 5000ng/mL with each concentration in duplicate. PCP was neat (PCP1),
and diluted 1:1 (PCP2), 1:2 (PCP3), 1:3 (PCP4) and 1:4 (PCP5) in duplicate. Results
show that the assay works for rrIDE with the highest reading of approximately
3.000, and the background is very low (0.011). However, while all PCP dilutions fall
above the OD of the blank, values were very low (all ≤0.025), inconsistent, and did
not demonstrate a dose-response.
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Figure 4.2 C (A) and (B) Screening of polyclonal IDE antibody AB9210 (Ab 1). Test
of indirect ELISA using polyclonal rabbit Ab 1 at a dilution of 1:1000, with a
recombinant rat IDE (rrIDE) standard curve (Graph A.) and pooled control plasma
(PCP) dilutions (Graph B.). The dashed line indicates the OD of the blank. Assay
was performed as detailed in Section 2.2.5.2. The standard curve ranged from
78ng/mL to 5000ng/mL with each concentration in duplicate. PCP was neat (PCP1),
and diluted 1:1 (PCP2), 1:2 (PCP3), 1:3 (PCP4) and 1:4 (PCP5) in duplicate. Results
show that the assay works for rrIDE with the highest reading of approximately
3.400, and the background is quite low (0.027). However, while all PCP dilutions fall
above the OD of the blank, values were very low (all ≤0.048) and not doseresponsive.
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Figure 4.2 D (A) and (B) Screening of polyclonal IDE antibody 250706 (Ab 4). Test
of indirect ELISA using polyclonal mouse Ab 4 at a dilution of 1:1000, with a
recombinant rat IDE (rrIDE) standard curve (Graph A.) and pooled control plasma
(PCP) dilutions (Graph B.). The dashed line indicates the OD of the blank. Assay
was performed as detailed in Section 2.2.5.2. The standard curve ranged from
78ng/mL to 5000ng/mL with each concentration in duplicate. PCP was neat (PCP1),
and diluted 1:1 (PCP2), 1:2 (PCP3), 1:3 (PCP4) and 1:4 (PCP5) in duplicate. Results
show that while the assay seems dose-responsive for rrIDE, the highest reading of
0.195 is very low. The background is reasonably low (0.034). However, readings for
the PCP dilutions were only just above the blank OD (all ≤0.064) and did not
demonstrate a dose-response.
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Figure 4.2 E (A) and (B) Screening of monoclonal IDE antibody 5282-1 (MAb 9).
Test of indirect ELISA using rabbit MAb 9 as detection antibody, at a dilution of
1:1000, with a recombinant rat IDE (rrIDE) standard curve (Graph A.) and pooled
control plasma (PCP) dilutions (Graph B.). Dashed line shows OD of blank. Assay
was performed as detailed in Section 2.2.5.2. The standard curve ranged from
5ng/mL to 500ng/mL. PCP was diluted 1:1 (PCP1), 1:5 (PCP2) and 1:20 (PCP3).
Results show that the assay works for rrIDE with the highest reading of
approximately 4.500, and the background is very low (0.014). However, while all
PCP dilutions fall above the OD of the blank, values are very low for 1:1 and 1:5
(<0.04), while diluting to 1:20 yields the highest signal of almost 0.100.
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Figure 4.2 F (A) and (B) Screening of polyclonal IDE antibody H00003416-A01 (Ab
6). Test of indirect ELISA using polyclonal mouse Ab 6 at a dilution of 1:1000, with a
recombinant rat IDE (rrIDE) standard curve (Graph A.) and pooled control plasma
(PCP) dilutions (Graph B.). The dashed line indicates the OD of the blank. Assay
was performed as detailed in Section 2.2.5.2. The standard curve ranged from
625ng/mL to 5000ng/mL. PCP was diluted 1:1 (PCP1), 1:5 (PCP2) and 1:20 (PCP3).
Results show that the assay works for rrIDE with the highest reading of
approximately 4.200, the background is negligible (0.082) and all PCP dilutions fall
well above the OD of the blank. However, PCP dilutions appear to be doseresponsive in the reverse direction.
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Figure 4.2 G (A) and (B) Screening of polyclonal IDE antibody LS-C55007 (Ab 2).
Test of indirect ELISA using polyclonal goat Ab 2 at a dilution of 1:1000, with a
recombinant rat IDE (rrIDE) standard curve (Graph A.) and pooled control plasma
(PCP) diluted samples (Graph B.). The dashed line indicates the OD of the blank.
Assay was performed as detailed in Section 2.2.5.2. The standard curve ranged from
117ng/mL to 7500ng/mL, with each concentration in duplicate. PCP was diluted 1:1
(PCP1), 1:2 (PCP2), 1:5 (PCP3) and 1:10 (PCP4) in duplicate. Results show that the
assay works for rrIDE, however the top three concentrations have exceeded the
maximum absorbance of 4.500. The background is reasonable (0.081) and all PCP
dilutions fall well above the OD of the blank. However, PCP dilutions have a very
small dynamic range, with less than 0.054 OD units between the 1:2 dilution and
1:10 dilution. In addition, PCP appears to be dose-responsive in the reverse
direction.
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Figure 4.2 H (A) and (B) Screening of polyclonal IDE antibody ab28561 (Ab 3).
Test of indirect ELISA using polyclonal rabbit Ab 3 at a dilution of 1:1000, with a
recombinant rat IDE (rrIDE) standard curve (Graph A.) and pooled control plasma
(PCP) dilutions (Graph B.). The dashed line indicates the OD of the blank. Assay
was performed as detailed in Section 2.2.5.2. The standard curve ranged from
78ng/mL to 5000ng/mL with each concentration in duplicate. PCP was neat (PCP1),
and diluted 1:1 (PCP2), 1:2 (PCP3) and 1:3 (PCP4) in duplicate. Results show that
the assay works for rrIDE, with the highest reading of almost 3.400, the background
being negligible (0.036) and all PCP dilutions falling well above the OD of the blank.
However, PCP dilutions again appear to be dose-responsive in the reverse direction.
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4.3.3 Optimisation of a sandwich ELISA for measuring plasma IDE in
the AIBL cohort.
The trials above of the indirect ELISA method demonstrate that this does not
appear to be an appropriate method to detect IDE from complex mixtures like
plasma. Due to the high content of other proteins, it may be that the levels of IDE
binding to the plate were not reflective of the levels in plasma, due to non-specific
binding of other proteins, both to the plate and to IDE itself, for example.
Therefore, the use of an indirect ELISA was determined to be unsuitable for the
measurement of plasma IDE.
As there was a selection of IDE antibodies available, raised to a variety of regions of
the IDE protein and from different sources (rabbit, goat, mouse), a sandwich ELISA
was then trialled. The sandwich ELISA was developed using polyclonal antibody
ab28561 (Ab 3) as the coating antibody and H00003416-A01 (Ab 6) as the detection
antibody (Figures 4.3 (A) and (B)). Ab 3 was used as a coating antibody for two
reasons; firstly, it was determined to be the antibody with the highest affinity for
plasma IDE. Secondly, it was affinity purified, which is essential for a coating
antibody, as impurities in the antibody will compete for binding sites on the ELISA
plate. Ab 6 is an unpurified antibody, it therefore was not appropriate as a coating
antibody, but could function well as a detection antibody. Ab 3 binds to a location
of IDE that spans the interface between Domains 1 and 2, between residues 238416, while Ab 6 binds to an epitope in Domain 4 between residues 920-1019.
Therefore these two antibodies bind to distinct sites and should not interfere with
each other as a result of steric hindrance. Results showed that the background was
considerably higher in the sandwich ELISA than using the antibodies separately in
an indirect ELISA. In addition, the standard curve values were considerably reduced
compared with the values seen in the indirect ELISA. However, the PCP sample
values were much higher than seen in the indirect ELISA and were appropriately
dose-responsive up to a dilution of 1:10.

188

Figures 4.3 (A) and (B) Optimisation of IDE sandwich ELISA using Ab 3 and Ab 6.
Sandwich ELISA trial using ab28561 (Ab 3) as coating antibody (1:400) and
H00003416-A01 (Ab 6) as detection antibody (1:750), using a recombinant rat IDE
(rrIDE) standard curve (Graph A.) and pooled control plasma (PCP) dilutions (Graph
B.) The dashed line indicates the OD of the blank. The assay was performed as
detailed in Section 2.2.5.3. The standard curve ranged from 78ng/mL to 5000ng/mL
with each concentration in duplicate. PCP was neat (PCP1), diluted 1:1 (PCP2) or
1:10 (PCP3) in duplicate. Results show that the assay has a low dynamic range for
rrIDE and background is high (0.318). PCP readings are above the blank OD, and
appear dose-responsive up to a 1:10 dilution.
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To determine if antibody LS-C55007 (Ab 2) would be a better detection antibody
than Ab 6, the sandwich ELISA was performed again, trialling both Ab 2 and Ab 6
(Figures 4.4 (A) and (B)). As Ab 2 bound to a similar region to Ab 6 (close to the Cterminus), it was expected that Ab 3 and Ab 2 would also not interfere with each
other when bound to IDE. As Ab 2 is affinity purified, it would also allow greater
control over the assay, as it would be possible to determine exact concentrations of
the antibody. In addition, there would be no other contaminants which could
potentially affect the function of the assay. The results were similar for both
antibodies, however Ab 2 demonstrated a slightly better dynamic range for both
the standard curve and plasma dilutions.

In addition, the background was

approximately 35% lower with Ab 2 than with Ab 6. It was concluded that Ab 2 was
the superior detection antibody.
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Figures 4.4 (A) and (B) Comparison of the potential detection antibodies Ab 6 and
Ab 2. Comparison of H00003416-A01 (Ab 6) and LS-C55007 (Ab 2) as detection
antibodies using ab28561 (Ab 3) as coating antibody, a recombinant rat IDE (rrIDE)
standard curve (Graph A.) and pooled control plasma (PCP) dilutions (Graph B.) The
assay was performed as detailed in Section 2.2.5.3. Data is shown without blankadjustment. Both primary antibodies were diluted to 1:1000. The standard curve
ranged from 78ng/mL to 5000ng/mL with each concentration in duplicate. PCP was
neat (0), and diluted 1:1, 1:2, 1:5, 1:8, 1:10 and 1:15 in duplicate. Results show that
Ab 2 demonstrated a slightly higher dynamic range for both the standard curve and
PCP dilutions, and lower background compared with Ab 6 (Background of 0.222 and
0.344, respectively). PCP dilutions for both antibodies fall above the OD of the
blanks and appear dose-responsive. Ab 2 shows linearity of dilution for PCP up to
approximately 1:5.
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4.3.4 Tests for non-specific binding of IDE sandwich ELISA reagents.
To determine if there was any signal being generated which was not specific to the
antigen being measured, the ELISA was tested by separate omission of the capture
antibody, detection antibody and blocking agent (Figure 4.5). Results showed that
omission of either the capture and detection antibody resulted in a low background
signal, indicating negligible cross-reactivity of the antibodies, with either the
secondary antibody or the blocking agent. However, it should be noted that there
were some differences in the protocol used to measure the AIBL samples from this
protocol: 1) The coating pH was 8.6 in this protocol instead of 9.6; 2) Tween-20 was
only present in the PBS wash following the secondary antibody, and 3) Fraction V
BSA was used instead of cell-culture grade BSA.

There was negligible cross-

reactivity observed between assay reagents using this protocol.

Figure 4.5 Testing for non-specific binding/cross-reactivity in the IDE sandwich
ELISA using ab28561 as coating antibody (1:400) and LS-C55007 as detection
antibody (1:750). Pooled control plasma (PCP) was run diluted at 1:2 and all
control wells contained 625 ng/mL of purified recombinant rat IDE (rrIDE). Plates
were coated at pH 8.6 O/N at 4°C. Otherwise, the assay was performed as detailed
in Section 2.2.5.3. Data is not blank adjusted – dashed line indicates blank. Results
show there is negligible signal generated when either coating or detection antibody
was omitted, whereas the signal was increased 2-fold when blocking agent was
omitted.
192

4.3.5 Optimising the coating conditions for the IDE sandwich ELISA
For this purpose, a comparison was made between coating overnight at 4°C and
coating for 2 hr at room temperature (RT ~ 25°C). The pH of the coating buffer was
also compared (original conditions of pH 8.6 were compared to pH 9.6), as the
recommended pH for the coating buffer was pH 9.6. The results show that coating
at a pH of 9.6 for 2hr at RT was superior to other conditions for the rrIDE standard
curve (Figure 4.6 (A)), with a larger dynamic range, however background was similar
for all conditions (difference of 0.049 between lowest and highest value).
For the plasma dilutions (Figure 4.6 (B)), the coating condition of overnight at 4°C
with the coating buffer at pH 8.6 was optimal.

Coating for 2 hr at room

temperature (pH 9.6) provided the next best result, however for the 1:2 dilution
there was negligible difference in signal compared with coating overnight at 4°C (pH
8.6) (difference of 0.032 OD units for 1:1 dilution and 0.002 units for 1:2). As the
plasma would need to be diluted to fall within the range of the standard curve, it
was concluded that overall the optimal coating condition was 2 hr at room
temperature (pH 9.6).
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Figures 4.6 (A) and (B) Optimisation of coating conditions for the IDE sandwich
ELISA. The sandwich ELISA used ab28561 (Ab 3) as coating antibody (1:400) and LSC55007 (Ab 2) as detection antibody (1:750). The assay was performed as detailed
in Section 2.2.5.3. Data is shown without blank-adjustment. Recombinant rat IDE
(rrIDE) used for the standard curve (Graph A.) at 50 to 5000ng/mL. Pooled control
plasma (PCP) was run neat (0) and diluted 1:1 and 1:2 (Graph B.). Plates were
coated at pH 8.6 or 9.6 O/N at 4°C, and pH 8.6 or 9.6 for 2hr at room temperature
(RT - approximately 25°C).
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4.3.6 Optimising the sample and detection antibody diluent in the IDE
sandwich ELISA.
The composition of the sample and antibody diluents in a sandwich ELISA can have
a dramatic impact on the binding behaviour of the antibodies to the antigen.
Phosphate-buffered saline at a pH of 7.4 is one of the most commonly used diluents
in ELISAs due to its stability at physiological pH. Often low concentrations of BSA
are added to buffers to stabilise proteins in solution. Therefore the addition of 1%
BSA to PBST as the sample diluent was tested compared with PBST alone (Figures
4.7 (A) and (B)). In addition, it has been shown that the addition of polyethylene
glycol (PEG) can increase the speed of an immune reaction and enhance the signal
in an ELISA (Morissette, et al., 1991). Consequently, PEG (6000) was also added to
the detection antibody buffer (PBST) and compared with using PBST alone (Figures
4.7 (A) and (B)). The buffer conditions were tested on purified rat IDE as well as
two plasma dilutions (1:1 and 1:2). The results showed that the addition of 1% BSA
to the sample diluents had virtually no effect on the standard curve (Graph A.),
however caused a reduction of signal in the plasma (Graph B.). The addition of PEG
to the detection antibody buffer (PBST) increased the signal for the standard curve,
however also increased the background in a similar fashion, resulting in no overall
benefit (Graph A.). Results for plasma were similar with or without the addition of
PEG. Overall, it was concluded that no benefit in signal amplification or dynamic
range was seen with either the addition of BSA or PEG to the buffers. PBST alone
was therefore considered to be the optimal buffer for all dilution steps in the
sandwich ELISA.
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Figures 4.7 (A) and (B) Optimising buffer constituents for the dilution of samples
and detection antibody in sandwich ELISA. Optimisation of sample and antibody
diluents for sandwich ELISA using ab28561 (Ab 3) as coating antibody (1:400) and
LS-C55007 (Ab 2) as detection antibody (1:750). The assay was performed as
detailed in Section 2.2.5.3. Recombinant rat IDE (rrIDE) was used for the standard
curve (Graph A.) at 50 to 5000ng/mL. Pooled control plasma (PCP) was diluted at
1:1 and 1:2 (Graph B.). Data is shown without blank-adjustment. Standard diluent
(PBST alone for sample and antibody) was compared with adding 1% BSA to the
sample diluent, and also compared to adding 2% PEG 6000 to the detection
antibody diluent.
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4.3.7 Improvements in detected signals in the IDE sandwich ELISA
following changes to the detection antibody incubation time and
temperature.
Overnight incubations of antibodies at 4°C rather than 2 hr at room temperature
have frequently been found to improve the signals obtained (Dako, Abcam, Cellsignalling technology (CST)). Therefore a 2 hr incubation (at room temperature) of
the detection antibody was compared with incubating overnight at 4°C (Figures 4.8
(A) and (B)).

The results demonstrated a considerably increased signal and

improved dynamic range when incubating overnight at 4°C for both the standard
curve and all of the individual plasma samples. Although the background was also
increased (background OD of 0.263 (2hr) compared with 0.377 (overnight)), this
increase was negligible compared to the increase in signal. Therefore, it was
concluded that overnight incubation of the detection antibody at 4°C was superior
to 2 hr at room temperature.
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Figures 4.8 (A) and (B) Optimisation of detection antibody incubation time and
temperature. Optimisation of detection antibody (Ab 2 diluted to 1:750)
incubation conditions for sandwich ELISA using Ab 3 as coating antibody (1:400).
The assay was performed as detailed in Section 2.2.5.3. Recombinant rat IDE
(rrIDE) was used for the standard curve (Graph A.) at 50 to 16000ng/mL. Individual
plasma samples were diluted at 1:2 (S1-S5 - Graph B.). Detection antibody was
applied and incubated for 2 hr (2hr or 2h) at room temperature (RT), compared
with overnight (O/N) incubation at 4°C. All other conditions were identical for both
plates. Data is shown without blank-adjustment.
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4.3.8

A trial IDE sandwich ELISA was linear to approximately 4000

ng/mL and upper detection limit was not reached at 64000 ng/mL.
The standard curve in an ELISA is generally sigmoidal in shape, therefore
discrimination between data points is reduced at the extreme ends of the curve. As
the concentration values of the samples are interpolated from the standard curve it
is necessary for the absorbance readings of the samples fall within the linear range.
The lower detection limit can be determined by calculating the mean of the optical
density of the blanks and adding three standard deviations. Values that fall below
this detection limit should be (and were) considered to be too low to differentiate
from background noise.
An ELISA was run to determine the upper detection limit; this involved setting up an
extended standard curve. On the same ELISA plate, five individual plasma samples
were diluted and measured to see if their readings fell within the linear portion of
the standard curve (Figures 4.9 (A) and (B)). The results showed that the assay was
linear to 4000 ng/mL, the curve flattened out somewhat above this concentration,
yet the signal continued to rise up to 64000 ng/mL. This observation suggests an
upper detection limit was not reached. Considerable variation can be seen in the
plasma samples; three of the five plasma samples assayed had values within the
standard curve range, yet two of the samples fell above the highest standard curve
value. It was concluded that the standard curve would need to be extended further
to establish the upper limit of detection.
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Figure 4.9 (A) and (B) Trial IDE sandwich ELISA to give an extended 11-point
standard curve and measure five individual plasma samples. Investigation of the
upper detection limit in the sandwich ELISA using Ab 3 as coating antibody (1:400)
and Ab 2 as detection antibody at 1:750. The assay was performed as detailed in
Section 2.2.5.3. Recombinant rat IDE (rrIDE) was used for the 11-point standard
curve (Graph A.) at 50 to 64000ng/mL. Individual plasma samples were diluted at
1:2 (S1-S5 - Graph B.) and shown on the graph, so can be compared with the lowest
and highest data point of the standard curve (0 ng (blank) and 64000 ng). Data is
shown without blank-adjustment, dashed line indicates blank.
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4.3.9 Coating concentration of Ab 3 in IDE sandwich ELISA produces
the highest signal at 5 μg/mL and upper detection limit is not reached
at 160000 ng/mL IDE.
To optimise the coating concentration for the ELISA, and to investigate further the
potential upper detection limit of the assay, three concentrations of Ab 3 were
trialled with a standard curve range of rat IDE from 50 to 160000 ng/mL (Figure
4.10). The three concentrations of Ab 3 used were 5, 1 and 0.1 μg/mL. It should be
noted that only 50 μL/well of diluted coating antibody was used in this particular
test therefore the concentration of 5 μg/mL would contain the same amount of
antibody as 100 μL/well of 2.5 μg/mL, which was the coating concentration used in
previous optimisation steps. The results demonstrated that a reduction of the
concentration of coating antibody caused a reduction in background, signal and
dynamic range. With all three concentrations the signal was linear to 10000 ng/mL
but continued to rise and a plateau was not reached, even at 160000 ng/mL.
However, the slope of the curve above 10000 ng/ml was flatter, and past the linear
range. Based on these observations it was determined that the 5 μg/mL was the
most suitable coating concentration, as regardless of the increased background, it
produced the highest signal to noise ratio and largest dynamic range.
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Figure 4.10 Optimisation of coating conditions with Ab 3 and extension of
standard curve to 160000 ng/mL. Comparison of coating antibody (Ab 3)
concentration for sandwich ELISA using Ab 2 as detection antibody (1:750). The
assay was performed as detailed in Section 2.2.5.3. Recombinant rat IDE (rrIDE)
was used for the standard curve at concentrations of 50 to 160000 ng/mL. Coating
antibody is diluted to 5µg/mL, 1.0µg/mL and 0.1µg/mL (50µl volume). Data is
shown without blank-adjustment. Results show that standard curve is linear to
approximately 10000 ng/mL for all three coating concentrations, however
continues to increase with increasing concentration of rrIDE. Increasing coating
antibody concentration also increases background, yet the signal to noise ratio is
optimal at 5 μg/mL.
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4.3.10 Testing a non-albumin containing blocking agent in the IDE
sandwich ELISA.
Due to the high background absorbance of the ELISA, and the observation that both
Ab 2 and Ab 3 cross-reacted with albumin in Western immunoblotting, the blocking
agent (BSA) was replaced by a 3% solution of a non-albumin containing blocking
agent (ECL™ Advance Blocking agent) to see if the background would decrease.
Results showed that the non-albumin blocking agent increased the background
compared with previous assays which used BSA (Figure 4.11). It should be noted
that the assays were not performed simultaneously and therefore a direct
comparison could not be made. However, when previously using BSA as the
blocking agent, the background absorbance was consistently approximately 0.35;
with the non-albumin block it was over 0.40. As BSA produced a lower background,
it was used as the blocking agent in subsequent experiments.

Figure 4.11 Test of non-albumin containing blocking agent in the IDE sandwich
ELISA. Test of ECL™ Advance Blocking Agent to improve background absorbance
for IDE sandwich ELISA using Ab 3 as coating antibody (1:400) and Ab 2 as detection
antibody (1:750). The assay was performed as detailed in Section 2.2.5.3.
Recombinant rat IDE (rrIDE) was used for the standard curve at 500 to 16000ng/mL.
Pooled control plasma (PCP) diluted to 1:2. Data is shown without blankadjustment. Blocking step was using 3% ECL Advance Blocking Agent in PBS.
Results show that using the non-albumin containing blocking reagent produces a
high background absorbance of >0.4 in the sandwich ELISA.
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4.3.11 Low-level data analysis.
Raw data was normalised for inter-plate variation by adjusting to a PCP internal
control which was included on each plate. Intra-assay variation (n = 215, based on
the 6 plates used in the analysis) was determined to be ~11% (including samples
with a CV of >15% that were subsequently removed from the analysis). Following
the removal of these samples, average CV was 5%. Inter-assay variation was
determined to be ~16% (n = 6). Coefficient of variation (CV) values of duplicates
which were >15% were excluded from the analysis. If the CV of the PCP duplicates
was >15%, the entire plate was excluded from the analysis. Values < mean + 3x
standard deviation of the blanks were considered as below the detection limit.
Sample values for each plate were normalised to the PCP sample. As some of the
sample values fell outside the range of the standard curve, the concentrations could
not be interpolated and therefore only relative differences in absorbance (minus
blank absorbance) were compared for all samples.
The data was noted to have a non-normal distribution as determined by visually
inspecting histograms, box-plots and normal Q-Q plots, as well as calculating zscores of skewness and kurtosis.

In addition, normality tests such as the

Kolmogorov-Smirnoff and Shapiro-Wilks tests were highly significant. A variety of
transformations were used to correct the normality issues (square root, natural log,
natural log +1, reciprocal), however these were not effective. Therefore nonparametric tests were used to analyse the data (Kruskall-Wallis, Mann-Whitney and
Spearman’s Rho).

4.3.12 Total plasma IDE levels are reduced in MCI and AD compared
with HC.
A sample standard curve and set of 10 AIBL samples is shown in Figures 4.12(A) and
(B). To determine IDE levels according to cognitive status, the cohort was divided
into the clinically classified groups, healthy controls (HC - including subjective
memory complainers), mild cognitive impairment (MCI) and probable AD (AD). As
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only a subset of the cohort was used, the HC and SMC groups were combined to
form the healthy control group. Mean age was significantly different between the
groups. It should be noted that the subset used to measure IDE levels by ELISA was
different from the subsets used to measure IDE levels by Western immunoblotting
and IDE activity (detailed in Chapters 3 and 5, respectively).
The demographics for this subset of the AIBL cohort are shown in Table 4.1. AD
patients were significantly older, and as expected had a significantly higher
percentage of APOE ε4 carriers than the control or MCI groups. The plasma Aβ1-42/140

ratio was significantly decreased in the MCI and AD groups, while Aβx-40 was

significantly increased in both MCI and AD groups as compared with HC. Plasma
ApoE was significantly lower in AD patients, while ApoE4 levels were higher in the
MCI group compared with HC and AD groups. P values were not shown for brain Aβ
load as in this subset there was only one individual in the HC group who underwent
the PiB-PET scan. All other variables were not significantly different between
groups.
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Figure 4.12 (A) and (B) Sample standard curve and 10 sets of samples. The assay
was conducted as detailed in Section 2.2.5.3. Recombinant rat IDE (rrIDE) was
diluted to concentrations of 50 to 16000 ng/mL (Graph A.) and plasma samples
(Graph B) including PCP were loaded at a dilution of 1:2 (33.3 μL plasma per well) in
duplicate. Error bars indicate ±SD. Data is not blank-adjusted, dashed line indicates
blank (Graph B). Some samples had absorbances outside of the range of the
standard curve; as a result only relative differences could be compared.
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Table 4.1 Basic demographics of the AIBL cohort subset of participants for whom
plasma IDE levels were measured by ELISA. Plasma samples (33.3 μL per well in
duplicate) from the AIBL cohort were assayed with an in-house sandwich ELISA as
detailed in Section 2.2.5.3. Other variables were measured as outlined in Section
2.2.2.1. Continuous variables are expressed as mean (median) ± standard
deviation. P values were determined by Kruskall-Wallis tests using the Monte Carlo
method. As only a subset of the cohort was tested, the HC and subjective memory
(SMC) groups were combined to provide the healthy controls for this assay. n
values vary due to missing values for some data or in the case of brain Aβ load, only
a subset of the cohort underwent Pib-PET scans. P value was not given for brain Aβ
load as there was only one healthy control in this subgroup. As ApoE4 is only
expressed in individuals carrying the APOE ε4 allele, the n-values are reduced for
this variable.
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Total IDE levels as determined by the developed sandwich ELISA (Figure 4.13(A))
were found to be significantly lower in the MCI (p = 0.000) group compared with
the HC group. IDE levels were also lower in the AD group compared with the
controls, however failed to reach significance (p = 0.062, after Bonferroni correction
for multiple testing p = 0.186). There was no significant difference between IDE
levels in the MCI and AD groups (p = 0.260, after Bonferroni correction p = 0.780).
No differences were observed in total IDE levels between males and females (Figure
4.13(B), p = 0.136).
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Figure 4.13(A) and (B) Levels of total plasma IDE are decreased in MCI and AD
compared with HC, and no different in males versus females. Plasma samples
(diluted 1:2 - 33.3 μL per well in duplicate) from the AIBL cohort were assayed with
an in-house sandwich ELISA to measure total IDE as detailed in Section 2.2.5.3. The
average absorbance of the duplicates was obtained for each sample, and the
median of these values by classification were compared by a Kruskall-Wallis test,
using Mann-Whitney tests for post-hoc analysis with Bonferroni correction applied
to adjust for multiple testing for significant comparisons only. Data represents
medians with 95% confidence interval (CI), n = 177 (57 HC/50 MCI/70 AD). Values
were blank adjusted and normalised to the internal standard sample value included
on each plate to control for plate-to-plate variation. Results showed a significant
reduction in total IDE for MCI compared with HC (p = 0.000), however the reduction
seen in AD compared with HC lost significance after Bonferroni correction (Graph
A., p = 0.186). No differences in total IDE levels were seen between males and
females (Graph B., p = 0.136).
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4.3.13 Total plasma IDE levels reduce (not significantly) with age.
As IDE levels in the hippocampus have previously been reported to decline with
ageing (Caccamo, et al., 2005), total levels measured with ELISA were analysed by
age quartiles to determine if this phenomenon occurs in the periphery (Figure
4.14). Results showed that similar to the hippocampus, IDE levels in the blood also
tend to decrease with age, particularly in age groups over 78 years, however the
reduction was not statistically significant.

Figure 4.14 Total plasma IDE levels reduce (not significantly) with age. Plasma
samples (diluted 1:2 - 33.3 μL per well in duplicate) from the AIBL cohort were
assayed with an in-house sandwich ELISA to measure total IDE as detailed in Section
2.2.5.3. The average absorbance of the duplicates was obtained for each sample,
and the median of the groups were compared by a Kruskall-Wallis test. Data
represents medians with 95% confidence interval (CI). n = 177 (Quartile 1 (60-68) n
= 52/Quartile 2 (69-77) n = 59/Quartile 3 (78-86) n = 50/Quartile 4 (87-96) n = 15).
Results show that IDE levels tend to reduce with age, albeit not significantly (p =
0.119).
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4.3.14

APOE ε4 carriers do not have significantly different total

plasma IDE levels compared with non-carriers.
Several studies have demonstrated a difference in cerebral IDE expression between
APOE ε4 carriers and non-carriers, with ε4 carriers shown to have reduced
expression of IDE. To ascertain if this effect also occurs in the plasma, total IDE
levels were compared between carriers and non-carriers (Figure 4.15(A)). Results
showed that ε4 carriers tended to have lower total IDE levels than non-carriers,
however this was not statistically significant (p = 0.109). When stratified by ε4
status and analysed by classification (Figures 4.15(B) and (C)), there was a nonsignificant trend toward lower IDE levels in MCI and AD compared with controls still
in ε4 carriers (p = 0.068), but not in non-carriers (p = 0.114).
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Figure 4.15(A) Total IDE levels are not significantly reduced, in APOE ε4 carriers
compared with non-carriers. Plasma samples (diluted 1:2 - 33.3 μL per well in
duplicate) from the AIBL cohort were assayed with an in-house sandwich ELISA to
measure total IDE as detailed in Section 2.2.5.3. The average absorbance of the
duplicates was obtained for each sample, and the median of these values by APOE
ε4 genotype status were compared by a Kruskall-Wallis test. Data represents
medians with 95% confidence interval (CI), n = 174 (89 ε4/85 non-ε4). Results show
no significant reduction in IDE levels between ε4 carriers and non-carriers (p =
0.109).
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Figure 4.15(B) and (C) Total IDE levels are reduced in MCI and AD (but not
significantly), in APOE ε4 carriers but not in non-carriers. Plasma samples (diluted
1:2 - 33.3 μL per well in duplicate) from the AIBL cohort were assayed with an inhouse sandwich ELISA to measure total IDE as detailed in Section 2.2.5.3. The
average absorbance of the duplicates was obtained for each sample, and the
median of these values (after stratification by APOE ε4 genotype status) by clinical
classification were compared by a Kruskall-Wallis test. Data represents medians
with 95% confidence interval (CI), (ε4 carriers) n = 88 (19 HC/23 MCI/46 AD), (noncarriers) n = 86 (38 HC/26 MCI/22 AD). Results show a trend toward lower IDE in
MCI and AD for ε4 carriers (Graph B., p = 0.068) but not for non-carriers (Graph C.,
p = 0.114).

218

219

4.3.15

Relationships between total plasma IDE levels and other

biochemical data collected in the AIBL study
4.3.15.1 Total IDE levels correlate with age, Aβ, testosterone,
and HDL cholesterol.
To determine if there were any relationships between total plasma IDE levels and
other biochemical data collected in AIBL study, correlation analyses were
performed (Table 4.2). Details of the methods used to measure the variables other
than IDE are outlined in Section 2.2.2.1.

Plasma IDE was analysed for any

correlation with age as it has been reported that IDE expression shows an agedependent reduction in the brain. Plasma insulin, Aβ40 and Aβ42 (and fragments),
and total ApoE and ApoE4 were analysed for correlations with IDE, as both insulin
and Aβ are substrates of IDE, and ApoE has been associated with reduced IDE
expression. Testosterone (total and calculated free), estradiol and cholesterol were
also examined for correlation with total IDE levels, as these have been associated
with changes in IDE expression. Total plasma IDE was also analysed against brain
Aβ load to see if any correlation existed. Results demonstrated a significant inverse
correlation between levels of total plasma IDE and both plasma Aβ1-42 (rs = -.236, p
= 0.002) and Aβ1-40 (rs = -.225, p = 0.003). IDE also tended towards an inverse
correlation with Aβx-42 (rs = -.144, p = 0.060), however this did not reach
significance. Total IDE in plasma also showed an inverse correlation with age (rs = .182, p = 0.015) and HDL cholesterol ( rs = -.158, p = 0.036), and a positive
correlation with total testosterone (rs = .173, p = 0.022) and free testosterone (rs =
.172, p = 0.022). No other variables correlated with plasma total IDE. Because
using Bonferroni correction to adjust the rejection criteria for multiple testing
would be too stringent in this instance (because of 18 tests in total), BonferroniHolm correction was instead used to reduce the chances of Type II errors (Holm,
1979). After the correction was made, only Aβ1-42 (p = 0.036) was still significant,
however Aβ1-40 almost reached significance (p = 0.051).
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Table 4.2 Correlation matrix of total plasma IDE levels with other variables.
Plasma levels of total IDE were analysed for relationships with sex (gender), age,
and plasma insulin, Aβ species, ApoE species, testosterone, oestradiol, lipids and
brain Aβ load (two tailed) (methods of data collection are outlined in Section
2.2.2.1). n values vary due to missing values for some data or in the case of brain
Aβ load only a subset of the cohort underwent PiB-PET scans. For ApoE4, n value is
lower as only the APOE ε4 carriers express this isoform. Results show a significant
but weak negative correlation exists between IDE levels and age (rs = -.182, p =
.015), Aβ1-42 (rs = -.236, p = .002), Aβ1-40 (rs = -.225, p = .003), and HDL cholesterol (rs
= -.158, p = .036). Significant positive correlations were observed with total
testosterone (rs = .173, p = .022) and free testosterone (rs = .172, p = .022). Aβx-42
approached a weak correlation however did not reach significance (rs = -.144, p =
.060). Following Bonferroni-Holm correction for multiple testing, only Aβ1-42 (p =
0.036) was still significant, although Aβ1-40 almost reached significance (p = 0.051).
* indicates significance at the 0.05 level, ** indicates significance at the 0.01 level.
(“unadj.” = unadjusted, prior to Bonferroni-Holm correction, “adj.” = adjusted by
Bonferroni-Holm correction).
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To exclude the possibility of an effect of gender on the results, particularly
regarding testosterone and oestradiol which differ greatly between males and
females, the overall subset was stratified by gender and correlation analyses
performed again (Tables 4.3(A) and (B)). Results showed that the unadjusted
correlation between IDE and Aβ1-42 was still significant in both males (rs = -.265, p =
0.031) and females (rs = -.225, p = 0.019). In males the correlation with Aβ1-40 was
also still significant (rs = -.287, p = 0.019), but in females was reduced to a nonsignificant trend (rs = -.180, p = 0.061). Similarly, the correlation with age was
reduced to a non-significant trend for both males (rs = -.224, p = 0.070) and females
(rs = -.160, p = 0.095). Associations between IDE and HDL cholesterol disappeared
when stratified by gender. The positive correlations of IDE with total and free
testosterone, however, were strengthened in males when stratified [(rs = .314, p =
0.010) and (rs = .334, p = 0.006), respectively] but in females this correlation
disappeared (rs = .039, p = 0.689).

When adjusted for multiple testing by

Bonferroni-Holm correction, all associations became non-significant.
When stratified by APOE ε4 status (Tables 4.4 (A) and (B)), for the non- ε4 carriers
significant inverse correlations were observed between total plasma IDE and Aβ1-40
(rs = -.255, p = 0.015), Aβ1-42 (rs = -.226, p = 0.038), and HDL cholesterol (rs = -.247, p
= 0.022). For ε4 carriers, an inverse correlation was seen with Aβ1-42 (rs = -.245, p =
0.022) and a positive correlation with total testosterone (rs = .213, p = 0.048) and
free testosterone (rs = .221, p = 0.038). Following Bonferroni-Holm correction
however, associations for both ε4 carriers and non-carriers were no longer
significant.
After stratification by clinical classification, the correlations seen between total IDE
and Aβ1-42 and Aβ1-40 were found to be restricted to AD patients only (rs = -.361, p =
0.002, n = 70) and (rs = -.268, p = 0.025, n = 70), respectively (not shown in tables).
Stratifying further by ε4 status showed that the association in AD was only in nonε4 carriers for Aβ1-42 (rs = -.634, p = 0.002, n = 22), and Aβ1-40 (rs = -.527, p = 0.012, n
= 22). This stratification strengthened the correlations by approximately two-fold.
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Tables 4.3 (A) Correlation matrix of total plasma IDE levels with other
biochemical variables separately by gender (males only). Table 4.3 (A) shows
correlation analysis of total plasma IDE with age, and plasma insulin, Aβ species,
ApoE species, testosterone, oestradiol, lipids and brain Aβ load (two tailed).
Methods of data collection are outlined in Section 2.2.2.1. n values vary due to
missing values for some data or in the case of brain Aβ load only a subset of the
cohort underwent PiB-PET scans. For ApoE4, n value is lower as only the APOE ε4
carriers express this isoform. Results show that significant negative correlations are
retained in males between IDE and Aβ1-42 (rs = -.265, p = 0.031), Aβ1-40 (rs = -.287, p =
.019), and the positive correlation in males was stronger with total testosterone (rs
= .314, p = .010) and free testosterone (rs = .334, p = .006). However, following
Bonferroni-Holm correction, all associations were no longer significant. **
indicates significance at the 0.01 level, * indicates significance at the 0.05 level.
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Tables 4.3 (B) Correlation matrix of total plasma IDE levels with other
biochemical variables separately by gender (females only). Table 4.3 (B) shows
correlation analysis of total plasma IDE with age, and plasma insulin, Aβ species,
ApoE species, testosterone, oestradiol, lipids and brain Aβ load (two tailed).
Methods of data collection are outlined in Section 2.2.2.1. n values vary due to
missing values for some data or in the case of brain Aβ load only a subset of the
cohort underwent PiB-PET scans. For ApoE4, n value is lower as only the APOE ε4
carriers express this isoform. Results show that significant negative correlations are
retained in females only between total IDE and Aβ1-42 (rs = -.225, p = 0.019),.
However, following Bonferroni-Holm correction, the association was no longer
significant. * indicates significance at the 0.05 level.
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Table 4.4 (A) Correlation matrix of total plasma IDE levels with other variables for
APOE ε4 non-carriers only. Plasma levels of full-length IDE were analysed for
relationships with sex, age, and plasma insulin, Aβ species, ApoE species,
testosterone, oestradiol, lipids and brain Aβ load (two tailed) after stratifying data
by APOE ε4 status (methods of data collection are outlined in Section 2.2.2.1). n
values vary due to missing values for some data or in the case of brain Aβ load only
a subset of the cohort underwent PiB-PET scans. For ApoE4, no values are shown
as only the APOE ε4 carriers express this isoform. Results show significant inverse
correlations between IDE levels and Aβ1-40 (rs = -.262, p = 0.015), Aβ1-42 (rs = -.226, p
= 0.038) and HDL cholesterol (rs = -.247, p = 0.022). Following Bonferroni-Holm
correction for multiple testing, no associations remained significant. * indicates
significance at the 0.05 level.
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Table 4.4 (B) Correlation matrix of total plasma IDE levels with other variables for
APOE ε4 carriers only. Plasma levels of full-length IDE were analysed for
relationships with sex, age, and plasma insulin, Aβ species, ApoE species,
testosterone, oestradiol, lipids and brain Aβ load (two tailed) after stratifying data
by APOE ε4 status (methods of data collection are outlined in Section 2.2.2.1). n
values vary due to missing values for some data or in the case of brain Aβ load only
a subset of the cohort underwent PiB-PET scans. Results show significant inverse
correlations between IDE levels Aβ1-42 (rs = -.245, p = 0.022) and a positive
correlation with total testosterone (rs = .213, p = 0.048) and free testosterone (rs =
.221, p = 0.038). Following Bonferroni-Holm correction for multiple testing, no
associations remained significant. * indicates significance at the 0.05 level.
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4.3.15.2 The ratio of total IDE to insulin is lower in MCI and AD
individuals.
As previously mentioned, IDE has a high affinity for both insulin and Aβ, and as a
result the levels of these substrates in relation to IDE may provide better
discrimination between clinical classifications than the levels of IDE alone.
Therefore the ratio of total IDE to insulin was calculated and compared between
classifications (Figure 4.16(A)). An increase in insulin relative to total IDE levels or a
decrease in IDE relative to insulin levels would lead to a reduction of the IDE/Insulin
ratio. Either of these changes could influence the degradation of Aβ (both directly
and indirectly via other effects of insulin, for example), and may lead to an increase
in plasma Aβ due to decreased degradation.

The results showed that the

IDE/insulin ratio was significantly lower in MCI subjects compared with HC subjects
(p = 0.009). After applying Bonferroni correction for multiple testing the difference
was still significant (p = 0.027). The IDE/insulin ratio was also lower in the AD group
compared with controls (p = 0.032) however after Bonferroni correction for
multiple testing was no longer significant (p = 0.096).
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Figure 4.16(A) AD and MCI individuals have a lower IDE/Insulin ratio than
controls (overall). Insulin levels were measured as outlined in Section 2.2.2.1.
Plasma samples (diluted 1:2 - 33.3 μL per well in duplicate) from the AIBL cohort
were assayed with an in-house sandwich ELISA to measure total IDE as detailed in
Section 2.2.5.3. The average absorbance of the duplicates was obtained for each
sample, and a ratio was calculated of total plasma IDE to plasma insulin (IDE/Insulin
ratio). The median of these values were compared between classifications by a
Kruskall-Wallis test with Mann-Whitney post-hoc tests (Bonferroni correction
applied for multiple testing). Data represents medians with 95% confidence
interval (CI), n = 176 (57 HC/50 MCI/69 AD). Results show the MCI group has a
lower IDE/insulin ratio than HC (p = 0.027 after Bonferroni correction).
When the groups were stratified for APOE ε4 status, only the non-ε4 carriers had
significantly different IDE/Insulin ratios by classification (Figure 4.16(B) and (C)).
Results for this group showed a significant reduction of the IDE/Insulin ratio in the
MCI group compared with HC group (p = 0.012, after Bonferroni correction p =
0.036). There was no significant differences observed between the AD group and
either MCI (p = 0.247), or HC group (p = 0.235). For the ε4 carriers there were no
significant differences between classifications (p = 0.386).
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Figure 4.16(B) and (C) MCI individuals that do not carry an APOE ε4 allele have a
lower IDE/Insulin ratio than non-ε4 controls. Insulin levels were measured as
outlined in Section 2.2.2.1. Plasma samples (diluted 1:2 - 33.3 μL per well in
duplicate) from the AIBL cohort were assayed with an in-house sandwich ELISA to
measure total IDE as detailed in Section 2.2.5.3. The average absorbance of the
duplicates was obtained for each sample, and a ratio was calculated of total plasma
IDE to plasma insulin (IDE/Insulin ratio). Data was stratified by APOE ε4 status and
the median of these values were compared between HC/MCI/AD classifications by a
Kruskall-Wallis test with Mann-Whitney post-hoc tests, and found to be significantly
different in the non-ε4 carriers only (p = 0.036 after Bonferroni correction applied
for multiple testing) but no differences were observed between classifications for
ε4 carriers (p = 0.386). Data represents medians with 95% confidence interval (CI),
(non-ε4) n = 85 (38 HC/26 MCI/21 AD), (ε4 carriers) n = 88 (19 HC/23 MCI/46 AD).
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4.3.15.3 The ratio of total IDE to Aβ42+40 is significantly lower in
MCI and AD compared with HC.
Similar to the IDE/insulin ratio, the ratio of IDE to total levels of both Aβ42 and Aβ40
may offer some information about AD, and in fact may be more relevant to
Alzheimer’s pathology than IDE/Insulin ratios. It has been observed that plasma Aβ
is generally elevated in early AD compared with controls and reduces as Aβ is
deposited into SP in the brain (Kawarabayashi, et al., 2001; Schupf, et al., 2008),
therefore the ratio of plasma IDE/Aβ levels may be pertinent in the prodromal
stages of AD with respect to the regulation of plasma Aβ levels. This may be
reflected in the MCI group, which represents the pre-symptomatic period prior to
full-blown AD symptoms becoming apparent. Hence, the IDE/Aβ42+40 ratios were
calculated (using Aβ1-42 and Aβ1-42) and analysed by classification (Figure 4.17(A)).
The results show a significant reduction in the IDE/Aβ42+40 ratio in MCI (p = 0.000)
and AD (p = 0.024) compared with HC after Bonferroni correction for multiple
testing (MCI<AD<HC). When stratified for APOE status (Figures 4.17(B) and (C)), no
significant differences were observed between clinical classifications for the
IDE/Aβ42+40 ratio, however a trend toward lower ratios were seen in the MCI group
compared with controls and AD (p = 0.071) but only in the non-ε4 carriers.
The decrease in IDE levels (as shown in the current study) relative to Aβ, together
with an increase in Aβ accounts for the reduction in IDE/Aβ42+40 ratios observed.
Only a slight increase was observed in Aβ40 species indicating that the reduction of
IDE was the major factor contributing to the differences observed.

It was

concluded that the IDE/Aβ42+40 ratio may be of benefit for differentiating between
healthy controls and pre-symptomatic or symptomatic AD patients.
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Figure 4.17(A) The plasma IDE/Aβ42+40 ratio is significantly reduced in MCI and AD
in comparison to HC. Aβ1-42 and Aβ1-40 were measured as outlined in Section
2.2.2.1. Plasma samples (diluted 1:2 - 33.3 μL per well in duplicate) from the AIBL
cohort were assayed with an in-house sandwich ELISA to measure total IDE as
detailed in Section 2.2.5.3. The average absorbance of the duplicates was obtained
for each sample, and a ratio of total plasma IDE to plasma Aβ42+40 (IDE/Aβ42+40 ratio)
was calculated. The median of these values were compared between classifications
by a Kruskall-Wallis test with Mann-Whitney post-hoc tests (with Bonferroni
correction applied for multiple testing). Data represents medians with 95%
confidence interval (CI), n = 175 (57 HC/48 MCI/70 AD). Results show that after
Bonferroni correction the IDE/Aβ42+40 ratio is significantly lower in MCI (p = 0.000)
and AD (p = 0.024) compared with HC.
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Figure 4.17(B) and (C) The plasma IDE/Aβ42+40 ratio is not significantly reduced in
MCI and AD in comparison to HC when stratified by APOE status. Aβ1-42 and Aβ1-40
were measured as outlined in Section 2.2.2.1. Plasma samples (diluted 1:2 - 33.3 μL
per well in duplicate) from the AIBL cohort were assayed with an in-house sandwich
ELISA to measure total IDE as detailed in Section 2.2.5.3. The average absorbance
of the duplicates was obtained for each sample, and a ratio of total plasma IDE to
plasma Aβ42+40 (IDE/Aβ42+40 ratio) was calculated. The median of these values were
compared between classifications by a Kruskall-Wallis test with Mann-Whitney
post-hoc tests (with Bonferroni correction applied for multiple testing). Data
represents medians with 95% confidence interval (CI). (Non-ε4 carriers) n = 85 (38
HC/25 MCI/22 AD), (ε4 carriers) n = 87 (19 HC/22 MCI/46 AD). Results show no
significant differences between classifications for ε4 carriers (p = 0.092), however a
trend toward lower IDE/Aβ42+40 ratio was seen in MCI for the ε4 non-carriers only (p
= 0.071).
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4.3.15.4 The ratio of total IDE to Insulin + Aβ42+40 is significantly
lower in MCI and AD compared with HC.
Because significant differences were observed between the classifications for both
the IDE/Insulin ratio and also the IDE/Aβ42+40 ratio, there may be a combined effect
of increased insulin and increased Aβ with reduced IDE in plasma, thus the ratio of
IDE to combined levels of insulin and Aβ could potentially differentiate MCI and AD
compared to control subjects better than the IDE/insulin or IDE/Aβ42+40 ratios. To
address this possibility, insulin values (in mU/L) were converted into pg/mL and
added to the Aβ42+40 values to give a total value of Insulin + Aβ42+40 in pg/mL. The
ratio of IDE to insulin + Aβ42+40 was then analysed by classification to see if it could
differentiate between MCI and/or AD with controls more effectively than insulin or
Aβ42+40 alone (Figure 4.18(A)).
The results show that the IDE/Insulin + Aβ42+40 ratio was similar to the IDE/Aβ42+40
ratio in that there was a highly significant decrease in MCI compared with controls
(p = 0.000) and a significant reduction in AD compared with controls (p = 0.024)
after Bonferroni correction for multiple testing (MCI<AD<HC).

Using the

combination of insulin and Aβ levels in the ratio rather than just Aβ alone did not
produce any additional benefits to using Aβ levels alone in this subgroup. However,
when stratified by APOE status (Figures 4.18(B) and (C)), the non-ε4 carriers showed
a similar result to the overall results with a significantly lower ratio in MCI
compared with HC (p = 0.048 after Bonferroni correction), while the ε4 carriers
were not significantly different between classifications (p = 0.172).

It was

concluded that similar to the IDE/Aβ42+40 ratio, the IDE/Insulin + Aβ42+40 ratio may
be useful for differentiating between healthy controls and pre-symptomatic or
symptomatic AD patients.
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Figure 4.18(A) The plasma IDE/Insulin+Aβ42+40 ratio is significantly reduced in MCI
and AD in comparison to HC. Insulin, Aβ1-42 and Aβ1-40 were measured as outlined
in Section 2.2.2.1. Plasma samples (diluted 1:2 - 33.3 μL per well in duplicate) from
the AIBL cohort were assayed with an in-house sandwich ELISA to measure total IDE
as detailed in Section 2.2.5.3. The average absorbance of the duplicates was
obtained for each sample, and a ratio of total plasma IDE to plasma Insulin + Aβ42+40
(IDE/Insulin+Aβ42+40 ratio) was calculated. The median of these values were
compared between classifications by a Kruskall-Wallis test with Mann-Whitney
post-hoc tests (with Bonferroni correction applied for multiple testing for significant
results only). Data represents medians with 95% confidence interval (CI), n = 174
(57 HC/48 MCI/69 AD). Results show that after Bonferroni correction MCI (p =
0.000) and AD (p = 0.024) were significantly lower than HC.
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Figure 4.18(B) and (C) The plasma IDE/Insulin+Aβ42+40 ratio is significantly
reduced in MCI in comparison to HC in APOE ε4 non-carriers only. Insulin, Aβ1-42
and Aβ1-40 were measured as outlined in Section 2.2.2.1. Plasma samples (diluted
1:2 - 33.3 μL per well in duplicate) from the AIBL cohort were assayed with an inhouse sandwich ELISA to measure total IDE as detailed in Section 2.2.5.3. The
average absorbance of the duplicates was obtained for each sample, and a ratio of
total plasma IDE to plasma Insulin + Aβ42+40 (IDE/Insulin+Aβ42+40 ratio) was
calculated. The median of these values were compared between classifications by a
Kruskall-Wallis test with Mann-Whitney post-hoc tests (with Bonferroni correction
applied for multiple testing for significant results only). Data represents medians
with 95% confidence interval (CI), (non-ε4 carriers) n = 84 (38 HC/25 MCI/21 AD),
(ε4 carriers) n = 87 (19 HC/22 MCI/46 AD). Results show that after Bonferroni
correction MCI (p = 0.000) and AD (p = 0.024) were significantly lower than HC.
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4.3.16 Follow-up optimisation (1): Cell-culture grade BSA produces a
dose-dependent signal in IDE sandwich ELISA but Fraction V BSA and
HSA do not.
After the AIBL samples were assayed in the IDE sandwich ELISA assays mentioned
above (using cell-culture grade BSA), some experiments were performed to find out
if a purer form of BSA could reduce the high background observed in the ELISA.
Cross-reactivity had been seen with both Ab 2 and Ab 3 with cell-culture grade BSA
and HSA at an equivalent range of concentrations of albumin found in human
serum with Western immunoblotting, therefore it was deemed worthwhile to
determine if there was still cross-reactivity under non-denaturing and reducing
conditions. Fraction V derived BSA is a purer formulation of BSA than cell-culture
grade, and hence may result in less background in the sandwich ELISA due to
reduced levels of contaminants. Therefore, cell-culture grade BSA was compared
with Fraction V BSA and human serum albumin (HSA) to determine if these latter
two could contribute to any part of the signal observed in the ELISA (Figure 4.19).
Fraction V BSA was used as the blocking agent. The results demonstrate that there
is no signal derived above the absorbance of the blank, from the Fraction V BSA or
from HSA at any of the concentrations tested. However, a dose-dependent signal
was observed with the cell-culture grade BSA.

Furthermore, the background

absorbance was considerably reduced by using the Fraction V BSA as a blocking
agent instead of the cell-culture grade BSA, compared with previous experiments.
Nevertheless, the cell-culture grade BSA was used in the experiments in this
chapter, and the background absorbance was removed prior to analysing the
values, therefore it was concluded that it was not a confounding issue in the assay.
In addition, since the readings of HSA in this assay were negligible, it is likely that
the human albumin in the plasma samples was not interfering with the detection of
IDE in the sandwich ELISA. Finally, Fraction V BSA was determined to be the
superior grade of BSA as a blocking agent in this assay as compared with cell-culture
grade BSA. This highlights the importance of choosing the correct blocking agent
for the assay.
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Figure 4.19 Determination and comparison of potential cross-reactivity of
different albumins in the IDE sandwich ELISA. A sandwich ELISA was carried out
using HSA and two types of BSA at different dilutions in place of plasma samples.
HSA was diluted to physiological concentrations (60, 45, 30 and 15mg/mL) and then
diluted as per plasma samples (1:2). The two types of BSA were also diluted to
concentrations equivalent to the highest and lowest physiological plasma levels of
HSA (60 and 30 mg/mL, respectively) and then diluted as per plasma samples (1:2).
The two types of BSA tested were Cell Culture Grade BSA (BSAS) and Fraction V BSA
(BSAV). Fraction V BSA was also used for the blocking step. The OD readings
obtained for the blank and a pooled plasma control sample are included in graph
(PCP diluted to 1:2). Data is shown without blank-adjustment, the blank reading is
indicated by the dashed line. The results show that the background absorbance can
be reduced considerably using Fraction V BSA or HSA as blocking agents, compared
with previous experiments which used cell-culture grade BSA.

243

4.3.17 Follow-up optimisation (2): Spike and recovery assessment of
IDE sandwich ELISA.
As plasma contains a plethora of constituents which potentially may interfere with
the detection of IDE in the ELISA, a spike and recovery assessment was performed
using recombinant rat IDE (Figure 4.20). The assay was performed as detailed in
Section 2.2.5.3 with the following exceptions. Rat IDE was used to prepare two
identical standard curves; one diluted in PBST alone (control) and the other diluted
in a 1:2 solution of PCP. Ideally, the two standard curves should be the same;
however values that fall within 80-120% of the control curve are considered to be
an acceptable recovery.

Results demonstrated significant interference by the

plasma matrix with 100% of the standard curve signal suppressed, even at the
highest concentrations of IDE.
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Figure 4.20 Assessment of the potential interference of plasma components in
the IDE sandwich ELISA. Spike and recovery assessment ELISA was carried out on
plasma using Ab 3 as coating antibody (1:400) and Ab 2 as detection antibody
(1:750) as detailed in Section 2.2.5.3. Recombinant rat IDE (rrIDE) used for the
standard curve at concentrations of 1250 to 10000ng/mL in PBST (PBST - Control).
Data is shown without blank-adjustment. Pooled control plasma (PCP) was diluted
1:2 in PBST, and used as the diluent for an identical standard curve to the control
(PCP/PBST). Values for the PCP/PBST samples were obtained by subtracting control
blank from the PCP/PBST blank to obtain the signal generated from the plasmacontaining diluent, then removing this value from the spiked values (without blank
adjustment).
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4.4 Discussion
The aim of this chapter was to determine IDE levels in human plasma, in samples
which had been obtained from AIBL study participants, using an ELISA method for
the enzyme measurement. The test was developed to ascertain if there were any
differences in total plasma IDE levels in AD or MCI patients, when compared with
healthy controls. Correlations between the IDE levels and levels of other ADrelated genetic or biochemical parameters which had been analysed in the AIBL
study were also investigated, to determine if there were any significant
relationships.
At the time of starting this project, there was only one available commercial IDE
ELISA kit recommended for the detection of IDE in human plasma. This kit was
screened for its suitability for measuring plasma IDE and reproducibility between
runs. From two runs, the kit showed a high coefficient of variation (CV) within
duplicates (intra-assay variation) and between runs (inter-assay variation); ideally
the variation should not exceed 15%. The reasons for the high coefficients of
variation were not clear; however one possibility may be related to the storage of
the plasma samples. The company states that plasma samples should be stored for
less than 2 months at -80°C. Although stored correctly, the samples used to test the
kit were in excess of 6 months old, as were the AIBL samples which were to be
assayed. Another possible reason for the variation may be related to the assay
procedure: during the first 37°C incubation on Run 1, the plate sealer provided with
the kit had warped and partially peeled off the plate. This may have introduced
some variation due to uneven evaporation of the wells and temperature
differences.

An alternate brand of plate sealers were therefore used for

subsequent incubations. However, this would not have accounted for the high CV
observed in the second test. While it would have been of value to screen the kit
further, this was not viable due to the high cost of the kit and therefore this kit was
deemed unsuitable for this project.
As a result, the development of an in-house ELISA was necessary. The indirect
(antigen coating) method was chosen initially due to its simpler design; only one
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primary antibody was required, negating the need to screen for matching pairs of
antibodies. There were considerable differences in assay results, dependent on the
primary antibody used.

Eight commercially-available IDE-specific primary

antibodies were screened for this purpose, and these were rated according to a
number of criteria. These included the amount of background signal produced, the
strength of the signal above the blank, dynamic range of the standard curve, and
linearity of dilution. MAb 7, one of two monoclonal antibodies that were screened,
was also the only antibody that produced a high background, with plasma signal
values being less than the background signal. This antibody had been reported
(Yfanti, et al., 2008) to cross-react with several proteins which are present in human
plasma; it is possible that it also cross-reacted with the BSA used as the blocking
agent, although this was not tested. Cross-reactivity with BSA may also have
accounted for the plasma signal being lower than the background as the HSA in
plasma would have bound to the plate, acting as a blocking agent itself and
preventing the BSA from binding. This would be feasible if the antibody crossreacted with BSA and reacted weakly or not at all with HSA. However, again this
was not tested. The other monoclonal MAb 9 produced an adequate standard
curve dynamic range, however the values for the plasma dilutions did not
demonstrate a dose-response.

These antibodies were therefore considered

unsuitable for the indirect ELISA.
The polyclonal antibodies screened showed considerable variation. While Ab 8 and
Ab 1 had good dynamic range on the standard curve, plasma values were very low
and there was no linearity of dilution. Similarly Ab 4 had low plasma values but also
a poor range on the standard curve. In addition there was no linearity of dilution
apparent for all three of these antibodies. Therefore Ab 8, 1 and 4 were excluded
as candidates for the indirect assay. The three remaining antibodies (Ab 6, Ab 2 and
Ab 3) showed an acceptable dynamic range on the standard curve, but plasma
dilutions demonstrated signal in the reverse direction: showing increasing
absorbance as the dilution increased. One reason for this observation that is likely
is that plasma proteins may have acted like a blocking agent, occupying binding
sites on the plate and essentially competing for space with IDE, therefore more
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dilution would result in less non-specific protein present, leading to less of a
blocking effect and a more specific signal. Therefore, it was concluded that the
indirect method would not be appropriate for the measurement of IDE in a complex
matrix such as plasma, and that a sandwich ELISA would be more suitable for this
purpose.
Three antibodies (Ab 6, 2 and 3) from the indirect ELISA tests were selected to
develop a sandwich ELISA based on a good dynamic range on the standard curve,
and positive signal above the blank in the plasma. Of these, Ab 6 was in an
unpurified form therefore was unsuitable to use as a coating antibody, as
contaminants in the antibody preparation would compete for binding sites on the
plate. In addition, as Ab 2 demonstrated a strong cross-reaction with HSA, which is
present in human plasma, it was also considered not to be suitable for a coating
antibody as it would be capturing the HSA from the plasma as well as the IDE.
Hence Ab 3 was tested as a coating antibody with both Ab 6 and Ab 2 tested as
potential detection antibodies. As both bind to similar regions which are distinct
from the Ab 3 IDE epitope, this reduced the likelihood of steric hindrance between
the capture and detection antibodies. Both Ab 6 and Ab 2 worked well as detection
antibodies, producing similar results and plasma dilutions being correctly reflected
dose-dependently in absorbances observed. Ab 2, however, had a marginally
higher dynamic range for both standard curve and plasma dilutions, a lower
background, and as Ab 2 was affinity purified it would not contain contaminants
which could potentially interfere with the assay. Therefore Ab 2 was chosen as
detection antibody.
The reagents for the sandwich ELISA were tested for cross-reactivity and generation
of any non-specific signal by omitting each from the assay separately. Omission of
the capture or detection antibodies resulted in low background signals, indicating
negligible cross-reactivity.

When the blocking agent was omitted, signal was

increased approximately two-fold. This would be expected as unbound sites on the
plate surface would therefore be available for the sample or detection antibody to
bind to, leading to a higher overall signal. However, there were two limitations of
this experiment; firstly the controls were performed using purified IDE and may not
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be reflective of potential cross-reactivity which may occur with the assay reagents
and other components of plasma.

Secondly, there were three differences in

protocol for this experiment compared with the protocol used to measure IDE in
the AIBL samples; the coating step was at pH 8.6 instead of 9.6, there was no
Tween-20 in the PBS buffer washes until the final wash step after the secondary
antibody, and Fraction V BSA was used instead of cell-culture grade BSA. The
change in pH would only be likely to affect the strength of binding of the antibody
to the microplate minimally, and potentially lead to a slightly lower overall signal.
However, it was demonstrated that coating at a pH of 8.6 produced a slightly higher
signal in rrIDE compared with pH 9.6. Similarly, the presence of Tween-20 in the
wash steps would probably only slightly reduce the likelihood of non-specific
binding, and its absence might lead to a higher overall signal. As there was only a
very low background observed by omission of both the coating and detection
antibodies, it is unlikely that these two factors would significantly alter the results
observed in a negative direction (ie. increase the background). At the time of this
particular experiment, the concept that assay results could be influenced by
different formulations of BSA had not been considered, and the results obtained
using Fraction V BSA possibly did not reflect potential cross-reactivity with cellculture grade BSA which was used in the protocol when testing the AIBL samples.
Therefore in hindsight, the control tests should have been done using the cellculture grade BSA, and this would need to be investigated in future. In addition, it
would have been of value to test the assay using plasma from an animal which had
the expression of IDE knocked out to ensure that other contaminants of the plasma
sample were not cross-reacting with the assay components. Unfortunately, no IDEknockout plasma samples were available at that time. The cross-reactivity of BSA
will be discussed in subsequent paragraphs. Nonetheless, while there were some
limitations, these control tests confirmed that negligible cross-reactivity exists
between the secondary antibody and both the capture and detection antibodies.
A number of conditions for the sandwich ELISA were subsequently optimised. For
the coating step; the antibody concentration, the buffer type and pH, and the time
and temperature of the coating incubation were tested. A shorter incubation time
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of two hours at room temperature in carbonate/bicarbonate buffer (pH 9.6) was
demonstrated to be superior for results. Regarding blocking agents, BSA (cellculture grade) versus a non-albumin blocking agent were also compared (discussed
below). PBST was chosen as sample diluent due to its superiority in maintaining its
pH at different temperatures (discussed further in Chapter 5). Additionally, as the
plasma sample dilutions were observed to be linear to 1:5, a dilution of 1:2 was
chosen as the dilution for the AIBL samples as a midpoint between undiluted
plasma and 1:5. Furthermore, the addition of BSA to the sample and detection
antibody diluents (common in ELISA assays) led to the slight reduction in signal.
However, this test used cell-culture grade BSA which was observed to be crossreactive with the antibodies, and this may have caused inhibition of the signal
through interfering with the antibody-antigen binding.

The addition of

polyethylene glycol (PEG) to incubation buffers has been reported to increase the
speed of the antigen-antibody reaction (Ka̧ tnik, et al., 1987), however in the
present study there was no overall benefit observed by its addition to the detection
antibody diluent.
The IDE sandwich ELISA, although not completely optimised due to time limitations,
was subsequently used to measure the total IDE in the plasma of a subset of AIBL
participants (n = 177, 57 HC/50 MCI/70 AD). The results showed that there was a
reduction of IDE levels for both MCI and AD groups, with only the MCI group being
statistically significant.

The trend was observed in both male and female

participants. The effect of the APOE ε4 allele was seen to reduce the level of IDE
but was not statistically significant.

Similarly, the levels of plasma IDE were

observed to reduce with age, similar to previous reports of cerebral IDE (Caccamo,
et al., 2005) but results were again not statistically significant; however there was a
significant inverse correlation between IDE levels and age, albeit very weak. The
high variation in IDE levels was evident, and may be related to diet, exercise or
medications which alter the expression of IDE. It would be of value to investigate
the potential effect of these factors on IDE expression.
Total plasma IDE levels also correlated inversely with levels of plasma Aβ40 and Aβ42,
and this result is supported by genetic evidence of a link between IDE
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polymorphisms and levels of plasma Aβ (Carrasquillo, et al., 2010; Ertekin-Taner, et
al., 2000). This may highlight the importance of IDE in the regulation of circulating
Aβ. This result would support the hypothesis that a reduction in plasma IDE may
contribute to an accumulation of Aβ species in the periphery. Statistically this
association was highly significant, yet the correlation was weak, which suggests that
there are other Aβ-degrading enzymes which contribute to the regulation of plasma
Aβ. However when stratified by classification and APOE ε4 status, the correlation
strengthened by two-fold only in AD non-carriers, while the association
disappeared in MCI, HC, and ε4 carriers. This suggests a major contribution of IDE
toward Aβ regulation in AD patients who do not carry an ε4 allele.
A positive correlation was also observed between plasma IDE levels and both total
and free testosterone levels, but when split by APOE ε4 status only the ε4 carriers
showed significant correlation. This is not entirely unexpected due to reports in the
literature which show that testosterone upregulates IDE expression (Udrisar, et al.,
2005; César Vieira, et al., 2011) but this has not been investigated by APOE
genotype. Statins have been found to lower levels of testosterone, and as there
was a high level of statin use amongst AIBL participants, this may have confounded
the results (Schooling, et al., 2013). While the literature reports that oestrogen and
progesterone also upregulate IDE (Udrisar, et al., 2005; Jayaraman, et al., 2012;
Zhao, et al., 2010), no association was found between ELISA-measured levels of
plasma IDE and oestrogen in the current study, and progesterone levels were not
measured. It would be useful to investigate the potential interaction between
progesterone and IDE, and perhaps the cumulative effect of sex hormones on the
regulation of IDE in future studies.
The negative correlation between total IDE levels and plasma levels of HDL
cholesterol is also puzzling. When split by APOE ε4 status, only the ε4 non-carriers
showed significance. This result appears counter-intuitive as HDL cholesterol is
considered to be beneficial, and as lower levels of IDE were found in the MCI and
AD groups compared with controls it would suggest that higher levels of HDL should
be found in the pathological state, which is contrary to what the literature has
reported. In fact, high levels of plasma HDL have been associated with a reduced
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risk of AD while low levels have been found in AD patients (Reitz, et al., 2010; Kuo,
et al., 1998) although the levels of HDL may be different prior to the MCI stage of
pathogenesis. No other studies have reported a potential interaction between IDE
and HDL cholesterol, however it has been shown that both IDE and HDL can be
regulated by dietary factors (Du, et al., 2010; Mensink, et al., 2003) and exercise
(Kim, et al., 2011; Kodama, et al., 2007). In particular, saturated fatty acids have
been shown to decrease expression of IDE while other studies have demonstrated
that they increase levels of HDL. This perhaps could be a chance association,
however while outside the scope of this project it would be of interest to
investigate this potential association further.
As the levels of insulin and Aβ were likely to be influenced by IDE levels, ratios of
IDE to these peptides were calculated (both individually and in combination). The
ratios of IDE/Aβ40+42, and IDE/insulin+Aβ40+42 showed better sensitivity for
differentiating between the HC/MCI/AD classifications than IDE levels alone.
Conversely, no improvement of sensitivity was seen with the ratio of IDE/insulin
compared to IDE alone. All ratios of IDE:peptides were consistently lower in MCI
than HC, and the IDE/Aβ40+42, and IDE/insulin+Aβ40+42 ratios were significantly lower
in both MCI and AD, when compared with HC. When stratified by APOE ε4 status,
all IDE:peptide ratios were considerably lower in MCI when compared to HC, yet for
non-ε4 carriers the ratios were higher in AD patients, almost to the same level as
the controls. Only in case of the IDE/Aβ40+42, and IDE/insulin+Aβ40+42 ratios did the
ε4 carriers remain significantly lower in the AD group. In the case of the non-ε4
carriers, only the IDE/insulin ratio and the IDE/insulin+Aβ40+42 ratio reached
statistical significance between MCI and HC. The differences observed in ratios
between ε4 carriers and non-carriers in the AD group may be related to insulin
resistance that has been previously observed to be characteristic of non-carriers
(Craft, et al., 2000). However, no significant differences in insulin levels were found
between classifications in the AIBL cohort either overall, or stratified by APOE ε4
status.
When Aβ1-42 and Aβ1-40 levels were analysed separately, there was no difference in
plasma Aβ42 between classifications in this AIBL subgroup. However, there was an
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increase in plasma Aβ1-40 for MCI and AD groups compared with HC, albeit not
significant, as well as a significant increase in Aβx-40. Although the results for Aβ1-40
were not significantly different between classifications in this subgroup, it was
shown that after controlling for a number of covariates the differences became
significant (Rembach, et al., 2014). It is possible that the combination of reduced
IDE and increased Aβ1-40 with Aβx-40 could lead to the saturation of, or at least a
major reduction in available IDE in the plasma.

Impairment of Aβ or insulin

degradation would then lead to an accumulation of these substrates in the
peripheral circulation, contributing to the characteristic hyperinsulinemia and
elevated plasma Aβ which has been linked with AD pathogenesis and pathology
(Ertekin-Taner, et al., 2008; Kuusisto, et al., 1997; Muller, et al., 2007).

Analysing ELISA background problems
One noteworthy observation was the considerably higher background of the
sandwich ELISA compared with the background of the indirect assays.

This

background was shown not to be related to the secondary antibody cross-reacting
with either the detection or coating antibodies.

Therefore, following the

measurement of the AIBL samples above, further optimisation tests were
performed.

The use of Fraction V BSA as the blocking agent reduced the

background OD reading to about 1/3 of that observed with cell-culture grade BSA
(used as a blocking agent in the AIBL sample assays). However, the background
signal observed with Fraction V BSA was still considerably higher than the
background observed when either the coating or detection antibody was omitted.
This result suggests that there may be some small degree of cross-reactivity
between the capture and detection antibody. This is not an unusual phenomenon
in sandwich ELISA assays, and as the concentrations and volumes were constant for
both antibodies the background generated was consistent across wells, and
therefore easily removed from the analysis. However, the potential interaction
between the antibodies may have reduced the overall specific signal due to this
non-specific binding which may have rendered a portion of the antibodies
inaccessible for binding to IDE. It is unfortunate that the cell-culture grade BSA was
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used in the protocol for the AIBL samples, however, a constant concentration and
amount was added to all the wells in the blocking step and the background OD
reading was subtracted from all samples, thus this may not be an issue. Similarly
though, the use of cell-culture grade BSA might lead to a reduced amount of Ab 3
available for specific binding to IDE. These factors may account for the decreased
values seen in the standard curve in the sandwich assay as compared with each of
the antibodies separately in the indirect assay. However, the low background
observed in the indirect assays for both of the antibodies suggests there was
negligible cross-reaction with BSA, as the antibody was applied subsequent to the
blocking agent.

Regardless, the sandwich assay could not be accurately

quantitative because of this interference and only relative differences could be
compared.

Future assays should use BSA preparations such as Fraction V to

minimise the background.
The use of antibodies raised in goat can be problematic, for example, BSA may
contain contaminating bovine IgG which may cross react with the anti-goat
secondary antibody, causing problems with detection. In addition, human samples
may contain anti-bovine IgG as well, which may cross-react with one or more of the
three antibodies used in the assay (Kragstrup, et al., 2013; Henning & Nielsen,
1992). As a goat raised antibody is used for detection in this assay, it was important
to make sure this was not occurring to ensure that there were not false positives.
However, a mouse raised antibody was initially used for detection, and was
compared against the goat antibody. Although the mouse antibody produced
slightly overall lower signal in the plasma, it demonstrated a very similar dilution
curve to the goat antibody. This suggests that there was unlikely to be interference
by anti-bovine IgG in the assay.
Although Ab 2 was shown to cross react with HSA in the Western immunoblotting
method, plasma-derived human albumin would have been washed away prior to
the detection antibody being applied so therefore it was determined not to be an
issue.

Even though Ab 3 demonstrated a weak cross-reactivity with HSA on

Western immunoblotting tests, activity experiments on degradation of a
fluorescent peptide substrate in plasma following immunocapture with Ab 3 show
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that 100% of activity can be inhibited with two known IDE inhibitors (to be
discussed further in Chapter 5), providing further evidence that IDE Ab 3 shows
negligible binding to anything else in the plate-based assays. In addition, when
testing purified HSA at levels found physiologically in plasma, the OD signal
produced in the sandwich ELISA was not above background, therefore it was
thought that HSA was unlikely to be a confounding factor in the plasma samples
tested in the assay. A major reason HSA was detected by Ab 3 in the Western Blot
but not in the sandwich ELISA may be related to the denatured conformation of the
protein under the denaturing and reducing conditions in the former method, while
the proteins in ELISA are in native conformation.
One limitation of this assay was related to the particularly high background
observed when using a non-albumin containing blocking agent (that is derived
mainly from bovine milk). One previous study reported that two IDE antibodies
(one monoclonal, one polyclonal) used in their project were observed to cross-react
with fibrinogen, casein and thrombin; clotting elements of plasma which are found
in bovine milk (Yfanti, et al., 2008). Even though the antibodies used in the current
study were not the same ones, it is possible therefore that the higher background
seen with the use of the non-albumin blocking agent was due to the IDE antibodies
similarly cross-reacting with these or other proteins in this preparation. If this is the
case, these elements being present in human plasma as well may be cross-reacting
with the assay. However, contrary to this there was little or no background
observed when using this antibody in Western immunoblotting experiments, which
used milk powder as a block. This may have been due to the fact that the milk
powder was in a less purified form, therefore having lower levels of potential crossreactants. Although not addressed within the time-frame of this project, it would
be of benefit to further investigate these potentially confounding factors. It may be
of value to assess circulating IDE levels in serum rather than plasma if this if the
case.
Perhaps the most concerning limitation of this IDE ELISA assay is the poor spike and
recovery results. Generally, recovery should be approximately 80-120% of the
control value (Shah, et al., 1992). In the current study 100% of the signal was
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suppressed by the plasma matrix, indicating major interference. The reason for this
result is unclear; however there are a number of possibilities to consider. It is
possible that the recombinant IDE is sequestered by plasma proteins and therefore
its detection is masked in the ELISA. This would not have been an issue in the
denaturing and reducing conditions of the Western blot as the conditions cause
most proteins to disassociate. It would be of value in the future to perform a spike
and recovery experiment using Western immunoblotting as the method of
measurement. Co-immunoprecipitation experiments in plasma would also help
determine if this is the case. As mentioned earlier, IDE has been shown to bind to
numerous other proteins that are present in human plasma (Bennett, et al.,
2000(a); Kurochkin & Goto, 1994; Roth, et al., 1984). It is also known that IDE can
be complexed with the proteasome, and that the proteasome is present in human
plasma (Bennett, et al., 2000(b); Ichihara, 1993; Egerer, et al., 2002).
Furthermore,

heterophilic antibodies,

human

anti-animal

antibodies and

rheumatoid factors, which are present in human plasma, can also be responsible for
analyte masking (Urbonaviciute, et al., 2007; reviewed in Tate & Ward, 2004).
Cross-reactants (including BSA) can weakly link the antigen to the antibodies which
are then removed by the washing steps along with the analyte or antibodies of
interest, leading to falsely negative results (Valdes & Jortani, 2002). Recent studies
have sought to address such issues by outlining some validation steps designed to
identify these confounding variables (Kragstrup, et al., 2013).
Another possibility for apparently low plasma readings of IDE is that IDE itself is
degraded by other proteases present in the plasma. It would be of value to repeat
the experiment with a protease inhibitor cocktail present in the plasma diluent.
An increase in IDE concentration may cause what is known as the “hook effect”
(reviewed in Tate & Ward, 2004) leading to a false negative result. This occurs due
to competition for the capture antibody. However, the likelihood of this is low
considering the observation that the highest concentration of standard tested in
this assay was 160000 ng/mL and did not show a reduction of signal at the higher
end of the curve. The lowest concentration used in the spike and recovery test was
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1250 ng/mL. Unless the concentration of IDE in the plasma was higher than 160000
ng/mL, it would be unlikely that this phenomenon would be the cause of the lack of
signal. Alternatively, the increase in IDE concentration in the plasma in association
with components of the plasma matrix may cause IDE to self-aggregate. This would
lead to the epitopes being masked and inaccessible for antibody binding.
Another potential factor may be that rat IDE and human IDE behave differently in
plasma.

Although rat IDE has 95% sequence similarity to human IDE, the

differences may still lead to structural or functional differences as observed with
other enzymes (Pearce, et al., 1992; Glatt and Oesch, 1987). It is also possible that
the recombinant protein behaves differently in plasma to the native protein, for
example altering conformation to an extent that would reduce or prevent
antibodies from binding to the rrIDE (Cavalcante Braga, et al., 2013).
However, failure of the spike and recovery test does not necessarily mean that the
signal observed from human plasma samples in the AIBL cohort is not IDE. It may
be that the recombinant rat IDE changes conformation in human plasma, and/or
binds to plasma proteins that do not influence human IDE. Alternatively, it may be
that only a portion of IDE present in the plasma is free protein, with a proportion of
it bound to other proteins, or present in the form of dimers and tetramers which
may not be detected by ELISA.

As mentioned previously, increasing the

concentration of IDE may also change the binding properties toward other plasma
constituents and/or may also induce self-aggregation. Regardless, in this project
there is good evidence that the capture antibody Ab 3 specifically and exclusively
binds to IDE (to be discussed further in Chapter 5) and therefore it is likely that this
in-house IDE sandwich ELISA is specifically measuring only IDE.

However, if

aggregation does occur, it is likely that the true level of IDE in plasma samples is
much higher than the values measured with this assay.
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4.4.1 Summary
The aim of this chapter was to develop and optimise an in-house ELISA which could
accurately and specifically measure IDE in human plasma from the AIBL cohort. The
development of the assay was complicated by a number of cross-reactivity issues
associated with the antibodies and blocking buffer chosen, and the finding that
factors in plasma appeared to interfere significantly with the detection of IDE. As
such, a fully-quantitative assay could not be developed, and only relative
differences could be compared. Promising results were observed, with altered
levels of plasma IDE in the prodromal and symptomatic stages of AD, particularly
when considered together with circulating insulin and Aβ levels. However, more
work needs to be done to ascertain the source/s of the confounders and to
determine if this has affected the accuracy of the IDE levels measured. The ELISA
protocol needs to be improved, and followed by validation studies and tests of
other cohorts before the results can be confirmed, and therefore, caution should be
exercised when considering the current results. Indeed, the IDE levels measured by
ELISA contradict the results obtained via Western immunoblotting. If the results
reflected by the sandwich ELISA are subsequently confirmed to be accurate, then
plasma IDE may be useful as part of a biomarker panel for very early stages of AD.
Studies of a much larger cohort would allow for the testing of a larger number of
classifications, for example HC under 65, HC over 65, memory complainers, MCI and
AD. This would then reveal how IDE changes in early AD pathogenesis, and also
help to determine IDE’s role in the development of AD.
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CHAPTER 5 –IDE enzyme activity in plasma is higher in
MCI compared with HC and AD.
5.1 Introduction
Changes in enzyme protein levels are often indicative of biochemical changes which
may cause or reflect pathological changes in human physiology. Often however,
these measurements are not truly representative of the functional abilities of the
protein in question. In the case of an enzyme, its catalytic activity may differ due to
a number of factors which are unrelated to enzyme protein levels themselves.
Some of these factors include different concentrations of enzyme substrates or cofactors such as metals, inhibitors or activators of the enzyme, or post translational
modifications such as phosphorylation, alkylation, oxidation, s-nitrosylation, sglutathionylation and ubiquitination. While there are many other types of posttranslational modifications that can occur, the types mentioned here have been
associated specifically with the inhibition of IDE. Other factors such as medications,
or even alternate isoforms or the aggregation status of IDE can also have an effect
on the function of the protein.
A number of studies suggest that the catalytic activity of IDE does not correlate with
IDE expression levels (Kim, et al., 2007; Miners, et al., 2009; Behl, et al., 2009).
Therefore, assessing IDE catalytic activity is an important consideration when
assessing IDE’s influence on Aβ and insulin levels. An immunocapture-based
fluorometric activity assay has been previously developed to assess the catalytic
activity of IDE in brain homogenates (Miners, et al., 2008(b); Wang, et al., 2010).
The assay uses a specific IDE antibody to capture IDE from the sample onto a solidphase (96-well microplate).

A fluorogenic substrate of IDE (derived from the

sequence of bradykinin), fluoresces when cleaved and directly represents activity
levels. In this chapter, the suitability of this assay for measuring IDE activity in
plasma is investigated, prior to assessing activity in samples from the AIBL cohort.

259

5.1.1 Aims
1. To use a fluorometric activity assay to measure the catalytic activity of IDE in
human plasma, and determine whether the catalytic activity can
differentiate between HC, MCI and AD.
2. To determine if the presence of the APOE4 allele has any impact on the catalytic
activity of plasma IDE.
3. To identify any relationships between plasma IDE catalytic activity, expression
levels of plasma IDE and other biochemical data obtained from the AIBL
study.
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5.2 Experimental summary
The catalytic activity assay was adapted from the original assay developed by
Miners and colleagues (2008(b), using amendements to the protocol as published
(Wang, et al., 2009). All of the catalytic activity assays performed were based on
this method. Gain adjustment was set at 1487 for all assays unless otherwise
specified. Assays were incubated with the fluorogenic peptide for 6 hours unless
otherwise specified.

5.2.1

Test of immunocapture-based fluorometric assay for the

measurement of the catalytic activity of plasma IDE.
The catalytic activity of plasma IDE was tested as detailed in Section 2.2.6.1 using
pooled control plasma (PCP), following a previously published method (Miners, et
al., 2008(b); Wang, et al., 2009).

5.2.2 Test of fluorometric IDE activity assay specificity
To test the specificity of the IDE catalytic activity assay further, the IDE
substrates/inhibitors insulin and Aβ were trialled as IDE enzyme inhibitors in the
assay, as detailed in Sections 2.2.6.2, 2.2.6.3, 2.2.6.4 and 2.2.6.5.

5.2.3

Comparison of EDTA-collected blood and lithium-heparin-

(LiHep) collected blood: determining which is better in the IDE activity
assay.
To ascertain if the presence of EDTA as an anticoagulant in the plasma samples was
inhibitory in the IDE activity assay, plasma isolated from EDTA-collected blood was
compared with plasma isolated from LiHep-collected blood in an assay performed
as described in Section 2.2.6.1.
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5.2.4 Determination of plasma IDE catalytic activity in the AIBL cohort
using the IDE immunocapture-based fluorometric activity assay.
IDE catalytic activity was measured in the sub-set of samples obtained from the
AIBL cohort as detailed in Section 2.2.6.1. An internal control of PCP was included
on each plate as a reference sample. IDE activity was interpolated from the
standard curve and expressed as the Equivalent Concentration of rrIDE (ng/mL).
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5.3 Results
5.3.1 PCP and rrIDE generate a time and dose-dependent signal in the
fluorometric activity assay.
The immunocapture-based fluorometric activity assay developed by Miners and
colleagues (2008(b)) was originally used to measure IDE activity in brain tissue
homogenates. The assay has not previously been used to assess IDE activity in
plasma, therefore it was important to carefully characterise the assay prior to
adapting it to be used for plasma. The capture antibody used for development of
the assay in plasma was Ab 3 (see Section 2.1.1 for details), since it was the most
suitable antibody to detect IDE protein in plasma by Western immunoblotting and
to capture IDE in ELISAs (see Sections 3.3.7 and 4.3.3, respectively). Miners, et al.,
(2008(b)) also found that, of the four IDE-specific antibodies tested, Ab 3 showed a
consistent dose-response in activity with purified human and rat IDE and produced
the highest signal in brain homogenates.
To initially assess the efficacy for Ab 3 to capture IDE, the activity of diluted rrIDE or
pooled control plasma (PCP) was measured. Purified recombinant rat IDE (rrIDE)
was chosen as it has similar activity to recombinant human IDE (rhIDE) (Miners, et
al., 2008(b)). A concentration range of rrIDE and or PCP was assessed, however
1250 to 12500 ng/mL rrIDE and 480-1680 µg total protein PCP were found to show
a signal above that observed for the blank. It is noted that the blank generated a
signal of an average of ~ 8000 fluorescence units, which may have impacted on the
sensitivity of the assay particularly detecting lower concentrations of the rrIDE or
PCP. Nevertheless, the results [Figure 5.1(A) and (B)] showed a strong linear
relationship between the amount of fluorescence and increasing concentrations of
rrIDE (A) or PCP (B).

This association was more prominent with increasing

incubation periods (up to the 6 hours), consistent with that shown for brain
homogenates by Miners and colleagues where a maximum signal level was
observed at 5 hours. There was little difference between the 1440 μg TP/well
samples and 1680 μg TP/well samples; the reason for this was not pursued, but it
was decided that the loading of plasma TP/well for the measurement of IDE
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catalytic activity needed to be restricted to between 480 and 1440 μg TP. Overall
these results indicate that a standard curve could be generated with Ab 3, and a
dose and time dependent fluorescence signal was observed for plasma. The
specificity of the observed activity in plasma was subsequently further investigated.
The assay was performed with PCP (480μg TP) under several conditions, including:
without the use of blocking agent, no substrate and no sample. The results are
shown in Figure 5.1(C). As before, the PCP sample generated a signal that increased
with time. Omission of the blocking agent (BSA) led to a negligible reduction in
signal, therefore it was concluded that there was no significant effect of the
blocking agent in the activity assay. Omission of the sample (vehicle buffer only)
did result in a moderate fluorogenic signal however this did not increase with time,
indicating that cleavage of the peptide was not occurring. This was considered to
be the background signal of the assay.

The majority of the background

fluorescence appeared to be related to the fluorogenic peptide itself, with omission
of the peptide reducing the fluorescence by ~85%. In addition, it was observed that
the gain adjustment setting was related to the background reading (as well as the
samples); for a single test plate the background signal changed from 8736 RFU with
a gain of 1712, 7435 RFU with a gain of 1679 and 3147 RFU with a gain of 1487. At
the higher gain settings the signal exceeded the maximum RFU of the plate reader,
thus it was decided that subsequent assays would be gain adjusted to 1487.
The specificity for the Ab 3 antibody to detect IDE in plasma samples was assessed
through incubating PCP (480μg TP) with IDE antibodies Ab 1 (final amount was 8 µL
anti-serum/well), Ab 2 (4 µg/well, purified), or with Aβ40 (8.2 µg/well). Ab 1 binds
to an epitope which is located within the catalytic domain of IDE (Domain 1),
whereas Ab 2 binds to an epitope distal to the catalytic domain in Domain 4 (see
section 2.1.1 for antibody details). As the Aβ40 peptide is a substrate for IDE it was
used as a competitive inhibitor thought to occupy the catalytic site of IDE, resulting
in reduced cleavage of the fluorogenic peptide and thus a reduced signal.
Results (Figure 5.1(D)) showed that pre-incubating the PCP sample with either Ab 1
or Aβ40 resulted in an approximately 50% reduction in cleavage of the fluorogenic
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peptide. Pre-incubating PCP with Ab 2 had no effect in reducing IDE activity. It is
possible that this reflects that Ab 2 binds too distal to the catalytic domain to have
an inhibitory effect on enzyme activity. The inhibition seen by Ab 1 and Aβ40
suggests however, that at least 50% of the fluorescence observed in the assay is
specifically due to the cleavage of the fluorogenic peptide by IDE.
The stocks of Ab 3 were exhausted at this stage and a new batch was obtained. As
batch to batch variations do occur amongst antibodies, the new batch required
similar validation as the old antibody, prior to any further analysis and assaying the
AIBL samples.
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Figures 5.1(A) and (B) Test of fluorometric IDE enzyme activity assay, using
ab28561 (Ab 3) as coating antibody. The activity assay was performed as detailed
in Section 2.2.6.1 for 6 hours. The recombinant rat IDE (rrIDE) standard curve is
represented in Graph A, and the assay results of the pooled control plasma (PCP)
dilutions are shown in Graph B. The standard curve ranged from 1250ng/mL to
12500ng/mL (50 μl/well) with each concentration in duplicate. PCP was diluted to
provide from 480 to 1680 μg of total protein per well in duplicate. Fluorescence
was generated by incubation with the fluorogenic substrate (Mca-RPPGFSAFK(Dnp)OH) and fluorescence measurements reflect the amount of cleavage of the
substrate at pH 7.5 by the immunocaptured IDE. Gain adjustment was set to 1712.
Data is not blank-adjusted.
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Figure 5.1(C). Test of immunocapture-based IDE fluorometric activity assay (with
Ab 3) to analyse components of the assay. The activity assay was performed as
detailed in Section 2.2.6.1 and 2.2.6.2. Controls include the addition of PCP at 480
μg TP for all wells with the exception of the “no sample” wells, and all samples were
run in duplicate. “No substrate” indicates all assay components as usual without
the addition of the fluorogenic peptide (HEPES only). Results show a low reading
without the addition of fluorogenic peptide. With all components added except the
sample (PBST only) there is a high level of background fluorescence with this gain
adjustment setting (1712). Negligible difference occurs with or without the
blocking step.
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Figure 5.1(D). Further validation test of fluorometric activity assay using specific
IDE antibodies and Aβ40 as inhibitors of IDE-based cleavage of the fluorogenic
peptide. Prior to being added to the microplate, PCP dilutions (480 μg TP/well)
were pre-incubated with 20 μL each of IDE antibodies Ab 1 or Ab 2, or with 20.5 μg
of Aβ40. IDE antibody Ab 1 was raised against an epitope of IDE which is within the
catalytic domain, while Ab 2 was raised against an epitope close to the C-terminus
of IDE distinct from the catalytic site. The assay was carried out as described in
section 2.2.6.1 and 2.2.6.2 over 6 hours, and all samples were run in duplicate.
Blank (background) is indicated by the dashed line. Gain adjustment was set to
1712. Results show that pre-incubation of PCP with Ab 2 had no effect on the
catalytic activity of plasma IDE, however Ab 1 and Aβ40 partially reduced the activity
of IDE by approximately 50% for the course of the experiment.

5.3.2 Validating the new batch of coating antibody Ab 3 (ab28561).
Polyclonal antibodies may vary considerably between batches due to a number of
factors. Therefore, it is essential to thoroughly screen each batch prior to use, and
if comparisons need to be made between runs of an assay, it is important to use the
same batch of antibody throughout. Hence, as stocks of the original batch of Ab 3
were exhausted, a new batch needed to be validated under the same conditions as
the previous batch.
Results (Figure 5.2(A) and (B)) showed the new batch of Ab 3 generated a similar
standard curve correlation to that of the original batch (see Figure 5.1(A)), with R2
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values of 0.9882 for Batch 1 and 0.9618 for Batch 2 at the 6 hour timepoint.
However the maximum signal achieved was ~4-fold lower than that observed for
the original batch.

Compared with the previous batch (using the same gain

adjustment setting) the background was similar, with values of 3090.5 for Batch 1
and 3114 for Batch 2. Signal was also reduced in the PCP for the new batch,
although not to the same extent. The lower fluorescence signals most likely
indicate lower IDE levels captured, possibly due to a lower affinity of IDE-specific
antibodies in the newest batch of Ab 3, however the original and new batches were
not tested on the same plate so could not be directly compared.
Similarly to the previous batch of Ab 3 (Figures 5.1(A) and (B)), using the new batch
in the fluorogenic assay resulted in standard curves that increased linearly in slope
with increasing IDE concentration, with apparently proportional increases in signal
up to at least 7500 ng/ml (375 ng/well IDE). For the PCP dilutions, the assay
demonstrated a good linear time- and protein loading-dependent response for all
dilutions tested up to 6 hr, and up to the concentration of 1200 μg TP/well. Similar
to the results from the previous batch of Ab 3, little difference between the 1200 μg
TP/well and the 1440 μg TP/well was observed. With this batch of antibody the
optimal protein loading of PCP appeared to be 960 μg TP/well, as this was the
highest concentration where the signal could be differentiated from the higher
concentrations of PCP. It was concluded that although the overall signal was
reduced with the new batch of Ab 3 compared to the old batch, it was still suitable
to use in the assay.
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Figures 5.2(A) and (B) Test of fluorometric IDE activity assay using new batch of
IDE Ab 3 as capture antibody. Recombinant rat IDE (rrIDE) was used to produce a
standard curve (Graph A) with wells containing concentrations from 625 to 12500
ng/mL. Pooled control plasma (PCP) was diluted to aliquot 480 to 1440 μg total
protein/well (Graph B). All samples were run in duplicate. The fluorogenic catalytic
assay was run according to the method described in section 2.2.6.1. Data is not
blank-adjusted. Results show that the new lot of Ab 3 produced fluorescence that
was, overall, considerably lower than the previous lot of antibody. However, the
fluorescent signal was consistently reflective of the amount of protein present up to
7500 ng/mL for the standard curve and 1200 μg total protein/well for PCP, as well
as the time incubated.
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Similar to the old batch, control tests were subsequently performed using the new
batch of Ab 3 to ascertain specificity. The first assessment was whether the
background observed was related to the capture antibody or its components, or
BSA which was used as the blocking agent (Figure 5.3). The plate was coated with
Ab 3 diluted to 2.5, 1.25 and 0.625 μg/mL, washed, and then assayed with the
fluorogenic peptide (diluted in HEPES as previously detailed in Section 2.2.6.1). As
50% glycerol was a component of Ab 3, glycerol alone was also tested (1.25 μL/mL)
with the peptide, with and without the blocking agent. Finally, the blocking agent
was tested alone with the peptide. These control tests were run alongside two
samples, containing all components of the assay with and without PCP. Results
showed that the signal was at the same intensity as the blank for all wells not
containing PCP, while the wells containing PCP increased in signal for the duration
of the assay (2 hours). The assay was incubated for 2 hours as increases in
fluorescent signal (above the blank) occurred within the first hour and reflected the
pattern of results at 6 hours. As samples wells that did not contain PCP did not
change over time, a true signal was observed at this time point. In addition, (on
separate plates) the peptide alone diluted in HEPES (no other assay components)
was tested as well as a no peptide control. The results showed that the diluted
peptide alone generated a similar signal to the background, with an average
reading of 3544.25 RFU (±83.7551 SD, n=4) for the diluted peptide, while omission
of the peptide reduced the signal by ~ 64%. This indicates that the background
observed is a product of the fluorogenic peptide itself, and not related to either the
capture antibody, glycerol contained in the antibody, or blocking agent reacting
with the fluorogenic peptide, in agreement with previous optimisation experiments
(see Graph 5.1 (C)). However, even though the extent of the reduction in signal
after omission of the peptide was not as pronounced in this experiment, this may
be related to the different gain adjustment settings. The assay was also tested to
see if different buffers may have any effect on the background or signal generated;
and results showed that there was little difference between using PBST or TBST as
the sample diluent and for washes (see Appendix). It was also demonstrated that
the highest physiological levels of HSA or BSA produced no signal above the blank,
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confirming no cross-reactivity was occurring with albumin in the plasma or in the
blocking agent (See Appendix).
Together, these results suggest that the background was a product of the peptide
alone, and not because of any cross-reactivity between components of the assay.
Therefore the background was not likely to be an interfering factor in the
measurement of IDE activity with this assay.

Therefore, for subsequent

experiments, data was subtracted from the background signal (from Section 5.3.3
onward).
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Figure 5.3 Test of immunocapture-based IDE fluorometric activity assay (with
new batch of Ab 3) to analyse components of the assay. The activity assay was
performed as detailed in Section 2.2.6.1 for 2 hours. The test includes blank wells
(all components except sample), and PCP at 480 μg TP/well (including all other
assay components), as well as Ab 3 coated at 2.5, 1.25 and 0.625 μg/mL with the
fluorogenic peptide (diluted in HEPES) only. Glycerol (1.25uL/mL) was also tested
with the peptide with and without the blocking agent (BSA – “Blk”), and BSA was
also tested alone with the peptide. All tests were done in duplicate. Negligible
difference occurs for the background signal obtained for all control wells including
the blank, while the PCP showed an increasing signal over the three readings. Error
bars indicate ±SD.

5.3.3 EDTA collected plasma produces a higher signal than Lithiumheparin collected plasma in the IDE fluorometric activity assay.
IDE is a metalloprotease which is dependent on the presence of a zinc atom for its
catalytic activity (Ansorge, et al., 1984; Ebrahim, et al., 1991), and therefore,
chelating agents such as EDTA or phenanthroline are likely to affect the measurable
activity of IDE. The collection protocol of plasma from blood requires the inclusion
of an anticoagulant such as EDTA or Lithium-Heparin (LiHep) so that the cellular
components of blood may be removed while retaining the other factors and
proteins, without activating the clotting cascade. Much of the anticoagulant is also
retained in the plasma, which may interfere with certain down-stream applications.
Plasma collected from the AIBL cohort is collected in the presence of either EDTA or
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Heparin, dependent on the assay that is performed. Thus, to determine which
collection method is suitable for the fluorescent assay, IDE activity was assayed in
either EDTA-collected plasma or LiHep-collected plasma.
The results showed that whilst LiHep-collected plasma generated a similar signal to
the blank (ie background fluorescence), EDTA collected plasma generated a signal
above the blank (Figure 5.4). The enzymatic activity measured in the LiHep plasma
was only approximately 15% of the signal generated from EDTA plasma. Although
the assay was incubated for 4 hours rather than the full 6 hours, it is not likely that
the signal would increase to a level comparable to that seen for EDTA plasma.
While the reasons for this difference in signal was not pursued, the findings indicate
that EDTA collected plasma was more suitable for measurements of IDE activity
than plasma collected in LiHep tubes.
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Figure 5.4 Comparison of IDE activity in PCP originating from blood collected in
EDTA tubes versus LiHep tubes. Pooled control plasma (PCP) isolated from blood
collection tubes originally containing EDTA or Lithium-Heparin (LiHep), were loaded
at a concentration of 960 μg total protein per well with 8 replicates of each. The
IDE activity assay was conducted over 4 hr, otherwise was carried out as described
in section 2.2.6.1 and 2.2.6.9. Data has been blank-adjusted. The results show that
PCP obtained from LiHep-collected blood had very little fluorescence compared
with PCP obtained from EDTA-collected blood, implying less active enzyme in the
LiHep-collected blood. Error bars indicate ±SD.

5.3.4 Investigating the specificity of the IDE catalytic activity assay
using the IDE inhibitors Aβ42 and insulin.
According to the company product datasheet, the fluorogenic peptide Mca-R-P-PG-F-S-A-F-K(Dnp)-OH (Substrate V) is able to be cleaved by a number of different
enzymes such as neprilysin (NEP), endothelin converting enzyme-1 (ECE-1),
angiotensin-converting enzyme (ACE), cathepsin A and cathepsin X (also called
cathepsin Z or P). The peptide may also theoretically be cleaved by any protease
capable of cleaving the amide bond between the amide group and quencher group.
While the signal derived in the assay is likely to be from IDE due to the initial
immunocapture step by a specific IDE antibody, specificity can also be assessed
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with competing substrates. For IDE the major substrates are Aβ and insulin which
binds to the catalytic site, rendering it unavailable for the fluorogenic peptide.
Plasma samples were therefore incubated with either Aβ42 or insulin prior to
assaying.
The results (Figures 5.5(A) and (B)) show that the signal generated from the
fluorogenic activity assay in plasma was reduced dose-dependently, by either Aβ42
or insulin. At concentrations of 100 μM Aβ42 and 1mM insulin, IDE activity was
inhibited completely. These results indicate that the activity observed in plasma is
most likely attributed to IDE.

Figure 5.5(A). Test of fluorometric activity assay specificity by inhibition with
beta-amyloid isoform 42 (Aβ42). The assay was conducted as detailed in Sections
2.2.4.15, 2.2.6.3 and 2.2.6.1 over 6 hours. Pooled control plasma (PCP) was loaded
at a dilution of 960 μg total protein per well in duplicate and subsequently
incubated with concentrations of 0, 25, 50 and 100 μM Aβ42. Data has been blankadjusted. Results show that Aβ42 inhibited the activity of immunocaptured IDE in a
dose-responsive fashion, and total inhibition was seen at a concentration of 100
μM. Error bars indicate ±SD.
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Figure 5.5(B). Test of fluorometric activity assay specificity by inhibition with
insulin. The assay was conducted as detailed in Sections 2.2.6.4, 2.2.6.5 and 2.2.6.1
over 5 hours. Pooled control plasma (PCP) was loaded at a dilution of 960 μg total
protein per well in duplicate and subsequently incubated with 0, 0.25, 0.5, and 1
mM concentrations of insulin. Data has been blank-adjusted. The results show that
insulin inhibited the activity of immunocaptured IDE in a dose-responsive fashion,
and total inhibition was seen at a concentration of 1.0 mM insulin. Error bars
indicate ±SD.

5.3.5 Optimisation Summary
The IDE fluorometric activity assay that had previously been used for assaying IDE
activity in brain homogenates was adapted for use in human plasma. It was
demonstrated that the fluorescent signal obtained for the standard curve and
plasma sample increased in a time- and concentration-dependent manner, and no
cross-reactivity occurred between the fluorogenic peptide and the capture
antibody, glycerol, BSA or HSA.

Although a moderate background signal was

observed, it was similar to that observed for the diluted peptide alone and did not
increase over time, indicating no cleavage of the peptide was occurring. Omission
of the fluorogenic peptide significantly reduced the signal by at least two-thirds,
indicating that the background was primarily due to the peptide alone.
Fluorescence signal obtained for the sample was above the blank and could be
completely inhibited by two known IDE substrates (insulin and Aβ).

This is
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consistent with the original study (Miners, et al., 2008(b)) demonstrating minimal
cross-reactivity with other related Aβ-degrading enzymes which cleave the
fluorogenic peptide. In addition, it was demonstrated that plasma collected with
Lithium-Heparin collection tubes had very little activity compared with samples
collected in EDTA-containing tubes, presumably due to differences in enzyme
stability. Therefore the assay was subsequently used to measure IDE catalytic
activity in EDTA-collected plasma samples from a subset of the AIBL cohort.

5.3.6 Low-level data analysis.
A total of 384 plasma samples from a subset of the AIBL cohort were assayed for
plasma IDE activity. Coefficient of variation (CV) values of duplicates which were
>15% were excluded from the analysis. Plates with standard curves that did not fall
within 2 times the standard deviation ± the mean of each concentration of rrIDE
were also excluded (n = 2).

Values that fell below the mean of the blank

(background) + 2 times the standard deviation were considered to be below the
lowest level of detection. Values were interpolated from the standard curve (rrIDE)
of each microplate, multiplied by the dilution factor (3.125) and expressed as
Equivalent amount of rrIDE (ng/mL). Intra-assay variation (n = 351, based on the 9
plates used in the analysis) was determined to be ~17% (including samples with a
CV of >15% that were subsequently removed from the analysis). Following the
removal of these samples, average CV was 6%.

Inter-assay variation was

determined to be ~15% based on low, medium and high concentrations of the
standard curve (n = 9).
The data was noted to have a non-normal distribution as determined by visually
inspecting histograms, box-plots and normal Q-Q plots, as well as calculating zscores of skewness and kurtosis.

In addition, normality tests such as the

Kolmogorov-Smirnoff and Shapiro-Wilks tests were highly significant. A variety of
transformations were used to correct the normality issues (square root, natural log,
natural log +1, reciprocal), however were not effective. Therefore non-parametric
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tests were used to analyse the data (Kruskall-Wallis, Mann-Whitney and
Spearman’s Rho).

5.3.7 Plasma IDE catalytic activity is higher in MCI compared with HC
and AD.
To determine IDE activity according to cognitive status, the cohort was divided into
the clinically classified groups, healthy controls (HC - including subjective memory
complainers), mild cognitive impairment (MCI) and probable AD (AD). As only a
subset of the cohort was used, the HC and SMC groups were combined to form the
healthy control group. It should be noted that the subset used to measure IDE
activity was different from the subsets used to measure IDE levels by Western
immunoblotting and ELISA (detailed in Chapters 3 and 4, respectively).
The demographics for this subset of the AIBL cohort are shown in Table 5.1. As
expected, AD patients were significantly older, and had a significantly higher
percentage of APOE ε4 carriers and brain Aβ load than the control or MCI groups.
Plasma Aβ1-42 was significantly decreased in the MCI and AD groups compared with
controls (HC>MCI>AD) while Aβx-42 was significantly reduced in both MCI and AD
groups as compared with HC. For Aβ1-40, AD patients also had a trend toward lower
plasma levels, however this did not quite reach significance. The Aβx-42/x-40 ratio
also showed significant alterations with AD and MCI being lower than controls
(HC>MCI>AD), along with levels of ApoE and ApoE4. All other variables were not
significantly different between groups.
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Figure 5.6(A) and (B) Sample standard curve and 10 sets of samples. The assay
was conducted as detailed in Sections 2.2.6.1 over 6 hours. Recombinant rat IDE
(rrIDE) was diluted to concentrations of 312.5 to 7500 ng/mL (Graph A.) and plasma
samples (Graph B) including PCP were loaded at a dilution of 960 μg total protein
per well (16 μL plasma per well) in duplicate. Error bars indicate ±SD. Graphs show
raw values of final readings at 6 hours. Data is blank-adjusted.
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Table 5.1 Basic demographics of the AIBL cohort subset of participants for whom
plasma IDE catalytic activity was measured by fluorometric assay. Plasma samples
(16 μL per well in duplicate) from the AIBL cohort were assayed in the IDE
fluorometric activity assay for 6 hours as detailed in Section 2.2.6.1. Other variables
were measured as outlined in Section 2.2.2.1. Continuous variables are expressed
as mean (median) ± standard deviation. P values were determined by KruskallWallis tests using the Monte Carlo method. As only a subset of the cohort was
tested, the HC and subjective memory (SMC) groups were combined to provide the
healthy controls for this assay. As ApoE4 is only expressed in individuals carrying
the APOE ε4 allele, the n-values are reduced for this variable. As only a subset of
the cohort were measured with Pib-PET (for Neocortical SUVR – Brain Aβ load), nvalues are reduced for this variable.
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The catalytic activity of plasma IDE determined by the fluorometric activity assay
(Figure 5.7) was found to be significantly higher in the MCI group (p = 0.007)
compared with the HC group. There was a trend towards higher IDE activity in the
AD group compared with the controls (p = 0.082). No significant difference was
observed in the catalytic activity of MCI compared with AD groups (p = 0.642).
After Bonferroni correction for multiple testing, the difference between HC and MCI
groups remained significant (p = 0.021). No differences were observed in total IDE
activity between males and females overall [(p = 0.726)(Figure 5.8(A)], however
when stratified by gender [Figures 5.8(B) and (C)] there was a trend toward higher
IDE activity in MCI compared with controls for males only. No difference was
observed between AD and HC in males, or between classifications in females. Large
standard deviation was observed within the each classification, particularly for the
MCI and AD groups.
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Figure 5.7 Catalytic activity of plasma IDE is increased in MCI compared with HC
and AD. Plasma samples (16 μL per well in duplicate) from the AIBL cohort were
assayed in the IDE fluorometric activity assay as detailed in Section 2.2.6.1. The
average value of the duplicates was obtained for each sample, and the median of
these values by classification were compared by a Kruskall-Wallis test, using MannWhitney tests for post-hoc analysis with Bonferroni correction applied to adjust for
multiple testing only with significant comparisons. The data represent medians
with 95% confidence interval (CI), n = 190 (84 HC/56 MCI/50 AD). The results show
a significantly higher level of plasma IDE catalytic activity in the MCI group when
compared with the HC group (p = 0.007, after Bonferroni correction p = 0.021). No
significant difference was observed in IDE activity in the MCI group compared with
the AD group (p = 0.642), however there was a trend toward the AD group being
higher than HC group (p = 0.082).
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Figure 5.8(A) Gender has no effect on the catalytic activity of plasma IDE overall.
Plasma samples (16 μL per well in duplicate) from the AIBL cohort were assayed in
the IDE fluorometric activity assay as detailed in Section 2.2.6.1. The average value
of the duplicates was obtained for each sample, and the median of these values by
classification were compared by a Kruskall-Wallis test. The data represent medians
with 95% confidence interval (CI), n = 190 (71 Males/119 Females). The results
show no difference in IDE activity between males and females (p = 0.726).
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Figure 5.8(B) and (C) Plasma IDE activity is increased (not significantly) in male
MCI compared with HC. Plasma samples (16 μL per well in duplicate) from the AIBL
cohort were assayed in the IDE fluorometric activity assay as detailed in Section
2.2.6.1. The average value of the duplicates was obtained for each sample, and the
median of these values by classification were compared by a Kruskall-Wallis test.
The data represent medians with 95% confidence interval (CI), (Males) n = 71 (32
HC/20 MCI/19 AD), (Females) n = 119 (52 HC/36 MCI/31 AD). The results show a
trend toward higher IDE activity in male MCI compared with HC and AD (p = 0.085),
while no differences were seen between classifications in females (p = 0.336).
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5.3.8 Plasma IDE catalytic activity does not increase with age.
As levels of IDE have been reported to reduce with age (Caccamo, et al., 2005), the
activity of plasma IDE was analysed according to age quartiles (Figure 5.9). No
significant effect of age was seen on IDE activity (p = 0.395).

There was

considerable variation in IDE activity in the oldest group, however it should be
noted that this group had a small sample size (n = 13).

Figure 5.9 Plasma IDE activity does not increase with age. Plasma samples (16 μL
per well in duplicate) from the AIBL cohort were assayed with a fluorometric
activity assay to measure the catalytic activity of IDE as detailed in Section 2.2.6.1.
The average value of the duplicates was obtained for each sample, and the median
of these values by age quartiles were compared by a Kruskall-Wallis test (Q16068/Q2=69-77/Q3=78-86/Q4=87-96). The data represent medians with 95%
confidence interval (CI), n = 189 (61=Q1/63=Q2/52=Q3/13=Q4). The results show
that there was no significant effect of age on IDE activity (p = 0.395). .
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5.3.9 APOE ε4 genotype does not impact on plasma IDE catalytic
activity.
Some studies have reported a reduction in levels of IDE in APOE ε4 carriers
compared with non-carriers in AD brains (Cook, et al., 2003) and other studies have
observed an increase in soluble and insoluble Aβ accumulation associated with the
ε4 allele and/or ApoE4 isoform in both transgenic mice and humans (Youmans, et
al., 2012; Reiman, et al., 2009; Bales, et al., 2009; Castellano, et al., 2011).
Furthermore, this observation has been associated with Aβ clearance, and it has
been shown that clearance of Aβ by IDE is facilitated by ApoE in an isoform-specific
manner (E4<E3<E2) (Jiang, et al, 2008). Hence there is a possibility that the
impairment of Aβ degradation in ε4 carriers may be associated with a reduction in
the catalytic activity of IDE. It should be noted that no APOE ε4 –related differences
in IDE levels were observed in the current study using either Western
immunoblotting or ELISA methods (see Sections 3.3.16 and 4.3.14). It is possible,
however, that catalytic activity may be altered without a change in protein levels.
To assess if this may be reflected in the IDE activity data in this project, the catalytic
activity of ε4 carriers was compared with non-carriers (Figure 5.10(A)).
The results indicate that there is no difference in the catalytic activity of plasma IDE
between ε4 carriers and non-carriers (p = 0.529). When the data was assessed in
relation to classification when stratified by ε4 status, the MCI and AD ε4 carriers
were observed to have a trend towards slightly higher IDE catalytic activity than the
HC (HC<AD<MCI) (p = 0.091), while the ε4 non-carriers had similar activity between
classifications (p = 0.277) (Figure 5.10(B) and (C)).
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Figure 5.10(A) Plasma IDE catalytic activity is not significantly different in APOE
ε4 carriers compared with non-carriers. Plasma samples (16 μL per well in
duplicate) from the AIBL cohort were assayed with a fluorometric activity assay to
measure the catalytic activity of IDE as detailed in Section 2.2.6.1. The average
value of the duplicates was obtained for each sample, and the median of these
values by APOE ε4 status was compared by a Kruskall-Wallis test. Data represents
medians with 95% confidence interval (CI), n = 189 (88 ε4/101 non-ε4). Results
show no difference in the catalytic activity of plasma IDE in the ε4 carriers as
compared with the non-carriers (p = 0.529).
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Figure 5.10(B) and (C) Plasma IDE catalytic activity is not significantly different
between HC/MCI/AD classifications after dividing results into APOE ε4 carriers
and non-carriers. Plasma samples (16 μL per well in duplicate) from the AIBL
cohort were assayed with a fluorometric activity assay to measure the catalytic
activity of IDE as detailed in Section 2.2.6.1. The average value of the duplicates
was obtained for each sample, and the median of these values by classification
separately by APOE ε4 status were compared by a Kruskall-Wallis test. Data
represents medians with 95% confidence interval (CI). (ε4 carriers) n = 88 (27
HC/26 MCI/35 AD), (non-carriers) n = 101 (57 HC/30 MCI/14 AD). The results show
no significant difference in the catalytic activity of plasma IDE between HC/MCI/AD
classifications for either ε4 carriers (p = 0.091, Graph B.) or non-carriers (p = 0.277,
Graph C.).
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5.3.10 The ratio of IDE activity to insulin levels in plasma is not
significantly different between classifications.
The ELISA results from this study demonstrated that there is a significant reduction
in the IDE levels/insulin levels ratio for MCI individuals who do not carry the APOE
ε4 allele compared with controls (see Section 4.3.14.1). Similar to the IDE/insulin
ratio (for levels), an increase in insulin level or a decrease in IDE activity would lead
to a reduction of the IDE activity/insulin level ratio. To characterise further this
potential relationship and to determine if the relationship of IDE activity to insulin
levels may be able to differentiate between classifications in this subgroup, the
ratio of plasma IDE catalytic activity and insulin levels was analysed both overall, as
well as after stratification by APOE ε4 genotype.
The results indicate no significant difference between classifications overall (p =
0.294, Figure 5.11(A)) or between males and females (p = 0.596, Figure 5.11(B)).
When stratified by APOE ε4 genotype (Figures 5.11(C) and (D), no significant
differences in IDE activity/insulin level ratio were seen between classifications for
the ε4 carriers (p = 0.141) or the non-carriers (p = 0.577), although in ε4 carriers the
MCI group was slightly higher when compared with the HC group.
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Figure 5.11(A) The IDE activity/insulin level ratio is not significantly different
between classifications in the overall subgroup. Plasma samples (16 μL per well in
duplicate) from the AIBL cohort were assayed with a fluorometric activity assay to
measure the catalytic activity of IDE as detailed in Section 2.2.6.1. The average
value of the duplicates was obtained for each sample, and the ratios of these values
to the level of plasma insulin were compared by classification using a Kruskall-Wallis
test. Data represents medians with 95% confidence interval (CI), n = 183 (79 HC/55
MCI/ 49 AD). Results show that the IDE activity/insulin ratio is not significantly
different between classifications (p = 0.294).
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Figure 5.11(B) The IDE activity/insulin level ratio is not significantly different
between males and females in the overall subgroup. Plasma samples (16 μL per
well in duplicate) from the AIBL cohort were assayed with a fluorometric activity
assay to measure the catalytic activity of IDE as detailed in Section 2.2.6.1. The
average value of the duplicates was obtained for each sample, and the ratios of
these values to the level of plasma insulin were compared by classification using a
Kruskall-Wallis test. Data represents medians with 95% confidence interval (CI), n =
183 (67 males/116 females). Results show that the IDE activity/insulin ratio is not
significantly different between males and females (p = 0.596).
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Figure 5.11(C) and (D) The IDE activity/insulin level ratio is not significantly
different between classification when stratified by APOE ε4 status. Plasma
samples (16 μL per well in duplicate) from the AIBL cohort were assayed with a
fluorometric activity assay to measure the catalytic activity of IDE as detailed in
Section 2.2.6.1. The average value of the duplicates was obtained for each sample,
and the ratios of these values to the level of plasma insulin were compared by
classification using a Kruskall-Wallis test. Data represents medians with 95%
confidence interval (CI), (ε4 carriers – Graph A.) n = 85 (25 HC/25 MCI/35 AD), (noncarriers – Graph B.) n = 97 (54 HC/30 MCI/13 AD). Results show that the IDE
activity/insulin ratio is not significantly different between classifications for ε4
carriers (p = 0.141) or non-carriers (p = 0.577).
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5.3.11 The ratio of IDE Activity:Aβ42 + Aβ40 levels increases in MCI and
AD compared with HC.
In the current study, it was shown that the ratio of plasma IDE levels to Aβ42 + Aβ40
was significantly lower in the MCI group when compared with the HC group, and
there was also a significant reduction in the ratio in AD compared with HC. To
determine if the ratio of plasma IDE activity to Aβ42 + Aβ40 was also significantly
different between classifications, the ratio was calculated and compared between
MCI, AD and controls (Figure 5.12(A)). The data was also stratified for APOE ε4
genotype and then compared by classification (Figure 5.12(B) and (C)).
Results showed that the IDE Activity/Aβ42+40 ratio was increased in MCI and AD
groups compared with HC, with HC having the lowest ratio values and AD having
the highest ratio values (HC<MCI<AD).

Although these differences showed

significance between HC vs MCI (p = 0.022) and HC vs AD (p = 0.008), only the AD
group compared with the HC group remained significant following Bonferroni
correction for multiple testing (p = 0.024). When stratified for APOE ε4 genotype,
no significant differences or trends were observed between classifications in the ε4
non-carriers (p = 0.182), however, similar to the overall results an increasing trend
was observed for the ε4 carriers (HC<MCI<AD, p = 0.058), however this did not
reach significance.
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Figure 5.12 (A) The IDE Activity/Aβ42+40 ratio is increased in MCI (not significantly)
and AD (significantly) when compared with HC. Plasma samples (16 μL per well in
duplicate) from the AIBL cohort were assayed with a fluorometric activity assay to
measure the catalytic activity of IDE as detailed in Section 2.2.6.1. The average
value of the duplicates was obtained for each sample, and the ratios of these values
to the combined levels of plasma Aβ42 and Aβ40 were compared by classification
using a Kruskall-Wallis test, using Mann-Whitney tests for post-hoc analysis with
Bonferroni correction applied to adjust for multiple testing only with significant
comparisons. Data represents medians with 95% confidence interval (CI), n = 186
(82 HC/54 MCI/50 AD). Results show that the IDE activity/Aβ42+40 ratio is
significantly different in the AD group compared with HC following Bonferroni
correction (p = 0.024), while the difference between MCI and HC is no longer
significant, however a trend towards an increase is observed (p = 0.066). No
significant difference was seen between the MCI and AD groups (p = 0.981).
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Figure 5.12 (B) and (C) The IDE Activity/Aβ42+40 ratio is increased in MCI and AD
(not significantly) when compared with HC in APOE ε4 carriers only. Plasma
samples (16 μL per well in duplicate) from the AIBL cohort were assayed with a
fluorometric activity assay to measure the catalytic activity of IDE as detailed in
Section 2.2.6.1. The average value of the duplicates was obtained for each sample,
and the ratios of these values to the combined levels of plasma Aβ42 and Aβ40 were
compared by classification after dividing by APOE ε4 status, using a Kruskall-Wallis
test. Data represents medians with 95% confidence interval (CI), n = 86 (26 HC/35
MCI/25 AD) for ε4 carriers and n = 99 (56 HC/29 MCI/14 AD) for ε4 non-carriers.
Results show that an increasing trend is observed in the IDE activity/Aβ42+40 ratio for
ε4 carriers (Graph B) however does not quite reach significance (p = 0.058), and no
significant differences were seen in non ε4 carriers (Graph C, p = 0.182).
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5.3.12 IDE Activity/Insulin + Aβ42+40 ratio increases in MCI compared
with HC and AD.
To determine if there was any additive effect of Aβ42+40 combined with insulin in
relation to the catalytic activity of IDE, a ratio of IDE Activity and insulin + Aβ42+40
was calculated and compared between classifications in the subset of the AIBL
cohort (Figure 5.13(A)). The results indicated that the MCI group was significantly
higher than the HC group (p = 0.045 after Bonferroni correction) for the IDE
Activity/insulin + Aβ42+40 ratio, while the increase in the AD group compared with
the HC was no longer significant after Bonferroni correction, but demonstrated a
trend (p = 0.072). When the data was stratified by APOE ε4 status, no significant
difference between classifications for ε4 carriers (p = 0.108, Figure 5.13(B)), or noncarriers (p = 0.168, Figure 5.13(C)) was observed.
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Figure 5.13(A) IDE Activity/Insulin + Aβ42+40 ratios are increased in MCI
(significantly) and AD (not significantly) compared with HC. Plasma samples (16 μL
per well in duplicate) from the AIBL cohort were assayed with a fluorometric
activity assay to measure the catalytic activity of IDE as detailed in Section 2.2.6.1.
The average value of the duplicates was obtained for each sample, and the ratios of
these values to the combined levels of plasma insulin, Aβ42 and Aβ40 were
calculated. The ratios were compared by classification using a Kruskall-Wallis test,
using Mann-Whitney tests for post-hoc analysis with Bonferroni correction applied
to adjust for multiple testing only with significant comparisons. Data represents
medians with 95% confidence interval (CI), n = 179 (77 HC/53 MCI/49 AD). Results
show that the IDE activity/Insulin + Aβ42+40 ratio is significantly increased in MCI
compared with HC (p = 0.045 after Bonferroni correction), while AD demonstrates a
trend towards an increase compared with HC (p = 0.072, after Bonferroni
correction). No significant difference was seen between MCI and AD groups (p =
0.951).
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Figure 5.13(B) and (C) IDE Activity/Insulin + Aβ42+40 ratios are no different by
classification when stratified by APOE ε4 status. Plasma samples (16 μL per well in
duplicate) from the AIBL cohort were assayed with a fluorometric activity assay to
measure the catalytic activity of IDE as detailed in Section 2.2.6.1. The average
value of the duplicates was obtained for each sample, and the ratios of these values
to the combined levels of plasma insulin, Aβ42 and Aβ40 were calculated. The ratios
were compared by classification using a Kruskall-Wallis test. Data was stratified by
APOE ε4 status. Data represents medians with 95% confidence interval (CI), (ε4
carriers) n = 83 (24 HC/24 MCI/35 AD), (non-carriers) n = 95 (53 HC/29 MCI/13 AD).
Results show no significant differences in IDE Activity/Insulin + Aβ42+40 ratio
between classifications for ε4 carriers (p = 0.108, Graph B.) or non-carriers (p =
0.168, Graph C.).
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5.3.13

Correlation analyses of plasma IDE catalytic activity with

multiple biochemical measures in the AIBL cohort.
To determine if there were any significant correlations between IDE activity and
other parameters for which biochemical data was collected as part of the AIBL
study, correlation analyses were performed. As with the IDE levels measured in the
ELISA, IDE activity was analysed for any correlations with sex, age, plasma insulin
levels, Aβ species/ratios, total ApoE/ApoE4 levels, levels of testosterone/estradiol,
plasma lipids (total cholesterol, LDL/HDL subfractions) and brain Aβ load. IDE
activity was also stratified by APOE ε4 status and analysed again for any
correlations.

The biochemical variables and their data collection details are

outlined in Section 2.2.2.1.
Results overall (Table 5.2) showed a weak positive correlation with oestradiol (rs =
.155, p = 0.047). A weak inverse correlation was also seen between IDE activity and
the Aβx42/x40 ratio (rs = -.156, p = .035). Following Bonferroni-Holm correction for
multiple testing, these correlations were no longer significant. No other significant
correlations or trends were observed with the remaining variables.
When stratified by gender (Tables 5.3(A) and (B)), IDE activity positively correlated
with age in males only (rs = .320, p = 0.065), however after correction was no longer
significant. In addition, the Aβx-42/x-40 ratio was observed to have a trend toward
significance, while no other variables showed any significant relationships or trends
with IDE activity.

For females, only estradiol was observed to be positively

associated with IDE activity, but again, after correction was no longer significant.
When stratified by ε4 status (Tables 5.4 (A) and (B)), IDE activity showed no
significant correlations in the ε4 non-carriers, however a trend toward an inverse
correlation with testosterone was observed (rs = -.176, p = 0.082). For the ε4
carriers, a significant positive correlation was shown between IDE activity and total
testosterone (rs = .250, p = 0.022), but not for calculated levels of free testosterone
which are considered a better measure of bioavailable testosterone (rs = .175, p =
0.102). Inverse correlations were observed between IDE activity and Aβ ratios
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(Aβ42/40 - rs = -.235, p = 0.030, Aβx-42/x-40 - rs = -.305, p = 0.004), and total cholesterol
(rs = -.214, p = 0.047). No other significant correlations were observed with the
remaining variables for ε4 carriers, however there were trends toward a negative
correlation with HDL cholesterol (rs = -.196, p = 0.070) and a positive correlation
with brain Aβ load (rs = .320, p = 0.065). Following Bonferroni-Holm correction,
however, none of the observed correlations were still significant, although there
was a trend toward significance for the Aβx-42/x-40 ratio (p = 0.072).
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Table 5.2 Correlation matrix of plasma IDE catalytic activity with other
biochemical variables measured as part of the AIBL study. The catalytic activity of
plasma IDE was analysed for relationships with sex, age, and plasma insulin, Aβ
species, ApoE species, testosterone, oestradiol, lipids and brain Aβ load (two
tailed). n values vary due to missing values for some data or in the case of brain Aβ
load only a subset of the cohort underwent PiB-PET scans. For ApoE4, n value is
lower as only the APOE ε4 carriers express this isoform. Results show a weak
positive correlation with oestradiol (rs = .155, p = .047) and a weak inverse
correlation between IDE activity and the Aβx42/x40 ratio (rs = -.156, p = .035)(“unadj.”
= unadjusted, prior to Bonferroni-Holm correction). No other variables showed
correlations with IDE activity. After Bonferroni-Holm correction these correlations
were no longer significant (“adj.” = Bonferroni-Holm adjusted).
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Table 5.3(A) Correlation matrix of plasma IDE catalytic activity with other
biochemical variables measured as part of the AIBL study after stratification for
gender – males only. The catalytic activity of plasma IDE was split by APOE ε4
status and analysed for relationships with sex, age, and plasma insulin, Aβ species,
ApoE species, testosterone, oestradiol, lipids and brain Aβ load (two tailed). n
values vary due to missing values for some data or in the case of brain Aβ load only
a subset of the cohort underwent PiB-PET scans. For ApoE4, only the APOE ε4
carriers express this isoform therefore is not included for the ε4 non-carriers.
Results show no correlations of IDE activity with these variables.
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Table 5.3(B) Correlation matrix of plasma IDE catalytic activity with other
biochemical variables measured as part of the AIBL study after stratification for
gender – females only. The catalytic activity of plasma IDE was split by APOE ε4
status and analysed for relationships with sex, age, and plasma insulin, Aβ species,
ApoE species, testosterone, oestradiol, lipids and brain Aβ load (two tailed). n
values vary due to missing values for some data or in the case of brain Aβ load only
a subset of the cohort underwent PiB-PET scans. For ApoE4, only the APOE ε4
carriers express this isoform therefore is not included for the ε4 non-carriers.
Results show no correlations of IDE activity with these variables.
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Table 5.4(A) Correlation matrix of plasma IDE catalytic activity with other
biochemical variables measured as part of the AIBL study after stratification for
APOE ε4 status - ε4 non-carriers only (unadjusted). The catalytic activity of plasma
IDE was split by APOE ε4 status and analysed for relationships with sex, age, and
plasma insulin, Aβ species, ApoE species, testosterone, oestradiol, lipids and brain
Aβ load (two tailed). n values vary due to missing values for some data or in the
case of brain Aβ load only a subset of the cohort underwent PiB-PET scans. For
ApoE4, only the APOE ε4 carriers express this isoform therefore is not included for
the ε4 non-carriers. Results show no correlations of IDE activity with these
variables.
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Table 5.4(B) Correlation matrix of plasma IDE catalytic activity with other
biochemical variables measured as part of the AIBL study after stratification for
APOE ε4 status - ε4 carriers only (unadjusted). The catalytic activity of plasma IDE
was split by APOE ε4 status and analysed for relationships with sex, age, and plasma
insulin, Aβ species, ApoE species, testosterone, oestradiol, lipids and brain Aβ load
(two tailed). n values vary due to missing values for some data or in the case of
brain Aβ load only a subset of the cohort underwent PiB-PET scans. Results show a
significant but weak positive correlation with testosterone (rs = -.250, p = .022) but
not calculated free testosterone, and IDE activity was also significantly correlated
inversely with cholesterol (rs = -.214, p = .047), Aβ42/40 ratio (rs = -.235, p = .030) and
Aβx42/x40 ratio (rs = -.305, p = .004)(“unadj.” = unadjusted, prior to Bonferroni-Holm
correction). Following Bonferroni-Holm correction for multiple testing (“adj.” =
Bonferroni-Holm adjusted), these correlations were no longer significant, however
a trend toward significance was seen for the Aβx42/x40 ratio (p = 0.072). * indicates
significance at the < 0.05 level. ** indicates significance at the < 0.01 level.
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5.4 Discussion
The aim of this chapter was to optimise a previously developed immunocapturebased IDE-specific fluorometric activity assay (Miners, et al., 2008(b)) in order to
measure the catalytic activity of IDE in plasma from individuals from the AIBL
cohort. The assay was used to determine if there were any differences in IDE
catalytic activity in AD and MCI individuals compared with healthy controls, or if any
differences in IDE catalytic activity were related to various AD-related genetic and
biochemical factors.
The assay was shown to reflect the concentration of protein over time both for
purified recombinant rat IDE (rrIDE) and human plasma using two different batches
of Ab 3. Using the new batch of antibody, no significant difference was observed
when using phosphate-based buffers for the blocking step, sample incubation and
washes as compared with using tris-based buffers. The signal had good linearity up
to a concentration of 7500 ng/mL purified rrIDE and also for plasma (up to
approximately 1200 μg total protein per well). Over the 6 hour incubation time
period the signal for rrIDE was linear for the first few hours but then appeared to
plateau slowly at all concentrations assayed, while the signal in plasma remained
linear for the duration of the assay. It is possible that the plasma IDE is more stable
than the purified enzyme due to the presence of endogenous proteins, while the
rrIDE began degrading early in the incubation period. Although the non-bound
components of the plasma were washed away prior to the fluorogenic peptide
being added, it is possible that the immunocaptured IDE is bound to other proteins
which do not interfere with the catalytic site.
It should be noted that Miners also found that the signal was maximal after 5 hours
for brain homogenates, however the current study demonstrated that the signal in
plasma continued to increase in a linear fashion up to at least 6 hours incubation.
The signal may have increased further after extending the incubation beyond 6
hours but this was not pursued; however it may be of value to investigate this in
the future. It may be that IDE levels are higher in the brain than in the plasma
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which may have saturated the fluorogenic peptide earlier, leading to the plateau in
signal observed in the Miners study.
The finding that the assay was linear for rrIDE up to 7500 ng/mL is contrary to the
results of Miners who found that the assay was linear only between 156 – 2500
ng/mL for rrIDE. Furthermore, the fluorescent values were more than double in the
Miners results compared to the values observed in this study. There were a
number of differences in the Miners protocol by comparison which may account for
these differences. Firstly, the coating antibody was diluted in PBS (pH 7.4) in
Miners study, while our study used a carbonate/bicarbonate coating buffer (pH
8.6). The microplate manufacturer advised that a coating buffer pH of 9.6 was
optimal for antibody adsorption. The lower pH though, would be more likely to
result in weaker binding of the capture antibody to the microplate, which may have
been displaced by the subsequent washes and led to a reduced signal, which is
opposite to what was observed.

However, as well as the pH, the different

components of the buffers may also have had an effect on the binding capabilities
of the antibody. Another difference was the use of BSA as a blocking agent in the
current study. This step was not included in the Miners assay and could potentially
have led to exposed binding sites on the plate which may have allowed additional
IDE or other enzymes to bind to the plate, leading to a higher signal. Although
omission of the blocking step did not alter the signal observed in plasma, it may be
that the presence of BSA in the incubation step provided some extra stability to the
purified IDE during the overnight incubation. The Miners protocol also included an
additional two washes in each washing step, although it is unclear how this would
have contributed to an increased signal; it is possible though that the extra washes
may have decreased the background leading to an improved signal to noise ratio.
Similarly, the samples in our study were incubated overnight at 4°C rather than 1.5
hours at RT; again it is not clear why this may contribute to a lower overall signal or
to the differences observed in the range of linearity of the rrIDE. Other differences
include the presence of Tween-20 in the wash buffers and sample buffer (PBS) in
the current study, which may have reduced the background reading and led to a
better signal to noise ratio. Perhaps though, most notable differences may be the
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dilution buffer composition and incubation temperature of the fluorogenic
substrate, which in the current study was 31°C compared with 37°C in the Miners
protocol. This was likely to have led to a reduction of enzyme activity and account
for the lower signal observed. In addition to this, the dilution buffer used for the
fluorogenic peptide in the current study was HEPES, while Miners used a Tris-based
buffer containing zinc. The addition of zinc in the incubation buffer may have
stimulated the activity of IDE, and this effect has been demonstrated in a recent
study (Grasso, et al., 2012). The combination of the activation of IDE by zinc, as
well as the increased incubation temperature in the Miners study would have
resulted in an increase in IDE activity by comparison with the current study, and
would have saturated the peptide earlier, perhaps providing an explanation for why
the linear range was lower in the Miners study. One other factor which was not
mentioned in the Miners study is the gain adjustment setting, which in our study
was found to have a large impact on the values obtained. This alone may have
accounted for the higher values observed in the Miners study.
The activity assay was seen to have a high level of background signal, and while the
source of this background noise has not been confirmed, there are a few possible
reasons.

It was determined that the background was not attributable to an

interaction of the fluorogenic peptide with BSA (or contaminating proteases within
the BSA preparation) used as the blocking agent, as no difference was seen when it
was omitted from the assay. Similarly, no interaction was seen between the
fluorogenic peptide and the capture antibody or its component glycerol. It was
shown that a similar background signal occurred with just the diluted peptide
alone, and omission of the peptide with all other assay components led to a
significantly reduced signal, suggesting that the background was primarily due to
the fluorescent peptide itself. Regardless, the background fluorescence for both
batches of antibody were similar, and also did not increase over time and this
indicated that ongoing cleavage of the peptide was not occurring. Although the
increased background may have reduced the sensitivity of the assay at the lower
limit of detection, the background was therefore not considered to be a significant
factor and was subtracted from the values observed. Furthermore, the reduced
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signal observed with the second batch of Ab 3 compared with the original batch is
likely due to a reduced affinity of the new batch of antibody to IDE, leading to
reduced amounts of the enzyme captured. This is not unusual for polyclonal
antibodies, and highlights the importance of using a single batch of antibody for
immunoassays which require comparisons between different experiments.
The activity assay was also tested using samples collected in tubes containing
different anticoagulants; namely EDTA and Lithium-Heparin (LiHep).

It was

expected that the samples containing EDTA might have a lower activity by
comparison due to the chelating effect of the EDTA on the essential zinc ion bound
to the catalytic site of IDE. Surprisingly, the opposite result was observed with
LiHep samples having only approximately 15% of the activity of EDTA samples. It is
not clear exactly why this difference would occur, however may be potentially
related to the tendency of EDTA collected samples to be vulnerable to haemolysis
during blood processing, releasing intracellular IDE into the plasma and leading to
an increased signal. Alternatively, the differences may be related to the reduced
stability of plasma proteins in LiHep collected blood, resulting in more degradation
of IDE over time in LiHep tubes. Other studies have shown that levels of certain
analytes measured in EDTA-collected plasma are higher than samples collected in
LiHep tubes or sodium-heparin tubes (Kragstrup, et al., 2013; de Jager, et al., 2009),
and while the levels of IDE were not compared for differences between the two
different anticoagulants in the current study, it would be of value to investigate in
future whether the activity differences were related to IDE protein level, and/or
due to haemolysis.
The internally-quenched fluorogenic peptide which was used for this assay is not
specific to IDE, and other enzymes such as neprilysin (NEP), endothelin converting
enzyme (ECE-1), angiotensin converting enzyme (ACE), cathepsin A and cathepsin X
(also called cathepsin Z or P) are also able to cleave this substrate according to the
company datasheet. Therefore it was essential to ensure that the capture antibody
(Ab 3) was able to specifically bind to IDE but not bind to any other enzyme capable
of degrading the peptide. When testing activity assays for specificity, a common
approach is to use specific inhibitors to block the activity generated by the assay.
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Unfortunately most inhibitors are not specific for just one enzyme; for example Aβ
is a substrate of IDE which inhibits its catalytic activity toward the fluorogenic
substrate by competitive inhibition. As some other proteases also cleave Aβ, it is
likely that it would also inhibit other Aβ-degrading enzymes. Therefore more than
one inhibitor may need to be used to confirm the specificity of an assay in
measuring a particular enzyme. In the current study, two commonly used IDE
inhibitors were employed; insulin and Aβ (both Aβ40 and Aβ42). Aβ and insulin are
both competitive inhibitors of IDE, by binding to the active site and preventing
binding or cleavage of the fluorogenic peptide. However, Aβ is also a substrate for
NEP, ECE-1 and ACE as well as IDE and therefore not specific. Insulin though, is
primarily degraded by, and has a high affinity for insulin-degrading enzyme and has
been previously used in IDE activity assays to determine specificity (Liu, et al.,
2012(a); Alper & Schmidt, 2009). However, it should be noted that there are other
enzymes present in the plasma that bind to insulin, and have been reported to be
inhibited by insulin, although it is unknown if these enzymes are capable of cleaving
the fluorogenic substrate (Lokhov, et al., 2004; Kashyap, et al., 2008). Miners and
colleagues (2008(b)) had previously showed that there was negligible signal from
recombinant NEP, ACE and ECE-1 using the same IDE-specific capture antibody as
the one in the current study (Ab 3), indicating that the signal observed is unlikely to
be contributed to substantially by these particular proteases. The signal observed
in this activity assay derived from human plasma could be completely inhibited by
both insulin and Aβ42, in a dose-dependent fashion. Although the reduction in
signal was only around 50% for Aβ40, this initial experiment used a lower
concentration of Aβ and was the reason that larger amounts of Aβ42 were
subsequently used.

These results indicate that it is likely that the signal is

attributable to cleavage of the substrate by IDE, although it would be of interest to
test other IDE-specific inhibitors in this assay. Recently this has been addressed
with the development of promising novel and specific IDE inhibitors (Abdul-Hay, et
al., 2013; Leissring, et al., 2010).
In addition, IDE-specific antibodies were also used in an attempt to neutralize the
activity of IDE in plasma by interference of the fluorogenic substrate cleavage. One
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antibody (Ab 1) was targeted to a region within Domain 1 of IDE which is in close
proximity to the catalytic site, while the other (Ab 2) targets a region near the Cterminus of IDE which is far away from the catalytic site. There was around 50%
reduction of signal when the sample was pre-incubated with Ab 1, while no such
decrease was observed with Ab 2. This may suggest that Ab 1, by binding close to
the catalytic site, is somehow interfering with the cleavage of the fluorogenic
substrate, possibly by physically blocking binding to the catalytic site, or by steric
hindrance.

It is also possible that binding of the antibody to IDE causes a

conformational change that negatively affects binding or cleavage of the substrate.
However, it should be noted that Ab 1 was in the form of anti-serum (as opposed to
Ab 2 which was purified), which would contain other components which may have
inhibited the signal also, and therefore this may not necessarily confirm specificity.
Nevertheless, in Western immunoblotting experiments (see Section 3.3.1), Ab 1
only detected a single band at the expected molecular weight, which could be
considerably reduced by pre-incubation of the antibody with purified IDE,
suggesting that the antibody is specific. The observation that Ab 2 does not
interfere with substrate cleavage indicates that the epitope location may be too
distal from the catalytic region to interfere with binding or cleavage. While it
cannot be completely ruled out that other components of the antiserum (Ab 1) may
have contributed to the reduction in signal in the activity assay, these results
support that the signal observed is derived from IDE.
The specificity of the assay was demonstrated by the complete reduction of signal
by IDE substrates, Aβ and insulin, and no cross-reactivity was observed between
assay reagents or with plasma albumin. Therefore the assay was used to measure
IDE activity in plasma samples obtained from the well-characterised AIBL cohort.
The results for the AIBL samples showed that IDE activity in plasma was significantly
higher in MCI individuals compared with healthy controls. AD patients also had
elevated IDE activity however this did not reach significance. These results for IDE
activity were contrary to what was expected; it was expected that MCI and AD
might have decreased activity compared with HC. A recent study by Liu, et al.,
2012(a) showed that MCI and AD individuals had lower serum IDE activity than
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healthy controls, and the subjects with the lowest serum IDE catalytic activity also
had correspondingly lower IDE levels compared with subjects with the highest
catalytic activity (who had higher IDE levels) as determined by Western
immunoblotting. In the current study, plasma IDE activity was increased in MCI
(and a trend toward an increase in AD) compared with HC, which was reflected by
an increase in IDE levels for MCI (but not AD) in Western immunoblotting results.
However, this was opposite to what was observed with IDE levels measured by
ELISA, where MCI levels were significantly reduced compared with HC. This will be
discussed further in Chapter 6. It should be noted that the study by Liu and
colleagues used serum samples as opposed to plasma; one consideration related to
this is that unlike serum samples, the plasma samples contained EDTA.

As

mentioned above, EDTA has been shown to increase the likelihood of haemolysis,
and as red blood cells contain IDE, this may have affected the results in this assay.
It was demonstrated that EDTA containing plasma had significantly higher IDE
activity than plasma sourced from Lithium-Heparin (LiHep) tubes and it is possible
this may be due to haemolysis. Conversely, it may be that IDE in the LiHep plasma
samples was less stable than IDE in the EDTA plasma, and this may be the case for
serum IDE also. Until the implications of these differences are investigated, caution
should be exercised when translating the results of this study. In addition, the
study by Liu and colleagues used a different capture antibody than the one used in
the current study. Although they demonstrated a reduction in activity with several
substances which are known to inhibit IDE activity (insulin, Aβ, amylin and EDTA),
the inhibition seen in their study was not complete (unlike in the current study
where complete inhibition was seen with Aβ and insulin) and therefore it cannot be
ruled out that proteases other than IDE were implicated in generating the
measurable activity observed in the Liu study.
As the Western immunoblotting data indicated that IDE levels differed between
males and females, the IDE catalytic activity was also analysed by gender. Although
no significant differences were seen in IDE activity overall between males and
females, when stratified by gender the males demonstrated a trend toward
increased activity in MCI compared with HC, while no differences in IDE activity was
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seen between classifications for females. While it was noted that the increase did
not reach significance, this may be due to reduced numbers as a result of stratifying
the subset. This indicates that the observed increase in IDE activity in MCI is
primarily due to the effects in males. The reason for the increase in the activity in
male MCI participants is not clear; there was no increase in IDE substrates or
hormones in the plasma that have been shown to upregulate IDE such as insulin,
Aβ, testosterone (free or total) or oestrogen levels in this subset of the AIBL cohort,
indicating other as yet unknown or non-assessed factors are involved. It would be
of value to investigate this finding in future studies.
Based on the results of the current study, it is possible that the activity of IDE is
upregulated in early AD (MCI) in an attempt to compensate for a reduction in total
IDE levels, as reflected in the IDE ELISA data (although the Western immunoblotting
results did not concur with the ELISA results; the different assays may be measuring
distinct forms of IDE and this will be discussed more in Chapter 6). This finding is
consistent with previous reports on IDE activity in the brain using the same
fluorometric activity assay; Miners and colleagues (2009) found an increase in brain
IDE activity in AD patients compared with controls, which was not influenced by
APOE ε4 genotype and independent of IDE levels.

Although not significant,

differences in activity patterns between classifications in the current study
observed between genders may be related to other factors such as intrinsic
hormonal differences, effects of sex hormone-based or other medications, or
lifestyle factors such as diet and exercise. Indeed the high variation seen in the MCI
and AD groups may indicate the influence of other variables. Due to time-restraints
it was not possible to investigate these possibilities within the time-frame of this
project; however it would be of value to explore these theories in the future.
The plasma catalytic activity of IDE was shown to be similar for APOE ε4 carriers and
non-carriers overall. When stratifying the classifications by ε4 status, although not
statistically significant MCI and AD ε4 carriers tended to have increased IDE activity
compared with control group, while no differences were seen in the non-carriers.
The difference in IDE activity between classifications in carriers versus non-carriers
may potentially reflect the pathological changes that may be occurring faster in ε4
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carriers; as mentioned in Chapter 1 it has been shown that the onset of AD tends to
be earlier, and the progression of degeneration faster for individuals carrying the ε4
allele (Corder, et al., 2003; Chen, et al., 2007).
To ascertain if there were any associations between IDE activity and other
biochemical data collected as part of the AIBL study, correlation analyses were
performed. The variables were chosen based on two criteria; variables which have
been associated with AD pathology such as age, plasma levels of Aβ (and Nterminally truncated species), ApoE/ApoE4, cholesterol (and LDL/HDL subtypes),
and brain Aβ load, and those which have been associated with alterations in IDE
levels (sex, insulin, testosterone, and estradiol).

The correlations that were

observed between IDE activity and other variables (only overall and in APOE ε4
carriers) were not significant following Bonferroni-Holm correction, however this
type of correction for multiple testing is very conservative and increases the
chances of Type II errors occurring, albeit not quite as stringent as the original
Bonferroni method. However, as a large number of correlates were analysed,
Bonferroni/Bonferroni-Holm is the best correction method to avoid the occurrence
of Type I errors. For the APOE ε4 carriers in the current study, four variables out of
seventeen tested were significantly correlated with IDE activity prior to correction,
which is more than would be expected by chance alone if none of these variables
had a true relationship with IDE activity.

Therefore, one or more of these

correlations may actually be true associations despite the corrected results. In
particular, the observation that both the Aβ42/40 ratio and Aβx-42/x-40 ratio showed a
negative correlation with IDE activity prior to Bonferroni correction, and the
correlation with Aβx-42/x-40 ratio was still close to significance following Bonferroni
correction, is probably worth investigating further in the future.
In the case of testosterone data, total levels were used in the correlation analyses
as well as calculated levels of free testosterone, which is regarded as a better
measure of bioavailable testosterone. Analysing males and females together may
be a limitation, as males have considerably higher levels of testosterone than
females, although there were no associations overall or after stratification by
gender in males or females between total or free testosterone and IDE activity.
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However, in females a positive correlation was observed between estradiol and IDE
activity; therefore the overall correlation seen with estradiol was due primarily to
the association in females.

Although not significant after correction, this

relationship is consistent with the published literature which suggests that estradiol
positively regulates IDE activity (Udrisar, et al., 2005).
As the subset of AIBL samples used in the IDE activity assay was different to the
subsets used to measure IDE levels by Western immunoblotting and ELISA, it was
not possible to assess any correlations between activity and levels due to the small
number of samples in common. However, a small sample set which were in
common with the activity and levels (by Western immunoblotting) subsets showed
a borderline correlation (data not shown).

5.4.1 Summary
In this project, a previously described fluorometric assay that had been developed
for the purpose of measuring the catalytic activity of IDE in brain homogenates was
adapted for measuring IDE activity in human plasma. Although factors such as
background signal may have impacted on the sensitivity of the assay at the lower
limit of detection, specificity of the assay was shown by demonstrating no crossreactivity between assay reagents, as well as a complete reduction of signal by the
use of IDE substrates that competitively and dose-dependently inhibited the activity
generated from plasma. Further development of the assay such as identifying ways
to reduce the background signal, as well as investigating the reason for the
differences in plasma collected with different anticoagulants would be of value.
The use of additional IDE inhibition studies as well as genetic knock-down or knockout studies to further characterise and validate this assay for use in plasma should
also be considered.
This initial pilot study on the catalytic activity of plasma IDE was promising, and
showed alterations in the plasma IDE activity which differed by clinical
classification. While gender did not have an effect on IDE activity overall, when
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stratified by gender the differences seen between classifications were only found in
the male subgroup. IDE activity overall did not differ by APOE status, however a
non-significant increasing trend was seen in IDE activity for MCI and AD compared
with controls in ε4 carriers only, as well as an association of IDE activity with the Aβ
ratios in ε4 carriers which requires further investigation. It is possible that with a
larger cohort these trends may become significant. Notably, the ratio of IDE activity
to Aβ levels was higher in MCI and AD participants compared with controls, as was
the ratio of IDE activity to the collective levels of insulin and Aβ. While only fulllength Aβ40 and Aβ42 was included in these ratios, it would be of interest to
investigate if the N-terminally truncated species of Aβ were also implicated.
However, there was high variation within each classification group, and this may be
related to hormone levels, lipid composition and/or other factors which may inhibit
or enhance the activity of IDE.
The results suggest that IDE activity in plasma is upregulated in both the prodromal
(represented by the MCI group) and symptomatic periods of AD, however whether
IDE activity might be clinically useful as an early diagnostic biomarker is not clear at
this stage. It may be that other factors which regulate IDE may prove to be more
relevant than IDE itself. Indeed the observed associations with sex hormones
requires further investigation. Further work towards understanding the complex
regulatory mechanisms of IDE catalytic activity in the peripheral circulation, and
specifically in relation to its role in Aβ degradation or other potential roles in AD
would therefore be of importance in future studies. It is notable that the results
are contrary to the only other published study on blood IDE activity who found
lower IDE activity in MCI and AD individuals (Liu, et al., 2012(a)), however in their
study they used serum rather than plasma, and a number of covariates were
controlled for. As non-parametric analyses were used in the current study this was
not possible.

While the results from the current study show potential, and

particularly in respect to plasma Aβ and insulin levels, they would require validation
following further assay characterisation in a larger cohort before any conclusions
could be made regarding the suitability of IDE activity as a plasma biomarker for the
early detection of Alzheimer’s disease.
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Chapter 6 – Final Discussion
6.1 Introduction
The number of AD sufferers is predicted to increase significantly in the coming
years, therefore the development of a blood-based diagnostic test is crucial. There
are no effective treatments for AD, therefore prevention and/or delaying the onset
of disease symptoms is the next best goal for anti-AD therapy. AD has a long presymptomatic phase, and thus diagnosis at the earliest stage possible will maximise
the effect of disease-delaying treatments. Therefore, the ideal panel of blood
biomarkers will identify AD patients in early pre-symptomatic stages with high
specificity and sensitivity. To this end, potential blood biomarkers need to be
characterised extensively, and reliable biomarker assays need to be developed. The
aim of the current study was to investigate insulin-degrading enzyme (IDE) in the
plasma of MCI individuals, AD patients and healthy controls to ascertain if it is a
suitable biomarker to include in such a biomarker panel.
The specific aims of this project were:
•

To characterise commercial IDE antibodies for the measurement of plasma
IDE levels using two distinct methods,

•

To measure the catalytic activity of plasma IDE using a previously developed
activity assay to determine if the levels are altered in the prodromal period
of AD (MCI) or in symptomatic AD,

•

To investigate any association between IDE (levels or activity) and other ADrelated biomarkers and genetic influences.

The potential implications of these results will be discussed in the context of the
current literature, and the limitations of the study will be addressed. Prospective
future directions will also be discussed.
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6.2 Assay development and validation
The only available commercial IDE ELISA kit on the market at the commencement of
the project did not perform within the acceptable limits of inter-assay and intraassay variation, therefore it was not used for the measurement of plasma IDE levels
in this project.

Although only two tests were performed using this kit, the

prohibitively high cost prevented further characterisation. Similarly, an in-house
indirect ELISA was not suitable for measuring levels of IDE in plasma, as other
proteins present in the matrix competed with IDE for binding to the ELISA plate.
Therefore, an in-house sandwich ELISA assay was developed for the measurement
of IDE levels.
An ELISA is an antibody-based assay, and this project has demonstrated some of the
numerous factors that should be considered when characterising antibodies for use
in such an assay, as the choice of antibody is central to the integrity of the results.
These are discussed in detail in Chapters 3 and 4, but highlighted below are some of
the factors that were found to have the greatest impact. Variable results were
obtained in this project when using different antibodies in all the applications
tested. The likely reasons for these variations or inconsistencies include differences
in IDE epitopes to which the antibodies bind, differences in the immunogens used
to initiate the immune response to generate the antibodies, or differences in host
species in which the antibodies were generated. Another important consideration
when trying to set up a reliable immunoassay is the batch-to-batch variability of the
antibodies. It was demonstrated in this project that there can be substantial
differences in assay results caused by differences in batches of polyclonal
antibodies (both from commercial as well as private sources), highlighting one of
the advantages of monoclonal antibodies, or if using polyclonals, the importance of
sourcing antibodies from a single batch. This is necessary to ensure consistency
when measuring an analyte which will be compared between subjects in a cohort.
In addition, at least two of the commercially-available IDE antibodies that were
tested cross-reacted significantly with components of blocking solutions such as
BSA, as well as plasma components such as HSA, under the denaturing and reducing
330

conditions of Western immunoblotting (WB), while not cross-reacting under the
native conditions of the ELISA or fluorometric activity assay. This outlines the
importance of testing the specificity and potential cross-reactivity of the antibody
within each application for which it is intended. It was also demonstrated that
some common reagents such as BSA that are used routinely in these applications
can vary in purity, and this can also have a major impact on the outcome of the
assay (Chapter 4, Section 4.3.16). The finding that Fraction V grade BSA did not
generate a signal in the ELISA while cell-culture grade BSA produced a dosedependent signal may have possibly been due to contaminants in the latter
preparation. Therefore it is critical that antibodies are tested thoroughly for crossreactivity with blocking reagents and with non-specific components of the sample
matrix. Although the ELISA assay cross-reacted with cell-culture grade BSA, no
cross-reactivity issues were demonstrated with the fluorometric activity assay,
which suggests that the cross-reactivity issues were related to the detection
antibody in the ELISA. While it is probably not feasible to test for cross-reactivity
with every component in a complex fluid such as plasma, at least the major proteins
or proteins known to be highly antigenic should be assessed, and ideally plasma
from an IDE knock-out animal model could be used to validate the assay.
The elimination of signal observed with the spike and recovery assessment in the
sandwich ELISA (Chapter 4, Section 4.3.17) indicates a significant matrix effect of
the plasma components on the assay. It is important to identify the reason for this
signal reduction, and the effect minimised, as part of assay validation. Regardless,
peptide blocking and immunoprecipitation experiments indicated that the 120-130
kDa protein band detected by Ab 3 in plasma samples was IDE (discussed further in
Chapter 3, Section 3.4).
As Ab 3 detected multiple other bands which appeared to be non-specific in the
Western immunoblotting results, it was also important to determine this antibody’s
specificity in the ELISA and the fluorometric activity assay. It was shown for the
sandwich ELISA that there was negligible cross-reactivity between the secondary
antibody and either the detection or capture antibodies. The slightly elevated
signal for the blank may indicate some cross-reactivity between the capture and
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detection antibodies; however, the concentrations of these were consistent
between wells and the background reading subtracted from results to account for
this. Nevertheless this high blank signal may have impacted on the sensitivity of the
assay, leading to a reduced overall signal. In addition, cell-culture grade BSA was
used in the ELISA for the AIBL samples and was responsible for some crossreactivity, which may also have blocked some of the available antibody, leading to a
reduced signal.
Recent research is beginning to address potential interfering factors and crossreactivity issues in immunoassays. Emerging studies on assay validation and crossreactivity show that interference can occur from other endogenous factors such as
heterophilic, anti-animal or auto-antibodies and rheumatoid factors (reviewed in
Tate & Ward, 2004). Some exogenous potentially interfering factors have also been
identified such as some plasticisers and organosilicone surfactants in plastic tubes
(Bowen, et al., 2005 and reviewed in Bowen, et al., 2010). While these factors were
not addressed in the current study, variables such as these need to be considered
carefully when developing and optimising an immunoassay, and therefore would be
important for further refinement of the ELISA.
The most robust specificity tests for Ab 3 were performed using the IDE activity
assay; firstly at least half of the signal generated could be removed by preincubation with Aβ40 and an IDE-specific antibody (Ab 1) which binds within the
catalytic domain of IDE. However, it should be noted that Ab 1 was in the form of
antiserum which potentially could contain other inhibitory components as well as
the specific IDE antibody. Conversely, another IDE-specific antibody (Ab 2) had no
effect on the catalytic activity observed, probably as it binds to an epitope of IDE
too distal from the catalytic site to block the activity. However it cannot be ruled
out that because Ab 2 binds IDE within the C-terminal region it may also be binding
to the inactive truncated isoform which is comprised of the C-terminal half of IDE.
This may have bound a large amount of available antibody leading to insufficient
antibody amounts left to neutralise active IDE. However, such an effect would
depend on the concentration of IDE fragments and the concentration of IDE-specific
antibody in the sample, neither of which were determined. Secondly, it was
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demonstrated

that

the

catalytic

activity

obtained

from

plasma

after

immunocapture with Ab 3 could be completely eliminated when the
immunocaptured sample was pre-incubated with either of the known IDE
substrates, Aβ42 or insulin. These results indicate strongly that the signal derived
from the immunocapture of protein using Ab 3 is specifically due to IDE. However,
it cannot be completely ruled out that part or all of the activity observed may be
due to an unknown peptidase with similar properties to IDE.

Despite this

possibility, Miners, et al., 2008(b) reported negligible cross-reactivity of the activity
assay with other known Aβ-degrading enzymes such as neprilysin (NEP),
angiotensin-converting enzyme (ACE) and endothelin-converting enzyme-1 (ECE-1),
further supporting the theory that IDE cleavage of the peptide was responsible for
the signal observed. Overall, these results strongly suggest that the antibody is
specifically binding IDE in the activity assay, and as the ELISA works on similar
immunocapture principles, it is likely that the ELISA is also specific, regardless of any
potential cross-reactivity of the detection antibody. Conversely, this does not
necessarily mean that Ab 3 is exclusively detecting IDE following the denaturing and
reducing conditions of WB. In fact, the observation of many additional bands in this
application may be a result of these denaturing and reducing conditions, exposing
different epitopes which were then detected by the primary antibody. However, it
cannot be ruled out that Ab 3 is detecting other fragments or forms of IDE.

6.3 Potential significance of plasma IDE in AD pathology
According to the “peripheral sink” hypothesis, the levels of brain Aβ may be
controlled by peripheral clearance mechanisms (reviewed by Kurz & Perneczky,
2011), and several studies have shown that this is possible. For example, recent
studies have demonstrated that peripherally-applied therapeutic compounds such
as γ-secretase inhibitors which reduce plasma Aβ, can also deplete levels of brain
Aβ (Sutcliffe, et al., 2011; Sivilia, et al., 2013). Immunotherapy studies (despite
autoimmune reactions) and studies of other compounds such as an extract of
Withania somnifera suggest strongly that peripheral clearance of Aβ will reduce
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brain Aβ levels (Sehgal, et al., 2012; Liu, et al., 2012(b)). Similarly, reducing levels of
peripheral Aβ by the upregulation of circulating proteases may also have some
therapeutic benefits. In accordance with this concept, it has been demonstrated
that the peripheral expression of the metalloproteinase neprilysin (NEP) in
transgenic mice reduces the levels of blood Aβ, and subsequently reduces levels of
soluble brain Aβ as well as oligomeric and insoluble Aβ (Liu, et al., 2009; Liu, et al.,
2010; Guan, et al., 2009). Importantly, other studies have shown that an increase
in NEP in the brain is associated with a reduction in cognitive deficits (Poirier, et al.,
2006; Spencer, et al., 2008). However, two recent studies have contradicted the
hypothesis (Walker, et al., 2013; Henderson, et al., 2013). These studies showed
that while NEP peripheral administration did in fact reduce the levels of soluble Aβ
in the plasma, it had no effect on cerebral Aβ accumulation in both wild-type and
AD mouse models, or in monkeys. However, these studies had a number of
limitations including small sample sizes. In both studies the degraded fragments of
Aβ in the periphery were not measured and it is possible that the presence of these
fragments may have had an effect on the Aβ efflux and/or influx across the BBB. In
the Walker study, they were also not able to measure circulating levels of Aβ42, and
this may be more relevant to AD pathology. Conversely, in the Henderson study,
the soluble levels of Aβ40 in the primate brain were not measured. It is likely that
both isoforms of Aβ need to be considered in conjunction, to conduct a more
thorough investigation between reduction of plasma Aβ and its potential effects on
brain Aβ. Furthermore, the transgenic mouse models used in the studies were
different, making comparisons difficult, and some (or all) of these transgenic
models may not be truly representative of the mechanisms of AD which occur in
humans.

For example, a recent study has shown that some commonly used

transgenic mouse models do not display the classic reduction in IDE levels and
corresponding reduction in Aβ degradation that is seen in very early AD pathology
in humans (Stargardt, et al., 2013). These transgenic mice have mutations in the
PS1 and/or APP genes which would be more relevant for EOFAD rather than LOAD.
In addition, while NEP and IDE are considered to be two of the major Aβ-degrading
enzymes, the two enzymes may function differently and perhaps have effects on
AD pathology which are independent of their catalytic function. Although the
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results from some of these studies might suggest that the efflux of brain Aβ may
not be able to be stimulated simply by reducing peripheral Aβ via increasing or
upregulating plasma metalloproteinases, there is evidence that the pools of
peripheral and cerebral Aβ exist in some kind of equilibrium and that the regulation
of plasma Aβ-degrading enzymes offers a promising treatment option for AD.
Further work which addresses these issues would need to be undertaken in order
to confirm or negate this hypothesis.

6.3.1 Findings of IDE levels/activity measurements by classification
The results from the current study are difficult to interpret. However, with all
methods used in this study, alterations were detected in IDE levels and activity in
the prodromal period of AD, represented by the MCI group. The Western blot (WB)
results show increased levels of full-length IDE in the MCI group, while for total IDE
levels as measured by ELISA the opposite was observed, with decreased levels of
IDE in MCI and also in the AD group compared with controls. This discrepancy is
likely to be related to the methods used for these measurements, but may also
offer some further information in respect to this.

While there were some

limitations in these applications, it is possible that these methods are reflecting
particular characteristics or mechanisms of IDE. It is probable that the denaturing
and reducing conditions of the WB dissociated IDE which may have been bound to
other proteins in the ELISA, and increased the overall detectable levels of IDE,
whereas the ELISA may not have detected a portion of the total IDE due to the
enzyme binding to other proteins. Alternatively, the ELISA may have detected both
full-length IDE as well as forms of IDE which were not full-length, which may have
been missed on the WB, or may have been present at a different molecular weight.
Supporting this idea, it cannot be discounted that some of the other bands seen in
the WB experiments might also be IDE, particularly the 80kDa band, which was
shown to be reduced in the peptide blocking experiments, and also was retained
following immunoprecipitation. These factors may at least partially account for the
discrepancies seen between the WB and ELISA data.
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Full-length IDE may not necessarily be catalytically active, as a portion of the
measured IDE may represent the inactive 15b isoform, although the increase in
protein levels in MCI individuals is reflected in the fluorometric activity assay, with a
corresponding increase in activity in the MCI group compared with controls.
However, it was observed that this trend of increased protein levels in MCI was
seen only in females, while for the activity data only the males showed a trend
toward increased activity in the MCI group. However, the loss of significance may
be because of smaller numbers due to stratification. Thus, MCI levels of full-length
IDE were higher than healthy control levels, yet interestingly, IDE levels in the AD
group were similar to the healthy controls, and differences between MCI and AD
almost reached significance. This may suggest a compensatory upregulation of fulllength IDE as the disease progresses from HC to MCI which is then reduced during
the progression from MCI to AD, possibly due to increasing severity of AD
pathology. However, when looking at the total IDE levels and activity data, the AD
group is not statistically different from the MCI group, indicating no significant
changes in IDE expression or activity occur during the progression from MCI to AD.
Changes in IDE levels and activity may occur at early stages in the disease process,
which would have been missed here as some of the healthy controls who will
eventually develop AD may have already experienced these undetected changes as
part of very early AD pathogenesis. Longitudinal studies of larger healthy control
cohorts may reveal earlier and greater changes in IDE expression and activity;
therefore this enzyme warrants further investigation.
In this project, the increase in full-length IDE as well as catalytic activity that was
detected in the MCI group compared with controls was somewhat unexpected, as it
was hypothesised that a reduction of IDE levels or activity might be seen in the MCI
and AD groups.

However this may be a reflection of some compensatory

mechanism in response to an earlier pathological event; since by the time MCI is
apparent, AD pathogenesis has already started.

Studies have reported an

upregulation in IDE levels and/or activity in the liver in response to a diet high in
sugar, salt and fat (Castell-Auvi, et al., 2012) and as a response to a number of
cellular stressors (Tundo, et al., 2013), both of which are related to AD pathology.
336

This may be regulated by the induction of heat-shock proteins (HSP), particularly
HSP70 which has been demonstrated to induce expression of IDE (Hoshino, et al.,
2011). More importantly, several studies in transgenic mice have reported an
upregulation in IDE expression that may be a compensatory response to Aβ
deposition in the brain (Leal, et al., 2006; Vepsäläinen, et al., 2008; Zhao, et al.,
2011).

One of these studies found that 17β-estradiol could upregulate IDE

expression, correlating with an attenuation of Aβ deposition in the brains of
ovariectomised AD-transgenic mice, also suggesting such a mechanism for the
oestrogen-mediated preventative effect against AD, when hormone treatment is
started at the onset of menopause (Zhao, et al., 2011). While it would appear that
the increase in IDE levels and/or activity in these studies may be in response to the
formation of insoluble Aβ plaques rather than soluble Aβ, many other metabolic
changes are likely to be occurring concurrently, and the changes that may be
occurring in the plasma were not measured in these studies. In another brain study
carried out by Miners and colleagues (2010), an increase in IDE activity was
reported with age which was not due to an increase in expression. This study
measured 4 enzymes involved in Aβ production and clearance in normal control
brains (beta-secretase (BACE-1), NEP, IDE and angiotensin-converting enzyme
(ACE)), and found that both Aβ-synthesising and -degrading enzyme activities
increase with age, coinciding with declining soluble Aβ and increasing insoluble Aβ
levels. Furthermore, IDE activity correlated directly with insoluble Aβ levels, NEP
activity was inversely related to soluble Aβ levels, whereas ACE level correlated
directly with insoluble and inversely with soluble Aβ, in controls but not AD (Miners,
et al., 2010). These enzymes may have quite different profiles in plasma, and all
should be characterised further to understand their involvement in AD.
One factor to consider was the observation of the plasma IDE band being higher
than the previously reported molecular weight of 110 kDa. Although it is possible
that the difference in molecular weight in this instance is due to incorrect
estimation because of the lack of resolution of the protein bands, it was shown that
the band was consistently higher than the 110 kDa molecular weight marker. In
addition, the single band observed for rrIDE was estimated to be approximately 118
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kDa, which is consistent with the UniProtKB database estimation of 117.968 kDa,
and the plasma band in question was consistently higher than that. Furthermore,
Ab 3 detected a band at 110 kDa for rat liver which is consistent with published
studies (Kurochkin, et al., 1994; Authier, et al., 1996(b)). Hence, it is perhaps more
likely that the higher estimated molecular weight was due to some posttranslational modification of IDE that may occur in the plasma. Sequence analysis
of IDE shows multiple sites that could be subject to processes such as
phosphorylation, acetylation, ubiquitination, and glycosylation, all of which would
increase molecular weight to some extent. In addition, IDE has been shown to be
modified by glutathionylation (Cordes, et al., 2011), nitrosylation (Cordes, et al.,
2009) and alkylation (Shinall, et al., 2005). Alternatively, there may be other
isoforms of IDE in the plasma which have yet to be identified. Thus, there may be
structural and functional differences associated with such potential modifications of
IDE that may also be relevant to Aβ clearance or to other AD-related pathological
processes, and as a future direction, these would be of interest to explore.
It is possible that total IDE levels (which potentially include truncated and inactive
forms as measured by ELISA) are low in the early stages of AD pathology, and the
full-length isoform is upregulated as a response to some event such as Aβ or insulin
accumulation in the plasma. The low IDE levels detected by ELISA may also have
more relevance in AD in respect to other reported functions of IDE that are
independent of its catalytic function. These roles could include as a chaperone
molecule to inhibit the fibrillisation of and toxicity of Aβ (de Tullio, et al., 2013), to
regulate the efflux of Aβ through the blood-brain barrier (Ito, et al., 2014), or
through regulation of IGF-1 signalling which may affect AD pathology via GSK-3αrelated effects on APP processing and GSK-3β-related effects on tau (Sharma, et al.,
2008; Hong & Lee, 1997). Another non-catalytic IDE-mediated mechanism may
involve the regulation of proteasomal degradation of AD-related proteins (Bennett,
et al., 2003). As the roles of IDE are diverse and probably relevant to many
different aspects of AD pathology, it would be of value to investigate these
potential functions further.
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6.3.2 Impact of APOE ε4 genotype on IDE levels and activity
There were no significant differences in full-length IDE protein levels or activity
levels when comparing APOE ε4 carriers with non-carriers in these studies. This was
unexpected, although total IDE levels did tend to be lower in the ε4 carriers than
the non-carriers (non-significantly). This result is consistent with a study by Miners,
et al. (2009), that showed no overall effect of the ε4 genotype on IDE levels or
activity in the frontal cortex.

The only study of IDE levels in blood did not

investigate the effects of ε4 genotype (Liu, et al., 2012(a)). When stratified by ε4
status, there were still no significant differences in IDE levels (full-length or total)
between classifications, although for total IDE only the ε4 carriers (but not noncarriers) showed a trend toward reduced IDE levels in MCI and AD compared with
controls.

This indicates that the overall results were primarily due to the

differences in the proportions of ε4 carriers in the 3 groups, with the healthy
control, MCI and AD groups consisting of approximately 33%, 47% and 68% ε4
carriers, respectively. After stratification of the IDE activity data by ε4 status, the
differences seen between classifications overall were once again only reflected in
the ε4 carriers, with a trend toward higher IDE in the MCI and AD groups. In fact,
correlation analyses showed differences between ε4 carriers and non-carriers for
both IDE levels (full-length and total) and enzyme activity. This indicates that the
presence of the ε4 allele may indeed have some effect on the levels and activity of
IDE. It is possible that these potential effects of the APOE ε4 allele on IDE are
indirect, as several factors reported to affect IDE expression and activity have been
observed to be affected by ε4 status; these include levels of glucocorticoids, plasma
lipids, insulin levels and even the ApoE4 protein as well as the lipidation status of
the ApoE protein (Peskind, et al., 2001; Knouff, et al., 1999; Dallongeville, et al.,
1992; Craft, et al., 1999; Jiang, et al., 2008; Du, et al., 2009). Hence the potential
effects of ε4 status on levels and activity of IDE may be mediated by any
combination of these factors, and this list is not exhaustive. In the current study, no
significant correlations were observed between IDE and plasma levels of the ApoE
or ApoE4 protein. It has been previously reported that ApoE protein regulates the
expression of IDE in brain (Cook, et al., 2003; Du, et al., 2009); however, this
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association may not be reflected in the blood. In addition, it may not simply be the
presence or absence of the ε4 allele that has an effect on IDE expression or activity,
but perhaps there are differential effects resulting from specific APOE genotypes. It
was not possible to stratify the subsets by genotype due to loss of power in our
study, but it would be of value to investigate this further with a larger cohort.

6.3.3 Associations between IDE levels and activity with biochemical
variables measured in the AIBL cohort
6.3.3.1 Testosterone
After Bonferroni-Holm correction, the results for full-length IDE levels in the overall
AIBL subset correlated negatively with free testosterone levels, and trended toward
a negative correlation with total testosterone levels. This appears counter-intuitive,
as testosterone has been reported to increase IDE levels (César Vieira, et al., 2011;
Udrisar, et al., 2005).

The associations with testosterone were absent after

stratifying the subset by gender, indicating that the association was not restricted
to males or females. This is interesting considering the much higher levels of
testosterone found in males. The association was again seen after stratification for
APOE status, but only in non-ε4 carriers.

However, after Bonferroni-Holm

adjustment it was no longer significant for total testosterone, though was still
significant for free testosterone. This may be due to the fact that free testosterone
is a better measure of bioactive testosterone than total testosterone. Conversely,
when looking only at total IDE levels, positive correlations (unadjusted) were seen
between IDE levels and total as well as free testosterone, which after stratification
appeared to be only in males and in ε4 carriers. It may be that females do not have
a high enough level of testosterone to be able to regulate IDE levels in this way.
Although not significant following correction for multiple testing, this would be
consistent with previously published reports. No overall association was seen in IDE
activity with testosterone (total or free), but a positive correlation was observed
with total testosterone only in ε4 carriers, although again this was not significant
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following correction.

Changes in testosterone have been implicated in the

pathogenesis of AD and differences related to APOE genotype have been reported
(Verdile, et al., 2012; Moffat, et al., 2004; Hogervorst, et al., 2004). Although the
association observed between testosterone and IDE levels by WB was negative
rather than positive which is a puzzling result, the results for the ELISA and activity
data are consistent with the published literature and hence the association of IDE
with testosterone in all three datasets is worth investigating further.

6.3.3.2 IDE levels and plasma Aβ
Numerous associations were observed between measurements of plasma Aβ and
IDE levels/activity in the current study.

Negative correlations were observed

between plasma Aβ1-40 and IDE levels (full-length and total), but not with the
activity data; for the full-length levels the association was only seen in non-APOE ε4
carriers, while with total IDE the association was seen in the overall subset and in
non-APOE ε4 carriers (but not in ε4 carriers). When stratified by gender, the
association with total IDE was only observed for males. Following correction for
multiple testing, these associations were no longer significant although the
correlation with total levels was close to significance. The observation that the
associations with Aβ1-40 and IDE levels were seen mainly in non-ε4 carriers is
interesting, as this was not seen with Aβ1-42, and may indicate that regulation of the
individual Aβ species by IDE is differentially affected by ε4 status; this raises the
possibility that the presence of the ε4 allele disrupts the normal interaction
between IDE and Aβ1-40. In the AIBL study, Aβ1-40 was shown to increase in MCI and
AD individuals compared to controls (Rembach, et al., 2014) and this would be
consistent with the reduction of total IDE in MCI and AD that is seen in the current
study. Furthermore, the observation that the reduction of total IDE was primarily
seen in the ε4 carriers supports the hypothesis that the presence of the ε4 allele
may reduce the normal expression of total IDE, hence disturbing the balance of
total IDE to Aβ1-40. Indeed in the brain and in vitro, the presence of the ε4 allele has
been reported to decrease the expression of IDE (Cook, et al., 2003; Du, et al.,
2009). Additionally, in non-ε4 carriers, an inverse relationship was seen between
levels of full-length IDE and brain Aβ load, although this lost significance after
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correction, while in ε4 carriers a trend toward a positive correlation was seen
between IDE activity and brain Aβ load. Although the levels of full-length IDE were
seen to increase in MCI compared to controls, this may be part of a compensatory
mechanism to try and control the rising levels of Aβ1-40 during early AD pathology
by upregulating the active form of IDE. However, as a decrease was seen in the
ELISA data, this may indicate that the levels of active (full-length) IDE contribute to
only a small proportion of total IDE protein.
Negative correlations were also seen between Aβ1-42 and total IDE levels (not with
full-length IDE or activity) and unlike Aβ1-40, the association was not affected by ε4
status or gender. After correction for multiple testing these associations were still
significant in the overall subset, but not after stratification for gender and ε4 status,
probably due to reduced numbers. Further analysis after stratifying by clinical
classification showed that the relationship between total IDE and Aβ1-42 was
restricted to AD patients only and this correlation was stronger than in the overall
subset. In accordance with these results, the relationship between total IDE and
Aβ1-40 also was only seen in AD patients.
It is probably not surprising that no relationship was seen between total IDE and Aβ
in the MCI group. Although the majority of MCI individuals will convert to AD at
some stage, some will remain stable and others revert to healthy status. In
addition, the progression and stage of pathology may differ between MCI
participants, therefore the heterogeneity in the MCI group may confound the
results.
Further investigation revealed that the correlation between total IDE and Aβ in AD
patients was only seen in non-ε4 carriers. This supports the idea that the presence
of the ε4 allele contributes to a dysregulation of the IDE/Aβ interaction, possibly by
reducing the efficiency of IDE to degrade Aβ (Jiang, et al., 2008). Alternatively, it
may also be related to differences in insulin sensitivity between ε4 carriers and noncarriers (Kuusisto, et al., 1997; Craft, et al., 2003).
Regarding IDE activity, no correlations were seen with levels of Aβ1-40 or Aβ1-42
species, however inverse relationships between activity and Aβ ratios were
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observed but only in ε4 carriers; following multiple testing correction these were no
longer significant, although a trend remained for the Aβx-42/x-40 ratio.

The

significance of this is uncertain, although as higher IDE activity was seen in MCI and
AD compared with controls, this would suggest that Aβ ratios were lower with AD
pathology, which is consistent with results from a meta-analysis of the published
literature (reviewed by Koyama, et al., 2012). The potential mechanisms behind
this association are not clear, however as a trend still remained with the Aβx-42/x-40
ratio following correction, it would be interesting to explore this further, in a larger
cohort.
As IDE was associated with levels of Aβ in plasma, the levels (both full-length and
total) and activity of plasma IDE relative to levels of Aβ (42+40) were analysed as an
IDE/Aβ42+40 ratio. As insulin is also a substrate for IDE, similar to Aβ, its plasma
concentration relative to IDE concentration may be more capable of differentiating
between clinical classifications than IDE alone. Therefore an IDE/insulin ratio as
well as an IDE/insulin+Aβ42+40 ratio were calculated. For full-length IDE, the results
showed no significant differences between classifications for all three ratios,
however, the IDE/Aβ42+40 ratio almost reached significance, with MCI having a
higher ratio than controls. When looking at total IDE on the other hand, the
IDE/insulin ratio for the MCI group was significantly lower than for the control
group, while for the IDE/Aβ42+40 and IDE/insulin+Aβ42+40 ratio, both MCI and AD
groups were significantly lower than the controls. Therefore, there may be some
value in using total levels of IDE as a ratio with insulin and Aβ in a biomarker panel.
Regarding IDE activity, the IDE activity/Aβ42+40 ratio was significantly higher in AD
compared with controls, and MCI individuals showed a trend toward being
significantly higher than controls after Bonferroni correction for multiple testing. In
addition, the IDE activity/insulin+Aβ42+40 ratio was significantly higher in MCI than
controls, while the AD group showed a trend toward being higher than controls
following correction.

While the consideration of insulin and Aβ levels in

conjunction with IDE activity may show differences between clinical classifications
which may be useful as a diagnostic biomarker, similar to full-length IDE there was
no additional benefit of including them in a ratio.
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As IDE is an Aβ-degrading enzyme, these observations support the notion that IDE
may have a role in regulating the plasma levels of Aβ, and in particular in AD
patients who do not carry an ε4 allele. However as the correlations were only
moderate/strong it indicates that other proteases are implicated. Plasma contains
other known Aβ-degrading enzymes such as neprilysin (NEP) and angiotensinconverting enzyme (ACE) which would contribute to the clearance of Aβ.
Nevertheless, these results do support the concept that IDE has a major role in the
regulation of plasma Aβ.

6.3.3.3 Associations with gender.
IDE protein and activity levels were also seen to have relationships with other
biochemical measures in the current study. For example, it was shown that females
have a higher level of full-length IDE than males. This association was not affected
by ε4 status, and was still significant after correction for multiple testing. Females
are considered to be at greater risk of AD than males generally (Bachman, et al.,
1992), and it was shown in the current study that full-length IDE levels are higher in
MCI, which may be indicative of upregulation of the active form of IDE due to
pathological mechanisms such as hyperinsulinemia or increased plasma Aβ levels.
As a greater proportion of women develop AD than men, it may be argued that the
higher IDE levels in women measured here reflect the greater level of AD pathology
that is developing in the MCI females of the cohort.

However this gender

difference was not seen with total (ELISA-measured) levels of IDE or activity.
There are several potential reasons for this gender difference, with differences in
sex hormones being the most likely. Although the hormones oestrogen (estradiol),
progesterone, testosterone, and luteinising hormone are best known for their roles
in reproduction, many studies show these hormones have other roles, including
neuroprotection.

Changes in the levels of these hormones that occur in

reproductive senescence are hypothesised to increase risk of AD, as a result of
reduced protection against oxidative insults (Barron, et al., 2006). Both oestrogen
and testosterone levels were lower in the females of this subset compared to the
males (progesterone was not measured), and both of these hormones have been
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shown to influence Aβ production and levels (Amtul, et al., 2010; Barron & Pike,
2012). Oestrogen has also been shown to influence lipid raft signalling complexes,
which may modulate susceptibility to Aβ toxicity (Marin, et al., 2011). Oestrogen
effects on IDE expression and protein levels may play an important role in the
oestrogen-mediated protection, as studies have shown that IDE expression is
significantly increased by both oestrogen and progesterone in cultured neurons as
well as in vivo, and is inversely associated with the soluble Aβ levels in vivo
(Jayaraman, et al., 2012). Others have shown in AD-model transgenic mice that
17β-estradiol increases IDE expression in a brain region-specific manner; for
example, in the hippocampus (but not the cerebellum) 17β-estradiol increased IDE
expression and attenuated Aβ accumulation/plaque formation. Furthermore, this
IDE regulation was shown to be mediated by an ERβ/PI3-K pathway (Zhao, et al.,
2011). It is interesting to note that in many AD-transgenic mouse models, the
females show earlier and more prominent Aβ accumulation and deposition, as well
as poorer behavioural performance, than the corresponding age-matched males
(Vest & Pike, 2013), supporting the concept that the differences in AD risk seen in
humans may be hormone-related, as diet and environmental factors are identical in
the studies of male and female mice.
In our studies, estradiol was observed to correlate negatively with levels of fulllength IDE (although only in non-ε4 carriers), and to correlate positively with IDE
activity levels, a finding which appeared to be primarily due to the females in the
cohort. These associations were not significant after correction, and are contrary to
the published reports which demonstrate that IDE expression is upregulated by
estradiol. However, other studies investigated effects of oestrogen in the brain or in
vitro (Jayaraman, et al., 2012; Zhao, et al., 2011). It is possible that estradiol may
have a different effect on plasma IDE, and future studies of oestrogen effects on
IDE and Aβ levels in animal models should expand to investigate Aβ levels and IDE
enzyme protein and activity level measurements in both brain and plasma.
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6.4 Limitations
Western immunoblotting is a commonly used method for the measurement of
proteins, however it has a number of limitations.

Firstly, the technique is

considered to be semi-quantitative; meaning only relative differences between
samples can be obtained without a standard curve; even then it is generally only
quantitative over a very narrow range. In addition, the molecular weight can only
be estimated rather than confirmed exactly. In the current study, the molecular
weight of full-length IDE was higher than reported previously, and while this may be
due to inaccurate estimation, it may also be indicative of post-translational
modifications. As there were a large number of samples, many gels needed to be
run, as only five samples could be measured in duplicate on any one gel. Therefore
errors may have been introduced when normalising for gel-to-gel variation,
although a single (pooled control plasma) sample was run on each gel to adjust for
this. Furthermore, the membranes were stripped of the original primary antibody
and re-probed with another antibody which may also have introduced variation.
Even the method of quantification can produce variable results (Gassmann, et al.,
2009).

Therefore Western immunoblotting is not ideal for measuring and

comparing analytes in large cohorts, and it cannot be excluded that potential
variations related to this method may have rendered the results less accurate.
A limitation of the sandwich ELISA assay is the poor spike and recovery results, with
the signal being completely suppressed in plasma. This indicates significant matrix
effects, which may be affecting the accuracy of the IDE measurements. However it
has been shown that NEP, a similar peptidase to IDE, is unstable when added to
plasma and quickly loses its catalytic activity, potentially by its rapid clearance (Liu,
et al., 2007). It is possible that the addition of recombinant IDE has the same effect;
it may be degraded by endogenous proteases. This could be overcome by the use
of a protease inhibitor cocktail, and/or by further dilution of the plasma sample;
these possibilities require further investigation.
It should be noted that because some of the samples had values which fell above
the standard curve range in the ELISA, and as cross-reactivity with the blocking
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agent was possibly reducing sensitivity, only relative differences could be obtained
and analysed.

However, as the standard curve began to plateau at higher

concentrations, it is possible that this occurs in plasma also, and hence the overall
results could have been affected because of reduced sensitivity at higher
concentrations. Ideally, a standard curve should only be used in the linear range,
with plasma samples diluted to fall within this linear region, from which plasma
concentrations of the protein in question are interpolated. It would be of value to
refine this assay to ensure this, possibly by screening alternative antibodies or
recombinant IDE.
Furthermore, cell-culture grade BSA was used to measure the AIBL samples, which
was later found to cross-react with the ELISA assay; this was more than likely the
reason for the high background. Ideally the samples should be re-assayed using
Fraction V BSA. In addition, there may have been some small degree of crossreactivity between the capture and detection antibody which may have also
contributed to the background. Although the background reading was deducted
from sample readings to account for this, both factors may have affected the
sensitivity of the assay. Moreover, cross-reactivity tests in the work-up of the assay
were performed using Fraction V BSA instead of cell-culture grade BSA, which was
used for the AIBL samples. This is a limitation which requires further investigation;
the control tests should be repeated using the cell-culture grade BSA.
Similar to the sandwich ELISA assay, the background readings in the IDE activity
assay were rather high. Although it was confirmed that this was not due to crossreactivity between reagents, and that most likely it was a product of the fluorogenic
peptide alone, the high background may have affected the sensitivity of the assay,
particularly at the lower limit of detection. In future studies it would be of interest
to investigate ways to reduce the level of background noise seen, to improve assay
sensitivity.
Enzyme catalytic activity appeared to be significantly influenced by the type of
anticoagulant used (EDTA or LiHep) in the plasma collection tubes, and clearly this
needs to be taken into consideration. It was shown that EDTA did not affect the
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measurement of IDE protein levels. However, in the activity assay, EDTA-collected
plasma samples produced a significantly higher signal than the very low signal
observed in the Lithium-heparin (LiHep)-collected plasma. This was contrary to the
expected result, despite the fact that there are some studies which have reported
similar findings; IDE is a thiolmetalloendopeptidase that requires zinc for activity,
thus EDTA would be expected to inhibit activity (depending on EDTA, enzyme and
metal ion concentrations, as well as a host of other factors). It is possible that the
increased activity in EDTA plasma may be related to haemolysis of erythrocytes; it
has been shown that in ostrich plasma, EDTA increases the likelihood of erythrocyte
haemolysis when compared with the LiHep anticoagulant (Mafuvadze & Erlwanger,
2007). As erythrocytes are a rich source of IDE, haemolysis may release IDE into the
plasma, thus increasing the levels measured. However, great care was taken during
plasma processing, and samples which had obvious haemolysis were not used.
Despite this, there may have been some level of haemolysis in the EDTA samples,
and the blood collection and processing methods would need to be investigated
and possibly improved to minimise this problem in the future. Another possibility is
that the stability of plasma proteins is affected differently by the two anti-clotting
agents, as it has been shown that plasma proteins in EDTA are less likely to be
subject to degradation than proteins in LiHep plasma (Evans, et al., 2001; Käkönen,
et al., 2000). Therefore it may be that active IDE was degraded during storage at a
faster rate in LiHep plasma compared with EDTA plasma. Until the reasons for the
differences have been identified, caution should be exercised when interpreting the
data. It would be of value to carry out further assay optimisation experiments,
comparing serum with plasma samples, and comparing anticoagulants in the
activity assay.
Another limitation of this study worth noting is that the samples used in each of the
experimental methods were from separate subsets, and very few individual
samples were run on all three assays. Therefore, it is difficult to compare the
results from all three methods, as analysing only the common samples would lead
to a loss of power to detect any differences due to small numbers. Ideally, it would
be of value to complete the analysis of all samples in the AIBL cohort as was the
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intention at the commencement of the study. However, due to the extended timeperiod required for optimisation of the assays, it was not possible to complete
these within the time-frame of the project.
Another general limitation for all assays is that the AIBL samples should have been
run at least twice to ensure accuracy of the results, however time and sample
availability were factors.

Regardless, the samples were run in duplicate, and

duplicates with a coefficient of variation greater than 15% were removed from the
analysis. In addition, assays were omitted from the analysis if any of the standard
curve values were more than 2 standard deviations from the mean of each
concentration.
A potentially confounding factor of this study is that it was not possible to analyse
potential effects of medications on plasma IDE levels due to the size of the cohort,
and the fact that only a small number of participants were not taking medication.
The AIBL cohort is comprised of elderly participants, the majority of whom take at
least one type of medication: at baseline for example, 79% of HC, 87% of MCI and
97% of AD participants were taking at least one medication (Ellis, et al., 2009). A
number of medications have been reported to increase levels of IDE; statins, for
example, have recently been shown to increase levels of IDE in the plasma of mice
via increased secretion (Tamboli, et al., 2010). Similarly, another recent study has
shown that propranolol (an antihypertensive drug) increases the blood (and
hippocampal) levels of IDE in rats (Solas, et al., 2009). Other medications such as
oestrogen, progesterone, testosterone, N-methyl-D-aspartate receptor (NMDAR)
antagonists and glucocorticoids have also all recently been reported to increase
expression of IDE in vitro or in vivo (Zhao, et al., 2010; Jayaraman, et al., 2012;
Vieira, et al., 2011; Du, et al., 2009). Therefore, as a substantial proportion of the
AIBL cohort were taking at least one, or a combination of these medications at the
time blood samples were taken, it is likely that these will have influenced the
results of this project.
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6.5 Future Directions
Greater assay characterisation is needed, as has been detailed in the sections
above, before any conclusions may be made about the results. For example,
additional cross-reactivity tests should be performed to identify potentially
confounding plasma components. In the Western immunoblotting assay, it would
be useful to increase the resolution to improve estimation of the molecular weight
of the bands, perhaps by performing SDS-PAGE on a lower percentage gel and
running the gels more slowly. It would also be of interest to characterise the 80
kDa band which was observed in plasma that appeared to be specific. It is possible
that this band is indeed IDE and has some function in plasma that might be relevant
to AD.

Testing other IDE antibodies, for example using immunoprecipitation

followed by Western blotting with a different antibody, may help determine
whether the 80 kDa band is IDE and whether it is relevant when determining
enzyme activity.
Further refinement of the IDE sandwich ELISA is also required to develop a
quantitative assay, by ensuring firstly that the standard curve provides a reasonable
linear range, and secondly that the plasma samples are diluted to fall within that
range. It would be of interest to screen additional antibodies to determine if there
are others more suitable (less cross-reactive), perhaps by the use of monoclonal
antibodies rather than polyclonal. While there are few commercially-available
monoclonal IDE antibodies currently, it may be of value to develop in-house
antibodies for this purpose. In addition, investigation of the potential effects of
interfering substances in blood such as heterophilic and anti-animal antibodies
should be carried out to ensure they are not affecting the assay.
Similarly, although the results from the current study indicate that the activity assay
is specifically detecting IDE, it requires further validation, perhaps by the use of
other known IDE inhibitors such as bacitracin, phenanthroline and Nethylmaleimide.

It would also be of interest to try other non-IDE protease

inhibitors to eliminate the possibility that other proteases are contributing to the
signal observed. The screening of alternate IDE antibodies may also be of value to
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compare the results obtained, particularly with monoclonal antibodies which are
generally considered to be more specific.
As the IDE was immunocaptured prior to adding the fluorogenic substrate, and the
remaining plasma washed away, it would not have been subject to regulatory
elements which may alter the activity when in the plasma matrix. It is quite
possible that that the regulatory elements governing IDE activity may be more
relevant to its function than expression levels. Alternatively, the assay may have
caused IDE to bind to other plasma constituents that it would normally not bind to,
which were captured as a complex, and this may have led to a loss of detectable
catalytic activity due to interference with the catalytic site. If possible, an activity
assay which could specifically measure IDE activity within the plasma, while in the
presence of normal regulatory factors, would give a better representation of its
true physiological activity.
The fluorogenic peptide substrate that was used in the activity assay was derived
from a bradykinin sequence, and this may not necessarily reflect the contribution of
IDE toward the cleavage of Aβ or insulin.

It would be of interest to use a

fluorescently-labelled peptide substrate derived from the sequence of Aβ to
analyse IDE more accurately toward Aβ cleavage activity. In fact, an Aβ-derived
fluorescent substrate has recently been generated by Stargardt and colleagues
(2013) which would be more relevant in future Aβ-degrading protease activity
studies.
The many bands observed by Western immunoblotting in plasma suggest that some
post-translational modifications occur to IDE in human plasma. In particular, the
finding in this study that the molecular weight of IDE was higher than expected
supports this possibility. Therefore, it would be of interest to investigate potential
modifications, and identify how they affect the catalytic or non-catalytic functions
of IDE. For example, initial experiments could include cell culture IDE transfection
experiments followed by treatment with N- and O-glycosylation inhibitors, then
Western immunoblotting to investigate changes in IDE molecular weight.

In

addition, co-purification experiments might assist with determining which other
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plasma proteins interact with IDE, and this could help not only with assay
development, but also may uncover functions of IDE which may directly or
indirectly impact on aspects of AD pathology. As a band of 160 kDa was retained in
some of the immunoprecipitation experiments, it may indicate that IDE is found as
part of a complex of proteins which are resistant to the denaturing and reducing
conditions of Western immunoblotting. Specifically, it would be of value to identify
and characterise any regulatory components in the blood which affect the ability of
IDE to degrade Aβ. Such components may also alter in some way in the earliest
stages of AD, and may be useful to identify, for the purposes of developing
therapeutic treatments.
Given the heterogeneity of the MCI group, it would also be of use to investigate
potential differences in IDE expression and activity in separate subsets of MCI,
including amnestic versus non-amnestic and MCI individuals who convert to AD
compared with those who remain stable, or revert back to healthy.

Such

longitudinal studies would reveal differences in those who are AD converters
compared with those who are not, and would be of great benefit for the
development of future diagnostic tests. The same argument may apply to the
control group, as AD pathology may already have started in some members of this
group.
Other factors may also affect the levels and activity of IDE, such as the presence or
absence of hyperinsulinemia, the levels of plasma glucose, the interaction of IDE
with the proteasome and effects of specific APOE genotypes. It is also not known if
IDE is subject to circadian fluctuations, although in the current study the samples
tested were all from overnight fasted participants. It would be of interest to
investigate these factors in relation to circulating levels and activity of IDE.
It is not currently known how IDE is cleared from the peripheral circulation (or the
brain for that matter), therefore alterations in levels or activity could be related to
the balance between production and clearance, similar to Aβ. Therefore it would
be interesting to explore this in a future study; it is probable that IDE could be
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regulated through such clearance mechanisms rather than the upregulation of IDE
expression, and this may have value in a therapeutic capacity.
Nutritional status and neutraceutical intake are likely to influence the regulation of
IDE, particularly sugar and carbohydrate intake, and the presence of, and/or
treatments for diabetes and insulin resistance. There are a number of dietary
supplements and neutraceutical treatments which have recently been shown to
offer some potential benefits in regulating IDE, such as docosahexaenoic acid (Du,
et al., 2010), withanolide A (Patil, et al., 2010), Geranylgeranylacetone (Hoshino, et
al., 2013), asiaticoside (Lin, et al., 2013), ginseng (Quan, et al., 2013), Tong Luo Jiu
Nao (Liu, et al., 2011) and curcumin (Wang, et al., 2014). A number of these have
been investigated for their effects on AD pathology, for example, Withanolide A has
been shown in primary neuronal cultures to upregulate IDE and downregulate
BACE-1, one of the enzymes necessary for Aβ production from APP, and to
upregulate ADAM10 which is necessary for non-amyloidogenic processing of APP
(Patil, et al., 2010). Even spirulina may have some benefits; there is no evidence as
yet that it regulates IDE but it has been shown to improve insulin sensitivity more
effectively than Pioglitazone and therefore may have indirect effects either by
suppressing insulin secretion which would reduce the competition for IDE, or by
increasing insulin signalling due to a reduction in insulin resistance (Ou, et al.,
2013). It may have further benefits in preventing or improving AD pathology
through its antioxidant properties and also its positive effects on dyslipidemia and
inflammation (Romay, et al, 2003; Devesh, et al., 2012; Fujimoto, et al., 2012;
reviewed by Deng & Chow, 2010).

6.6 Conclusions
Despite the potential limitations with the assays developed in this project, the main
findings of the present study have demonstrated that plasma IDE levels and activity
were significantly different in MCI compared with controls. This may be of value
eventually as part of an AD biomarker panel, and is an interesting finding
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considering the heterogeneity of the MCI group. The strength of these differences
were improved by considering levels of plasma Aβ in conjunction with IDE (for total
levels), which then demonstrated a similar significant finding in AD as seen in MCI.
The significance of plasma Aβ in AD is still under investigation, however may prove
to be a contributing factor in the initiation or progression of AD pathology. There
was still some overlap between groups, and as such this may limit the usefulness of
IDE as a clinically relevant biomarker.

However, identifying the effects of

potentially confounding variables may help address these issues. It appears from
these results and others that the regulation and functions of IDE are particularly
complex, and require ongoing work to unravel the potential significance these may
have in the pathology of AD. Overall, however, based on the results from the
current study it does appear that there are changes in both the levels and activity of
plasma IDE in the early stages of AD, and while this pilot study suggests that IDE
may have potential as an AD biomarker, further investigation is needed to confirm
or negate the putative benefits of using IDE in a biomarker panel.

354

REFERENCES
Alzheimer Research Forum - Diagnosis. (2009).

Retrieved May 3, 2009, from

http://www.alzforum.org/dis/dia/default.asp
2012 Alzheimer’s disease facts and figures. (2012). Alzheimer's & Dementia, 8(2),
131-168.
Abdul-Hay, S. O., Lane, A. L., Caulfield, T. R., Claussin, C., Bertrand, J., Masson, A., et
al. (2013). Optimization of peptide hydroxamate inhibitors of insulindegrading enzyme reveals marked substrate-selectivity. Journal of medicinal
chemistry, 56(6), 2246-2255.
Abdullah, L., Paris, D., Luis, C., Quadros, A., Parrish, J., Valdes, L., et al. (2007). The
influence of diagnosis, intra- and inter-person variability on serum and
plasma Aβ levels. Neuroscience Letters, 428(2-3), 53-58.
Abraham, R., Myers, A., Wavrant-De Vriesé, F., Hamshere, M. L., Thomas, H. V.,
Marshall, H., et al. (2001). Substantial linkage disequilibrium across the
insulin-degrading enzyme locus but no association with late-onset
alzheimer’s disease. Human Genetics, 109(6), 646-652.
Affholter, J. A., Fried, V. A., & Roth, R. A. (1988). Human insulin-degrading enzyme
shares structural and functional homologies with E. coli Protease III. Science,
242(4884), 1415-1418.
Affholter, J. A., Hsieh, C. L., Francke, U., & Roth, R. A. (1990). Insulin-degrading
enzyme:

stable

expression

of

the

human

complementary

DNA,

characterization of its protein product, and chromosomal mapping of the
human and mouse genes. Molecular Endocrinology, 4(8), 1125-1135.
Agnosta, F., Vossel, K. A., Miller, B. L., Migliaccio, R., Bonasera, S. J., Filippi, M., et al.
(2009). Apolipoprotein E ε4 is associated with disease-specific effects on
brain atrophy in Alzheimer's disease and frontotemporal dementia. .
Proceedings of the National Academy of Sciences, 106(6), 2018-2022.
Aisen, P. S. (1997). Inflammation and Alzheimer's disease: Mechanisms and
therapeutic strategies. Gerontology, 43(1-2), 143-149.

355

Ait-Ghezala, G., Abdullah, L., Crescentini, R., Crawford, F., Town, T., Singh, S., et al.
(2002). Confirmation of association between D10S583 and Alzheimer’s
disease in a case–control sample. Neuroscience Letters, 325(2), 87-90.
Akiyama, H., Shii, K., Yokono, K., Yonezawa, K., Sato, S., Watanabe, K., et al. (1988).
Cellular localization of insulin-degrading enzyme in rat liver using
monoclonal antibodies specific for this enzyme. Biochemical and Biophysical
Research Communications, 155(2), 914-922.
Akomolafe, A., Beiser, A., Meigs, J. B., Au, R., Green, R. C., Farrer, L. A., et al. (2006).
Diabetes mellitus and risk of developing Alzheimer disease. Results from the
Framingham Study. Archives of Neurology, 63(11), 1551-1555.
Ali, M., & Plas, C. (1989). Glucocorticoid regulation of chloroquine nonsensitive
insulin degradation in cultured fetal rat hepatocytes. The Journal of
Biological Chemistry, 264(35), 20992-20997.
Allain, C. C., Poon, L. S., Chan, C. S., Richmond, W., & Fu, P. C. (1974). Enzymatic
determination of total serum cholesterol. Clinical chemistry, 20(4), 470-475.
Alper, B. J., & Schmidt, W. K. (2009). A capillary electrophoresis method for
evaluation of Aβ proteolysis in vitro. Journal of Neuroscience Methods,
178(1), 40-45.
Altschul, S. F., Gish, W., Miller, W., Myers, E. W., & Lipman, D. J. (1990). Basic local
alignment search tool. Journal of Molecular Biology, 215(3), 403-410.
Amata, O., Marino, T., Russo, N., & Toscano, M. (2009). Human insulin-degrading
enzyme working mechanism. Journal of the American Chemical Society,
131(41), 14804-14811.
American Psychiatric Association. (2000). Diagnostic and Statistical Manual of
Mental disorders, 4th Edition Text Revision (DSM-IV-TR). Washington DC.
Amtul, Z., Wang, L., Westaway, D., & Rozmahel, R. (2010). Neuroprotective
mechanism conferred by 17beta-estradiol on the biochemical basis of
Alzheimer's disease. Neuroscience, 169(2), 781-786.
Anastasio, T. J. (2013). Exploring the contribution of estrogen to amyloid-Beta
regulation: a novel multifactorial computational modeling approach.
Frontiers in pharmacology, 4.

356

Ansorge, S., Bohley, P., Kirschke, H., Langner, J., & Wiederanders, B. (1983). The
insulin and glucagon degrading proteinase of rat liver: a metal-dependent
enzyme. Biomedica biochimica acta, 43(1), 39-46.
Ardy, C., & Pontremoli, S. (1953). Blood insulinase activity in diabetics abnormally
sensitive to insulin. Archivio 'E. Maragliano' Di Patologia E Clinica, 8(4), 821830.
Arrigada, P. V., Marzloff, K., & Hyman, B. T. (1992). Distribution of Alzheimer-type
pathologic changes in nondemented elderly individuals matches the pattern
in Alzheimer's disease. . Neurology, 42(9), 1681-1688.
Arvanitakis, Z., Wilson, R. S., Bienias, J. L., Evans, D. A., & Bennett, D. A. (2004).
Diabetes mellitus and risk of Alzheimer disease and decline in cognitive
function. Archives of Neurology, 61(5), 661-666.
Association, A. s. (2012). 2012 Alzheimer's disease facts and figures. Alzheimer's &
dementia: the journal of the Alzheimer's Association, 8(2), 131.
Authier, F., Cameron, P. H., & Taupin, V. (1996(b)). Association of insulin-degrading
enzyme with a 70 kDa cytosolic protein in hepatoma cells. Biochemical
Journal, 319(Pt 1), 149-158.
Authier, F., Posner, B. I., & Bergeron, J. J. M. (1996(a)). Insulin-degrading enzyme.
Clinical and Investigative Medicine, 19(3), 149-160.
Bachman, D., Wolf, P. A., Linn, R., Knoefel, J., CobbS, J., Belanger, A., et al. (1992).
Prevalence of dementia and probable senile dementia of the Alzheimer type
in the Framingham Study. Neurology, 42(1), 115-115.
Bales, K. R., Liu, F., Wu, S., Lin, S., Koger, D., DeLong, C., et al. (2009). Human APOE
isoform-dependent effects on brain β-amyloid levels in PDAPP transgenic
mice. The Journal of Neuroscience, 29(21), 6771-6779.
Banks, W. A., Jaspan, J. B., & Kastin, A. J. (1997). Selective, physiological transport of
insulin across the blood-brain barrier: novel demonstration by speciesspecific radioimmunoassays. Peptides, 18(8), 1257-1262.

357

Barger, S. W., DeWall, K. M., Liu, L., Mrak, R. E., & Griffin, W. S. T. (2008).
Relationships between expression of apolipoprotein E and β-amyloid
precursor protein are altered in proximity to Alzheimer β-amyloid plaques:
Potential explanations from cell culture studies. Journal of Neuropathology
and Experimental Neurology, 67(8), 773-783.
Barron, A. M., Fuller, S. J., Verdile, G., & Martins, R. N. (2006). Reproductive
hormones modulate oxidative stress in Alzheimer's disease. Antioxidants &
redox signaling, 8(11-12), 2047-2059.
Barron, A. M., & Pike, C. J. (2012). Sex hormones, aging, and Alzheimer’s disease.
Frontiers in bioscience (Elite edition), 4, 976.
Barter, P. J., Brandrup-Wognsen, G., Palmer, M. K., & Nicholls, S. J. (2010). Effect of
statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis
of the VOYAGER Database. Journal of lipid research, 51(6), 1546-1553.
Bates, K. A., Sohrabi, H. R., Rodrigues, M., Beilby, J., Dhaliwal, S. S., Taddei, K., et al.
(2009). Association of Cardiovascular Factors and Alzheimer's Disease
Plasma Amyloid-β Protein in Subjective Memory Complainers. Journal of
Alzheimer's Disease, 17(2), 305-318.
Bauer, J., Strauss, S., Schreitergasser, U., Ganter, U., Schlegel, P., Witt, I., et al.
(1991). Interleukin-6 and alpha-2-macroglobulin indicate an acute-phase
state in Alzheimer's-disease cortices. FEBS Letters, 285(1), 111-114.
Baura, G. D., Foster, D. M., Kaiyala, K., Porte (Jnr), D., Kahn, S. E., & Schwartz, M. W.
(1996). Insulin transport from plasma into the central nervous system is
inhibited by dexamethasone in dogs. Diabetes, 45(1), 86-90.
Behl, M., Zhang, Y., & Zheng, W. (2009). Involvement of insulin-degrading enzyme in
the clearance of beta-amyloid at the blood-CSF barrier: Consequences of
lead exposure. Cerebrospinal Fluid Res, 6(11).
Bell, R. D., Sagare, A. P., Friedman, A. E., Bedi, G. S., Holtzman, D. M., Deane, R., et
al. (2007). Transport pathways for clearance of human Alzheimer’s amyloid
β-peptide and apolipoproteins E and J in the mouse central nervous system.
Journal of Cerebral Blood Flow and Metabolism, 27(5), 909-918.

358

Bennett, R., Fawcett, J., Kruer, M., Duckworth, W., & Hamel, F. (2003). Insulin
inhibition of the proteasome is dependent on degradation of insulin by
insulin-degrading enzyme. Journal of endocrinology, 177(3), 399-405.
Bennett, R. G., Duckworth, W. C., & Hamel, F. G. (2000(a)). Degradation of amylin
by insulin-degrading enzyme. The Journal of Biological Chemistry, 275(47),
36621-36625.
Bennett, R. G., Hamel, F. G., & Duckworth, W. C. (2000(b)). Insulin inhibits the
ubiquitin-dependent

degrading

activity

of

the

26S

proteasome.

Endocrinology, 141(7), 2508-2517.
Bentley, N. M., LaDu, M. J., Rajan, C., Getz, G. S., & Reardon, C. A. (2002).
Apolipoprotein E structural requirements for the formation of SDS-stable
complexes with β-amyloid-(1–40): the role of salt bridges. Biochemical
Journal, 366, 273-279.
Bergem, A. L., Engedal, K., & Kringlen, E. (1997). The role of heredity in late-onset
alzheimer disease and vascular dementia. A twin study. Archives of General
Psychiatry, 54(3), 264-270.
Bernstein, H. G., Ansorge, S., Riederer, P., Reiser, M., Frolich, L., & Bogerts, B.
(1999). Insulin-degrading enzyme in the Alzheimer's disease brain:
prominent localization in neurons and senile plaques. . Neuroscience Letters,
263(2-3), 161-164.
Bernstein, H.-G., Stricker, R., Lendeckel, U., Bertram, I., Dobrowolny, H., Steiner, J.,
et al. (2009). Reduced neuronal co-localisation of nardilysin and the putative
α-secretases ADAM10 and ADAM17 in Alzheimer’s disease and Down
syndrome brains. Age, 31(1), 11-25.
Bertram, L., Blacker, D., Mullin, K., Keeney, D., Jones, J., Basu, S., et al. (2000).
Evidence for genetic linkage of Alzheimer's disease to chromosome 10q.
Science, 290(5500), 2302-2303.
Bhamra, M. S., & Ashton, N. J. (2012). Finding a pathological diagnosis for
Alzheimer's

disease:

Are

inflammatory

molecules

the

answer?

Electrophoresis, 33(24), 3598-3607.

359

Bian, L., Yang, J. D., Guo, T. W., Sun, Y., Dian, S. W., Chen, W. Y., et al. (2004).
Insulin-degrading enzyme and Alzheimer disease: a genetic association
study in the Han Chinese. Neurology, 63(2), 241-245.
Björk, B. F., Katzov, H., Kehoe, P., Fratiglioni, L., Winblad, B., Prince, J. A., et al.
(2007). Positive association between risk for late-onset alzheimer disease
and genetic variation in IDE. Neurobiology of Aging, 28(9), 1374-1380.
Blacker, D., Bertram, L., Saunders, A. J., Moscarillo, T. J., Albert, M. S., Wiener, H., et
al. (2003). Results of a high-resolution genome screen of 437 Alzheimer’s
disease families. Human Molecular Genetics, 12(1), 23-32.
Blennow, K. (2004). Cerebrospinal fluid protein biomarkers for Alzheimer's disease.
NeuroRx: The Journal of the American Society for Experimental
Neurotherapeutics, 1(2), 213-225.
Blennow, K., De Meyer, G., Hansson, O., Minthon, L., Wallin, A., Zetterberg, H., et al.
(2009). Evolution of Aß42 and Aß40 levels and Aß42/Aß40 ratio in plasma
during progression of Alzheimer’s disease: A multicenter assessment. The
Journal of Nutrition, Health and Aging, 13(3), 205-208.
Blomqvist, M. E. L., Chalmers, K., Andreasen, N., Bogdanovic, N., Wilcock, G. K.,
Cairns, N. J., et al. (2005). Sequence variants of IDE are associated with the
extent of β-amyloid deposition in the Alzheimer’s disease brain.
Neurobiology of Aging, 26(6), 795-802.
Blomqvist, M. E. L., Silburn, P. A., Buchanan, D. D., Andreasen, N., Blennow, K.,
Pedersen, N. L., et al. (2004). Sequence variation in the proximity of IDE may
impact age at onset of both Parkinson disease and Alzheimer disease.
Neurogenetics, 5(2), 115-119.
Borroni, B., Di Luca, M., & Padovani, A. (2006). Predicting Alzheimer dementia in
mild cognitive impairment patients.

Are biomarkers useful? European

Journal of Pharmacology, 545(1), 73-80.
Bouras, C., Hof, P. R., Giannakopoulos, P., Michel, J. P., & Morrison, J. H. (1994).
Regional distribution of neurofibrillary tangles and senile plaques in the
cerebral cortex of elderly patients: a quantitative evaluation of a one-year
autopsy population from a geriatric hospital. Cerebral Cortex, 4(2), 138-150.

360

Boussaha, M., Hannequin, D., Verpillat, P., Brice, A., Frebourg, T., & Campion, D.
(2002). Polymorphisms of insulin degrading enzyme gene are not associated
with Alzheimer’s disease. Neuroscience Letters, 329(1), 121-123.
Brookmeyer, R., Gray, S., & Kawas, C. (1998). Projections of Alzheimer's disease in
the United States and the public health impact of delaying disease onset.
American Journal of Public Health, 88(9), 1337-1342.
Brown, B., Peiffer, J., Sohrabi, H., Mondal, A., Gupta, V., Rainey-Smith, S., et al.
(2012(b)). Intense physical activity is associated with cognitive performance
in the elderly. Translational psychiatry, 2(11), e191.
Brown, B., Peiffer, J., Taddei, K., Lui, J., Laws, S., Gupta, V., et al. (2012(a)). Physical
activity and amyloid-β plasma and brain levels: results from the Australian
Imaging, Biomarkers and Lifestyle Study of Ageing. Molecular Psychiatry.
Brown, M. C., Joaquim, T. R., Chambers, R., Onisk, D. V., Yin, F., Moriango, J. M., et
al. (2011). Impact of immunization technology and assay application on
antibody performance–a systematic comparative evaluation. PLoS ONE,
6(12), e28718.
Bulloj, A., Leal, M. C., Surace, E. I., Zhang, X., Xu, H., Ledesma, M. D., et al. (2008).
Detergent resistant membrane-associated IDE in brain tissue and cultured
cells:

Relevance

to

Aβ

and

insulin

degradation.

Molecular

Neurodegeneration, 3(1), 22-34.
Burdick, D., Soreghan, B., Kwon, M., Kosmoski, J., Knauer, M., Henschen, A., et al.
(1991). Assembly and aggregation properties of synthetic Alzheimer’s A4/β
amyloid peptide analogs. The Journal of Biological Chemistry, 267(1), 546554.
Burghen, G. A., Kitabchi, A. E., & Brush, J. S. (1972). Characterization of a rat liver
protease with specificity for insulin. Endocrinology, 91(3), 633-642.
Cabrejo, L., Guyant-Maréchal, L., Laquerrière, A., Vercelletto, M., De La Fournière,
F., Thomas-Antérion, C., et al. (2006). Phenotype associated with APP
duplication in five families. Brain, 129(11), 2966-2976.
Cabrol, C., Huzarska, M. A., Dinolfo, C., Rodrigues, M. C., Reinstatler, L., Ni, J., et al.
(2009). Small-molecule activators of insulin-degrading enzyme discovered
through high-throughput compound screening. PLoS ONE, 4(4), e5274.
361

Caccamo, A., Oddo, S., Sugarman, M. C., Akbari, Y., & LaFerla, F. M. (2005). Age- and
region-dependent alterations in Aβ-degrading enzymes: implications for Aβinduced disorders. Neurobiology of Aging, 26(5), 645-654.
Cagnin, A., Gerhard, A., & Banati, R. B. (2002). In vivo imaging of
neuroinflammation. European Neuropsychopharmacology: The Journal of
the European College of Neuropsychopharmacology, 12(6), 581-586.
Camberos, M. C., & Cresto, J. C. (2007). Insulin-degrading enzyme hydrolyzes ATP.
Experimental Biology and Medicine, 232(2), 281-292.
Camberos, M. C., Perez, A. A., Udrisar, D. P., Wanderley, M. I., & Cresto, J. C. (2001).
ATP inhibits insulin-degrading enzyme activity. Experimental Biology and
Medicine, 226(4), 334-341.
Cappellano, G., Carecchio, M., Fleetwood, T., Magistrelli, L., Cantello, R., Dianzani,
U., et al. (2013). Immunity and inflammation in neurodegenerative diseases.
American journal of neurodegenerative disease, 2(2), 89.
Carantoni, M., Zuliani, G., Munari, M. R., D'Elia, K., Palmieri, E., & Fellin, R. (2000).
Alzheimer disease and vascular dementia: Relationships with fasting glucose
and insulin levels. Dementia and Geriatric Cognitive Disorders, 11(3), 176180.
Cardon, L. R., Smith, S. D., Fulker, D. W., Kimberling, W. J., Pennington, B. F., &
DeFries, J. C. (1994). Quantitative trait locus for reading disability on
chromosome 6. Science, 266(5183), 276-279.
Carpenter, J., Jackson, W., De Souza, G., Haarr, L., & Grose, C. (2010). InsulinDegrading Enzyme Binds to the Nonglycosylated Precursor of VaricellaZoster Virus gE Protein Found in the Endoplasmic Reticulum. Journal of
virology, 84(2), 847-855.
Carrasquillo, M. M., Belbin, O., Zou, F., Allen, M., Ertekin-Taner, N., Ansari, M., et al.
(2010). Concordant Association of Insulin Degrading Enzyme Gene (IDE)
Variants with IDE mRNA, Aß, and Alzheimer's Disease. PLoS ONE, 5(1),
e8764.

362

Caspersen, C., Wang, N., Yao, J., Sosunov, A., Chen, X., Lustbader, J. W., et al.
(2005). Mitochondrial Abeta: a potential focal point for neuronal metabolic
dysfunction in Alzheimer's disease. The FASEB journal: official publication of
the Federation of American Societies for Experimental Biology, 19(14), 2040.
Castellano, J. M., Kim, J., Stewart, F. R., Jiang, H., DeMattos, R. B., Patterson, B. W.,
et al. (2011). Human apoE isoforms differentially regulate brain amyloid-β
peptide clearance. Science translational medicine, 3(89), 89ra57.
Castell-Auvı, A., Cedó, L., Pallares, V., Blay, M., Ardévol, A., & Pinent, M. (2012). The
effects of a cafeteria diet on insulin production and clearance in rats. The
British journal of nutrition, 108(7), 1155-1162.
Cavalcante Braga, A. R., Manera, A. P., da Costa Ores, J., Sala, L., Maugeri, F., &
Juliano Kalil, S. (2013). Kinetics and Thermal Properties of Crude and Purified
β-Galactosidase

with

Potential

for

the

Production

of

Galactooligosaccharides. Food Technology and Biotechnology, 51(1), 45-52.
Cedazo-Mínguez, A. (2007). Apolipoprotein E and Alzheimer’s disease: molecular
mechanisms and therapeutic opportunities. Journal of Cellular and
Molecular Medicine, 11(6), 1227-1238.
Cedazo-Mínguez, A., Huttinger, M., & Cowburn, R. F. (2001). Beta-VLDL protects
against A beta(1-42) and apoE toxicity in human SH-SY5Y neuroblastoma
cells. Neuroreport, 12(2), 201-206.
Cellini, E., Bagnoli, S., Tedde, A., Nacmias, B., Piacentini, S., & Sorbi, S. (2005).
Insulin degrading enzyme and alpha-3 catenin polymorphisms in Italian
patients with Alzheimer disease. Alzheimer Disease and Associated
Disorders, 19(4), 246-247.
César Vieira, J. S., Saraiva, K. L., Barbosa, M. C., Porto, R. C., Cresto, J. C., Peixoto, C.
A., et al. (2011). Effect of dexamethasone and testosterone treatment on
the regulation of insulin-degrading enzyme and cellular changes in ventral
rat prostate after castration. International Journal of Experimental
Pathology, 92(4), 272-280.
Chander, H., Chauhan, A., & Chauhan, V. (2007). Binding of proteases to fibrillar
amyloid-beta protein and its inhibition by Congo red. Journal of Alzheimer's
Disease, 12(3), 261-269.
363

Chang, C. L. (2008). Obesity and Alzheimer's disease. Hong Kong Journal of
Psychiatry, 18(1), 28-35.
Chen, J. X., & Yan, S. S. (2010). Role of mitochondrial amyloid-β in Alzheimer's
disease. Journal of Alzheimer's Disease, 20, 569-578.
Chen, K., Reiman, E. M., Alexander, G. E., Caselli, R. J., Gerkin, R., Bandy, D., et al.
(2007). Correlations between apolipoprotein E ε4 gene dose and whole
brain atrophy rates. The American Journal of Psychiatry, 164(6), 916-921.
Chen, M., Tegg, M., Avdesh, A., Mondal, A., Lardelli, M., Verdile, G., et al. (2012).
Analysis of insulin-degrading enzyme (IDE) expression and function in
zebrafish embryos. Alzheimer's & Dementia: The Journal of the Alzheimer's
Association, 8(4), P674-P674.
Chesneau, V., Pierotti, A. R., Barré, N., Creminon, C., Tougard, C., & Cohen, P.
(1994).

Isolation

and

characterization

of

a

dibasic

selective

metalloendopeptidase from rat testes that cleaves at the amino terminus of
arginine residues. Journal of Biological Chemistry, 269(3), 2056-2061.
Chesneau, V., Vekrellis, K., Rosner, M. R., & Selkoe, D. J. (2000). Purified
recombinant insulin-degrading enzyme degrades amyloid β-protein but does
not promote its oligomerization. Biochemical Journal, 351(Pt 2), 509-516.
Cholerton, B., Baker, L. D., Trittschuh, E. H., Crane, P. K., Larson, E. B., Arbuckle, M.,
et al. (2012). Insulin and sex interactions in older adults with mild cognitive
impairment. Journal of Alzheimer's Disease, 31(2), 401-410.
Chou, Y.-H., Kuo, W.-L., Rosner, M. R., Tang, W.-J., & Goldman, R. D. (2009).
Structural changes in intermediate filament networks alter the activity of
insulin-degrading enzyme. The FASEB Journal, 23(11), 3734-3742.
Chow, K. M., Oakley, O., Goodman, J., Ma, Z., Juliano, M. A., Juliano, L., et al. (2003).
Nardilysin cleaves peptides at monobasic sites. Biochemistry, 42(7), 22392244.
Ciaccio, C., Tundo, G. R., Grasso, G., Spoto, G., Marasco, D., Ruvo, M., et al. (2009).
Somatostatin: a novel substrate and a modulator of insulin-degrading
enzyme activity. Journal of Molecular Biology, 385(5), 1556-1567.

364

Clement, K., Garner, C., Hager, J., Philippi, A., LeDuc, C., Carey, A., et al. (1996).
Indication for linkage of the human OB gene region with extreme obesity.
Diabetes, 45(5), 687-690.
Clifford, P. M., Zarrabi, S., Siu, G., Kinsler, K. J., Kosciuk, M. C., Venkataraman, V., et
al. (2007). Abeta peptides can enter the brain through a defective bloodbrain barrier and bind selectively to neurons. . Brain Research, 1142, 223236.
Cohen, J. (1988). Statistical power analysis for the behavioural sciences. (2nd ed.).
Hillsdale, New Jersey: Lawrence Erlbaum Associates.
Cole, G. M., & Ard, M. D. (2000). Influence of lipoproteins on microglial degradation
of Alzheimer’s amyloid beta-protein. Microscopy Research and Technique,
50(4), 316-324.
Cole, G. M., & Frautschy, S. A. (2006). Docosahexaenoic acid protects from amyloid
and dendritic pathology in an Alzheimer's disease mouse model. Nutrition
and health, 18(3), 249-259.
Constantini, C., Scrable, H., & Puglielli, L. (2006). An aging pathway controls the
TrkA to p75NTR receptor switch and amyloid β-peptide generation. The
EMBO Journal, 25(9), 1997-2006.
Cook, D. G., Leverenz, J. B., McMillan, P. J., Kulstad, J. J., Ericksen, S., Roth, R. A., et
al. (2003). Reduced hippocampal insulin-degrading enzyme in late-onset
alzheimer’s disease is associated with the apolipoprotein E-ε4 allele.
American Journal of Pathology, 162(1), 313-319.
Cooper, G. J. S., Willis, A. C., Clark, A., Turner, R. C., Sim, R. B., & Reid, K. B. M.
(1987). Purification and characterization of a peptide from amyloid-rich
pancreases of type 2 diabetic patients. Proceedings of the National Academy
of Sciences, 84(23), 8628-8632.
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. J., Gaskell, P. C.,
Small, G. W., et al. (1993). Gene dose of apolipoprotein E type 4 allele and
the risk of Alzheimer's disease in late onset families. Science, 261(5123),
921-923.

365

Cordes, C. M., Bennett, R. G., Siford, G. L., & Hamel, F. G. (2009). Nitric oxide
inhibits insulin-degrading enzyme activity and function through Snitrosylation. Biochemical Pharmacology, 77(6), 1064-1073.
Cordes, C. M., Bennett, R. G., Siford, G. L., & Hamel, F. G. (2011). Redox regulation
of insulin degradation by insulin-degrading enzyme. PloS one, 6(3), e18138.
Craft, S. (2005). Insulin resistance syndrome and Alzheimer’s disease: Age- and
obesity-related

effects

on

memory,

amyloid,

and

inflammation.

Neurobiology of Aging, 26S, S65-S69.
Craft,

S.

(2006).

Insulin

resistance

syndrome

and

Alzheimer

disease:

Pathophysiologic mechanisms and therapeutic implications. Alzheimer
Disease and Associated Disorders, 20(4), 298-301.
Craft, S., Asthana, S., Cook, D. G., Baker, L. D., Cherrier, M., Purganan, K., et al.
(2003). Insulin dose-response effects on memory and plasma amyloid
precursor protein in Alzheimer's disease: interactions with apolipoprotein E
genotype. Psychoneuroendocrinology, 28(6), 809-822.
Craft, S., Asthana, S., Schellenberg, G., Baker, L., Cherrier, M., Boyt, A. A., et al.
(2000). Insulin Effects on Glucose Metabolism, Memory, and Plasma
Amyloid Precursor Protein in Alzheimer's Disease Differ According to
Apolipoprotein‐E Genotype. Annals of the New York Academy of Sciences,
903(1), 222-228.
Craft, S., Asthana, S., Schellenberg, G., Cherrier, M., Baker, L. D., Newcomer, J., et al.
(1999). Insulin metabolism in Alzheimer's disease differs according to
apolipoprotein E genotype and gender. Neuroendocrinology, 70(2), 146-152.
Craft, S., Baker, L. D., Montine, T. J., Minoshima, S., Watson, G., Claxton, A., et al.
(2012). Intranasal insulin therapy for Alzheimer disease and amnestic mild
cognitive impairment: a pilot clinical trial. Archives of Neurology, 69(1), 29.
Craft, S., Peskind, E., Schwartz, M. W., Schellenberg, G. D., Raskind, M., & Porte, D.
(1998). Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease Relationship to severity of dementia and apolipoprotein E genotype.
Neurology, 50(1), 164-168.

366

Craft, S., & Watson, G. S. (2004). Insulin and neurodegenerative disease: shared and
specific mechanisms. Insulin and Neurodegenerative disease, 3(3), 169-178.
Cummings, J. L. (2001). Treatment of Alzheimer's disease. Clinical Cornerstone, 3(4),
27-39.
Cummings, J. L., & Cole, G. (2002). Alzheimer Disease. Journal of the American
Medical Association, 287(18), 2335-2338.
Dahlgren, K. N., Manelli, A. M., Stine, W. B., Baker, L. K., Krafft, G. A., & LaDu, M. J.
(2002). Oligomeric and fibrillar species of amyloid-β peptides differentially
affect neuronal viability. The Journal of Biological Chemistry, 277(35), 3204632053.
Dallongeville, J., Lussier-Cacan, S., & Davignon, J. (1992). Modulation of plasma
triglyceride levels by apoE phenotype: a meta-analysis. Journal of lipid
research, 33(4), 447-454.
Davidson, M. B. (1979). The effect of aging on carbohydrate metabolism: a review
of the English literature and a practical approach to the diagnosis of
diabetes mellitus in the elderly. Metabolism: Clinical and Experimental,
28(6), 688-705.
Davies, L., Wolska, B., Hilbich, C., Multhaup, G., Martins, R., Simms, G., et al. (1988).
A4 amyloid protein deposition and the diagnosis of Alzheimer's disease:
prevalence in aged brains determined by immunocytochemistry compared
with conventional neuropathologic techniques. Neurology, 38(11), 16881693.
Davis, J., & Van Nostrand, W. E. (1996). Enhanced pathologic properties of Dutchtype mutant amyloid β-protein. Proceedings of the National Academy of
Sciences, 93(2), 2996-3000.
Davis, K. L. (1986). Cortisol and Alzheimer's disease: I. Basal studies. American
Journal of Psychiatry, 143(3), 300-305.
Daw, E. W., Payami, H., Nemens, E. J., Nochlin, D., Bird, T. D., Schellenberg, G. D., et
al. (2000). The number of trait loci in late-onset alzheimer disease. American
Journal of Human Genetics, 66(1), 196-204.

367

de Jager, W., Bourcier, K., Rijkers, G. T., Prakken, B. J., & Seyfert-Margolis, V. (2009).
Prerequisites for cytokine measurements in clinical trials with multiplex
immunoassays. BMC immunology, 10(1), 52.
De Santi, S., de Leon, M. J., Rusinek, H., Convit, A., Tarshish, C. Y., Roche, A., et al.
(2001). Hippocampal formation glucose metabolism and volume losses in
MCI and AD. Neurobiology of Aging, 22(4), 529-539.
De Santi, S., de Leon, M. J., Rusinek, H., Convit, A., Tarshish, C. Y., Roche, A., et al.
(2001). Hippocampal formation glucose metabolism and volume losses in
MCI and AD. Neurobiology of Aging, 22(4), 529-539.
de Tullio, M. B., Castelletto, V., Hamley, I. W., Adami, P. V. M., Morelli, L., &
Castaño, E. M. (2013). Proteolytically Inactive Insulin-Degrading Enzyme
Inhibits Amyloid Formation Yielding Non-Neurotoxic Aβ Peptide Aggregates.
PLoS ONE, 8(4), e59113.
Deane, R., Bell, R., Sagare, A., & Zlokovic, B. (2009). Clearance of amyloid-β peptide
across the blood-brain barrier: implication for therapies in Alzheimer’s
disease. CNS & neurological disorders drug targets, 8(1), 16.
Deane, R., Yan, S. D., Submamaryan, R. K., LaRue, B., Jovanovic, S., Hogg, E., et al.
(2003). RAGE mediates amyloid-β peptide transport across the blood-brain
barrier and accumulation in brain. Nature Medicine, 9(7), 907-914.
DeMattos, R. B., Bales, K. R., Cummins, D. J., Paul, S. M., & Holtzman, D. M. (2002).
Brain to plasma amyloid-β efflux: a measure of brain amyloid burden in a
mouse model of Alzheimer's disease. Science, 295(5563), 2264-2267.
Deng, R., & Chow, T. J. (2010). Hypolipidemic, antioxidant, and antiinflammatory
activities of microalgae Spirulina. Cardiovascular therapeutics, 28(4), e33e45.
Desmarais, W. T., Bienvenue, D. L., Bzymek, K. P., Holz, R. C., Petsko, G. A., & Ringe,
D. (2002). The 1.20 Å Resolution Crystal Structure of the Aminopeptidase
from Aeromonas proteolytica Complexed with Tris: A Tale of Buffer
Inhibition. Structure, 10(8), 1063-1072.

368

Devaskar, S. U., Giddings, S. J., Rajakumar, P. A., Carnaghi, L. R., Menon, R. K., &
Zahm, D. S. (1994). Insulin gene expression and insulin synthesis in
mammalian neuronal cells. The Journal of Biological Chemistry, 269(11),
8445-8454.
Devesh, C., Kritika, M., Anroop, N., Kumar, S., & Gupta, S. (2012). Spirulina Reverses
Histomorphological Changes in Diabetic Osteoporosis in Pioglitazone
Treated Rats. Journal of Diabetes & Metabolism.
Dickson, D. W., Lee, S. C., Mattiace, L. A., Yen, S. H., & Brosnan, C. (1993). Microglia
and cytokines in neurological disease, with special reference to AIDS and
Alzheimer's disease. Glia, 7(1), 75-83.
Dickson, M. R., Li, J., Wiener, H. W., Perry, R. T., Blacker, D., Bassett, S. S., et al.
(2008). A genomic scan for age at onset of Alzheimer’s disease in 437
families from the NIMH Genetic Initiative. American Journal of Medical
Genetics Part B (Neuropsychiatric Genetics), 147B(6), 784-792.
Diniz, B. S. O., Pinto(Jnr), J. A., & Forlenza, O. V. (2008). Do CSF total tau,
phosphorylated tau, and β-amyloid 42 help to predict progression of mild
cognitive impairment to Alzheimer’s disease? A systematic review and
meta-analysis of the literature. The World Journal of Biological Psychiatry,
9(3), 172-182.
Dobarro, M., Gerenu, G., & Ramírez, M. J. (2013). Propranolol reduces cognitive
deficits, amyloid and tau pathology in Alzheimer's transgenic mice. The
International Journal of Neuropsychopharmacology, 1-13.
Dobarro, M., Orejana, L., Aguirre, N., & Ramírez, M. J. (2012). Propranolol reduces
cognitive deficits, amyloid β levels, tau phosphorylation and insulin
resistance in response to chronic corticosterone administration. The
International Journal of Neuropsychopharmacology, 1(1), 1-10.
Dragicevic, N., Mamcarz, M., Zhu, Y., Buzzeo, R., Tan, J., Arendash, G. W., et al.
(2010). Mitochondrial amyloid-β levels are associated with the extent of
mitochondrial dysfunction in different brain regions and the degree of
cognitive impairment in Alzheimer's transgenic mice. Journal of Alzheimer's
Disease, 20, 535-550.

369

Du, J., Chang, J., Guo, S., Zhang, Q., & Wang, Z. (2009). ApoE 4 reduces the
expression of Aβ degrading enzyme IDE by activating the NMDA receptor in
hippocampal neurons. Neuroscience Letters, 464(2), 140-145.
Du, J., Zhang, L., Liu, S., & Wang, Z. (2010). Palmitic acid and docosahexaenoic acid
opposingly regulate the expression of insulin-degrading enzyme in neurons.
Die Pharmazie-An International Journal of Pharmaceutical Sciences, 65(3),
231-232.
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S., Barberger-Gateau, P., Cummings,
J., et al. (2007). Research criteria for the diagnosis of Alzheimer’s disease:
revising the NINCDS–ADRDA criteria. The Lancet Neurology, 6(8), 734-746.
Duckworth, W. C. (1988). Insulin degradation: mechanisms, products and
significance. Endocrine Reviews, 9(3), 319-345.
Duckworth, W. C., Bennett, R. G., & Hamel, F. G. (1998). Insulin degradation:
Progress and potential. Endocrine Reviews, 19(5), 608-624.
Duckworth, W. C., Hamel, F. G., Bennett, R., Ryan, M. P., & Roth, R. A. (1990).
Human red blood cell insulin-degrading enzyme and rat skeletal muscle
insulin protease share antigenic sites and generate identical products from
insulin. The Journal of Biological Chemistry, 265(5), 2984-2987.
Duckworth, W. C., & Kitabchi, A. E. (1974). Insulin and glucagon degradation by the
same enzyme. Diabetes, 23(6), 536-543.
Duggirala, R., Blangero, J., Almasy, L., Dyer, T. D., Williams, K. L., Leach, R. J., et al.
(1999). Linkage of type 2 diabetes mellitus and of age at onset to a genetic
location on chromosome 10q in Mexican Americans. American Journal of
Human Genetics, 64(4), 1127-1140.
Duyckaerts, C., Delatour, B., & Potier, M.-C. (2009). Classification and basic
pathology of Alzheimer disease. Acta Neuropathologica, 118(1), 5-36.
Ebrahim, A., Hamel, F. G., Bennett, R. G., & Duckworth, W. C. (1991). Identification
of the metal associated with the insulin degrading enzyme. Biochemical And
Biophysical Research Communications, 181(3), 1398-1406.
Eckel, R. H., Grundy, S. M., & Zimmet, P. Z. (2005). The metabolic syndrome. The
Lancet, 365(9468), 1415-1428.

370

Economics, D. A. (2011). DEMENTIA ACROSS AUSTRALIA: 2011-2050. Canberra:
Delloite Access Economics Pty Ltd.
Edbauer, D., Willem, M., Lammich, S., Steiner, H., & Haass, C. (2002). Insulindegrading enzyme rapidly removes the β-amyloid precursor protein
intracellular domain (AICD). The Journal of Biological Chemistry, 277(16),
13389-13393.
Edland, S. D., Wavrant-De Vriesé, F., Compton, D., Smith, G. E., Ivnik, R., Boeve, B.
F., et al. (2003). Insulin degrading enzyme (IDE) genetic variants and risk of
Alzheimer’s disease: evidence of effect modification by apolipoprotein E
(APOE). Neuroscience Letters, 345(1), 21-24.
Egerer, K., Kuckelkorn, U., Rudolph, P. E., Rückert, J. C., Dörner, T., Burmester, G.-R.,
et al. (2002). Circulating proteasomes are markers of cell damage and
immunologic activity in autoimmune diseases. The Journal of rheumatology,
29(10), 2045-2052.
Ehm, M. G., Karnoub, M. C., Sakul, H., Gottschalk, K., Holt, D. C., Weber, J. L., et al.
(2000). Genomewide search for type 2 diabetes susceptibility genes in four
American populations. American Journal of Human Genetics, 66(6), 18711881.
Eisele, Y. S., Bolmont, T., Heikenwalder, M., Langer, F., Jacobson, L. H., Yan, Z.-X., et
al. (2009). Induction of cerebral β-amyloidosis: Intracerebral versus systemic
Aβ inoculation. Proceedings of the National Academy of Sciences, 106(31),
12926-12931.
Eisele, Y. S., Obermüller, U., Heilbronner, G., Baumann, F., Kaeser, S. A., Wolburg,
H., et al. (2010). Peripherally applied Aβ-containing inoculates induce
cerebral β-amyloidosis. Science, 330(6006), 980-982.
Ellis, K. A., Bush, A. I., Darby, D., De Fazio, D., Foster, J., Hudson, P., et al. (2009). The
Australian Imaging, Biomarkers and Lifestyle Study of ageing (AIBL):
methodology and baseline characteristics of 1112 individuals recruited for a
longitudinal study of Alzheimer’s disease. International Psychogeriatrics,
21(4), 672-687.

371

Engel, T., Goñi-Oliver, P., Lucas, J. J., Avila, J., & Hernández, F. (2006). Chronic
lithium administration to FTDP-17 tau and GSK-3β overexpressing mice
prevents tau hyperphosphorylation and neurofibrillary tangle formation,
but pre-formed neurofibrillary tangles do not revert. Journal of
Neurochemistry, 99(6), 1445-1455.
Ertekin-Taner, N., Allen, M., Fadale, D., Scanlin, L., Younkin, L., Petersen, R. C., et al.
(2004). Genetic variants in a haplotype block spanning IDE are significantly
associated with plasma Aβ42 levels and risk for Alzheimer disease. Human
Mutation, 23(4), 334-342.
Ertekin-Taner, N., Graff-Radford, N., Younkin, L. H., Eckman, C., Adamson, J., Schaid,
D. J., et al. (2001). Heritability of plasma amyloid β in typical late-onset
alzheimer’s disease pedigrees. Genetic Epidemiology, 21(1), 19-30.
Ertekin-Taner, N., Graff-Radford, N., Younkin, L. H., Eckman, C., Baker, M.,
Adamson, J., et al. (2000). Linkage of plasma Aβ42 to a quantitative locus on
chromosome 10 in late-onset alzheimer's disease pedigrees. Science,
290(5500), 2303-2304.
Ertekin-Taner, N., Younkin, L., Yager, D., Parfitt, F., Baker, M., Asthana, S., et al.
(2008). Plasma amyloid β protein is elevated in late-onset alzheimer disease
families. Neurology, 70(8), 596-606.
Espinosa, R., Lemons, R. S., Perlman, R. K., Kuo, W. L., Rosner, M. R., & Lebeau, M.
M. (1991). Localization of the gene encoding insulin-degrading enzyme to
human chromosome-10, bands q23-q25 Cytogenetics and Cell Genetics,
57(4), 184-186.
Estey, T., Kang, J., Schwendeman, S. P., & Carpenter, J. F. (2006). BSA degradation
under acidic conditions: a model for protein instability during release from
PLGA delivery systems. Journal of pharmaceutical sciences, 95(7), 16261639.
Evans, M. J., Livesey, J. H., Ellis, M. J., & Yandle, T. G. (2001). Effect of anticoagulants
and storage temperatures on stability of plasma and serum hormones.
Clinical biochemistry, 34(2), 107-112.

372

Fakhrai-Rad, H., Nikoshkov, A., Kamel, A., Fernström, M., Zierath, J. R., Norgren, S.,
et al. (2000). Insulin-degrading enzyme identified as a candidate diabetes
susceptibility gene in GK rats. Human Molecular Genetics, 9(14), 2149-2158.
Farrer, L. A., Cupples, L. A., Haines, J. L., Hyman, B., Kukull, W. A., Mayeux, R., et al.
(1997). Effects of age, sex, and ethnicity on the association between
apolipoprotein E genotype and Alzheimer disease. JAMA: the journal of the
American Medical Association, 278(16), 1349-1356.
Farris, W., Leissring, M. A., Hemming, M. L., Chang, A. Y., & Selkoe, D. J. (2005).
Alternative splicing of human insulin-degrading enzyme yields a novel
isoform with a decreased ability to degrade insulin and amyloid β-protein.
Biochemistry, 44(17), 6513-6525.
Farris, W., Mansourian, S., Chang, Y., Lindsley, L., Eckman, E. A., Frosch, M. P., et al.
(2003). Insulin-degrading enzyme regulates the levels of insulin, amyloid βprotein, and the β-amyloid precursor protein intracellular domain in vivo.
Proceedings of the National Academy of Sciences, 100(7), 4162-4167.
Farris, W., Mansourian, S., Leissring, M. A., Eckman, E. A., Bertram, L., Eckman, C. B.,
et al. (2004). Partial loss-of-function mutations in insulin-degrading enzyme
that induce diabetes also impair degradation of amyloid β-protein. American
Journal of Pathology, 164(4), 1425-1434.
Ferretti, M., Partridge, V., C Leon, W., Canneva, F., Allard, S., N Arvanitis, D., et al.
(2011). Transgenic mice as a model of pre-clinical Alzheimer's disease.
Current Alzheimer Research, 8(1), 4-23.
Feuk, L., McCarthy, S., Andersson, B., Prince, J. A., & Brookes, A. J. (2005). Mutation
screening of a haplotype block around the insulin degrading enzyme gene
and association with Alzheimer’s disease. American Journal of Medical
Genetics Part B (Neuropsychiatric Genetics), 136B(1), 69-71.
Fishel, M. A., Watson, G. S., Montine, T. J., Wang, Q., Green, P. S., Kulstad, J. J., et al.
(2005). Hyperinsulinemia provokes synchronous increases in central
inflammation and beta-amyloid in normal adults. Archives of Neurology,
62(10), 1539-1544.

373

Florez, J. C., Wiltshire, S., Agapakis, C. M., Burtt, N. P., de Bakker, P. I. W., Almgren,
P., et al. (2006). High-density haplotype structure and association testing of
the insulin-degrading enzyme (IDE) gene with type 2 diabetes in 4,206
people. Diabetes, 55(1), 128-135.
Francis, G. J., Martinez, J. A., Liu, W. Q., Xu, K., Ayer, A., Fine, J., et al. (2008).
Intranasal insulin prevents cognitive decline, cerebral atrophy and white
matter changes in murine type I diabetic encephalopathy. Brain, 131(12),
3311-3334.
Frank, R. A., Galasko, D., Hampel, H., Hardy, J., de Leon, M. J., Mehta, P. D., et al.
(2003). Biological markers for therapeutic trials in Alzheimer’s disease.
Proceedings of the biological markers working group; NIA initiative on
neuroimaging in Alzheimer’s disease. Neurobiology of Aging, 24(4), 521-536.
Fratiglioni, L. (1996). Epidemiology of Alzheimer's disease and current possibilities
for prevention. Acta Neurologica Scandinavica Supplementum, 165, 33-40.
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972). Estimation of the
concentration of low-density lipoprotein cholesterol in plasma, without use
of the preparative ultracentrifuge. Clinical chemistry, 18(6), 499-502.
Fujimoto, M., Tsuneyama, K., Fujimoto, T., Selmi, C., Gershwin, M. E., & Shimada, Y.
(2012). Spirulina improves non-alcoholic steatohepatitis, visceral fat
macrophage aggregation, and serum leptin in a mouse model of metabolic
syndrome. Digestive and Liver Disease, 44(9), 767-774.
Fujisawa, Y., Sasaki, K., & Akiyama, K. (1991). Increased insulin levels after OGTT
load in peripheral blood and cerebrospinal fluid of patients with dementia of
Alzheimer type. Biological Psychiatry, 30(12), 1219-1228.
Fukumoto, H., Tennis, M., Locascio, J. J., Hyman, B. T., Growdon, J. H., & Irizarry, M.
C. (2003). Age but not diagnosis is the main predictor of plasma amyloid
beta-protein levels. Archives of Neurology, 60(7), 958-964.
Funk, K., Mrak, R., & Kuret, J. (2011). Granulovacuolar degeneration (GVD) bodies of
Alzheimer's disease (AD) resemble late-stage autophagic organelles.
Neuropathology and Applied Neurobiology, 37(3), 295-306.

374

Furukawa, Y., Shimada, T., Furuta, H., Matsuno, S., Kusuyama, A., Doi, A., et al.
(2008). Polymorphisms in the IDE-KIF11-HHEX gene locus are reproducibly
associated with type 2 diabetes in a Japanese population. Journal of Clinical
Endocrinology and Metabolism, 93(1), 310-314.
Gao, W. W., Eisenhauer, P. B., Conn, K., Lynch, J. A., Wells, J. M., Ullman, M. D., et
al. (2004). Insulin degrading enzyme is expressed in the human
cerebrovascular endothelium and in cultured human cerebrovascular
endothelial cells. Neuroscience Letters, 371(1), 6-11.
Garcia, J. V., Gehm, B. D., & Rosner, M. R. (1989). An evolutionarily conserved
enzyme degrades transforming growth factor-alpha as well as insulin. The
Journal of Cell Biology, 109(3), 1301-1307.
Gascón-Bayarri, J., Reñé, R., Del Barrio, J. L., De Pedro-Cuesta, J., Ramón, J. M.,
Manubens, J. M., et al. (2007). Prevalence of dementia subtypes in El Prat de
Llobregat, Catalonia, Spain: The PRATICON Study. Neuroepidemiology, 28(4),
224-234.
Gasparini, L., Gouras, G. K., Wang, R., Gross, R. S., Beal, M. F., Greengard, P., et al.
(2001). Stimulation of β-amyloid precursor protein trafficking by insulin
reduces intraneuronal β-amyloid and requires mitogen-activated protein
kinase signaling. The Journal of Neuroscience, 21(8), 2561-2570.
Gassmann, M., Grenacher, B., Rohde, B., & Vogel, J. (2009). Quantifying Western
blots: pitfalls of densitometry. Electrophoresis, 30(11), 1845-1855.
Gatz, M., Pedersen, N. L., Berg, S., Johansson, B., Johansson, K., Mortimer, J. A., et
al. (1997). Heritability for Alzheimer's disease: The study of dementia in
Swedish twins. Journal of Gerontology: Medical Sciences, 52A(2), M117M125.
Gauthier, S., Reisberg, B., Zaudig, M., Petersen, R. C., Ritchie, K., Broich, K., et al.
(2006). Mild cognitive impairment. The Lancet, 367(9518), 1262-1270.
Geerlings, M. I., Jonker, C., Bouter, L. M., Adèr, H. J., & Schmand, B. (1999).
Association between memory complaints and incident Alzheimer's disease
in elderly people with normal baseline cognition. The American Journal of
Psychiatry, 156(4), 531-537.

375

Ghalanbor, Z., Ghaemi, N., Marashi, S.-A., Amanlou, M., Habibi-Rezaei, M., Khajeh,
K., et al. (2008). Binding of Tris to Bacillus licheniformis alpha-Amylase Can
Affect Its Starch Hydrolysis Activity. Protein and peptide letters, 15(2), 212214.
GhersiEgea, J. F., Gorevic, P. D., Ghiso, J., Frangione, B., Patlak, C. S., &
Fenstermacher, J. D. (1996). Fate of cerebrospinal fluid-borne amyloid betapeptide: Rapid clearance into blood and appreciable accumulation by
cerebral arteries. Journal of Neurochemistry, 67(2), 880-883.
Ghosh, S., Watanabe, R. M., Valle, T. T., Hauser, E. R., Magnuson, V. L., Langefeld, C.
D., et al. (2000). The Finland--United States investigation of non--insulindependent diabetes mellitus genetics (FUSION) Study. I. An autosomal
genome scan for genes that predispose to type 2 diabetes. American Journal
of Human Genetics, 67(5), 1174-1185.
Gibson, P. H., & Tomlinson, B. E. (1977). Numbers of Hirano bodies in the
hippocampus of normal and demented people with Alzheimer's disease.
Journal of the Neurological Sciences, 33(1–2), 199-206.
Glatt, H., & Oesch, F. (1987). Species differences in enzymes controlling reactive
epoxides. In Mouse Liver Tumors (pp. 111-124): Springer.
Glebov, K., & Walter, J. (2011). Statins in Unconventional Secretion of InsulinDegrading

Enzyme

and

Degradation

of

the

Amyloid-β

Peptide.

Neurodegenerative Diseases, 10(1-4), 309-312.
Glenner, G. G., & Wong, C. W. (1984). Alzheimer's disease: initial report of the
purification and characterization of a novel cerebrovascular amyloid protein.
. Biochemical And Biophysical Research Communications, 120(3), 885-890.
Gluschankof, P., Gomez, S., Morel, A., & Cohen, P. (1987). Enzymes that process
somatostatin precursors. A novel endoprotease that cleaves before the
arginine-lysine doublet is involved in somatostatin-28 convertase activity of
rat brain cortex. Journal of Biological Chemistry, 262(20), 9615-9620.
Goate, A. M. (1997). Molecular genetics of Alzheimer's disease. Geriatrics,
52(Supplement 2), S9-S12.

376

Goate, A. M., Chartier-Harlin, M. C., Mullan, M., Brown, J., Crawford, F., Fidani, L., et
al. (1991). Segregation of a missense mutation in the amyloid precursor
protein gene with familial Alzheimer's disease. Nature, 349(6311), 704-706.
Goldfine, I. D., Williams, J. A., Bailey, A. C., Wong, K. Y., Iwamoto, Y., Yokono, K., et
al. (1984). Degradation of insulin by isolated mouse pancreatic acini.
Evidence for cell surface protease activity. Diabetes, 33(1), 64-72.
Gouras, G. K., Tsai, J., Naslund, J., Vincent, B., Edgar, M., Checler, F., et al. (2000).
Intraneuronal Aβ42 accumulation in human brain. American Journal of
Pathology, 156(1), 15-20.
Graff-Radford, N. R., Crook, J. E., Lucas, J., Boeve, B. F., Knopman, D. S., Ivnik, R. J.,
et al. (2007). Association of low plasma Aβ42/Aβ40 ratios with increased
imminent risk for mild cognitive impairment and Alzheimer disease. Archives
of Neurology, 64(3), 354-362.
Grasso, G., Rizzarelli, E., & Spoto, G. (2008). How the binding and degrading
capabilities of insulin degrading enzyme are-affected by ubiquitin.
Biochimica et Biophysica Acta - Proteins & Proteomics, 1784(7-8), 11221126.
Grasso, G., Salomone, F., Tundo, G. R., Pappalardo, G., Ciaccio, C., Spoto, G., et al.
(2012). Metal ions affect insulin-degrading enzyme activity. Journal of
Inorganic Biochemistry, 117, 351-358.
Griffin, W. S. T., Stanley, L. C., Ling, C., White, L., MacLeod, V., Perrot, L. J., et al.
(1989). Brain interleukin 1 and S-100 immunoreactivity are elevated in Down
syndrome and Alzheimer disease. Proceedings of the National Academy of
Sciences, 86(19), 7611-7615.
Grisel, J. E. (2000). Quantitative trait locus analysis. Alcohol Research and Health,
24(3), 169-174.
Grodstein, F., Wilson, R. S., Chen, J., & Manson, J. E. (2001). Type 2 diabetes and
cognitive function in community-dwelling elderly women. Diabetes Care,
24(6), 1060-1065.

377

Groves, C. J., Wiltshire, S., Smedley, D., Owen, K. R., Frayling, T. M., Walker, M., et
al. (2003). Association and haplotype analysis of the insulin-degrading
enzyme (IDE) gene, a strong positional and biological candidate for type 2
diabetes susceptibility. Diabetes, 52(5), 1300-1305.
Grundke-Iqbal, I., Iqbal, K., Quinlan, M., Tung, Y. C., Zaidi, M. S., & Wisniewski, H. M.
(1986). Microtubule-associated protein tau. A component of Alzheimer
paired helical filaments. The Journal of Biological Chemistry, 261(13), 60846089.
Grupe, A., Abraham, R., Li, Y., Rowland, C., Hollingworth, P., Morgan, A., et al.
(2007). Evidence for novel susceptibility genes for late-onset alzheimer’s
disease from a genome-wide association study of putative functional
variants. Human Molecular Genetics, 16(8), 865-873.
Grupe, A., Li, Y., Rowland, C., Nowotny, P., Hinrichs, A. L., Smemo, S., et al. (2006). A
scan of chromosome 10 identifies a novel locus showing strong association
with late-onset alzheimer disease. American Journal of Human Genetics,
78(1), 78-88.
Gu, H. F., Efendic, S., Nordman, S., Östenson, C. G., Brismar, K., Brookes, A. J., et al.
(2004). Quantitative trait loci near the insulin-degrading enzyme (IDE) gene
contribute to variation in plasma insulin levels. Diabetes, 53(8), 2137-2142.
Guan, H., Liu, Y., Daily, A., Police, S., Kim, M. H., Oddo, S., et al. (2009). Peripherally
expressed neprilysin reduces brain amyloid burden: a novel approach for
treating Alzheimer's disease. Journal of neuroscience research, 87(6), 14621473.
Guiroy, D. C., Miyazaki, M., Multhaup, G., Fischer, P., Garruto, R. M., Beyreuther, K.,
et al. (1987). Amyloid of neurofibrillary tangles of Guamanian parkinsonismdementia and Alzheimer disease share identical amino acid sequence.
Proceedings of the National Academy of Sciences, 84(7), 2073-2077.
Gupta, R., & Brunak, S. (2002). Prediction of glycosylation across the human
proteome and the correlation to protein function. Paper presented at the
Pacific Symposium on Biocomputing.

378

Gupta, V., Laws, S. M., Villemagne, V. L., Ames, D., Bush, A. I., Ellis, K. A., et al.
(2011). Plasma apolipoprotein E and Alzheimer disease risk The AIBL study
of aging. Neurology, 76(12), 1091-1098.
Gyure, K. A., Durham, R., Stewart, W. F., Smialek, J. E., & Troncoso, J. C. (2001).
Intraneuronal Aβ-amyloid precedes development of amyloid plaques in
Down syndrome. Archives of pathology & laboratory medicine, 125(4), 489492.
Haass, C., Schlossmacher, M. G., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A.,
Ostaszewski, B. L., et al. (1992). Amyloid β-peptide is produced by cultured
cells during normal metabolism. Nature, 359(6393), 322-325.
Hahs, D. W., McCauley, J. L., Crunk, A. E., McFarland, L. L., Gaskell, P. C., Jiang, L., et
al. (2006). A genome-wide linkage analysis of dementia in the Amish.
American Journal of Medical Genetics Part B (Neuropsychiatric Genetics),
141B(2), 160-166.
Hamel, F. G., Mahoney, M. J., & Duckworth, W. C. (1991). Degradation of
intraendosomal insulin by insulin-degrading enzyme without acidification.
Diabetes, 40(4), 436-443.
Hamel, F. G., Upward, J. L., & Bennett, R. G. (2003). In vitro inhibition of insulindegrading enzyme by long-chain fatty acids and their coenzyme A
thioesters. Endocrinology, 144(6), 2404-2408.
Hampel, H., Frank, R., Broich, K., Teipel, S. J., Katz, R. G., Hardy, J., et al. (2010).
Biomarkers for Alzheimer's disease: academic, industry and regulatory
perspectives. Nature Reviews Drug Discovery, 9(7), 560-574.
Hamshere, M. L., Holmans, P. A., Avramopoulos, D., Bassett, S. S., Blacker, D.,
Bertram, L., et al. (2007). Genome-wide linkage analysis of 723 affected
relative pairs with late-onset alzheimer’s disease. Human Molecular
Genetics, 16(22), 2703-2712.
Harada, S., Smith, R. M., Hu, D. Q., & Jarett, L. (1996). Dexamethasone inhibits
insulin binding to insulin-degrading enzyme and cytosolic insulin-binding
protein p82. Biochemical And Biophysical Research Communications, 218(1),
154-158.

379

Hardy, J. (1997). Amyloid, the presenilins and Alzheimer's disease. Trends in
Neurosciences, 20(4), 154-159.
Hardy, J., & Allsop, D. (1991). Amyloid deposition as the central event in the
aetiology of Alzheimer's disease. Trends in pharmacological sciences, 12(10),
383.
Hardy, J., & Higgins, G. A. (1992). Alzheimer's disease: the amyloid cascade
hypothesis. Science, 256(5054), 184-186.
Hardy, J., & Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer's Disease:
progress and problems on the road to therapeutics. . Science, 297(5580),
353-356.
Hartley, D. M., Walsh, D. M., Ye, C. P., Diehl, T., Vasquez, S., Vassilev, P. M., et al.
(1999). Protofibrillar intermediates of amyloid β-protein induce acute
electrophysiological changes and progressive neurotoxicity in cortical
neurons. The Journal of Neuroscience, 19(20), 8876-8884.
Hartmann, A., Veldhuis, J. D., Deuschle, M., Standhardt, H., & Heuser, I. (1997).
Twenty-four hour cortisol release profiles in patients with Alzheimer's and
Parkinson's disease compared to normal controls: ultradian secretory
pulsatility and diurnal variation. Neurobiology of Aging, 18(3), 285-289.
Hassing, L. B., Johansson, B., Nilsson, S. E., Berg, S., Pedersen, N. L., Gatz, M., et al.
(2002). Diabetes mellitus is a risk factor for vascular dementia, but not for
Alzheimer's disease: A population-based study of the oldest old.
International Psychogeriatrics, 14(3), 239-248.
Hastie, T., Tibshirani, R., Friedman, J., & Franklin, J. (2005). The elements of
statistical learning: data mining, inference and prediction. The Mathematical
Intelligencer, 27(2), 83-85.
Henderson, S. J., Andersson, C., Narwal, R., Janson, J., Goldschmidt, T. J., Appelkvist,
P., et al. (2013). Sustained peripheral depletion of amyloid-β with a novel
form of neprilysin does not affect central levels of amyloid-β. Brain, awt308.
Henning, D., & Nielsen, K. (1992). Cross-reactivity of monoclonal antibodies to
bovine immunoglobulins with immunoglobulins of other species. Veterinary
immunology and immunopathology, 34(3), 235-243.

380

Herukka, S. K., Helisalmi, S., Hallikainen, M., Tervo, S., Soininen, H., & Pirttilä, T.
(2007). CSF Aβ42, tau and phosphorylated tau, APOE ε4 allele and MCI type
in progressive MCI. Neurobiology of Aging, 28(4), 507-514.
Hirsch-Reinshagen, V., Burgess, B. L., & Wellington, C. L. (2009). Why lipids are
important for Alzheimer disease? Molecular and Cellular Biochemistry,
326(1-2), 121-129.
Hirsch-Reinshagen, V., Maia, L. F., Burgess, B. L., Blain, J. F., Naus, K. E., McIsaac, S.
A., et al. (2005). The absence of ABCA1 decreases soluble apoE levels but
does not diminish amyloid deposition in two murine models of Alzheimer
disease. The Journal of Biological Chemistry, 280(52), 43243-43256.
Hixson, J. E., & Vernier, D. T. (1990). Restriction isotyping of human apolipoprotein
E by gene amplification and cleavage with HhaI. Journal of lipid research,
31(3), 545-548.
Ho, L., Qin, W., Pompl, P. N., Zhongmin, X., Wang, J., Zhao, Z., et al. (2004). Dietinduced insulin resistance promotes amyloidosis in a transgenic mouse
model of Alzheimer’s disease. The FASEB Journal, 18(3), 902-904.
Hogervorst, E., Bandelow, S., Combrinck, M., & Smith, A. (2004). Low free
testosterone is an independent risk factor for Alzheimer's disease.
Experimental gerontology, 39(11), 1633-1639.
Holm, S. (1979). A simple sequentially rejective multiple test procedure.
Scandinavian journal of statistics, 65-70.
Holmans, P., Hamshere, M., Hollingworth, P., Rice, F., Tunstall, N., Jones, S., et al.
(2005). Genome screen for loci influencing age at onset and rate of decline
in late onset alzheimer’s disease. American Journal of Medical Genetics Part
B (Neuropsychiatric Genetics), 135B(1), 24-32.
Holmes, C. (2013). Systemic inflammation and Alzheimer's disease. Neuropathology
and Applied Neurobiology, 39(1), 51-68.
Hone, E., Martins, I. J., Fonte, J., & Martins, R. N. (2003). Apolipoprotein E
influences amyloid-beta clearance from the murine periphery. Journal of
Alzheimer's Disease, 5(1), 1-8.

381

Hong, M., & Lee, V. M. Y. (1997). Insulin and insulin-like growth factor-1 regulate
tau phosphorylation in cultured human neurons. The Journal of Biological
Chemistry, 272(31), 19547-19553.
Hopkins, P. C., Huang, Y., McGuire, J. G., & Pitas, R. E. (2002). Evidence for
differential effects of apoE3 and apoE4 on HDL metabolism. Journal of lipid
research, 43(11), 1881-1889.
Hoshino, T., Murao, N., Namba, T., Takehara, M., Adachi, H., Katsuno, M., et al.
(2011). Suppression of Alzheimer's disease-related phenotypes by
expression of heat shock protein 70 in mice. The Journal of Neuroscience,
31(14), 5225-5234.
Hoshino, T., Suzuki, K., Matsushima, T., Yamakawa, N., Suzuki, T., & Mizushima, T.
(2013). Suppression of Alzheimer’s Disease-Related Phenotypes by
Geranylgeranylacetone in Mice. Plos one, 8(10), e76306.
Ichihara, A. (1993). Serum concentration and localization in tumor cells of
proteasomes in patients with hematologic malignancy and their
pathophysiologic significance. J Lab Clin Med.
Ignatius, M. J., Gebicke-Härter, P. J., Pate Skene, J. H., Schilling, J. W., Weisgraber, K.
H., Mahley, R. W., et al. (1986). Expression of apolipoprotein E during nerve
degeneration and regeneration. Proceedings of the National Academy of
Sciences, 83(4), 1125-1129.
Ikonomovic, M. D., Klunk, W. E., Abrahamson, E. E., Mathis, C. A., Price, J. C.,
Tsopelas, N. D., et al. (2008). Post-mortem correlates of in vivo PiB-PET
amyloid imaging in a typical case of Alzheimer’s disease. Brain, 131(Pt 6),
1630-1645.
Im, H., Manolopoulou, M., Malito, E., Shen, Y., Zhao, J., Neant-Fery, M., et al.
(2007). Structure of substrate-free human insulin-degrading enzyme (IDE)
and biophysical analysis of ATP-induced conformational switch of IDE. The
Journal of Biological Chemistry, 282(35), 25453-25463.
Ionushas, B. S., Matuliavichus, V. A., Ostrauskas, R. V., Brazauskas, A. P., & Vareikis,
E. I. (1987). Blood insulinase activity in patients with diabetes mellitus.
Terapevticheskii Arkhiv, 59(11), 12-15.

382

Irizarry, M. C. (2004). Biomarkers of Alzheimer disease in plasma. NeuroRx, 1(2),
226-234.
Ito, S., Ohtsuki, S., Murata, S., Katsukura, Y., Suzuki, H., Funaki, M., et al. (2014).
Involvement of Insulin-Degrading Enzyme in Insulin-and Atrial Natriuretic
Peptide-Sensitive Internalization of Amyloid-β Peptide in Mouse Brain
Capillary Endothelial Cells. Journal of Alzheimer's Disease, 38(1), 185-200.
Iwata, N., Tsubuki, S., Takaki, Y., Shirotani, K., Lu, B., Gerard, N. P., et al. (2001).
Metabolic regulation of brain Aβ by neprilysin. Science, 292(5521), 15501552.
Iwata, N., Tsubuki, S., Takaki, Y., Watanabe, K., Sekiguchi, M., Hosoki, E., et al.
(2000). Identification of the major Aβ1–42-degrading catabolic pathway in
brain parenchyma: suppression leads to biochemical and pathological
deposition. Nature Medicine, 6(2), 143-150.
Jack, C. R., Albert, M. S., Knopman, D. S., McKhann, G. M., Sperling, R. A., Carrillo,
M. C., et al. (2011). Introduction to the recommendations from the National
Institute on Aging-Alzheimer's Association workgroups on diagnostic
guidelines for Alzheimer's disease. Alzheimer's and Dementia, 7(3), 257-262.
James, A. P., & Mamo, J. C. L. (2005). The immunodetection of lipoprotein-bound
amyloid-β is attenuated because of the presence of lipids. Annals of Clinical
Biochemistry, 42(Pt 1), 70-72.
Janson, J., Laedtke, T., Parisi, J. E., O'Brien, P., Petersen, R. C., & Butler, P. C. (2004).
Increased risk of type 2 diabetes in Alzheimer disease. Diabetes, 53(2), 474481.
Jarrett, J. T., Berger, E. P., & Lansbury, P. T. (1993). The carboxy terminus of the
beta amyloid protein is critical for the seeding of amyloid formation:
implications for the pathogenesis of Alzheimer's disease. Biochemistry,
32(18), 4693-4697.
Jayaraman, A., Carroll, J. C., Morgan, T. E., Lin, S., Zhao, L., Arimoto, J. M., et al.
(2012). 17β-Estradiol and progesterone regulate expression of β-amyloid
clearance factors in primary neuron cultures and female rat brain.
Endocrinology, 153(11), 5467-5479.

383

Jeong, J. S., Ansaloni, A., Mezzenga, R., Lashuel, H. A., & Dietler, G. (2013). Novel
mechanistic insight into the molecular basis of amyloid polymorphism and
secondary nucleation during amyloid formation. Journal of Molecular
Biology.
Jiang, Q., Daniel Lee, C. Y., Mandrekar, S., Wilkinson, B., Cramer, P., Zelcer, N., et al.
(2008). ApoE promotes the proteolytic degradation of Aβ. Neuron, 58(5),
681-693.
Jordan, J., Cena, V., & Prehn, J. H. M. (2003). Mitochondrial control of neuron death
and its role in neurodegenerative disorders. Journal of Physiology and
Biochemistry, 59(2), 129-141.
Kaiyala, K. J., Prigeon, R. L., Kahn, S. E., Woods, S. C., & Schwartz, M. W. (2000).
Obesity induced by a high-fat diet is associated with reduced brain insulin
transport in dogs. Diabetes, 49(9), 1525-1533.
Käkönen, S.-M., Hellman, J., Karp, M., Laaksonen, P., Obrant, K. J., Väänänen, H. K.,
et al. (2000). Development and evaluation of three immunofluorometric
assays that measure different forms of osteocalcin in serum. Clinical
Chemistry, 46(3), 332-337.
Kalaria, R. N., Premkumar, D. R., Pax, A. B., Cohen, D. L., & Lieberburg, I. (1996).
Production and increased detection of amyloid β protein and amyloidogenic
fragments in brain microvessels, meningeal vessels and choroid plexus in
Alzheimer's disease. Molecular brain research, 35(1), 58-68.
Karamohamed, S., Demissie, S., Volcjak, J., Liu, C., Heard-Costa, N., Liu, J., et al.
(2003). Polymorphisms in the insulin-degrading enzyme gene are associated
with type 2 diabetes in men from the NHLBI Framingham Heart Study.
Diabetes, 52(6), 1562-1567.
Karran, E., Mercken, M., & De Strooper, B. (2011). The amyloid cascade hypothesis
for Alzheimer's disease: an appraisal for the development of therapeutics.
Nature, 10, 698-712.
Ka̧ tnik, I., Podgórska, M., & Dobryszycka, W. (1987). Polyethylene glycol enzyme
immunoassay for screening anti-haptoglobin monoclonal antibodies. Journal
of immunological methods, 102(2), 279-282.

384

Kaur, M., & Balgir, P. P. (2006). APOE polymorphism and susceptibility to dementia
of the Alzheimer's type in the Indian population. Internet Journal of Mental
Health, 3(1).
Kawarabayashi, T., Younkin, L. H., Saido, T. C., Shoji, M., Ashe, K. H., & Younkin, S. G.
(2001). Age-dependent changes in brain, CSF, and plasma amyloid β protein
in the Tg2576 transgenic mouse model of Alzheimer’s disease. The Journal
of Neuroscience, 21(2), 372-381.
Kayalar, C., & Wong, W. T. (1989). Metalloendoprotease inhibitors which block the
differentiation of L6 myoblasts inhibit insulin degradation by the
endogenous insulin-degrading enzyme. Journal of Biological Chemistry,
264(15), 8928-8934.
Kehoe, P., Wavrant-De Vriesé, F., Crook, R., Wu, W. S., Holmans, P., Fenton, I., et al.
(1999). A full genome scan for late onset alzheimer's disease. Human
Molecular Genetics, 8(2), 237-245.
Kim, H. S., Kim, E. M., Lee, J. P., Park, C. H., Kim, S., Seo, J. H., et al. (2003). Cterminal fragments of amyloid precursor protein exert neurotoxicity by
inducing glycogen synthase kinase-3beta expression. The FASEB Journal,
17(13), 1951-1953.
Kim, J., Basak, J. M., & Holtzman, D. M. (2009). The role of apolipoprotein E in
Alzheimer's disease. Neuron, 63(3), 287-303.
Kim, M., Hersh, L. B., Leissring, M. A., Ingelsson, M., Matsui, T., Farris, W., et al.
(2007). Decreased catalytic activity of the insulin-degrading enzyme in
chromosome 10-linked Alzheimer disease families. The Journal of Biological
Chemistry, 282(11), 7825-7832.
Kim, M. S., Goo, J. S., Kim, J. E., Nam, S. H., Choi, S. I., Lee, H. R., et al. (2011).
Overexpression of Insulin Degrading Enzyme could Greatly Contribute to
Insulin Down-regulation Induced by Short-Term Swimming Exercise.
Laboratory animal research, 27(1), 29-36.
Kinoshita, A., Fukumoto, H., Shah, T., Whelan, C. M., Irizarry, M. C., & Hyman, B. T.
(2003). Demonstration by FRET of BACE interaction with the amyloid
precursor protein at the cell surface and in early endosomes. Journal of Cell
Science, 116(16), 3339-3346.
385

Kinoshita, A., Whelan, C. M., Berezovska, O., & Hyman, B. T. (2002). The γ
Secretase-generated carboxyl-terminal domain of the amyloid precursor
protein induces apoptosis via tip60 in H4 cells. The Journal of Biological
Chemistry, 277(32), 28530-28536.
Kivipelto, M., Helkala, E. L., Hanninen, T., Laakso, M. P., Hallikainen, M., Alhainen,
K., et al. (2001). Midlife vascular risk factors and late-life mild cognitive
impairment: A population-based study. Neurology, 56(12), 1683-1689.
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., et al.
(2004). Imaging brain amyloid in Alzheimer’s disease with Pittsburgh
Compound-B. Annals of Neurology, 55(3), 306-319.
Knight, J. C. (2003). Functional implications of genetic variation in non-coding DNA
for disease susceptibility and gene regulation. Clinical Science, 104(5), 493502.
Knobloch, M., Konietzko, U., Krebs, D. C., & Nitsch, R. M. (2007). Intracellular Abeta
and cognitive deficits precede beta-amyloid deposition in transgenic
arcAbeta mice. Neurobiology of Aging, 28(9), 1297-1306.
Knopman, D. S., Dekosky, S. T., Cummings, J. L., Chui, H., Corey-Bloom, J., Relkin, N.,
et al. (2001). Practice parameter: Diagnosis of dementia. American Academy
of Neurology, 56, 1143-1153.
Knouff, C., Hinsdale, M. E., Mezdour, H., Altenburg, M. K., Watanabe, M., Quarfordt,
S. H., et al. (1999). Apo E structure determines VLDL clearance and
atherosclerosis risk in mice. Journal of Clinical Investigation, 103(11), 15791586.
Kodama, S., Tanaka, S., Saito, K., Shu, M., Sone, Y., Onitake, F., et al. (2007). Effect
of aerobic exercise training on serum levels of high-density lipoprotein
cholesterol: a meta-analysis. Archives of internal medicine, 167(10), 9991008.
Kolb, H. J., & Standl, E. (1980). Purification to homogeneity of an insulin-degrading
enzyme from human erythrocytes. Hoppe-Seyler´ s Zeitschrift für
physiologische Chemie, 361(2), 1029-1040.

386

Koldamova, R., Staufenbiel, M., & Lefterov, I. (2005). Lack of ABCA1 considerably
decreases brain apoE level and increases amyloid deposition in APP23 mice.
The Journal of Biological Chemistry, 280(52), 43224-43235.
Kong, Y., Ruan, L., Qian, L., Liu, X., & Le, Y. (2010). Norepinephrine promotes
microglia to uptake and degrade amyloid β peptide through upregulation of
mouse formyl peptide receptor 2 and induction of insulin-degrading
enzyme. The Journal of Neuroscience, 30(35), 11848-11857.
Korovkina, V. P., Stamnes, S. J., Brainard, A. M., & England, S. K. (2009). Nardilysin
convertase regulates the function of the maxi-K channel isoform mK44 in
human myometrium. American Journal of Physiology-Cell Physiology, 296(3),
C433-C440.
Kosik, K. S., Joachim, C. L., & Selkoe, D. J. (1986). Microtubule-associated protein
tau is a major antigenic component of paired helical filaments in Alzheimer
disease. Proceedings of the National Academy of Sciences, 83, 4044-4048.
Koudinov, A., Matsubara, E., Frangione, B., & Ghiso, J. (1994). The Soluble Form of
Alzheimer′ s Amyloid β Protein Is Complexed to High Density Lipoprotein 3
and Very High Density Lipoprotein in Normal Human Plasma. Biochemical
And Biophysical Research Communications, 205(2), 1164-1171.
Koyama, A., Okereke, O. I., Yang, T., Blacker, D., Selkoe, D. J., & Grodstein, F. (2012).
Plasma Amyloid-beta as a Predictor of Dementia and Cognitive Decline: A
Systematic Review and Meta-analysis. Archives of Neurology, archneurol.
2011.1841 v2011.
Kragstrup, T. W., Vorup-Jensen, T., Deleuran, B., & Hvid, M. (2013). A simple set of
validation steps identifies and removes false results in a sandwich enzymelinked immunosorbent assay caused by anti-animal IgG antibodies in plasma
from arthritis patients. SpringerPlus, 2(1), 263.
Kril, J. J., Hodges, J., & Halliday, G. (2004). Relationship between hippocampal
volume and CA1 neuron loss in brains of humans with and without
Alzheimer's disease. Neuroscience Letters, 361(1-3), 9-12.
Kulstad, J. J., Green, P. S., Cook, D. G., Watson, G. S., Reger, M. A., Baker, L. D., et al.
(2006). Differential modulation of plasma ß-amyloid by insulin in patients
with Alzheimer disease. Neurology, 66(10), 1506-1510.
387

Kulstad, J. J., McMillan, P. J., Leverenz, J. B., Cook, D. G., Green, P. S., Peskind, E. R.,
et al. (2005). Effects of chronic glucocorticoid administration on insulindegrading enzyme and amyloid-beta peptide in the aged macaque. Journal
of Neuropathology and Experimental Neurology, 64(2), 139-146.
Kuo, W. L., Gehm, B. D., Rosner, M. R., Li, W., & Keller, G. (1994). Inducible
expression and cellular localization of insulin-degrading enzyme in a stably
transfected cell line. The Journal of Biological Chemistry, 269(36), 2259922606.
Kuo, W. L., Montag, A. G., & Rosner, M. R. (1993). Insulin-degrading enzyme is
differentially expressed and developmentally regulated in various rat
tissues. Endocrinology, 132(2), 604-611.
Kuo, Y. M., Crawford, F., Mullan, M., Kokjohn, T. A., Emmerling, M. R., Weller, R. O.,
et al. (2000). Elevated Aβ and apolipoprotein E in AβPP transgenic mice and
its relationship to amyloid accumulation in Alzheimer’s disease. Molecular
Medicine, 6(5), 430-439.
Kuo, Y. M., Emmerling, M. R., Bisgaier, C. L., Essenburg, A. D., Lampert, H. C.,
Drumm, D., et al. (1998). Elevated low-density lipoprotein in Alzheimer's
disease correlates with brain A beta 1-42 levels. Biochemical And Biophysical
Research Communications, 252(3), 711-715.
Kuo, Y. M., Emmerling, M. R., Lampert, H. C., Hempelman, S. R., Kokjohn, T. A.,
Woods, A. S., et al. (1999). High levels of circulating Aβ42 are sequestered
by plasma proteins in Alzheimer’s disease. Biochemical And Biophysical
Research Communications, 257(3), 787-791.
Kupfer, S. R., Wilson, E. M., & French, F. S. (1994). Androgen and glucocorticoid
receptors interact with insulin degrading enzyme. Journal of Biological
Chemistry, 269(32), 20622-20628.
Kurklinsky, S., Abdul-Hay, S., McGuire, M., Howard, E., Knight, J., & Leissring, M. The
Blood Glucose-lowering Effect of Racecadotril is not Attributable to
Inhibition

of

Insulin-degrading

Enzyme.

Hormone

and

metabolic

research(EFirst).
Kurochkin, I. V. (1998). Amyloidogenic determinant as a substrate recognition motif
of insulin-degrading enzyme. FEBS Letters, 427(2), 153-156.
388

Kurochkin, I. V. (2001). Insulin-degrading enzyme: embarking on amyloid
destruction. Trends in Biochemical Sciences, 26(7), 421-425.
Kurochkin, I. V., & Goto, S. (1994). Alzheimer’s β-amyloid peptide specifically
interacts with and is degraded by insulin degrading enzyme. FEBS Letters,
345(1), 33-37.
Kurz, A., & Perneczky, R. (2011). Amyloid clearance as a treatment target against
Alzheimer's disease. Journal of Alzheimer's Disease, 24, 61-73.
Kuusisto, J., Koivisto, K., Mykkänen, L., Helkala, E. L., Vanhanen, M., Hänninen, T., et
al. (1997). Association between features of the insulin resistance syndrome
and Alzheimer's disease independently of apolipoprotein E4 phenotype:
cross sectional population based study. BMJ, 315, 1045-1049.
Kuwano, R., Miyashita, A., Arai, H., Asada, T., Imagawa, M., Shoji, M., et al. (2006).
Dynamin-binding protein gene on chromosome 10q is associated with lateonset alzheimer’s disease. Human Molecular Genetics, 15(13), 2170-2182.
Kwak, S. H., Cho, Y. M., Moon, M. K., Kim, J. H., Park, B. L., Cheong, H. S., et al.
(2008). Association of polymorphisms in the insulin-degrading enzyme gene
with type 2 diabetes in the Korean population. Diabetes Research and
Clinical Practice, 79(2), 284-290.
Laakso, M. (1993). How good a marker is insulin level for insulin resistance?
American Journal of Epidemiology, 137(9), 959-965.
LaDu, M. J., Falduto, M. T., Manelli, A. M., Reardon, C. A., Getz, G. S., & Frail, D. E.
(1994). Isoform-specific binding of apolipoprotein E to β-amyloid. The
Journal of Biological Chemistry, 269(38), 23403-23406.
LaDu, M. J., Pederson, T. M., Frail, D. E., Reardon, C. A., Getz, G. S., & Falduto, M. T.
(1995). Purification of apolipoprotein E attenuates isoform-specific binding
to β-amyloid. The Journal of Biological Chemistry, 270(16), 9039-9042.
LaFerla, F. M., Green, K. N., & Oddo, S. (2007). Intracellular amyloid-β in Alzheimer’s
disease. Nature Reviews. Neuroscience, 8(7), 499-509.
Lan, X., Xu, J., Kiyota, T., Peng, H., Zheng, J. C., & Ikezu, T. (2011). HIV-1 reduces Aβdegrading enzymatic activities in primary human mononuclear phagocytes.
The Journal of Immunology, 186(12), 6925-6932.

389

Launer, L. J., Andersen, K., Dewey, M. E., Letenneur, L., Ott, A., Arnaducci, L. A., et
al. (1999). Rates and risk factors for dementia and Alzheimer's disease Results from EURODEM pooled analyses. Neurology, 52(1), 78-84.
Laws, S. M., Clarnette, R. M., Taddei, K., Martins, G., Paton, A., Hallmayer, J., et al.
(2002). APOE-ε4 and APOE −491A polymorphisms in individuals with
subjective memory loss. Molecular Psychiatry, 7, 768-775.
Lazarov, O., Lee, M., Peterson, D. A., & Sisodia, S. S. (2002). Evidence that
synaptically released β-amyloid accumulates as extracellular deposits in the
hippocampus of transgenic mice. The Journal of Neuroscience, 22(22), 97859793.
Le, A., Barton, L. D., Sanders, J. T., & Zhang, Q. (2010). Exploration of bovine milk
proteome in colostral and mature whey using an ion-exchange approach.
Journal of proteome research, 10(2), 692-704.
Le Bastard, N., Aerts, L., Leurs, J., Blomme, W., De Deyn, P. P., & Engelborghs, S.
(2009). No correlation between time-linked plasma and CSF Aβ levels.
Neurochemistry international, 55(8), 820-825.
Leal, M. C., Dorfman, V. B., Gamba, A. F., Frangione, B., Wisniewski, T., Castaño, E.
M., et al. (2006). Plaque-associated overexpression of insulin-degrading
enzyme in the cerebral cortex of aged transgenic tg2576 mice with
Alzheimer pathology. Journal of Neuropathology & Experimental Neurology,
65(10), 976-987.
Leal, M. C., Magnani, N., Villordo, S., Buslje, C. M., Evelson, P., Castańo, E. M., et al.
(2013). Transcriptional regulation of Insulin Degrading Enzyme modulates
mitochondrial A [beta] catabolism and functionality. Journal of Biological
Chemistry.
Lee, C. D., Tse, W., Smith, J. D., & Landreth, G. E. (2012). Apolipoprotein E promotes
β-amyloid trafficking and degradation by modulating microglial cholesterol
levels. Journal of Biological Chemistry, 287(3), 2032-2044.
Lee, J.-P., Cheng, K.-C., Chung, H.-H., Wu, H.-T., Chen, C.-T., & Cheng, J.-T. (2011).
Inhibition of insulin degrading enzyme by racecadotril in the brain of Wistar
rats. Hormone and metabolic research, 43(07), 489-493.

390

Leibson, C. L., Rocca, W. A., Hanson, V. A., Cha, R., Kokmen, E., O'Brien, P. C., et al.
(1997). Risk of dementia among persons with diabetes mellitus: A
population-based cohort study. American Journal of Epidemiology, 145(4),
301-308.
Leissring, M. A., Farris, W., Chang, A. Y., Walsh, D. M., Wu, X., Sun, X., et al. (2003).
Enhanced proteolysis of β-Amyloid in APP transgenic mice prevents plaque
formation, secondary pathology, and premature death. Neuron, 40(6), 10871093.
Leissring, M. A., Farris, W., Wu, X., Christodoulou, D. C., Haigis, M. C., Guarente, L.,
et al. (2004). Alternative translation initiation generates a novel isoform of
insulin-degrading enzyme targeted to mitochondria. Biochemical Journal,
383(Pt 3), 439-446.
Lesort, M., & Johnson, G. V. (2000). Insulin-like growth factor-1 and insulin mediate
transient site-selective increases in tau phosphorylation in primary cortical
neurons. Neuroscience, 99(2), 305-316.
Lesort, M., Jope, R. S., & Johnson, G. V. W. (1999). Insulin transiently increases tau
phosphorylation: involvement of glycogen synthase kinase-3β and fyn
tyrosine kinase. Journal of Neurochemistry, 72(2), 576-584.
Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H.,
et al. (1995). Candidate gene for the chromosome 1 familial Alzheimer's
disease locus. Science, 269(5226), 973-975.
Li, A., Xue, Y., Jin, C., Wang, M., & Yao, X. (2006). Prediction of N-acetylation on
internal lysines implemented in Bayesian Discriminant Method. Biochemical
And Biophysical Research Communications, 350(4), 818-824.
Li, H., Wetten, S., Li, L., St Jean, P. L., Upmanyu, R., Surh, L., et al. (2008). Candidate
single-nucleotide polymorphisms from a genomewide association study of
Alzheimer disease. Archives of Neurology, 65(1), 45-53.
Li, P., Kuo, W.-L., Yousef, M., Rosner, M. R., & Tang, W.-J. (2006). The C-terminal
domain of human insulin degrading enzyme is required for dimerization and
substrate

recognition.

Biochemical

And

Biophysical

Research

Communications, 343(4), 1032-1037.

391

Li, Q., Ali, M. A., & Cohen, J. I. (2006). Insulin degrading enzyme is a cellular receptor
mediating varicella-zoster virus infection and cell-to-cell spread. Cell, 127(2),
305-316.
Li, Y. J., Scott, W. K., Hedges, D. J., Zhang, F., Gaskell, P. C., Nance, M. A., et al.
(2002). Age at onset in two common neurodegenerative diseases is
genetically controlled. American Journal of Human Genetics, 70(4), 985-993.
Liang, K. Y., Mintun, M. A., Fagan, A. M., Goate, A. M., Bugg, J. M., Holtzman, D. M.,
et al. (2010). Exercise and Alzheimer's disease biomarkers in cognitively
normal older adults. Annals of Neurology, 68(3), 311-318.
Liang, X., Martin, E. R., Schnetz-Boutaud, N., Bartlett, J., Anderson, B., Züchner, S.,
et al. (2007). Effect of heterogeneity on the chromosome 10 risk in lateonset alzheimer disease. Human Mutation, 28(11), 1065-1073.
Liao, L., Cheng, D., Wang, J., Duong, D. M., Losik, T. G., Gearing, M., et al. (2004).
Proteomic characterization of postmortem amyloid plaques isolated by laser
capture microdissection. Journal of Biological Chemistry, 279(35), 3706137068.
Lin, M. T., & Beal, M. F. (2006). Mitochondrial dysfunction and oxidative stress in
neurodegenerative diseases. Nature, 443(7113), 787-795.
Lin, X., Huang, R., Zhang, S., Wei, L., Zhuo, L., Wu, X., et al. (2013). Beneficial effects
of asiaticoside on cognitive deficits in senescence-accelerated mice.
Fitoterapia.
Lindgren, C. M., Mahtani, M. M., Widen, E., McCarthy, M. I., Daly, M. J., Kirby, A., et
al. (2002). Genomewide search for type 2 diabetes mellitus susceptibility
loci in Finnish families: The Botnia study. American Journal of Human
Genetics, 70(2), 509-516.
Lindsay, J., Laurin, D., Verreault, R., Hébert, R., Helliwell, B., Hill, G. B., et al. (2002).
Risk factors for Alzheimer’s disease: A prospective analysis from the
Canadian Study of Health and Aging. American Journal of Epidemiology,
156(5), 445-453.

392

Liu, F., Arias-Vásquez, A., Sleegers, K., Aulchenko, Y. S., Kayser, M., Sanchez-Juan, P.,
et al. (2007). A genomewide screen for late-onset alzheimer disease in a
genetically isolated Dutch population. American Journal of Human Genetics,
81(1), 17-31.
Liu, Y., Guan, H., Beckett, T. L., Juliano, M. A., Juliano, L., Song, E. S., et al. (2007). In
vitro and in vivo degradation of Aβ peptide by peptidases coupled to
erythrocytes. Peptides, 28(12), 2348-2355.
Liu, Y., Hua, Q., Lei, H., & Li, P. (2011). Effect of Tong Luo Jiu Nao on Aβ-degrading
enzymes in AD rat brains. Journal of ethnopharmacology, 137(2), 1035-1046.
Liu, Y., Studzinski, C., Beckett, T., Murphy, M. P., Klein, R. L., & Hersh, L. B. (2010).
Circulating neprilysin clears brain amyloid. Molecular and Cellular
Neuroscience, 45(2), 101-107.
Liu, Y.-H., Giunta, B., Zhou, H.-D., Tan, J., & Wang, Y.-J. (2012(b)). Immunotherapy
for Alzheimer disease—the challenge of adverse effects. Nature Reviews
Neurology, 8(8), 465-469.
Liu, Z., Zhu, H., Fang, G. G., Walsh, K., Mwamburi, M., Wolozin, B., et al. (2012(a)).
Characterization of Insulin Degrading Enzyme and Other Amyloid-β
Degrading Proteases in Human Serum: A Role in Alzheimer's Disease?
Journal of Alzheimer's Disease, 29(2), 329-340.
Llovera, R. E., de Tullio, M., Alonso, L. G., Leissring, M. A., Kaufman, S. B., Roher, A.
E., et al. (2008). The Catalytic Domain of Insulin-degrading Enzyme Forms a
Denaturant-resistant Complex with Amyloid β Peptide IMPLICATIONS FOR
ALZHEIMER DISEASE PATHOGENESIS. Journal of Biological Chemistry,
283(25), 17039-17048.
Lokhov, P. G., Moshkovskii, S. A., Ipatova, O. M., & Prozorovskii, V. N. (2004).
Cytosolic insulin-binding proteins of mouse liver cells. Protein and peptide
letters, 11(1), 29-33.
Luchsinger, J. A., Tang, M., Shea, S., & Mayeux, R. (2004). Hyperinsulinemia and risk
of Alzheimer disease. Neurology, 63(7), 1187-1192.
Luchsinger, J. A., Tang, M. X., Stern, Y., Shea, S., & Mayeux, R. (2001). Diabetes
mellitus and risk of Alzheimer’s disease and dementia with stroke in a
multiethnic cohort. American Journal of Epidemiology, 154(7), 635-641.
393

Lue, L. F., Kuo, Y. M., Roher, A. E., Brachova, L., Shen, Y., Sue, L., et al. (1999).
Soluble amyloid β peptide concentration as a predictor of synaptic change in
Alzheimer’s disease. American Journal of Pathology, 155(3), 853-862.
Lui, J. K., Laws, S. M., Li, Q.-X., Villemagne, V. L., Ames, D., Brown, B., et al. (2010).
Plasma amyloid-β as a biomarker in Alzheimer's disease: the AIBL study of
aging. Journal of Alzheimer's Disease, 20(4), 1233-1242.
Lundgren, H., Bengtsson, C., Blohme, G., Lapidus, L., & Waldenstrom, J. (1990).
Fasting serum insulin concentration and early insulin response as risk
determinants for developing diabetes. Diabetic Medicine: A Journal of the
British Diabetic Association, 7(5), 407-413.
Luo, D., Hou, X., Hou, L., Wang, M., Xu, S., Dong, C., et al. (2011). Effect of
pioglitazone on altered expression of Aβ metabolism-associated molecules
in the brain of fructose-drinking rats, a rodent model of insulin resistance.
European Journal of Pharmacology, 664(1), 14-19.
MacKnight, C., Rockwood, K., Awalt, E., & McDowell, I. (2002). Diabetes mellitus
and the risk of dementia, Alzheimer's disease and vascular cognitive
impairment in the Canadian Study of Health and Aging. Dementia and
Geriatric Cognitive Disorders, 14(2), 77-83.
Maechler, P. (2002). Mitochondria as the conductor of metabolic signals for insulin
exocytosis in pancreatic β-cells. Cellular and Molecular Life Sciences, 59(11),
1803-1818.
Mafuvadze, B., & Erlwanger, K. H. (2007). The effect of EDTA, heparin and storage
on the erythrocyte osmotic fragility, plasma osmolality and haematocrit of
adult ostriches (Struthio camelus). Veterinarski arhiv, 77(5), 427-434.
Mahley, R. W. (1988). Apolipoprotein E: Cholesterol transport protein with
expanding role in cell biology. Science, 240(4852), 622-630.
Mahley, R. W., Weisgraber, K. H., & Huang, Y. (2006). Apolipoprotein E4: A
causative factor and therapeutic target in neuropathology, including
Alzheimer’s disease. Proceedings of the National Academy of Sciences,
103(15), 5644-5651.

394

Mahtani, M. M., Widen, E., Lehto, M., Thomas, J., McCarthy, M., Brayer, J., et al.
(1996). Mapping of a gene for type 2 diabetes associated with an insulin
secretion defect by a genome scan in Finnish families. Nature Genetics,
14(1), 90-94.
Malito, E., Ralat, L. A., Manolopoulou, M., Tsay, J. L., Wadlington, N. L., & Tang, W. J.
(2008). Molecular bases for the recognition of short peptide substrates and
cysteine-directed modifications of human insulin-degrading enzyme.
Biochemistry, 47(48), 12822-12834.
Manczak, M., Anekonda, T. S., Henson, E., Park, B. S., Quinn, J., & Reddy, P. H.
(2006). Mitochondria are a direct site of Aβ accumulation in Alzheimer's
disease neurons: implications for free radical generation and oxidative
damage in disease progression. Human Molecular Genetics, 15(9), 14371449.
Manelli, A. M., Bulfinch, L. C., Sullivan, P. M., & LaDu, M. J. (2007). Abeta42
neurotoxicity in primary co-cultures: effect of apoE isoform and Abeta
conformation. Neurobiology of Aging, 28(8), 1139-1147.
Marfaing-Jallat, P., Portha, B., & Penicaud, L. (1995). Altered conditioned taste
aversion and glucose utilization in related brain nuclei of diabetic GK rats.
Brain Research Bulletin, 37(6), 639-643.
Marin, R., Marrero-Alonso, J., Fernandez, C., Cury, D., & Diaz, M. (2011). Estrogen
receptors in lipid raft signalling complexes for neuroprotection. Frontiers in
bioscience (Elite edition), 4, 1420-1433.
Marlowe, L., Peila, R., Benke, K. S., Hardy, J., White, L. R., Launer, L. J., et al. (2006).
Insulin-degrading enzyme haplotypes affect insulin levels but not dementia
risk. Neurodegenerative Diseases, 3(6), 320-326.
Martin, B. L., Schrader-Fischer, G., Busciglio, J., Duke, M., Paganetti, P., & Yankner,
B. A. (1995). Intracellular accumulation of β-amyloid in cells expressing the
Swedish mutant amyloid precursor protein. Journal of Biological Chemistry,
270(45), 26727-26730.
Martini, F. H., Ober, W. C., Garrison, C. W., Welch, K., & Hutchings, R. T. (1998).
Fundamentals of Anatomy and Physiology (4th ed.): New Jersey, USA:
Prentice Hall, Inc.
395

Martins, R. (2009). Exploring the association between plasma apoE levels and
Alzheimer's disease: Australian Imaging, Biomarker and Lifestyle (AIBL)
flagship study of ageing. Alzheimer's and Dementia: The Journal of the
Alzheimer's Association, 5(4), P308-P309.
Masters, C. L., Multhaup, G., Simms, G., Pottgiesser, J., Martins, R. N., & Beyreuther,
K. (1985). Neuronal origin of a cerebral amyloid: neurofibriliary tangles of
Alzheimer's disease contain the same protein as the amyloid of plaque cores
and blood vessels. The EMBO Journal, 4(11), 2757-2763.
Mattsson, N., Zetterberg, H., Hansson, O., Andreasen, N., Parnetti, L., Jonsson, M.,
et al. (2009). CSF biomarkers and incipient Alzheimer disease in patients
with mild cognitive impairment. JAMA: the journal of the American Medical
Association, 302(4), 385-393.
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., et
al. (2010). Decreased clearance of CNS β-amyloid in Alzheimer’s disease.
Science, 330(6012), 1774-1774.
Mayeux, R., Honig, L. S., Tang, M. X., Manly, J., Stern, Y., Schupf, N., et al. (2003).
Plasma Aβ40 and Aβ42 and Alzheimer's disease: Relation to age, mortality,
and risk. Neurology, 61(9), 1185-1190.
Mayeux, R., Tang, M. X., Jacobs, D. M., Manly, J., Bell, K., Merchant, C., et al. (1999).
Plasma amyloid β-peptide 1–42 and incipient Alzheimer’s disease. Annals of
Neurology, 46(3), 412-416.
McDermott, J. R., & Gibson, A. M. (1997). Degradation of Alzheimer's β-amyloid
protein by human and rat brain peptidases: involvement of

insulin-

degrading enzyme. Neurochemical Research, 22(1), 49-56.
McKee, A. C., Kosik, K. S., & Kowall, N. W. (1991). Neuritic pathology and dementia
in Alzheimer’s disease. Annals of Neurology, 30(2), 156-165.
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M.
(1984). Clinical diagnosis of Alzheimer's disease: report of the NINCDSADRDA Work Group under the auspices of Department of Health and
Human Services Task Force on Alzheimer's disease. Neurology, 34, 939-944.

396

McLean, C. A., Cherny, R. A., Fraser, F. W., Fuller, S. J., Smith, M. J., Beyreuther, K.,
et al. (1999). Soluble pool of Aβ amyloid as a determinant of severity of
neurodegeneration in Alzheimer’s disease. Annals of Neurology, 46(6), 860866.
McQueen, M. B., Bertram, L., Lange, C., Becker, K. D., Albert, M. S., Tanzi, R. E., et al.
(2007). Exploring candidate gene associations with neuropsychological
performance. American Journal of Medical Genetics Part B (Neuropsychiatric
Genetics), 144B(8), 987-991.
Mega, M. S., Masterman, D. M., O'Connor, S. M., Barclay, T. R., & Cummings, J. L.
(1999). The spectrum of behavioral responses to cholinesterase inhibitor
therapy in Alzheimer disease. Archives of Neurology, 56, 1388-1393.
Mehta, P. D., Pirttilä, T., Mehta, S. P., Sersen, E. A., Aisen, P. S., & Wisniewski, H. M.
(2000). Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40
and 1-42 in Alzheimer disease. . Archives of Neurology, 57(1), 100-105.
Meigs, J. B., Panhuysen, C. I. M., Myers, R. H., Wilson, P. W. F., & Cupples, L. A.
(2002). A genome-wide scan for loci linked to plasma levels of glucose and
HbA1c in a community-based sample of Caucasian pedigrees. Diabetes,
51(3), 833-840.
Mensink, R. P., Zock, P. L., Kester, A. D., & Katan, M. B. (2003). Effects of dietary
fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol
and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled
trials. The American journal of clinical nutrition, 77(5), 1146-1155.
Mielke, M. M., & Lyketsos, C. G. (2006). Lipids and the pathogenesis of Alzheimer's
disease: Is there a link? International Review of Psychiatry, 18(2), 173-186.
Miller, B. C., Eckman, E. A., Sambamurti, K., Dobbs, N., Chow, K. M., Eckman, C. B.,
et al. (2003). Amyloid-β peptide levels in brain are inversely correlated with
insulysin activity levels in vivo. Proceedings of the National Academy of
Sciences, 100(10), 6221-6226.
Miller, D. L., Papayannopoulos, I. A., Styles, J., Bobin, S. A., Lin, Y. Y., Biemann, K., et
al. (1993). Peptide compositions of the cerebrovascular and senile plaque
core amyloid deposits of Alzheimer's disease. . Archives of Biochemistry and
Biophysics, 301(1), 41-52.
397

Milord, E., & Gragnoli, C. (2007). Chromosome 10 locus in linkage to type 2 diabetes
in Italians. Obesity and Metabolism - Milan, 3(1), 44-47.
Miners, J. S., Baig, S., Palmer, J., Palmer, L. E., Kehoe, P. G., & Love, S. (2008a). Aβdegrading enzymes in Alzheimer’s disease. Brain Pathology, 18(2), 240-252.
Miners, J. S., Baig, S., Tayler, H., Kehoe, P. G., & Love, S. (2009). Neprilysin and
insulin-degrading enzyme levels are increased in Alzheimer disease in
relation to disease severity. Journal of Neuropathology and Experimental
Neurology, 68(8), 902-914.
Miners, J. S., Kehoe, P. G., & Love, S. (2008b). Immunocapture-based fluorometric
assay for the measurement of insulin-degrading enzyme activity in brain
tissue homogenates. Journal of Neuroscience Methods, 169(1), 177-181.
Mirsky, I. A., & Broh-Kahn, R. H. (1949). The inactivation of insulin by tissue extracts;
the distribution and properties of insulin inactivating extracts. Archives of
biochemistry, 20(1), 1-9.
Misbin, R. I., Almira, E. C., & Cleman, M. W. (1981). Insulin degradation in serum of
a patient with apparent insulin resistance. The Journal of Clinical
Endocrinology and Metabolism, 52(2), 177-180.
Moffat, S. D., Zonderman, A. B., Metter, E. J., Kawas, C., Blackman, M. R., Harman,
S. M., et al. (2004). Free testosterone and risk for Alzheimer disease in older
men. Neurology, 62(2), 188-193.
Mölsä, P. K., Marttila, R. J., & Rinne, U. K. (1986). Survival and cause of death in
Alzheimer's disease and multi-infarct dementia. Acta Neurologica
Scandinavica, 74(2), 103-107.
Mooradian, A. D. (2009). Dyslipidemia in type 2 diabetes mellitus. Nature clinical
practice endocrinology & metabolism, 5(3), 150-159.
Morelli, L., Llovera, R. E., Mathov, I., Lue, L. F., Frangione, B., Ghiso, J., et al. (2004).
Insulin-degrading enzyme in brain microvessels. The Journal of Biological
Chemistry, 279(53), 56004-56013.
Mori, C., Spooner, E. T., Wisniewski, K. E., Wisniewski, T. M., Yamaguchi, H., Saido,
T. C., et al. (2002). Intraneuronal A42 accumulation in Down syndrome
brain. Amyloid, 9(2), 88-102.

398

Morissette, C., Goulet, J., & Lamoureux, G. (1991). Rapid and sensitive sandwich
enzyme-linked immunosorbent assay for detection of staphylococcal
enterotoxin B in cheese. Applied and environmental microbiology, 57(3),
836-842.
Morris, M. C., Evans, D. A., Bienias, J. L., Tangney, C. C., Bennett, D. A., Aggarwal, N.,
et al. (2003). Dietary fats and the risk of incident Alzheimer disease. Archives
of Neurology, 60(2), 194.
Mukherjee, A., Song, E. S., Kihiko-Ehmann, M., Goodman (Jnr), J. P., St Pyrek, J.,
Estus, S., et al. (2000). Insulysin hydrolyzes amyloid β peptides to products
that are neither neurotoxic nor deposit on amyloid plaques. The Journal of
Neuroscience, 20(23), 8745-8749.
Müller, D., Baumeister, H., Buck, F., & Richter, D. (1991). Atrial natriuretic peptide
(ANP) is a high-affinity substrate for rat insulin-degrading enzyme. European
Journal of Biochemistry, 202(2), 285-292.
Muller, M., Tang, M. X., Schupf, N., Manly, J. J., Mayeux, R., & Luchsinger, J. A.
(2007). Metabolic syndrome and dementia risk in a multiethnic elderly
cohort. Dementia and Geriatric Cognitive Disorders, 24(3), 185-192.
Myers, A., Holmans, P., Marshall, H., Kwon, J., Meyer, D., Ramic, D., et al. (2000).
Susceptibitity locus for Alzheimer's disease on chromosome 10. . Science,
290(5500), 2304-2305.
Namba, Y., Tomonaga, M., Kawasaki, H., Otomo, E., & Ikeda, K. (1991).
Apolipoprotein E immunoreactivity in cerebral amyloid deposits and
neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in
Creutzfeldt-Jakob disease. Brain Research, 541(1), 163-166.
Nathan, B. P., Bellosta, S., Sanan, D. A., Weisgraber, K. H., Mahley, R. W., & Pitas, R.
E. (1994). Differential effects of apolipoproteins E3 and E4 on neuronal
growth in vitro. Science, 264(5160), 850-852.
Neant-Fery, M., Garcia-Ordoñez, R. D., Logan, T. P., Selkoe, D. J., Li, L., Reinstatler,
L., et al. (2008). Molecular basis for the thiol sensitivity of insulin-degrading
enzyme. Proceedings of the National Academy of Sciences, 105(28), 95829587.

399

Nelson, P. T., Alafuzoff, I., Bigio, E. H., Bouras, C., Braak, H., Cairns, N. J., et al.
(2012). Correlation of Alzheimer disease neuropathologic changes with
cognitive status: a review of the literature. Journal of Neuropathology &
Experimental Neurology, 71(5), 362.
Noinaj, N., Bhasin, S. K., Song, E. S., Scoggin, K. E., Juliano, M. A., Juliano, L., et al.
(2011(a)). Identification of the allosteric regulatory site of insulysin. PLoS
ONE, 6(6), e20864.
Nordberg, A. (2004). Is amyloid plaque imaging the key to monitoring brain
pathology of Alzheimer's disease in vivo? European Journal of Nuclear
Medicine and Molecular Imaging, 31(11), 1540-1543.
Notkola, I. L., Sulkava, R., Pekkanen, J., Erkinjuntti, T., Ehnholm, c., Kivinen, P., et al.
(1998 ). Serum total cholesterol, apolipoprotein E epsilon 4 allele, and
Alzheimer's disease. Neuroepidemiology, 17(1), 14-20.
Nowotny, P., Hinrichs, A. L., Smemo, S., Kauwe, J. S. K., Maxwell, T., Holmans, P., et
al. (2005). Association studies between risk for late-onset alzheimer’s
disease and variants in insulin degrading enzyme. American Journal of
Medical Genetics Part B (Neuropsychiatric Genetics), 136B(1), 62-68.
O'Brien, J. T., Beats, B., Hill, K., Howard, R., Sahakian, B., & Levy, R. (1992). Do
subjective memory complaints precede dementia - a 3-year follow-up of
patients with supposed benign senescent forgetfulness. International
Journal of Geriatric Psychiatry, 7(7), 481-486.
O'Brien, T. D., Butler, A. E., Roche, P. C., Johnson, K. H., & Butler, P. C. (1994). Islet
amyloid polypeptide in human insulinomas: evidence for intracellular
amyloidogenesis. Diabetes, 43(2), 329-336.
O'Brien, T. D., Butler, P. C., Kreutter, D. K., Kane, L. A., & Eberhardt, N. L. (1995).
Human islet amyloid polypeptide expression in COS-1 cells. A model of
intracellular amyloidogenesis. American Journal of Pathology, 147(3), 609616.
O'Bryant, S. E., Xiao, G., Barber, R., Reisch, J., Doody, R., Fairchild, T., et al. (2010). A
serum protein-based algorithm for the detection of Alzheimer disease.
Archives of Neurology, 67(9), 1077.

400

Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., et al.
(2003). Triple-transgenic model of Alzheimer's disease with plaques and
tangles: intracellular Abeta and synaptic dysfunction. Neuron, 39(3), 409421.
Okello, A., Koivunen, J., Edison, P., Archer, H. A., Turkheimer, F. E., Nagren, K., et al.
(2009). Conversion of amyloid positive and negative MCI to AD over 3 years.
An C-11-PIB PET study. Neurology, 73(10), 754-760.
Okereke, O. I., Xia, W., Selkoe, D. J., & Grodstein, F. (2009). Ten-Year Change in
Plasma Amyloid {beta} Levels and Late-Life Cognitive Decline. Archives of
Neurology, 66(10), 1247.
Ott, A., Stolk, R. P., Hofman, A., van Harskamp, F., Grobbee, D. E., & Breteler, M. M.
(1996). Association of diabetes mellitus and dementia: the Rotterdam Study.
Diabetologia, 39(11), 1392-1397.
Ott, A., Stolk, R. P., van Harskamp, F., Pols, H. A. P., Hofman, A., & Breteler, M. M. B.
(1999). Diabetes mellitus and the risk of dementia. Neurology, 53(9), 19371942.
Ou, Y., Lin, L., Yang, X., Pan, Q., & Cheng, X. (2013). Antidiabetic potential of
phycocyanin: Effects on KKAy mice. Pharmaceutical biology, 51(5), 539-544.
Ozturk, A., DeKosky, S. T., & Kamboh, M. I. (2006). Lack of association of 5 SNPs in
the vicinity of the insulin-degrading enzyme (IDE) gene with late-onset
alzheimer’s disease. Neuroscience Letters, 406(3), 265-269.
Paganini-Hill, A., & Clark, L. J. (2000). Preliminary assessment of cognitive function
in breast cancer patients treated with tamoxifen. Breast cancer research and
treatment, 64(2), 165-176.
Pappolla, M. A., Bryant-Thomas, T. K., Herbert, D., Pacheco, J., Fabra Garcia, M.,
Manjon, M., et al. (2003). Mild hypercholesterolemia is an early risk factor
for the development of Alzheimer amyloid pathology. Neurology, 61(2), 199205.
Parachikova, A., Agadjanyan, M. G., Cribbs, D. H., Blurton-Jones, M., Perreau, V.,
Rogers, J., et al. (2007). Inflammatory changes parallel the early stages of
Alzheimer disease. Neurobiology of Aging, 28(12), 1821-1833.

401

Park, C. R., Seeley, R. J., Craft, S., & Woods, S. C. (2000). Intracerebroventricular
insulin enhances memory in a passive-avoidance task. Physiology and
Behaviour, 68(4), 509-514.
Parmentier, N., Stroobant, V., Colau, D., De Diesbach, P., Morel, S., Chapiro, J., et al.
(2010). Production of an antigenic peptide by insulin-degrading enzyme.
Nature immunology, 11(5), 449-454.
Patil, S., Melrose, J., & Chan, C. (2007). Involvement of astroglial ceramide in
palmitic acid induced Alzheimer like changes in primary neurons. European
Journal of Neuroscience, 26(8), 2131-2141.
Patil, S. P., Maki, S., Khedkar, S. A., Rigby, A. C., & Chan, C. (2010). Withanolide A
and asiatic acid modulate multiple targets associated with amyloid-β
precursor protein processing and amyloid-β protein clearance. Journal of
natural products, 73(7), 1196-1202.
Pearce, R., Greenway, D., & Parkinson, A. (1992). Species differences and
interindividual variation in liver microsomal cytochrome P450 2A enzymes:
effects on coumarin, dicumarol, and testosterone oxidation. Archives of
Biochemistry and Biophysics, 298(1), 211-225.
Peila, R., Rodriguez, B. L., & Launer, L. J. (2002). Type 2 Diabetes, APOE Gene, and
the risk for dementia and related pathologies. The Honolulu-Asia Aging
Study. Diabetes, 51(2002), 1256-1262.
Pérez, A., Morelli, L., Cresto, J. C., & Castaño, E. M. (2000). Degradation of soluble
amyloid β-peptides 1-40, 1-42, and the Dutch variant 1-40Q by insulin
degrading

enzyme

from

Alzheimer

disease

and

control

brains.

Neurochemical Research, 25(2), 247-255.
Perlman, R. K., & Rosner, M. R. (1994). Identification of zinc ligands of the insulindegrading enzyme. The Journal of Biological Chemistry, 269(52), 3314033145.
Peskind, E. R., Wilkinson, C. W., Petrie, E. C., Schellenberg, G. D., & Raskind, M. A.
(2001). Increased CSF cortisol in AD is a function of APOE genotype.
Neurology, 56(8), 1094-1098.

402

Petersen, K. F., Dufour, S., Befroy, D., Garcia, R., & Shulman, G. I. (2004). Impaired
mitochondrial activity in the insulin-resistant offspring of patients with type
2 diabetes. The New England Journal of Medicine, 350(7), 664-671.
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E.
(1999). Mild cognitive impairment: Clinical characterization and outcome.
Archives of Neurology, 56, 303-308.
Phiel, C. J., Wilson, C. A., Lee, V. M. Y., & Klein, P. S. (2003). GSK-3α regulates
production of Alzheimer's disease amyloid-β peptides. Nature, 423(6938),
435-439.
Phillips, K.-A., Aldridge, J., Ribi, K., Sun, Z., Thompson, A., Harvey, V., et al. (2011).
Cognitive function in postmenopausal breast cancer patients one year after
completing adjuvant endocrine therapy with letrozole and/or tamoxifen in
the BIG 1-98 trial. Breast cancer research and treatment, 126(1), 221-226.
Phillips, K.-A., Ribi, K., Sun, Z., Stephens, A., Thompson, A., Harvey, V., et al. (2010).
Cognitive function in postmenopausal women receiving adjuvant letrozole
or tamoxifen for breast cancer in the BIG 1-98 randomized trial. The Breast,
19(5), 388-395.
Pike, C. J., Burdick, D., Walencewicz, A. J., Glabe, C. G., & Cotman, C. W. (1993).
Neurodegeneration induced by β-amyloid peptides in vitro: The role of
peptide assembly state. The Journal of Neuroscience, 13(4), 1676-1687.
Pike, C. J., Walencewicz, A. J., Glabe, C. G., & Cotman, C. W. (1991). In vitro aging of
beta-amyloid protein causes peptide aggregation and neurotoxicity. Brain
Research, 563(1-2), 311-314.
Pike, K. E., Savage, G., Villemagne, V. L., Ng, S., Moss, S. A., Maruff, P., et al. (2007).
Beta-amyloid imaging and memory in non-demented individuals: evidence
for preclinical Alzheimer's disease. . Brain: A Journal of Neurology, 130(11),
2837-2844.
Pivovarova, O., Gögebakan, Ö., Pfeiffer, A., & Rudovich, N. (2009). Glucose inhibits
the insulin-induced activation of the insulin-degrading enzyme in HepG2
cells. Diabetologia, 52(8), 1656-1664.

403

Poirier, R., Wolfer, D. P., Welzl, H., Tracy, J., Galsworthy, M. J., Nitsch, R. M., et al.
(2006). Neuronal neprilysin overexpression is associated with attenuation of
Aβ-related spatial memory deficit. Neurobiology of disease, 24(3), 475-483.
Portelius, E., Zetterberg, H., Gobom, J., Andreasen, U., & Blennow, K. (2008).
Targeted proteomics in Alzheimer's disease: focus on amyloid-β. Expert
Review of Proteomics, 5(2), 225-237.
Prasad, T. K., Goel, R., Kandasamy, K., Keerthikumar, S., Kumar, S., Mathivanan, S.,
et al. (2009). Human protein reference database—2009 update. Nucleic
Acids Research, 37(suppl 1), D767-D772.
Prasanthi, R. P. J., Schommer, E., Thomasson, S., Thompson, A., Feist, G., & Ghribi,
O. (2008). Regulation of beta-amyloid levels in the brain of cholesterol-fed
rabbit, a model system for sporadic Alzheimer's disease. Mechanisms of
Ageing and Development, 129(11), 649-655.
Preston, S. D., Steart, P. V., Wilkinson, A., Nicoll, J. A. R., & Weller, R. O. (2003).
Capillary and arterial cerebral amyloid angiopathy in Alzheimer’s disease:
defining the perivascular route for the elimination of amyloid β from the
human brain. Neuropathology and Applied Neurobiology, 29(2), 106-117.
Prince, J. A., Feuk, L., Gu, H. F., Johansson, B., Gatz, M., Blennow, K., et al. (2003).
Genetic variation in a haplotype block spanning IDE influences Alzheimer
disease. Human Mutation, 22(5), 363-371.
Qin, W., & Jia, J. (2008). Down-regulation of insulin-degrading enzyme by presenilin
1 V97L mutant potentially underlies increased levels of amyloid beta 42. The
European Journal of Neuroscience, 27(9), 2425-2432.
Qiu, W. Q., & Folstein, M. F. (2006). Insulin, insulin-degrading enzyme and amyloidβ peptide in Alzheimer’s disease: review and hypothesis. Neurobiology of
Aging, 27(2), 190-198.
Qiu, W. Q., Walsh, D. M., Ye, Z., Vekrellis, K., Zhang, J., Podlisny, M. B., et al. (1998).
Insulin-degrading enzyme regulates extracellular levels of amyloid β-protein
by degradation. The Journal of Biological Chemistry, 273(49), 32730-32738.

404

Qiu, W. Q., Ye, Z., Kholodenko, D., Seubert, P., & Selkoe, D. J. (1997). Degradation of
amyloid β-protein by a metalloprotease secreted by microglia and other
neural and non-neural cells. The Journal of Biological Chemistry, 272(10),
6641-6646.
Quan, Q., Wang, J., Li, X., & Wang, Y. (2013). Ginsenoside Rg1 Decreases Aβ1–42
Level by Upregulating PPARγ and IDE Expression in the Hippocampus of a
Rat Model of Alzheimer's Disease. PLoS ONE, 8(3), e59155.
Ralat, L. A., Kalas, V., Zheng, Z., Goldman, R. D., Sosnick, T. R., & Tang, W.-J. (2011).
Ubiquitin is a novel substrate for human insulin-degrading enzyme. Journal
of Molecular Biology, 406(3), 454-466.
Ray, S., Britschgi, M., Herbert, C., Takeda-Uchimura, Y., Boxer, A., Blennow, K., et al.
(2007). Classification and prediction of clinical Alzheimer’s diagnosis based
on plasma signaling proteins. Nature Medicine, 13(11), 1359-1362.
Rebeck, G. W., Reiter, J. S., Strickland, D. K., & Hyman, B. T. (1993). Apolipoprotein E
in sporadic Alzheimer's disease: allelic variation and receptor interactions.
Neuron, 11(4), 575-580.
Reddy, P. H., & Beal, M. F. (2008). Amyloid beta, mitochondrial dysfunction and
synaptic damage: implications for cognitive decline in aging and Alzheimer’s
disease. Trends in molecular medicine, 14(2), 45.
Reger, M. A., Watson, G. S., Baker, L. D., Cholerton, B., Fishel, M. A., Plymate, S. R.,
et al. (2008(a)). Intranasal insulin administration dose-dependently
modulates verbal memory and plasma amyloid-beta in memory-impaired
older adults. Journal of Alzheimer's Disease, 13(3), 323-331.
Reger, M. A., Watson, G. S., Frey (2nd), W. H., Baker, L. D., Cholerton, B., Keeling, M.
L., et al. (2006). Effects of intranasal insulin on cognition in memoryimpaired older adults: modulation by APOE genotype. . Neurobiology of
Aging, 27(3), 451-458.
Reger, M. A., Watson, G. S., Green, P. S., Wilkinson, C. W., Baker, L. D., Cholerton,
B., et al. (2008(b)). Intranasal insulin improves cognition and modulates
beta-amyloid in early AD. Neurology, 70(6), 440-448.

405

Reiman, E. M., Chen, K., Liu, X., Bandy, D., Yu, M., Lee, W., et al. (2009). Fibrillar
amyloid-β burden in cognitively normal people at 3 levels of genetic risk for
Alzheimer's disease. Proceedings of the National Academy of Sciences,
106(16), 6820-6825.
Reiman, E. M., Webster, J. A., Myers, A. J., Hardy, J., Dunckley, T., Zismann, V. L., et
al. (2007). GAB2 alleles modify Alzheimer’s risk in APOE ε4 carriers. Neuron,
54(5), 713-720.
Reinhart, P. H., Kaltenbach, L. S., Essrich, C., Dunn, D. E., Eudailey, J. A., DeMarco, C.
T., et al. (2011). Identification of anti-inflammatory targets for Huntington's
disease using a brain slice-based screening assay. Neurobiology of Disease,
43(1), 248-256.
Reitz, C., Tang, M.-X., Schupf, N., Manly, J. J., Mayeux, R., & Luchsinger, J. A. (2010).
Association of higher levels of high-density lipoprotein cholesterol in elderly
individuals and lower risk of late-onset alzheimer disease. Archives of
Neurology, 67(12), 1491.
Rembach, A., Faux, N. G., Watt, A. D., Pertile, K. K., Rumble, R. L., Trounson, B. O., et
al. (2013). Changes in plasma amyloid beta in a longitudinal study of aging
and Alzheimer's disease. Alzheimer's & Dementia.
Rembach, A., Faux, N. G., Watt, A. D., Pertile, K. K., Rumble, R. L., Trounson, B. O., et
al. (2014). Changes in plasma amyloid beta in a longitudinal study of aging
and Alzheimer's disease. Alzheimer's & Dementia, 10(1), 53-61.
Rissman, R. A., Trojanowski, J. Q., Shaw, L. M., & Aisen, P. S. (2012). Longitudinal
plasma amyloid beta as a biomarker of Alzheimer’s disease. Journal of
Neural Transmission, 1-8.
Rizzo, F., Riboldi, G., Salani, S., Nizzardo, M., Simone, C., Corti, S., et al. (2013).
Cellular therapy to target neuroinflammation in amyotrophic lateral
sclerosis. Cellular and Molecular Life Sciences, 1-17.
Roberts, S. B., MacLean, C. J., Neale, M. C., Eaves, L. J., & Kendler, K. S. (1999).
Replication of linkage studies of complex traits: An examination of variation
in location estimates. American Journal of Human Genetics, 65(3), 876-884.

406

Roeschlau, P., Bernt, E., & Gruber, W. (1974). Enzymatic determination of total
cholesterol in serum. Zeitschrift für klinische Chemie und klinische
Biochemie, 12(5), 226.
Roher, A. E., Chaney, M. O., Kuo, Y. M., Webster, S. D., Stine, W. B., Haverkamp, L.
J., et al. (1996). Morphology and toxicity of Aβ-(1–42) dimer derived from
neuritic and vascular amyloid deposits of Alzheimer’s disease. The Journal of
Biological Chemistry, 271(34), 20631-20635.
Roher, A. E., Esh, C. L., Kokjohn, T. A., Castaño, E. M., Van Vickle, G. D., Kalback, W.
M., et al. (2009). Amyloid beta peptides in human plasma and tissues and
their significance for Alzheimer’s disease. Alzheimer's and Dementia, 5(1),
18-29.
Roher, A. E., Kuo, Y. M., Kokjohn, K. M., Emmerling, M. R., & Gracon, S. (1999).
Amyloid and lipids in the pathology of Alzheimer disease. Amyloid, 6(2), 136145.
Romay, C., Gonzalez, R., Ledon, N., Remirez, D., & Rimbau, V. (2003). Cphycocyanin: a biliprotein with antioxidant, anti-inflammatory and
neuroprotective effects. Current protein and peptide science, 4(3), 207-216.
Rosvall, L., Rizzuto, D., Wang, H. X., Winblad, B., Graff, C., & Fratiglioni, L. (2009).
APOE-related mortality: Effect of dementia, cardiovascular disease and
gender. Neurobiology of Aging, 30(10), 1545-1552.
Roth, R. A., Mesirow, M. L., Yokono, K., & Baba, S. (1984). Degradation of insulinlike growth factors I and II by a human insulin degrading enzyme. Endocrine
Research, 10(2), 101-112.
Ryan, K. A., & Pimplikar, S. W. (2005). Activation of GSK-3 and phosphorylation of
CRMP2 in transgenic mice expressing APP intracellular domain. The Journal
of Cell Biology, 171(2), 327-335.
Safavi, A., Miller, B., Cottam, L., & Hersh, L. B. (1996). Identification of γ-endorphingenerating enzyme as insulin-degrading enzyme. Biochemistry, 35(45),
14318-14325.
Sagare, A., Deane, R., Bell, R. D., Johnson, B., Hamm, K., Pendu, R., et al. (2007).
Clearance of amyloid-β by circulating lipoprotein receptors. Nature
Medicine, 13(9), 1029-1031.
407

Sakai, A., Ujike, H., Nakata, K., Takehisa, Y., Imamura, T., Uchida, N., et al. (2004).
No association between the insulin degrading enzyme gene and Alzheimer’s
disease in a Japanese population. American Journal of Medical Genetics Part
B (Neuropsychiatric Genetics), 125B(1), 87-91.
Saric, T., Muller, D., Seitz, H. J., & Pavelic, K. (2003). Non-covalent interaction of
ubiquitin

with

insulin-degrading

enzyme.

Molecular

and

Cellular

Endocrinology, 204(1-2), 11-20.
Saunders, A. M., Schmader, K., Breitner, J. C. S., Benson, M. D., Brown, W. T.,
Goldfarb, L., et al. (1993). Apolipoprotein E ε4 allele distributions in lateonset alzheimer's disease and in other amyloid-forming diseases. The
Lancet, 342(8873), 710-711.
Savage, M. J., Trusko, S. P., Howland, D. S., Pinsker, L. R., Mistretta, S., Reaume, A.
G., et al. (1998). Turnover of amyloid β-protein in mouse brain and acute
reduction of its level by phorbol ester. The Journal of Neuroscience, 18(5),
1743-1752.
Scacchi, R., Gambina, G., Ruggeri, M., Martini, M. C., Ferrari, G., Silvestri, M., et al.
(1999). Plasma levels of apolipoprotein E and genetic markers in elderly
patients with Alzheimer's disease. Neuroscience Letters, 259(1), 33-36.
Scahill, R. I., Schott, J. M., Stevens, J. M., Rossor, M. N., & Fox, N. C. (2002). Mapping
the evolution of regional atrophy in Alzheimer's disease: Unbiased analysis
of fluid-registered serial MRI. Proceedings of the National Academy of
Sciences, 99(7), 4703-4707.
Schechter, R., Holtzclaw, L., Sadiq, F., Kahn, A., & Devaskar, S. (1988). Insulin
synthesis by isolated rabbit neurons. Endocrinology, 123(1), 505-513.
Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., et al. (1996).
Secreted amyloid beta-protein similar to that in the senile plaques of
Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP
mutations linked to familial Alzheimer's disease. Nature Medicine, 2(8), 864870.

408

Schiele, F., De Bacquer, D., Vincent-Viry, M., Beisiegel, U., Ehnholm, C., Evans, A., et
al. (2000). Apolipoprotein E serum concentration and polymorphism in six
European countries: the ApoEurope Project. Atherosclerosis, 152(2), 475488.
Schilder, C. M., Seynaeve, C., Beex, L. V., Boogerd, W., Linn, S. C., Gundy, C. M., et
al. (2010). Effects of tamoxifen and exemestane on cognitive functioning of
postmenopausal

patients

with

breast

cancer:

results

from

the

neuropsychological side study of the tamoxifen and exemestane adjuvant
multinational trial. Journal of Clinical Oncology, 28(8), 1294-1300.
Schmand, B., Jonker, C., Hooijer, C., & Lindeboom, J. (1996). Subjective memory
complaints may announce dementia. Neurology, 46(1), 121-125.
Schmidtke, K., & Hermeneit, S. (2008). High rate of conversion to Alzheimers'
disease in a cohort of amnestic MCI patients. International Psychogeriatrics,
20(1), 96-108.
Schooling, C. M., Yeung, S. L. A., Freeman, G., & Cowling, B. J. (2013). The effect of
statins on testosterone in men and women, a systematic review and metaanalysis of randomized controlled trials. BMC medicine, 11(1), 1-9.
Schupf, N., Tang, M. X., Fukuyama, H., Manly, J., Andrews, H., Mehta, P., et al.
(2008). Peripheral Aβ subspecies as risk biomarkers of Alzheimer’s disease.
Proceedings of the National Academy of Sciences, 105(37), 14052-14057.
Sehgal, N., Gupta, A., Valli, R. K., Joshi, S. D., Mills, J. T., Hamel, E., et al. (2012).
Withania somnifera reverses Alzheimer's disease pathology by enhancing
low-density lipoprotein receptor-related protein in liver. Proceedings of the
National Academy of Sciences, 109(9), 3510-3515.
Selkoe, D. J. (1994). Alzheimer's disease: a central role for amyloid. Journal of
Neuropathology and Experimental Neurology, 53(5), 438-447.
Selkoe, D. J. (2001). Clearing the brain’s amyloid cobwebs. Neuron, 32, 177-180.
Selkoe, D. J. (2011). Resolving controversies on the path to Alzheimer's
therapeutics. Nature, 17(9), 1060-1065.
Seta, K. A., & Roth, R. A. (1997). Overexpression of insulin degrading enzyme:
cellular localization and effects on insulin signaling. Biochemical And
Biophysical Research Communications, 231(1), 167-171.
409

Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., et al. (1992).
Isolation and quantification of soluble Alzheimer's β-peptide from biological
fluids. Nature, 359(6393), 325-327.
Shah, V. P., Midha, K. K., Dighe, S., McGilveray, I. J., Skelly, J. P., Yacobi, A., et al.
(1992). Analytical methods validation: bioavailability, bioequivalence, and
pharmacokinetic studies. Journal of pharmaceutical sciences, 81(3), 309-312.
Sharma, S., Prasanthi, R. P. J., Schommer, E., Feist, G., & Ghribi, O. (2008).
Hypercholesterolemia-induced Aβ accumulation in rabbit brain is associated
with alteration in IGF-1 signaling. Neurobiology of Disease, 32(3), 426-432.
Shearer, J. D., Coulter, C. F., Engeland, W. C., Roth, R. A., & Caldwell, M. D. (1997).
Insulin is degraded extracellularly in wounds by insulin-degrading enzyme.
American Journal of Physiology: Endocrinology and Metabolism, 273(4),
E657-E664.
Shen, Y. (2006). Structures of human insulin-degrading enzyme reveal a new
substrate recognition mechanism. Nature, 443(7113), 870-874.
Shen, Y. (2006). University of Chigaco. Retrieved August 13, 2009, from Argonne
National

Laboratory

website:

http://www.aps.anl.gov/Science/Highlights/2006/20061012.htm
Sheng, J. G., Mrak, R. E., & Griffin, W. S. T. (1996). Apolipoprotein E distribution
among different plaque types in Alzheimer's disease: implications for its role
in plaque progression. Neuropathology and Applied Neurobiology, 22, 334341.
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., et al.
(1995). Cloning of a gene bearing missense mutations in early-onset familial
Alzheimer's disease. Nature, 375(6534), 754-760.
Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., et al.
(2000). Clearance of Alzheimer’s amyloid-β 1-40 peptide from brain by LDL
receptor–related protein-1 at the blood-brain barrier. The Journal of Clinical
Investigation, 106(12), 1489-1499.
Shimizu, E., Kawahara, K., Kajizono, M., Sawada, M., & Nakayama, H. (2008). IL-4Induced Selective Clearance of Oligomeric β-Amyloid Peptide1–42 by Rat
Primary Type 2 Microglia. The Journal of Immunology, 181(9), 6503-6513.
410

Shin, J., Lee, S. Y., Kim, S. H., Kim, Y. B., & Cho, S. J. (2008). Multitracer PET imaging
of amyloid plaques and neurofibrillary tangles in Alzheimer's disease .
Neuroimage, 43(2), 236-244.
Shinall, H., Song, E. S., & Hersh, L. B. (2005). Susceptibility of amyloid β peptide
degrading enzymes to oxidative damage: A potential Alzheimer’s disease
spiral. Biochemistry, 44(46), 15345-15350.
Siest, G., Bertrand, P., Qin, B., Herbeth, B., Serot, J. M., Masana, L., et al. (2000).
Apolipoprotein E polymorphism and serum concentration in Alzheimer's
disease in nine European centres: The ApoEurope Study. Clinical Chemistry
and Laboratory Medicine`, 38(8), 721-730.
Sinclair, A. J., Girling, A. J., & Bayer, A. J. (2000). Cognitive dysfunction in older
subjects with diabetes mellitus: impact on diabetes self-management and
use of care services. All Wales Research into Elderly (AWARE) Study.
Diabetes Research and Clinical Practice, 50(3), 203-212.
Sivilia, S., Lorenzini, L., Giuliani, A., Gusciglio, M., Fernandez, M., Baldassarro, V. A.,
et al. (2013). Multi-target action of the novel anti-Alzheimer compound
CHF5074: in vivo study of long term treatment in Tg2576 mice. BMC
neuroscience, 14(1), 1-14.
Sladek, R., Rocheleau, G., Rung, J., Dina, C., Shen, L., Serre, D., et al. (2007). A
genome-wide association study identifies novel risk loci for type 2 diabetes.
Nature, 445(7130), 881-885.
Slooter, A. J., de Knijff, P., Hofman, A., Cruts, M., Breteler, M. M., Van Broeckhoven,
C., et al. (1998). Serum apolipoprotein E level is not increased in Alzheimer's
disease: the Rotterdam study. Neuroscience Letters, 248(1), 21-24.
Snyder, S. W., Ladror, U. S., Wade, W. S., Wang, G. T., Barrett, L. W., Matayoshi, E.
D., et al. (1994). Amyloid-β aggregation: Selective inhibition of aggregation
in mixtures of amyloid with different chain lengths. Biophysical Journal,
67(3), 1216-1228.
Soares, H. D., Potter, W. Z., Pickering, E., Kuhn, M., Immermann, F. W., Shera, D. M.,
et al. (2012). Plasma biomarkers associated with the Apolipoprotein E
genotype and Alzheimer's disease. Archives of Neurology, 69(10), 13101317.
411

Sokolova, A., Hill, M. D., Rahimi, F., Warden, L. A., Halliday, G. M., & Shepherd, C. E.
(2009). Monocyte chemoattractant protein-1 plays a dominant role in the
chronic inflammation observed in Alzheimer’s disease. Brain Pathology,
19(3), 392-398.
Song, E. S., Daily, A. D., Fried, M. G., Juliano, M. A., Juliano, L., & Hersh, L. B. (2005).
Mutation of active site residues of insulin-degrading enzyme alters allosteric
interactions. The Journal of Biological Chemistry, 280(18), 17701-17706.
Song, E. S., & Hersh, L. B. (2005). Insulysin - An allosteric enzyme as a target for
Alzheimer's disease. Journal of Molecular Neuroscience, 25(3), 201-206.
Song, E. S., Juliano, M. A., Juliano, L., & Hersh, L. B. (2003). Substrate activation of
insulin-degrading enzyme (insulysin). The Journal of Biological Chemistry,
278(50), 49789-49794.
Song, E. S., Rodgers, D. W., & Hersh, L. B. (2010). A monomeric variant of insulin
degrading enzyme (IDE) loses its regulatory properties. PLoS ONE, 5(3),
e9719.
Song, F., Poljak, A., Valenzuela, M., Mayeux, R., Smythe, G. A., & Sachdev, P. S.
(2011). Meta-analysis of plasma amyloid-β levels in Alzheimer's disease.
Journal of Alzheimer's Disease, 26(2), 365-375.
Spencer, B., Marr, R. A., Rockenstein, E., Crews, L., Adame, A., Potkar, R., et al.
(2008). Long-term neprilysin gene transfer is associated with reduced levels
of intracellular Abeta and behavioral improvement in APP transgenic mice.
BMC neuroscience, 9(1), 109.
Stargardt, A., Gillis, J., Kamphuis, W., Wiemhoefer, A., Kooijman, L., Raspe, M., et al.
(2013). Reduced amyloid-β degradation in early Alzheimer's disease but not
in the APPswePS1dE9 and 3xTg-AD mouse models. Aging cell.
Steen, E., Terry, B. M., Rivera, E. J., Cannon, J. L., Neely, T. R., Tavares, R., et al.
(2005). Impaired insulin and insulin-like growth factor expression and
signaling mechanisms in Alzheimer's disease--is this type 3 diabetes? Journal
of Alzheimer's Disease, 7(1), 63-80.
Stelzmann, R. A., Schnitzlein, H. N., & Murtagh, F. R. (1995). An English translation
of Alzheimer's 1907 paper, "Über eine eigenartige Erkankung der Hirnrinde".
Clinical Anatomy, 8, 429-431.
412

Stewart, R., & Liolitsa, D. (1999). Type 2 diabetes mellitus, cognitive impairment and
dementia. Diabetic Medicine, 16(2), 93-112.
Stine, W. B., Dahlgren, K. N., Krafft, G. A., & LaDu, M. J. (2003). In vitro
characterization of conditions for amyloid-β peptide oligomerization and
fibrillogenesis. The Journal of Biological Chemistry, 278(13), 11612-11622.
Stolk, R. P., Breteler, M. M. B., Ott, A., Pols, H. A. P., Lamberts, S. W. J., Grobbee, D.
E., et al. (1997). Insulin and cognitive function in an elderly population. The
Rotterdam Study. Diabetes Care, 20(5), 792-795.
Strittmatter, W. J., Saunders, A. M., Schmechel, D. J., Pericak-Vance, M. A., Enghild,
J., Salvesen, G. S., et al. (1993(a)). Apolipoprotein E: High-avidity binding to
B-amyloid and increased frequency of type 4 allele in late-onset familial
Alzheimer disease. Proceedings of the National Academy of Sciences, 90(5),
1977-1981.
Strittmatter, W. J., Weisgraber, K. H., Huang, D. Y., Dong, L. M., Salvesen, G. S.,
Pericak-Vance, M. A., et al. (1993(b)). Binding of human apolipoprotein E to
synthetic amyloid B peptide: Isoform-specific effects and implications for
late-onset alzheimer disease. Proceedings of the National Academy of
Sciences, 90(17), 8098-8102.
Su, A. I., Cooke, M. P., Ching, K. A., Hakak, Y., Walker, J. R., Wiltshire, T., et al.
(2002). Large-scale analysis of the human and mouse transcriptomes.
Proceedings of the National Academy of Sciences, 99(7), 4465-4470.
Sudoh, S., Frosch, M. P., & Wolf, B. A. (2002). Differential effects of proteases
involved in intracellular degradation of amyloid β-protein between
detergent-soluble and -insoluble pools in CHO-695 cells. Biochemistry, 41(4),
1091-1099.
Sutcliffe, J. G., Hedlund, P. B., Thomas, E. A., Bloom, F. E., & Hilbush, B. S. (2011).
Peripheral reduction of β‐amyloid is sufficient to reduce brain β‐amyloid:
Implications for Alzheimer's disease. Journal of neuroscience research, 89(6),
808-814.
Suzuki, N., Cheung, T. T., Cai, X. D., Odaka, A., Otvos Jr., L., Eckman, C., et al. (1994).
An increased percentage of long amyloid Beta protein secreted by familial
amyloid Beta protein precursor mutants. Science, 264(5163), 1336-1340.
413

Szoeke, C., Ellis, K. A., Bush, A., Darby, D., De Fazio, D., Foster, J., et al. (2009). The
AIBL study: Baseline data from a multicenter, prospective longitudinal study
of ageing in 1,100 volunteers. Alzheimer's and Dementia: The Journal of the
Alzheimer's Association, 5(4), P184-P185.
T Ferretti, M., Partridge, V., C Leon, W., Canneva, F., Allard, S., N Arvanitis, D., et al.
(2011). Transgenic Mice as a Model of Pre-Clinical Alzheimers Disease.
Current Alzheimer Research, 8(1), 4-23.
Taddei, K., Clarnette, R., Gandy, S. E., & Martins, R. N. (1997). Increased plasma
apolipoprotein E (apoE) levels in Alzheimer's disease. Neuroscience Letters,
223(1), 29-32.
Takata, K., Hirata-Fukae, C., Becker, A. G., Chishiro, S., Gray, A. J., Nishitomi, K., et
al. (2007). Deglycosylated anti-amyloid beta antibodies reduce microglial
phagocytosis and cytokine production while retaining the capacity to induce
amyloid beta sequestration. European Journal of Neuroscience, 26(9), 24582468.
Talbot, K., Wang, H.-Y., Kazi, H., Han, L.-Y., Bakshi, K. P., Stucky, A., et al. (2012).
Demonstrated brain insulin resistance in Alzheimer’s disease patients is
associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline.
The Journal of Clinical Investigation, 122(4), 1316.
Tamboli, I. Y., Barth, E., Christian, L., Siepmann, M., Kumar, S., Singh, S., et al.
(2010). Statins promote the degradation of extracellular amyloid β-peptide
by microglia via stimulation of exosome-associated insulin-degrading
enzyme (IDE) secretion. Journal of Biological Chemistry, 285(48), 3740537414.
Tate, J., & Ward, G. (2004). Interferences in immunoassay. The Clinical Biochemist
Reviews, 25(2), 105.
Thal, D. R., Griffin, W. S. T., de Vos, R. A. I., & Ghebremedhin, E. (2008). Cerebral
amyloid angiopathy and its relationship to Alzheimer’s disease. Acta
Neuropathologica, 115(6), 599-609.

414

Thambisetty, M., Simmons, A., Velayudhan, L., Hye, A., Campbell, J., Zhang, Y., et al.
(2010). Association of plasma clusterin concentration with severity,
pathology, and progression in Alzheimer disease. Archives of General
Psychiatry, 67(7), 739.
The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and
the National Institute on Aging Working Group. (1998). Consensus report of
the working group on molecular and biochemical markers of Alzheimer's
disease. Neurobiology of Aging, 19(2), 109-116.
Tiraboschi, P., Hansen, L. A., Thal, L. J., & Corey-Bloom, J. (2004). The importance of
neuritic plaques and tangles to the development and evolution of AD.
Neurology, 62(11), 1984-1989.
Tokuda, T., Calero, M., Matsubara, E., Vidal, R., Kumar, A., Permanne, B., et al.
(2000). Lipidation of apolipoprotein E influences its isoform-specific
interaction with Alzheimer’s amyloid β peptides. Biochemical Journal, 348(Pt
2), 359-365.
Tundo, G., Ciaccio, C., Sbardella, D., Boraso, M., Viviani, B., Coletta, M., et al. (2012).
Somatostatin modulates insulin-degrading-enzyme metabolism: implications
for the regulation of microglia activity in AD. PLoS ONE, 7(4), e34376.
Tundo, G. R., Sbardella, D., Ciaccio, C., Bianculli, A., Orlandi, A., Desimio, M. G., et al.
(2013). Insulin-degrading Enzyme (IDE) A NOVEL HEAT SHOCK-LIKE PROTEIN.
Journal of Biological Chemistry, 288(4), 2281-2289.
Udrisar, D. P., Wanderley, M. I., Porto, R. C., Cardoso, C. L., Barbosa, M. C.,
Camberos, M. C., et al. (2005). Androgen-and estrogen-dependent
regulation of insulin-degrading enzyme in subcellular fractions of rat
prostate and uterus. Experimental Biology and Medicine, 230(7), 479-486.
Umegaki, H., Ikari, H., Nakahata, H., Endo, H., Suzuki, Y., Ogawa, O., et al. (2000).
Plasma cortisol levels in elderly female subjects with Alzheimer's disease: a
cross-sectional and longitudinal study. Brain Research, 881(2), 241-243.
UniProt Consortium. (2014). Activities at the Universal Protein Resource (UniProt).
Nucleic Acids Research, 42(D1), D191-D198.

415

Urbonaviciute, V., Fürnrohr, B. G., Weber, C., Haslbeck, M., Wilhelm, S., Herrmann,
M., et al. (2007). Factors masking HMGB1 in human serum and plasma.
Journal of leukocyte biology, 81(1), 67-74.
Valdes, R., & Jortani, S. A. (2002). Unexpected suppression of immunoassay results
by cross-reactivity: now a demonstrated cause for concern. Clinical
Chemistry, 48(3), 405-406.
van den Berg, E., Kessels, R. P. C., de Haan, E. H. F., Kappelle, L. J., & Biessels, G. J.
(2005). Mild impairments in cognition in patients with type 2 diabetes
mellitus: the use of the concepts MCI and CIND. Journal of Neurology,
Neurosurgery, and Psychiatry, 76(10), 1466-1467.
van Duijn, C. M. (1996). Epidemiology of the dementias: recent developments and
new approaches. Journal of Neurology, Neurosurgery, and Psychiatry, 60(5),
478-488.
van Duijn, C. M., Clayton, D. G., Chandra, V., Fratiglioni, L., Graves, A. B., Heyman,
A., et al. (1994). Interaction between genetic and environmental risk factors
for Alzheimer's disease: a reanalysis of case-control studies. Genetic
Epidemiology, 11(6), 539-551.
van Oijen, M., Hofman, A., Soares, H. D., Koudstaal, P. J., & Breteler, M. M. B.
(2006). Plasma A beta(1-40) and A beta(1-42) and the risk of dementia: a
prospective case-cohort study. Lancet Neurology, 5(8), 655-660.
Vanderstichele, H., Van Kerschaver, E., Hesse, C., Davidsson, P., Buyse, M. A.,
Andreasen, N., et al. (2000). Standardization of measurement of -amyloid(142) in cerebrospinal fluid and plasma. Amyloid, 7(4), 245-258.
Vanhanen, M., Koivisto, K., Kuusisto, J., Mykkänen, L., Helkala, E. L., Hänninen, T., et
al. (1998). Cognitive function in an elderly population with persistent
impaired glucose tolerance. Diabetes Care, 21(3), 398-402.
Vega, C. A., Butler, R. A., Perez, B., & Torres, C. (1985). Thermodynamics of the
dissociation of protonated tris (hydroxymethyl) aminomethane in 25 and 50
wt% 2-propanol from 5 to 45 ° C. Journal of Chemical and Engineering Data,
30(4), 376-379.

416

Vekrellis, K., Ye, Z., Qiu, W. Q., Walsh, D. M., Hartley, D., Chesneau, V., et al. (2000).
Neurons regulate extracellular levels of amyloid β-protein via proteolysis by
insulin-degrading enzyme. The Journal of Neuroscience, 20(5), 1657-1665.
Venugopal, C., Pappolla, M. A., & Sambamurti, K. (2007). Insulysin cleaves the APP
cytoplasmic fragment at multiple sites. Neurochemical Research, 32(12),
2225-2234.
Vepsäläinen, S., Hiltunen, M., Helisalmi, S., Wang, J., van Groen, T., Tanila, H., et al.
(2008). Increased expression of Aβ degrading enzyme IDE in the cortex of
transgenic mice with Alzheimer's disease-like neuropathology. Neuroscience
Letters, 438(2), 216-220.
Vepsäläinen, S., Parkinson, M., Helisalmi, S., Mannermaa, A., Soininen, H., Tanzi, R.
E., et al. (2007). Insulin-degrading enzyme is genetically associated with
Alzheimer’s disease in the Finnish population. Journal of Medical Genetics,
44(9), 606-608.
Verdile, G., Fuller, S., Atwood, C. S., Laws, S. M., Gandy, S. E., & Martins, R. N.
(2004). The role of beta amyloid in Alzheimer's disease: still a cause of
everything or the only one who got caught? . Pharmacological Research: The
Official Journal of the Italian Pharmacological Society, 50(4), 397-409.
Verdile, G., Laws, S., Henley, D., Ames, D., Bush, A., Ellis, K., et al. (2012).
Associations between gonadotropins, testosterone and β amyloid in men at
risk of Alzheimer’s disease. Molecular psychiatry.
Vest, R. S., & Pike, C. J. (2013). Gender, sex steroid hormones, and Alzheimer's
disease. Hormones and behavior, 63(2), 301-307.
Vincent-Viry, M., Schiele, F., Gueguen, R., Bohnet, K., Visvikis, S., & Siest, G. (1998).
Biological variations and genetic reference values for apolipoprotein E
serum concentrations: results from the STANISLAS cohort study. Clinical
Chemistry, 44(5), 957-965.
Visser, P. J., Verhey, F., Knol, D. L., Scheltens, P., Wahlund, L. O., Freund-Levi, Y., et
al. (2009). Prevalence and prognostic value of CSF markers of Alzheimer’s
disease pathology in patients with subjective cognitive impairment or mild
cognitive impairment in the DESCRIPA study: a prospective cohort study.
Lancet Neurology, 8(7), 619-627.
417

von Strauss, E., Viitanen, M., De Ronchi, D., Winblad, B., & Fratiglioni, L. (1999).
Aging and the occurrence of dementia: Findings from a population-based
cohort with a large sample of nonagenarians. Archives of Neurology, 56(5),
587-592.
Wahrle, S. E., Jiang, H., Parsadanian, M., Hartman, R. E., Bales, K. R., Paul, S. M., et
al. (2005). Deletion of ABCA1 Increases Aβ deposition in the PDAPP
transgenic mouse model of Alzheimer disease. The Journal of Biological
Chemistry, 280(52), 43236-43242.
Wahrle, S. E., Jiang, H., Parsadanian, M., Legleiter, J., Han, X., Fryer, J. D., et al.
(2004). ABCA1 is required for normal central nervous system apoE levels and
for lipidation of astrocyte-secreted apoE. The Journal of Biological
Chemistry, 279(39), 40987-40993.
Walker, J. R., Pacoma, R., Watson, J., Ou, W., Alves, J., Mason, D. E., et al. (2013).
Enhanced Proteolytic Clearance of Plasma Aβ by Peripherally Administered
Neprilysin Does Not Result in Reduced Levels of Brain Aβ in Mice. The
Journal of Neuroscience, 33(6), 2457-2464.
Wallin, A. K., Blennow, K., Andreasen, N., & Minthon, L. (2006). CSF biomarkers for
Alzheimer’s disease: Levels of β-amyloid, tau, phosphorylated tau relate to
clinical symptoms and survival. Dementia and Geriatric Cognitive Disorders,
21(3), 131-138.
Wallum, B. J., Taborsky, G. J., Porte, D., Figlewicz, D. P., Jacobson, L., Beard, J. C., et
al. (1987). Cerebrospinal fluid insulin levels increase during intravenous
insulin infusions in man. The Journal of Clinical Endocrinology, 64(1), 190194.
Walsh, D. M., Lomakin, A., Benedek, G. B., Condron, M. M., & Teplow, D. B. (1997).
Amyloid β-protein fibrillogenesis. Detection of a protofibrillar intermediate.
The Journal of Biological Chemistry, 272(35), 22364-22372.
Walsh, D. M., & Selkoe, D. J. (2007). Ab oligomers – a decade of discovery. Journal
of Neurochemistry, 101(5), 1172-1184.

418

Walsh, D. M., Townsend, M., Podlisny, M. B., Shankar, G. M., Fadeeva, J. V., El
Agnaf, O., et al. (2005). Certain inhibitors of synthetic amyloid β-peptide
(Aβ) fibrillogenesis block oligomerization of natural Aβ and thereby rescue
long-term potentiation. The Journal of Neuroscience, 25(10), 2455-2462.
Wang, D. S., Dickson, D. W., & Malter, J. S. (2006). β-amyloid degradation and
Alzheimer’s disease. Journal of Biomedicine and Biotechnology, 2006(3), 112.
Wang, H. W., Pasternak, J. F., Kuo, H., Ristic, H., Lambert, M. P., Chromy, B., et al.
(2002). Soluble oligomers of beta amyloid (1-42) inhibit long-term
potentiation but not long-term depression in rat dentate gyrus. . Brain
Research, 924(2), 133-140.
Wang, L., Yu, C.-j., Liu, W., Cheng, L.-y., & Zhang, Y.-n. (2011). Rosiglitazone protects
neuroblastoma cells against advanced glycation end products-induced
injury. Acta Pharmacologica Sinica, 32(8), 991-998.
Wang, P., Su, C., Li, R., Wang, H., Ren, Y., Sun, H., et al. (2014). Mechanisms and
effects of curcumin on spatial learning and memory improvement in
APPswe/PS1dE9 mice. Journal of neuroscience research, 92(2), 218-231.
Wang, R., Wang, S., Malter, J. S., & Wang, D.-S. (2009). Effects of 4-HydroxyNonenal and Amyloid-β on Expression and Activity of Endothelin Converting
Enzyme and Insulin Degrading Enzyme in SH-SY5Y Cells. Journal of
Alzheimer's Disease, 17(3), 489-501.
Wang, S., Wang, R., Chen, L., Bennett, D. A., Dickson, D. W., & Wang, D. S. (2010).
Expression and functional profiling of neprilysin, insulin-degrading enzyme,
and endothelin-converting enzyme in prospectively studied elderly and
Alzheimer’s brain. Journal of Neurochemistry, 115(1), 47-57.
Watanabe, R. M., Ghosh, S., Langefeld, C. D., Valle, T. T., Hauser, E. R., Magnuson,
V. L., et al. (2000). The Finland--United States investigation of non--insulindependent diabetes mellitus genetics (FUSION) study. II. An autosomal
genome scan for diabetes-related quantitative-trait loci. American Journal of
Human Genetics, 67(5), 1186-1200.

419

Watson, G. S., Peskind, E. R., Asthana, S., Purganan, K., Wait, C., Chapman, D., et al.
(2003). Insulin increases CSF Abeta42 levels in normal older adults.
Neurology, 60(12), 1886-1887.
Wehr, H., Bednarska-Makaruk, M., Lojkowska, W., Graban, A., Hoffman-Zacharska,
D., Kuczynska-Zardzewialy, A., et al. (2006). Differences in risk factors for
dementia with neurodegenerative traits and for vascular dementia.
Dementia and Geriatric Cognitive Disorders, 22(1), 1-7.
Weirich, G., Mengele, K., Yfanti, C., Gkazepis, A., Hellmann, D., Welk, A., et al.
(2008). Immunohistochemical evidence of ubiquitous distribution of the
metalloendoprotease insulin-degrading enzyme (IDE; insulysin) in human
non-malignant tissues and tumor cell lines. Biological Chemistry, 389(11),
1441-1445.
Weisgraber, K. H., & Mahley, R. W. (1996). Human apolipoprotein E: the
Alzheimer’s disease connection. The FASEB Journal, 10(13), 1485-1494.
Weller, S. K. (2011). Alphaherpesviruses: Molecular Virology: Horizon Scientific
Press.
Wertkin, A. M., Turner, R. S., Pleasure, S. J., Golde, T. E., Younkin, S. G., Trojanowski,
J. Q., et al. (1993). Human neurons derived from a teratocarcinoma cell line
express solely the 695-amino acid amyloid precursor protein and produce
intracellular β-amyloid or A4 peptides. Proceedings of the National Academy
of Sciences, 90(20), 9513-9517.
Westermark, P., Wernstedt, C., Wilander, E., Hayden, D. W., O'Brien, T. D., &
Johnson, K. H. (1987). Amyloid fibrils in human insulinoma and islets of
Langerhans of the diabetic cat are derived from a neuropeptide-like protein
also present in normal islet cells. Proceedings of the National Academy of
Sciences, 84(11), 3881-3885.
Weyer, C., Hanson, R. L., Tataranni, P. A., Bogardus, C., & Pratley, R. E. (2000). A
high fasting plasma insulin concentration predicts type 2 diabetes
independent of insulin resistance. Evidence for a pathogenic role of relative
hyperinsulinemia. Diabetes, 49(12), 2094-2101.
Williams, J., Lye, D. C. B., & Umapathi, T. (2008). Diagnostic lumbar puncture:
minimizing complications. Internal Medicine Journal, 38(7), 587-591.
420

Wilson, C. A., Doms, R. W., & Lee, V. M. (1999). Intracellular APP Processing and A
[beta] Production in Alzheimer Disease. Journal of Neuropathology &
Experimental Neurology, 58(8), 787-794.
Wiltshire, S., Hattersley, A. T., Hitman, G. A., Walker, M., Levy, J. C., Sampson, M., et
al. (2001). A genomewide scan for loci predisposing to type 2 diabetes in a
U.K. population (The Diabetes UK Warren 2 Repository): Analysis of 573
pedigrees provides independent replication of a susceptibility locus on
chromosome 1q. American Journal of Human Genetics, 69(3), 553-569.
Wisniewski, T., Castaño, E. M., Golabek, A., Vogel, T., & Frangione, B. (1994).
Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro.
American Journal of Pathology, 145(5), 1030-1035.
Wisniewski, T., & Frangione, B. (1992). Apolipoprotein-E - a pathological chaperone
protein in patients with cerebral and systemic amyloid. Neuroscience
Letters, 135(2), 235-238.
Wolfe, M. S., Xia, W., Moore, C. L., Leatherwood, D. D., Ostaszewski, B., Rahmati, T.,
et al. (1999). Peptidomimetic probes and molecular modeling suggest that
Alzheimer’s γ-secretase is an intramembrane-cleaving aspartyl protease.
Biochemistry, 38(15), 4720-4727.
Xia, W., Yang, T., Shankar, G., Smith, I. M., Shen, Y., Walsh, D. M., et al. (2009). A
specific enzyme-linked immunosorbent assay for measuring β-amyloid
protein oligomers in human plasma and brain tissue of patients with
Alzheimer disease. Archives of Neurology, 66(2), 190-199.
Xu, H., Greengard, P., & Gandy, S. (1995). Regulated formation of Golgi secretory
vesicles containing Alzheimer β-amyloid precursor protein. The Journal of
Biological Chemistry, 270(40), 23243-23245.
Xu, W. L., Qiu, C. X., Wahlin, A., Winblad, B., & Fratiglioni, L. (2004). Diabetes
mellitus and risk of dementia in the Kungsholmen project: a 6-year followup study. Neurology, 63(7), 1181-1186.
Yamaguchi, H., Hirai, S., Morimatsu, M., Shoji, M., & Harigaya, Y. (1988). Diffuse
type of senile plaques in the brains of Alzheimer-type dementia. Acta
Neuropathologica, 77(2), 113-119.

421

Yamaguchi, H., Sugihara, S., Ogawa, A., Oshima, N., & Ihara, Y. (2001). Alzheimer β
amyloid deposition enhanced by apoE ε4 gene precedes neurofibrillary
pathology in the frontal association cortex of nondemented senior subjects.
Journal of Neuropathology and Experimental Neurology, 60(7), 731-739.
Yamamoto, M., Kiyota, T., Walsh, S. M., Liu, J., Kipnis, J., & Ikezu, T. (2008).
Cytokine-mediated inhibition of fibrillar amyloid-β peptide degradation by
human mononuclear phagocytes. The Journal of Immunology, 181(6), 38773886.
Yan, H., Yuan, W., Velculescu, V. E., Vogelstein, B., & Kinzler, K. W. (2002). Allelic
variation in human gene expression. Science, 297(5584), 1143.
Yang, D. S., Small, D. H., Seydel, U., Smith, J. D., Hallmayer, J., Gandy, S. E., et al.
(1999). Apolipoprotein E promotes the binding and uptake of beta-amyloid
into Chinese hamster ovary cells in an isoform-specific manner.
Neuroscience, 90(4), 1217-1226.
Yankner, B. A., Duffy, L. K., & Kirschner, D. A. (1990). Neurotrophic and neurotoxic
effects of amyloid beta protein: reversal by tachykinin neuropeptides.
Science, 250(4978), 279-283.
Yenki, P., Khodagholi, F., & Shaerzadeh, F. (2013). Inhibition of Phosphorylation of
JNK Suppresses Aβ-Induced ER Stress and Upregulates Prosurvival
Mitochondrial Proteins in Rat Hippocampus. Journal of Molecular
Neuroscience, 49(2), 262-269.
Yfanti, C., Mengele, K., Gkazepis, A., Weirich, G., Giersig, C., Kuo, W.-L., et al. (2008).
Expression of metalloprotease insulin-degrading enzyme insulysin in normal
and malignant human tissues. International journal of molecular medicine,
22(4), 421.
Yokono, K. (1981(a)). [Studies on insulin metabolism: enzymatic characteristics and
biological significance of insulin-degrading activities in rat liver cell fraction
(author's transl)]. Nihon Naibunpi Gakkai Zasshi, 57(12), 1683-1698.
Yokono, K., Imamura, Y., Shii, K., Sakai, H., & Baba, S. (1981(b)). Purification and
characterization of insulin-degrading enzyme from pig skeletal muscle.
Endocrinology, 108(4), 1527-1532.

422

Youmans, K. L., Tai, L. M., Nwabuisi-Heath, E., Jungbauer, L., Kanekiyo, T., Gan, M.,
et al. (2012). APOE4-specific changes in Aβ accumulation in a new transgenic
mouse model of Alzheimer disease. Journal of Biological Chemistry, 287(50),
41774-41786.
Zanetti, O., Solerte, S., & Cantoni, F. (2009). Life expectancy in Alzheimer's disease
(AD). Archives of Gerontology and Geriatrics, 49, 237-243.
Zeggini, E., Weedon, M. N., Lindgren, C. M., Frayling, T. M., Elliott, K. S., Lango, H.,
et al. (2007). Replication of genome-wide association signals in UK samples
reveals risk loci for type 2 diabetes. Science, 316(5829), 1336-1341.
Zhang, L., Ding, Q., & Wang, Z. (2012). Nuclear Respiratory Factor 1 Mediates the
Transcription Initiation of Insulin-Degrading Enzyme in a TATA Box-Binding
Protein-Independent Manner. PLoS ONE, 7(8), e42035.
Zhang, Y., Wang, B., Wan, H., Zhou, Q., & Li, T. (2013). Meta-analysis of the Insulin
degrading enzyme polymorphisms and susceptibility to Alzheimer's disease.
Neuroscience Letters.
Zhao, L., Teter, B., Morihara, T., Lim, G. P., Ambegaokar, S. S., Ubeda, O. J., et al.
(2004). Insulin-degrading enzyme as a downstream target of insulin receptor
signaling cascade: implications for Alzheimer’s disease intervention. The
Journal of Neuroscience, 24(49), 11120-11126.
Zhao, L., Yao, J., Mao, Z., Chen, S., Wang, Y., & Brinton, R. D. (2011). 17β-Estradiol
regulates insulin-degrading enzyme expression via an ERβ/PI3-K pathway in
hippocampus: Relevance to Alzheimer's prevention. Neurobiology of Aging,
32(11), 1949-1963.
Zhao, X., Pan, F., Garcia-Gancedo, L., Flewitt, A. J., Ashley, G. M., Luo, J., et al.
(2012). Interfacial recognition of human prostate-specific antigen by
immobilized monoclonal antibody: effects of solution conditions and surface
chemistry. Journal of The Royal Society Interface, 9(75), 2457-2467.
Zhao, Z., Xiang, Z., Haroutunian, V., Buxbaum, J. D., Stetka, B., & Pasinetti, G. M.
(2007). Insulin degrading enzyme activity selectively decreases in the
hippocampal formation of cases at high risk to develop Alzheimer's disease.
Neurobiology of Aging, 28(6), 824-830.

423

Zlokovic, B. V., Deane, R., Sallstrom, J., Chow, N., & Miano, J. M. (2005).
Neurovascular pathways and Alzheimer amyloid β-peptide. Brain Pathology,
15(1), 78-83.
Zubenko, G. S. (1997). Molecular neurobiology of Alzheimer's disease. Harvard
Review of Psychiatry, 5(4), 177-213.
Zuo, X., & Jia, J. (2009). Promoter polymorphisms which modulate insulin degrading
enzyme expression may increase susceptibility to Alzheimer's disease. Brain
Research, 1249, 1-8.

424

APPENDIX

–

Further

optimisation

tests

for

Fluorometric Activity Assay
A1

Determination of fluorometric activity assay cross-

reactivity with human (HSA) and bovine (BSA) serum albumin
It was demonstrated in the IDE ELISA assay that cell-culture grade BSA was crossreactive and produced a dose-responsive signal. As the capture antibody Ab 3 was
used for both the IDE ELISA and also the IDE fluorometric activity assay, it was
important to test for any interference of both BSA (cell-culture grade) and HSA in
the activity assay. PCP as a control was also included to compare the extent of any
HSA/BSA signal generated.
HSA and BSA were prepared as described in section 2.2.5.3.1 to a concentration of
60 mg/mL each (representing the highest concentration of human albumin in
plasma) diluted in PBST (Figure A1). Each dilution was further diluted as per plasma
samples (40 μl + 85 μL PBST), and then assayed in duplicate along with PCP using
the fluorometric activity assay protocol as detailed in Section 2.2.6.1. The test was
terminated after 2 hours incubation.

Cross-reactivity was determined to be

fluorescence generated above the value of the (PBST only) blank.
Results showed that neither BSA nor HSA generated a signal above the level of the
blank, while the PCP control did generate a signal as expected. It can be concluded
by these results that neither HSA nor BSA was an interfering factor in this assay.
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Figure A1 Investigating potential interference in the IDE fluorometric activity
assay by purified human (HSA) or bovine serum albumin (BSA). All tests were
done in duplicate. Solutions of BSA and HSA were prepared to a concentration of
60mg/mL and diluted as per PCP in PBST. PCP was determined to contain 960 μg
total protein per well. The assay was carried out as described in section 2.2.6.1,
although conducted for only 2 hr. The results show that purified HSA and BSA
generate no detectable signal above the blank in the IDE fluorometric activity assay
at the equivalent of the highest physiological level of albumin found in human
plasma. Error bars indicate ±SD.
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A2

Testing phosphate-based buffers against tris-based

buffers as sample diluents in the IDE fluorometric activity
assay.
Phosphate-based buffers have been known to have a chelating effect on some
enzymes, and particularly when using long incubation times. Similar to some other
enzymes, IDE catalytic activity has previously been shown to be dependent on
metal ions such as zinc. As the samples in the IDE activity assay are diluted in PBST,
and incubated overnight, it was important to determine if the chelating effect of
the phosphates in PBST were having an effect on the amount of IDE activity
measured. Therefore the assay was tested with purified rrIDE and PCP using either
PBST or TBST for blocking agents, sample dilutions and washes (Figure A2(A) and
(B)).
Results showed minimal differences between TBST and PBST in the fluorometric
assay for both the standard curve (Graph A.), and for the plasma (Graph B.). It was
concluded that due to the pH instability of tris-based buffers with temperature
changes, and the overnight incubation of the samples at 4°C in the protocol, PBST
would be used for the IDE fluorometric assay.
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Figure A2(A) and (B).

Test of PBST versus TBST as dilution buffers in the

fluorescent activity assay for IDE. Assay was performed as detailed in Section
2.2.6.1 over 4 hours. Recombinant rat IDE (rrIDE) was diluted to concentrations of
312.5 to 7500 ng/mL (Graph A.) and pooled control plasma (PCP) was loaded at a
dilution of 960 μg total protein per well (Graph B) in duplicate, using either PBST or
TBST as assay diluents. Data is shown at the 4 hour timepoint. Results show that
there is negligible difference in the rrIDE standard curve or plasma values when
using either PBST or TBST diluents. Error bars in Graph B indicate ±SD.
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